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Abstract  
The progress of human genome sequencing has revealed the existence of several hundred orphan G 
protein-coupled receptors (GPCRs), whose endogenous ligands are not yet identified, thus their 
deorphanization and characterization is fundamental in order to clarify their physiological and 
pathological role as well as their relevance as new drug targets. Recently, the orphan GPCR GPR17 
that is phylogenetically and structurally related to the known P2Y and CysLT receptors has been 
identified as a dual uracil nucleotide/cysteinyl-leukotriene receptor. In spite of this, these 
deorphanization efforts could not be verified yet by independent laboratories, thus this classification 
remains a controversial matter and GPR17 most likely still represents an orphan GPCR. Additionally, a 
subsequent study revealed a ligand-independent regulatory role for GPR17 suppressing CysLT1 
receptor function via GPCR-GPCR interactions. By means of a high throughput pharmacogenomic 
approach our group has identified a small molecule agonist for GPR17 that is used as 
pharmacological tool for characterization of ligand-dependent behaviors triggered by this receptor. 
As a consequence, in the present thesis, evidence is provided that GPR17 does not lack the common 
features of GPCR signaling. Upon agonist challenge GPR17 induces signaling via promiscuous G 
protein-coupling (Gαi/o, Gαq and Gαs) in an agonist-concentration-dependent manner, as 
determined by means of traditional second messenger assays (cAMP and IP1) and by the label-free 
dynamic mass redistribution (DMR) technology in two different cellular backgrounds (CHO and 
HEK293 cells) engineered to stably express the short isoform of human GPR17. The use of ELISA and 
immunofluorescence techniques revealed that activation of GPR17 with the agonist is also linked 
with a time-dependent reduction of cell surface expression. Furthermore, GPR17 recruits β-arrestin2 
upon ligand-stimulation in a G protein-dependent and –independent manner as monitored by use of 
bioluminescence resonance energy transfer (BRET2) analyses. The GPR17-mediated signaling can be 
efficiently abrogated by the CysLT1 antagonist pranlukast in a non-competitive mode of action, but 
not by montelukast, zafirlukast and MK571, as investigated by use of DMR analyses, traditional 
second messenger assays and BRET2 approach. Additionally, evidence is provided that pranlukast 
acts as a mixed agonist/antagonist at GPR17, differentially modulating individual signaling pathways. 
Furthermore, it is demonstrated that β-arrestin2, known as scaffolding protein involved in 
desensitization and trafficking processes of GPCRs, exhibits the capability to fine-tune G protein 
signaling specifity of GPR17 via shifting the preference to the most preferred G protein subunit (here 
Gαi/o), a phenomenon that has not been described before. 
 
Keywords:  G protein-coupled receptor (GPCR), GPR17, pranlukast, β-arrestin2, dynamic mass 
redistribution, multiplicity  
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Kurzbeschreibung 
Die Sequenzierungsfortschritte des menschlichen Erbgutes offenbarten die Existenz von mehreren 
hundert orphanen G Protein-gekoppelten Rezeptoren (GPCRs), dessen endogene Liganden noch nicht 
identifiziert wurden. Ihre Deorphanisierung sowie Charakterisierung sind elementar um die 
physiologische und pathologische Rolle aufzuklären und sie können als neue potenzielle Arzneimittel 
Targets betrachtet werden. Kürzlich ist der orphane GPCR GPR17, der phylogenetisch und strukturell 
mit P2Y und CysLT Rezeptoren verwandt ist, als ein Uracil Nukleotid/Cysteinyl-Leukotrien Rezeptor 
identifiziert worden. Diese Deorphanisierung konnte jedoch noch nicht durch unabhängige Labore 
verifiziert werden, somit bleibt diese Klassifikation eine umstrittene Postulierung und GPR17 muss 
weiterhin als orphaner GPCR betrachtet werden. Weiterhin zeigte eine nachfolgende Studie eine 
Ligand-unabhängige Funktion für GPR17 über GPCR-GPCR Wechselwirkungen als negativer Regulator 
der CysLT1 Rezeptor-vermittelten Signalwegsaktivierung. Dennoch hat unsere Arbeitsgruppe einen 
synthetischen GPR17-Agonisten identifiziert, der als pharmakologisches Werkzeug für die 
Charakterisierung von Ligand-induzierten Rezeptor-nachgeschalteten Ereignissen verwendet wird. 
Entgegen der bisher postulierten Thesen wird in der gegenwärtigen Arbeit gezeigt, dass GPR17 
allgemeine Eigenschaften der GPCR-Signaltransduktion aufweist. Agonist-Stimulierung des GPR17 
induziert Signaltransduktion über Kopplung mit promiskuitiven G Proteinen (Gαi/o, Gαq und Gαs) in 
einer konzentrationsabhängigen Weise, wie mittels der klassischen funktionellen GPCR Analysen 
(cAMP und IP1) und durch die Technologie der dynamischen Massenumverteilung (DMR) gezeigt 
werden konnte, unter Verwendung von zwei verschiedenen rekombinanten Zelllinien (CHO und 
HEK293), welche die kurze Isoform des humanen GPR17 stabil exprimieren. Der Gebrauch von ELISA 
und Immunfluoreszenz Techniken offenbarte, dass die Aktivierung von GPR17 mit dem Agonisten 
auch mit einer zeitabhängigen Verminderung des Zelloberflächenexpression verbunden ist. 
Außerdem wird unter Verwendung der Biolumineszenz Resonanz Energietransfer (BRET2) Methode 
gezeigt, dass GPR17 β-Arrestin2 nach Ligand-Stimulierung rekrutiert, und zwar in einer G Protein-
abhängigen als auch -unabhängigen Weise. Die GPR17-vermittelte Signaltransduktion kann vom 
CysLT1 Antagonisten Pranlukast in einer nicht-kompetitiven Weise gehemmt werden, aber nicht 
durch Montelukast, Zafirlukast und MK571. Weiterhin wird gezeigt, dass Pranlukast als ein 
gemischter Agonist/Antagonist am GPR17 wirkt, der partial und funktionell selektiv die Gαi/o-
vermittelte Signalwegstransduktion aktiviert. Weiterhin wird dargelegt, dass β-Arrestin2, bekannt als 
Gerüst-Protein, das an der Desensibilisierung und Internalisierung von GPCRs beteiligt ist, die 
Fähigkeit besitzt die gemischte G Protein-Kopplung von GPR17 zu modulieren, und zwar über die 
Verschiebung der Kopplungspräferenzen zur bevorzugtesten G Protein-Untereinheit (hier Gαi/o). 
Dies stellt ein Phänomen dar, das zuvor nicht beschrieben worden ist. 
  
Schlüsselwörter: G Protein-gekoppelte Rezeptoren (GPCR), GPR17, Pranlukast, β-Arrestin2, 
Dynamische Massenumverteilung (DMR), Multiplizität  
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1 Introduction 
The word ‘receptor’ originates from the Latin word ‘recipere’, which means to receive or to accept. 
Hence, in biochemistry a receptor is known to be a protein that receives signals (endogenous ligands 
or synthetic drugs), which initiate a cellular response.  
Guanine nucleotide-binding protein (G protein) coupled receptors (GPCRs) are integral membrane 
proteins, which convey extracellular signals into intracellular events. The “superfamily” of GPCRs, 
also known as seven-transmembrane receptors (7TMR), represents the largest group of cell surface 
receptors expressed by the human genome. Over 800 GPCR sequences can be found, making up 
approximately 2% of all human genes (Fredriksson et al. 2003, Vassilatis et al. 2003).  
GPCRs respond to a wide variety of extracellular molecules, such as Ca2+ ions, small biogenic amines, 
nucleotides, eicosanoids, peptides, glycoproteins and sensory stimuli (Ji, Grossmann & Ji 1998, Wess 
1998). They play a crucial role in cell-to-cell communication, as they control a broad range of cellular 
responses such as metabolism, contractility, secretion, motility, transcription and growth. Integration 
of these cellular responses at systemic levels leads to the regulation of many physiological functions 
such as embryonic development, gonadal development, learning and memory and organismal 
homeostasis (Neves, Ram & Iyengar 2002). 
Due to their ubiquitous cell surface expression, and their involvement in a variety of physiological 
and pathophysiological processes, GPCRs represent an important class of very tractable drug targets. 
Approximately 30% of all pharmaceutical drugs on the market unfold their therapeutic effect on 
GPCRs, although only a small percentage of GPCRs are currently targeted (reviewed by Drews 2000, 
Drews 2006, Overington, Al-Lazikani & Hopkins 2006). These drugs typically function as agonists or 
antagonists to GPCRs for the treatment of various diseases including asthma, hypertension, peptic 
ulcers and schizophrenia (reviewed by Wise, Jupe & Rees 2004). 
1.1 Structural architecture and classification of GPCRs 
GPCRs are composed of a single peptide, usually 400-500 but also up to 1200 amino acids (Flower 
1999). Conserved structural GPCR motifs include seven α-helical transmembrane domains of 
approximately 25-35 amino acids with connecting intracellular and extracellular loops, an 
extracellular amino terminus and an intracellular C-terminal domain (Lagerström & Schiöth 2008, 
Palczewski et al. 2000, Pierce, Premont & Lefkowitz 2002). The seven transmembrane helices (TM1-
7) represent the conserved hydrophobic core of G protein-coupled receptors (Figure 1). In general 
the extracellular N-terminus and the exofacial portions of the transmembrane segments are involved 
in the interaction of the receptor with the ligand. Intracellular parts of the GPCR, including the C-
terminal domain and the intracellular loops (in particular the endo2 and the endo3, see Figure 1), 
participate in the G protein activation and the interaction with other cellular proteins (Kobilka 1992; 
Wess 1997, Wess 1998). Furthermore, most GPCRs have two cysteines, which form an intramolecular 
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disulfide bridge between the first and second extracellular loops (Baldwin 1994). This covalent 
interaction enhances receptor stability and is involved in various functions including activation and 
binding, depending on the respective receptor. 
 
Figure 1 Snake plot of human seven transmembrane receptor GPR17 
The schematic representation of hGPR17 (short (336 aa) and long (367 aa) splice variant) as a serpentine model 
demonstrates conserved structural features of family A of GPCRs, which are characterized by having a relatively 
small extracellular N-terminus (NH2), 7 transmembrane (TM) domains linked by three intracellular and three 
extracellular loops and an intracellular C-terminus (COOH). Intracellular loops are marked as endo1 to endo3 
and the extracellular loops as exo1 to exo3. The 28 amino acids comprising elongated N-terminus of the long 
GPR17splice variant are indicated as black circles with white letters. The conserved typical amino acid motif in 
TM6 (H-X-X-R), which is believed (at least for nucleotide receptors) to be essential for ligand binding, and that 
can be found in several GPCRs including all known P2Y and CysLT receptors (Ciana et al. 2006), is indicated with 
purple circles. Cysteine residues are highlighted in magenta circles and respective disulphide-bridge is denoted 
as a magenta staple line.   
(Plot was designed with the help of an online available TM prediction server and a snake plot construction 
program from http://www.enzim.hu/hmmtop/html/submit.html (HMMTOP prediction of TM helices) and 
http://www.sacs.ucsf.edu/TOPO (TOPO2 Transmembrane Protein Display Page)).  
Although the GPCRs do not show the overall sequence homology, a significant homology is found 
within the defined subfamilies (Gether 2000). GPCRs can be classified into three distinct families 
based on specific structural characteristics, and the degree of sequence identity in their TM domains. 
Family A is the rhodopsin-like receptor family with ligands such as neuropeptides, chemokines and 
prostanoids, family B are also referred to as secretin and glucagon receptor-like family, and family C 
receptors are related to metabotrophic neurotransmitter receptors. Compared to family A receptors, 
family B and C receptors have large extracellular N-terminal domains. Despite the fact that there is 
only little amino acid identity (less than 20%) between families, the overall helical arrangement of 
exo1
exo2 exo3
endo1
endo2 endo3
NH2
COOH
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the 7TM domain appears to be conserved across the entire superfamily (Pierce, Premont & Lefkowitz 
2002).  
1.2 Classical model of G protein-dependent signaling  
As the name implies, GPCRs mediate signaling with the help of G proteins. These heterotrimeric 
guanine nucleotide binding proteins are composed of the α-subunit (Gα) and the dimer of the βγ-
subunits (Gβγ). To date over 20 α-subunits, 6 β-subunits and 12 γ-subunits have been identified 
(Simon, Strathmann & Gautam 1991). The classical model of a G protein-coupled receptor signal 
transduction cascade requires the binding of an extracellular ligand to its respective receptor, 
causing a conformational change of the stimulated GPCR, which allows the receptor to activate an 
intracellular heterotrimeric G protein. The GPCR can be regarded as a guanine-nucleotide exchange 
factor (GEF) for the Gα subunit. Agonist-induced stimulation of the receptor results in the activation 
of its GEF activity toward the Gα subunit. This GEF activity triggers an increase in the dissociation of 
bound GDP from Gα, enabling a fast exchange with GTP. Following this replacement, the 
heterotrimer can dissociate into the separate Gα and Gβγ subunits (Downes & Gautam 1999, Hepler 
& Gilman 1992), even though some data imply that the G protein activation may also comprise the 
subunit rearrangement rather than the dissociation (Bünemann, Frank & Lohse 2003, Frank et al. 
2005). However, the GTP-bound Gα subunits and Gβγ dimers can modulate a number of second 
messenger generating pathways including the activation of phospholipase C and the 
activation/inhibition of adenylate cyclase in addition to a variety of other downstream effectors, 
depending on the respective coupling preferences (Gilman 1987, Marinissen & Gutkind 2001). To 
date, there are four main classes of Gα proteins according to the amino acid sequence similarity 
(Gαs, Gαi/o, Gαq/11, Gα12/13), and furthermore based on functional similarities, regarding the 
effect that they elicit on downstream effectors (Pierce, Premont & Lefkowitz 2002, Simon, 
Strathmann & Gautam 1991). The heterotrimeric G proteins are conventionally named according to 
their α-subunits. 
It has been demonstrated, that certain amino acid residues in the C-terminal regions of Gα protein 
can directly interact with the receptor and play a key role in regulating the specificity of coupling 
(Wess 1998). As this region is rather conserved for Gα proteins belonging to the same family, 
receptors are often capable of stimulating all the members of this family. Thus, based on their 
G protein-coupling preference, GPCRs can be broadly subclassified into Gαs-, Gαi/o-, Gαq/11- and 
Gα12/13-coupled receptors (Pierce, Premont & Lefkowitz 2002, Wess 1998).  
1.2.1 Guanine nucleotide binding proteins and their major signaling characteristics 
Activation of one G protein may give rise to a bifurcating signal, as not only the GTP-bound α-subunit 
does transmit a signal to effector molecules, but βγ-dimers can also generate part of the information 
(reviewed by Marinissen & Gutkind 2001). The major involved signal transduction pathways are 
roughly described in the following chapter and depicted in Figure 2, providing crucial information for 
the present thesis.  
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Figure 2 G protein-dependent and -independent signaling pathways of GPCRs 
Ligand-induced activation of the seven-transmembrane receptor by an external stimulus initiates exchange of 
GDP to GTP, which promotes an activation of the G protein heterotrimer. The GTP-bound Gα subunit 
dissociates from the Gβγ complex, and both subunits activate their respective cytoplasmic effectors resulting in 
a modulation of intracellular second messenger levels. Besides the classical G protein-mediated signaling 
pathways, G protein-independent signaling upon agonist-induced stimulation occurs, mainly initiated by the 
scaffolding protein β-arrestin. (modified from Lefkowitz & Shenoy 2005 and Marinissen & Gutkind 2001) 
1.2.1.1 Gαs-mediated signaling cascades 
The Gαs-protein family, including Gαs and olfactory Gαolf, was the first to be identified. The 
regulatory component of adenylate cyclase was firstly described by Ross and Gilman in 1980 as 
“guanine nucleotide-binding regulator protein” (Ross & Gilman 1980). Furthermore, it has been 
found to be the least abundant of G proteins in the body (Gilman 1995). The “s” refers to the 
stimulatory effect, as the common property of Gαs is stimulation of the adenylate cyclase (AC) 
leading to an increase of intracellular cyclic adenosine monophosphate (cAMP) concentration.  
1.2.1.2 Gαi/o-mediated signaling cascades 
The class of Gαi/o-proteins represents the biggest family of the four Gα-subunits. It includes the 
almost ubiquitously expressed Gαi1, Gαi2, Gαi3 and Gαo proteins, as well as the brain- and the 
adrenal platelets-specific Gαz and the Gαt, and the Gαg expressed in the retina and the taste buds, 
respectively (reviewed by Woehler & Ponimaskin 2009). The protein was firstly isolated by Sternweis 
and Robishaw and characterized by Gilman’s group in 1984 (Sternweis & Robishaw 1984, Bokoch et 
al. 1984, Katada et al. 1984). The Gαi family was initially named for its ability to inhibit adenylate 
cyclase activity, thus promoting decreased intracellular cAMP synthesis in a pertussis toxin (PTX) 
sensitive manner (Katada & Ui 1982). This property of the bacterial toxin was widely exploited to 
check the involvement of Gαi and Gαo in cellular responses. 
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1.2.1.3 Gαq/11-mediated signaling cascades 
The G proteins of this class, including Gαq, Gα11, Gα14 and Gα15/16 (mouse and human 
orthologues, respectively) activate the phospholipase C (PLC), an enzyme that catalyzes the 
hydrolysis of the phosphatidylinositol (4,5)-bisphosphate (PIP2), promoting the generation of 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). These second messengers serve to 
propagate and amplify the Gαq-mediated signal with intracellular calcium mobilization. DAG 
stimulates the protein kinase C (PKC), while IP3 triggers intracellular Ca2+ release by activation of 
receptors in the endoplasmic reticulum. The increase of intracellular Ca2+ has many effects, including 
activation of the phospholipase A2 (PLA) and PKC, respectively (reviewed by Marinissen & Gutkind 
2001, Woehler & Ponimaskin 2009). Cockcroft and Gomperts were the first to demonstrate that PLC 
is activated by a G protein (Cockcroft & Gomperts). 
1.2.1.4 Gα12/13-mediated signaling cascades 
In 1991 Strathmann and Simon identified the Gα12 and the Gα13 subunits, which show relatively low 
sequence homology with the other Gα proteins (Strathmann & Simon 1991). These proteins are 
involved in the modulation of small GTPases activity (Rho family), thus in regulation of the cell 
morphology (Suzuki et al. 2003). The Gα12/13 proteins are also shown to activate an extracellular 
signal regulated activated kinase (ERK) (Voyno-Yasenetskaya et al. 1996) and the Na+/H+ exchange 
(Voyno-Yasenetskaya et al. 1994).  
1.2.1.5 Gβγ-mediated signaling cascades 
The β and γ subunits of the G proteins can be considered as one functional unit due to their 
continuous tight interaction. The five known mammalian β-subunits are characterized by a high 
degree of amino acid sequence identity, whereas γ-subunits are considerably more diverse (Simon, 
Strathmann & Gautam 1991). The βγ-dimers do not only act as an anchor for Gα subunits to form the 
functional heterotrimer, they also possess regulatory functions, such as the regulation of the GIRK 
channels, the activation of the phospholipases C and A2, the activation of the MAPK, and the 
modulation of some isoforms of adenylate cyclase (reviewed by Marinissen & Gutkind 2001, Woehler 
& Ponimaskin 2009). 
1.2.2 Multiplicity in G protein-coupling and functional selectivity 
It is becoming generally accepted that a single GPCR has the ability to simultaneously activate 
multiple pools of related and even unrelated G proteins, both when expressed endogenously and 
following transfection into heterologous systems. Multiplicity in G protein-coupling is more 
frequently observed in artificial expression systems where usually high densities of receptors are 
present. This raises the question whether such complex signaling reveals artefactual promiscuous 
coupling or whether it is a genuine property of GPCRs (reviewed by Gudermann, Schöneberg & 
Schultz 1997, Hermans 2003, Milligan 1993). The emerging knowledge of such promiscuous 
G protein-coupling adds more complexity and flexibility to this signaling system. In some cases, a 
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single receptor was found to simultaneously activate members of three or even four unrelated 
classes of G proteins (reviewed by Hermans 2003 and depicted in Table 1).  
Table 1 Typical examples of GPCRs showing multiplicity in G protein-coupling (modified from 
Hermans 2003) 
receptor Gαs Gαi/o Gαq/11 Gα12/13 
β-Adrenergic x x   
Corticotropin-releasing 
hormone 
x x x  
Metabotrophic glutamate (1a) x x x  
Gonadotropin releasing 
hormone 
x x x  
Melatonin  x x  
Muscarinic (M1 and M3) x x x  
Prostacyclin x x x  
Prostaglandin (EP3D) x x   
Thyrotropin  x x x x 
Thrombin  x x x 
 
However, although many GPCRs can mediate their effects by coupling to multiple G proteins, the 
majority of GPCRs only interacts with a definite subset or even a specific G protein heterotrimer 
(Wess 1997; Gudermann, Schöneberg & Schultz 1997). The 20 Gα-subunits, 6 Gβ-subunits and 12 
Gγ-subunits theoretically may assemble to 1.440 combinations of Gαβγ-heterotrimers, but it has 
been demonstrated by several groups, that not all potential combinations are possible (Iñiguez-Lluhi 
et al. 1992; Pronin & Gautam 1992; Yan, Kalyanaraman & Gautam 1996). Considering the high 
homology in the G protein sequences (Simon, Strathmann & Gautam 1991), it is a challenging task to 
understand how a specific receptor can distinguish among these highly homologous G proteins. As 
reviewed by Wess (Wess 1998), all four intracellular domains have been indicated to be involved in 
G protein-coupling with the most significant regions being the second intracellular loop, and the 
amino and carboxyl portions of the third intracellular loop (Wess 1997). 
Besides the mentioned GPCR-dependent coupling-specifity and -multiplicity there is accumulating 
evidence that some ligands are able to bias the functional response in a selective manner. These 
compounds, promoting functional selectivity, are also referred to as biased ligands (reviewed by 
Evans et al. 2010, Kenakin 2007, Kenakin & Miller 2010). The antipsychotic drug aripiprazole, for 
example, reveals functional selectivity at the dopamine D2 receptor (Urban et al. 2007). These in 
vitro data were proposed to explain its therapeutic efficacy, as under treatment with aripiprazole, 
the useful antipsychotic effects prevail the undesired motor side effects. Likewise, the hallucinogenic 
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action of selected psychoactive substances interacting with 5-HT receptors is expected to be 
associated with the differential activation of a subset of signaling cascades (Nichols 2004). Along with 
other studies, these experimental data emphasize the importance of the emerging concept of 
functional selectivity, which should lead to the development of drugs showing enhanced clinical 
efficacy with less unwanted side effects (reviewed by Bosier & Hermans 2007). 
In case a GPCR shows independent coupling with multiple distinct G proteins, a ligand might reveal 
diverse intrinsic efficacies as it can simultaneously act as a full or partial agonist and inverse agonist, 
respectively, or as an antagonist, at one single receptor when in view of the different involved 
signaling pathways (referred to as “pluridimensional efficacy”, Kenakin 2011). At the molecular level, 
this observation is widely explained by considering that several active conformations of the receptor 
exist, which differ in their coupling preferences with distinct G proteins (reviewed by Kenakin 2003, 
Kenakin 2007, Kenakin 2011, Perez & Karnik 2005). 
1.3 Classical and new roles of β-arrestin 
Herman Kühn was the first to discover the soluble 48-kDa protein arrestin during studies on the 
deactivation of the rhodopsin receptor (Kühn & Wilden 1987). Some years later while studying 
homologous desensitization of β-adrenergic receptor, two different isoforms named β-arrestin1 
(Lohse et al. 1990) and β-arrestin2 (Attramadal et al. 1992) were purified and characterized. There 
are four main members of the arrestin family. Visual arrestin (arrestin1) and cone arrestin (arrestin4) 
are predominantly localized in the retina, whereas β-arrestins 1 and 2 (arrestin2 and arrestin3) are 
ubiquitously expressed in various tissue types (Ferguson 2001).  
1.3.1 Desensitization 
The agonist-induced activation of GPCRs leads to a number of processes that can attenuate GPCR 
signal transduction. The early events of signaling by GPCRs, such as generation of second messengers 
(e.g. cAMP and inositol 1,4,5-trisphosphate), are usually rapidly attenuated by regulatory processes 
collectively known as receptor desensitization (reviewed by Chuang et al. 1996, Freedman & 
Lefkowitz 1996). Two major patterns of rapid GPCR desensitization can be distinguished based on the 
underlying mechanisms. Homologous desensitization describes the process whereby stimulation of a 
particular GPCR leads to desensitization of the activated receptor, whereas heterologous 
desensitization occurs when GPCR stimulation leads to desensitization of other types of GPCRs 
(Chuang et al. 1996). Under conditions of continued agonist exposure, the receptor must respond in 
a rapid manner to dampen its own persistent activation. An important component of desensitization, 
which occurs within seconds to minutes of receptor activation, is uncoupling of the activated 
receptor from its cognate heterotrimeric G proteins by receptor phosphorylation, followed by a rapid 
recruitment of arrestins, which associate with activated and phosphorylated GPCRs. The binding of 
arrestins sterically interdicts further interactions with G proteins and effectively terminates the 
signaling. This ‘arrest’ interaction was originally eponymous for arrestins (Ferguson et al. 1996, 
Ferguson 2001, Goodman et al. 1996, Laporte et al. 1999). A number of protein kinases have been 
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discovered to phosphorylate serine and threonine residues within the intracellular domains of GPCRs 
following agonist exposure, including the second messenger-dependent kinases such as cAMP-
dependent protein kinase (PKA) and protein kinase C (PKC), as well as specific G protein-coupled 
receptor kinases (GRKs) (Ferguson & Caron 1998; Ferguson et al. 1998, Lefkowitz 1993, Pierce, 
Premont & Lefkowitz 2002). The GRK family members have been demonstrated to selectively 
phosphorylate agonist-activated receptors and therefore initiate homologous desensitization, which 
depends on their functional co-factors, the arrestins. Conversely, the second messenger-dependent 
protein kinases do not only phosphorylate agonist-activated GPCRs, but also indiscriminately 
phosphorylate receptors that have not been exposed to agonists; hence these protein kinases are 
involved in the process of heterologous desensitization (Lefkowitz 1993). Although most of the 
activated GPCRs are supposed to be phosphorylated prior to β-arrestin recruitment, it has been 
demonstrated that there exist receptors whereby β-arrestin binding is independent of receptor 
phosphorylation, such as the protease-activated receptor (PAR)-1 and leukotriene B4 receptors, 
respectively (Chen, Paing & Trejo 2004, Jala, Shao & Haribabu 2005). 
 
 
Figure 3 Classical and new roles of β-arrestin (modified from Lefkowitz & Shenoy 2005) 
Following ligand-induced activation, GPCRs are phosphorylated (P) by kinases such as G protein-coupled 
receptor kinases (GRKs) resulting in binding of β-arrestins (1 and 2) to the phosphorylated third intracellular 
loops and carboxy-terminal tails. The presence of β-arrestins leads to a rapid desensitization due to steric 
hindrance of further G protein-coupling. In addition to their role as desensitizer, arrestins act as scaffolding 
proteins triggering the internalization of activated GPCRs to clathrin coated pits by interaction of the carboxy-
terminal portions of arrestin with both the clathrin heavy chain and the β2-adaptin subunit of AP-2. These 
coated vesicles fuse with early endosomes where the receptors may be dephosphorylated by specific 
phosphatases and recycled back to the plasma membrane or targeted to lysosomes for degradation. Recent 
studies revealed furthermore that arrestins, acting as scaffold adaptors, are capable of initiating their own 
signaling cascade, such as extracellular signal-regulated kinase (ERK) and Src kinase. 
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1.3.2 Internalization 
In addition to desensitization by steric hindrance, GPCRs are also sequestered into the cell by an 
agonist-dependent mechanism. The endocytosis of GPCRs to intracellular compartments is an 
important regulatory process for desensitization, recycling and down-regulation of GPCRs (Lefkowitz 
1998). The prototypical and best-characterized agonist-induced internalization pathway of GPCRs is 
mediated through clathrin coated pits (reviewed by Ferguson 2001, Takei & Haucke 2001). This 
pathway requires the binding of arrestins; and due to their ability to bind simultaneously to agonist-
occupied GPCRs and elements of the cellular endocytotic machinery, β-arrestins facilitate receptor 
endocytosis by clustering receptors within clathrin-coated pits. Following the association of β-
arrestins with the phosphorylated receptor, GPCR-arrestin complexes migrate to clathrin-coated pits 
for subsequent endocytosis via the interaction of arrestin with both the heavy chain of clathrin 
(Goodman et al. 1996) and with the β2-adaptin subunit of the adaptor protein AP-2, which also 
interacts with clathrin (Laporte et al. 1999). After targeting to endosomal compartments, GPCRs can 
be rapidly de-phosphorylated and recycled back to the plasma membrane as fully functional 
receptors in a process known as resensitization and recycling, respectively, or are targeted to the 
lysosomal compartments for degradation, resulting in a down-regulation of cell surface expression. 
Several studies from confocal microscopy have revealed that there are differences in the 
translocation kinetics of β-arrestin 1 and β-arrestin 2 to activated GPCRs, accordingly dividing them 
into two classes (A and B) based on their nature of internalization (Oakley et al. 1999, Oakley et al. 
2000, Oakley et al. 2001). In the case of Class A receptors, β-arrestin 2 translocates to the receptor 
more readily than β-arrestin 1. This interaction is transient as β-arrestin rapidly dissociates from the 
receptor and does not co-internalize. The β2-adrenergic, mu opioid, endothelin type A and the D1 
dopamine receptors are examples of GPCRs that belong to this class (Oakley et al. 2000). In contrast, 
Class B receptors including the AT1a angiotensin, vasopressin V2 and neurotensin receptor 1 have no 
preference for either β-arrestin isoform. Agonist activation of these receptors recruits β-arrestin into 
a stable association that is usually found in endosomes even after internalization. In addition to these 
different affinities for β-arrestin, the resensitization and recycling kinetics are much slower for Class 
B receptors than for Class A receptors (Oakley et al. 2000). The carboxyl tail appears to contain the 
molecular determinants that define these internalization properties as demonstrated by studies 
using chimeric GPCRs in which this region is exchanged between Class A and B receptors (Oakley et 
al. 2001). 
1.3.3 Signaling 
Initially, negative regulation of G protein signaling was the only known role for β-arrestins in GPCR 
regulation. Over the past decade, evidence has emerged that in addition to arrest ‘classical’ receptor-
G protein signaling and to promote trafficking of activated receptors, β-arrestins are able to initiate 
their own signaling cascade, without the need of G proteins. The range of GPCR-coupled signaling 
systems that are engaged through the β-arrestins has grown rapidly. Receptor-stimulated activation 
of effectors such as the MAP kinases pathways, including extracellular signal-regulated kinase1/2 
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(ERK1/2), p38 kinase and c-Jun N-terminal kinase 3 (JNK3), as well as protein kinase B (AKT) and 
phosphatidylinositol 3-kinase (PI3K) pathways were reported (extensively reviewed by e.g. Pierce & 
Lefkowitz 2001, Luttrell & Lefkowitz 2002, Lefkowitz & Shenoy 2005, Reiter & Lefkowitz, DeWire et 
al. 2007, Defea 2008, Luttrell & Gesty-Palmer 2010).  
The discovery that β-arrestins bind to a number of signaling proteins and are able to act as ligand-
regulated scaffold proteins, further augmented the complexity of GPCR function. In general, these 
findings offer a multitude of new therapeutic opportunities. It opened access to develop ligands, 
which can uniquely activate or inhibit the β-arrestin-dependent pathway without affecting the 
G protein-dependent pathway. Such ligands are referred to as β-arrestin-biased ligands (in contrast 
to G protein-biased ligands), and dramatically change the current understanding of receptor agonism 
and antagonism, respectively. Such biased-ligands could more selectively target beneficial signaling 
and even block unwanted actions of receptor activation (e.g. side effects, tolerance or toxicity). A 
number of biased ligands for 7TMRs have been identified that selectively activate or counteract β-
arrestins, and several of these seem to have distinct functional consequences when compared to 
traditional ligands (reviewed by Violin & Lefkowitz 2007, Rajagopal, Rajagopal & Lefkowitz 2010, 
Whalen, Rajagopal & Lefkowitz 2010). 
The distinct nature of β-arrestin signaling was clearly demonstrated by the discovery of a perfectly 
biased ligand, Sar1, Ile4, Ile8- AngII (SII), an angiotensin AT1a receptor activator, that exclusively 
promotes β-arrestin recruitment and initiates signaling, such as mitogen-activated protein kinases 
extracellular signal-regulated kinase (ERK) 1/2, but fails to stimulate G protein-dependent signaling 
(Holloway et al. 2002, Wei et al. 2003, Violin et al. 2010). Further examples are the two β2-adrenergic 
receptor ligands propranolol and carvedilol, that act as partial inverse agonists with respect to Gαs 
activation, but as partial agonists for the ERK1/2 pathway through stimulation of β-arrestins (Azzi et 
al. 2003; Wisler et al. 2007; Drake et al. 2008). Recently, the selective histamine H4 receptor 
antagonist JNJ7777120 was shown to recruit β-arrestin to the H4 receptor, independent of G protein 
activation (Rosethorne & Charlton 2010). Besides biased activation of β-arrestin, there is also 
evidence about inhibition, such as the two CRTH2-antagonists that do not interfere with PGD2-
initiated G protein-mediated signal transduction, but counteract the PGD2-promoted translocation of 
β-arrestin, and nevertheless were able to inhibit chemotactic activation of human eosinophilic 
granulocytes (Mathiesen et al. 2005). Another interesting observation regarding β-arrestin-mediated 
signaling, was the observation by Walters and coworkers, who demonstrated that the cutaneous 
flushing, a side effect of treatment with nicotinic acid, is promoted by activation of β-arrestin1, 
whereas the positive effects like elevation of high density lipoproteins (HDL) and decrease of 
triglycerides was mediated via Gαi/o-proteins (Walters et al. 2009). For a detailed summary of β-
arrestin-biased ligands and their therapeutic potential see (Whalen, Rajagopal & Lefkowitz 2010).  
Taken together, the change in the β-arrestin/GRK system over the last ten years revealed 
bifunctional properties, as there is on one side the desensitization mechanism, but on the other side 
simultaneously the G protein-independent signal transduction mechanism. This clearly highlights that 
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in order to fully characterize the molecular pharmacology of a GPCR it is necessary to consider the 
complete emerging spectrum of events induced upon ligand stimulation.  
1.4 Orphan GPCRs 
Recent genome sequencing projects and publicly available information on the human genome 
sequence revealed that approximately 720 sequences in the human genome belong to the GPCR 
family (Lander et al. 2001, Venter et al. 2001). It is assumed that half of the GPCRs are activated by 
sensory stimuli, whereas the other half can be regarded as potential drug targets (Fredriksson et al. 
2003, Vassilatis et al. 2003). For about 145 out of these 360 GPCRs a defined endogenous relevant 
ligand is still lacking and nothing or only little is known about their physiological role (Wise, Jupe & 
Rees 2004). These uncharacterized heptahelical receptors are also referred to as “orphan GPCRs” 
and they provide a valuable and novel field of targets for the development of new drugs with unique 
therapeutic properties (Civelli 2005, Civelli et al. 2006). Strategies that were successfully employed 
and still applied as current methods to identify the endogenous ligand are reverse pharmacology 
(Civelli 2005, e.g. P2Y5, Pasternack et al. 2008), orphan receptor strategy (“tissue-extract based 
approach”) (Civelli et al. 2001, e.g. ORL-1 receptor, Reinscheid et al. 1995) and cross genome 
phylogenetic analyses (Metpally & Sowdhamini 2005, e.g. GPR55, Ryberg et al. 2007). Additional 
investigations as the determination of the expression pattern (e.g. GPR109B, Tunaru et al. 2003) and 
generation of knock-out mice (e.g. GPR85, Matsumoto et al. 2008) provide important information 
about physiological role and pathophysiological functions, respectively.  
1.5 G protein-coupled receptor 17 
In 1996, Raport et al. were the first to isolate the GPR17 gene (referred to as R12) by means of PCR 
using degenerated oligonucleotides based on regions conserved between interleukin-8 receptor 
(IL8RA) and the angiotensin II chemokine GPCR (Raport et al. 1996). Independently in 1998, Bläsius et 
al. identified novel P2Y nucleotide GPCRs by means of degenerated RT-PCR using primers of regions 
conserved between TM3 and TM7 of chicken P2Y1 and murine P2Y2 receptors (Bläsius et al. 1998). 
GPR17 cDNA was reported to undergo splicing events, yielding two different isoforms, which were 
designated as HIP4 and FB1, and which only differ by the length of the N-terminus. The short GPR17 
isoform encodes a polypeptide with 339 amino acids with typical rhodopsin type 7TM motifs. The 
long isoform encodes a protein, where the N-terminus is 28 amino acids longer for a total length of 
367 amino acids. The gene was localized to human chromosomal band 2q21 using fluorescence in 
situ hybridization (Bläsius et al. 1998).  
1.5.1 Classification of GPR17 as dual nucleotide/lipid receptor is a controversial matter 
Although GPR17 appears to be closely related to the P2Y family of GPCRs, Bläsius et al. (1998) stated 
that preliminary functional data, obtained by investigations of second messengers (IP1 and cAMP) in 
1321N1 cells expressing GPR17, did not support the hypothesis that classical P2Y agonists serve as 
1 Introduction 
 
12
ligands for this receptor (Bläsius et al. 1998). Controversially, 8 years later, Ciana et al. (2006) 
‘deorphanized’ GPR17 as a dual uracil nucleotides/cysteinyl-leukotrienes receptor, which is 
consistent with its intermediate phylogenetic position between purinergic P2Y and cysteinyl-
leukotriene (CysLT) receptors, as depicted in the phylogenetic tree (Figure 4). It was shown that 
stimulation with uracil nucleotides (UDP, UDP-glucose and UDP-galactose) and cysteinyl-leukotrienes 
(LTC4 and LTD4), resulted in specific and concentration-dependent responses. Confirmation for 
GPR17 functionality was established in different cellular backgrounds (1321N1, COS7, CHO and 
HEK293 cells), based on [35S]GTPγS binding, cAMP inhibition assays as well as in single cell calcium 
imaging assays (Ciana et al. 2006).  
Activation of GPR17 by uracil nucleotides and cysteinyl-leukotrienes was further reported by the 
same research group in several subsequent publications (Lecca et al. 2008, Temporini et al. 2009, 
Pugliese et al. 2009, Daniele et al. 2010, Calleri et al. 2010, Fumagalli et al. 2011).  
 
Figure 4 Phylogenetic tree (modified from Ciana et al. 2006) 
Consistent to this phylogenetic tree, showing the relationship between GPR17 and P2Y and CysLT receptors, 
Ciana et al (2006) deorphanized GPR17 as a dualistic receptor responding to uracil nucleotides and cysteinyl-
leukotrienes. However, this postulated characterization remains a contentious issue. 
However, in our laboratory, these proposed endogenous ligands did not display any functional 
activity in different cell lines stably (1321N1, CHO and HEK293 cells) and transiently (HEK293), 
respectively, expressing the short isoform of GPR17 (PhD thesis of Andreas Spinrath, and informed 
personally by Lucas Peters, AK Kostenis). In agreement with our observations, the lack of activity of 
these ligands was further demonstrated by Maekawa et al., who postulated GPR17 to be a ligand-
independent negative regulator of cysteinyl leukotriene receptor 1 (Maekawa et al. 2009). 
Additional, two independent laboratories were not able to reproduce GPR17 activation by LTD4 and 
LTC4, respectively, (Benned-Jensen & Rosenkilde 2010, Wunder et al. 2010), whereat Benned-Jensen 
et al. confirmed functional activity of uracil nucleotides (UDP, UDP-glucose and UDP-galactose) at 
GPR17. Furthermore, Benned-Jensen et al. observed that both GPR17 isoforms (short and long) were 
constitutively active through Gαi/o, based on CREB gene reporter assays as well as [35S]GTPγS binding 
studies in transiently transfected HEK293 and 1321N1 cells, respectively. This ligand-independent 
activity of GPR17 has not been further proven by any other research group so far. Taken together, 
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deorphanization of GPR17 as a dual nucleotide/lipid receptor remains a controversial matter, and 
additional investigations are required to probe GPR17 pharmacology and function in more detail. 
1.5.2 Expression patterns of GPR17 
Bläsius and his working group were the first to report, that human GPR17 was expressed exclusively 
in brain, as 2.3- and 6.3-kb mRNAs, which was detected by northern blot analyses (Bläsius et al. 
1998). In agreement with this publication, Ciana et al. published GPR17, human and rat, to be highly 
expressed in the brain as well as in other organs that may undergo ischemic damage, such as heart 
and kidney, with only little expression in the liver and lung, as determined by RT-PCR. In addition, 
human GPR17 was also found in HUVEC (human umbilical vein endothelial cells) and breast 
adenocarcinoma MCF7 cells (Ciana et al. 2006, Banfi et al. 2005). Benned-Jensen and Rosenkilde 
performed quantitative real time PCR analyses in eight different brain regions as well as whole brain, 
heart and kidney, in consideration of the two existing isoforms (short and long) (Benned-Jensen & 
Rosenkilde 2010). Examinations of both isoforms revealed lowest expression in thalamus, with 
progressively rising expression levels through the hypothalamus, cerebellum, amygdala cerebellar 
hemisphere, frontal cortex, hippocampus and striatum. The short isoform was predominantly 
expressed in the brain when compared to the long isoform (~10 fold higher), whereas heart and 
kidney revealed converse expression patterns, since the long splice variant was expressed at ~12-fold 
higher levels in the heart, while in the kidney the short isoform was completely absent (Benned-
Jensen & Rosenkilde 2010). On the contrary, Pugliese et al. observed by RT-PCR that the long isoform 
was primarily detected in brain and not in the other tested human tissues (liver, kidney, lung, heart 
and skeletal muscle) or cell lines (HUVEC and the acute lymphocytic leukemia cells THP-1), which 
instead expressed the short isoform (Pugliese et al. 2009).  
Upon physiological conditions, immunohistochemical analyses revealed that mouse and rat GPR17 
was found to be expressed by pyramidal neurons, non-proliferating oligodendrocyte precursor cells 
(OPCs) and by ependymal cells lining the central canal, but never by astroglial cells in the adult CNS 
(Ciana et al. 2006, Lecca et al. 2008, Ceruti et al. 2009). Additionally human GPR17 was identified as 
one of the genes that are specifically expressed by hippocampal neuronal progenitor cells (NPCs) 
(Maisel et al. 2007). In contrast, Chen et al. described GPR17 to be restricted to the CNS (not heart, 
kidney, liver, lungs, smooth muscle, spleen, testes), and amongst neuronal cells limited to the 
oligodendrocyte lineage in the developing mouse CNS, with increasing expression levels until the 
beginning of the third postnatal week, followed by a decrease until adulthood (Chen et al. 2009). The 
restriction of GPR17 to very early differentiation stages of OPCs was further demonstrated by 
Fumagalli et al., where GPR17 was shown to be transiently upregulated at postnatal day 6, 
completely segregated from myelin markers such as the myelin basic protein (MBP). In primary rat 
postnatal OPCs, GPR17 was located on two subsets of slowly proliferating highly ramified NG2+ pre-
oligodendrocytes and its expression was turned down in morphologically mature myelinating cells 
(Fumagalli et al. 2011).  
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GPR17 was also reported to be expressed on CD11c+ dendritic cells (Itagaki et al. 2009), mouse bone 
marrow-derived macrophages (Maekawa et al. 2009) and in nerve growth factor (NGF) induced rat 
pheocromocytoma cells (PC12) (Daniele et al. 2010). 
Furthermore GPR17 was shown to be transiently upregulated on neurons (~24h) upon ischemic brain 
damages induced by middle cerebral artery occlusion (MCAo) model, in mouse and rat, followed 
(~48-72h) by an increase of GPR17 expressing microglia and macrophages recruited from distal 
parenchymal areas and moving towards the lesioned area. Starting from 72h after MCAo, OPCs 
expressing GPR17 were also significantly increased around the damaged zone (Ciana et al. 2006, 
Lecca et al. 2008). Additionally, GPR17 upregulation was observed in murine demyelinating lesions 
induced by experimental autoimmune encephalomyelitis (EAE) and in human multiple sclerosis 
plaques (Chen et al. 2009). Moreover, GPR17 was shown to be expressed on lymphocytic cells from 
patients with chronic lymphocytic leukemia (CLL) and its expression was reported to be associated 
with fast lymphocyte doubling time (Aalto et al. 2001).  
Consequently, besides the mentioned tissue-specific expression pattern, GPR17 expression seems to 
be dependent on diverse physiological (development, maturation) as well as pathophysiological 
conditions (ischemic damage, demyelination, lymphocytic leukemia), which might be an explanation 
for the controversial GPR17 expression patterns published so far. 
1.5.3 Current thoughts on the physiological role of GPR17  
Although in the last years increasing information about GPR17 was reported, the clear physiological 
importance of the receptor remains rather elusive. The actual published knowledge about its 
potential role can be roughly divided into two main fields, specifically its impact on immune system 
and on neuronal dysfunctions, respectively, which will be further described in the following two 
chapters. 
1.5.3.1 Role of GPR17 in allergic inflammations 
The mouse receptor was reported to act as a ligand-independent negative regulator of the type 1 
cysteinyl leukotriene receptor (CysLT1R) (Maekawa et al. 2009, Maekawa et al. 2010), which is 
known to exert a range of proinflammatory effects, possessing a clear role in pathophysiological 
conditions such as asthma and allergic rhinitis (reviewed by Capra et al. 2007, Rovati & Capra 2007). 
Cotransfection of GPR17 with CysLT1R in several cell lines (1321N1, CHO and HEK293T cells) 
completely suppressed CysLT1R-induced calcium flux and ERK phosphorylation upon activation with 
LTD4. Additionally, the binding of [3H]LTD4 by cell membranes (CHO and 1321N1 cells) was 
suppressed by GPR17 cotransfection. Conversely, knock down of GPR17 in primary mouse bone 
marrow-derived macrophages by lentivirus infection with siRNA, clearly augmented CysLT1R 
expression, and likewise the calcium response to LTD4. The physiological evidence of this regulatory 
role was further demonstrated using GPR17-deficient mice, where CysLT1R-mediated vascular 
permeability in mast cell-mediated passive cutaneous anaphylaxis (PCA) was significantly increased 
(Maekawa et al. 2009). Additionally, GPR17 deficiency was shown to increase CysLT1R-initiated 
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pulmonary inflammation, inflammatory cell accumulation in the bronchoalveolar lavage (BAL) fluid, 
serum levels of total IgE and Th2/th17 cytokine expression in lungs upon challenge with house dust 
mites. These findings were shown to be completely abrogated in lungs from double knock-out mice, 
lacking GPR17 and CysLT1R, establishing a core role for both receptors (Maekawa et al. 2010).  
1.5.3.1.1 Cysteinyl leukotriene receptor antagonists 
The already marketed CysLT1R ‘selective’ antagonists (“lukasts”) have been approved in various 
models of induced asthma as well as for the treatment of chronic asthma (reviewed by Brink et al. 
2003, Capra et al. 2007). Zafirlukast (Accolate®, AstraZeneca) was the first CysLT1 receptor antagonist 
to be marketed in the USA (Krell et al. 1990); montelukast (Singulair, Merck &Co) has been 
introduced to market in 1998 for the treatment of asthma and allergic rhinitis (Jones et al. 1995); 
pranlukast is still waiting for a global extension of its commercialization and it is currently available 
only in Japan (Onon®, Ono Pharmaceutical) and Mexico (Azlaire®, Schering Plough corp). These 
antagonists are orally effective over a wide range of asthma severity, preventing the airway 
inflammatory response to cysteinyl-leukotrienes action as well as acting as bronchodilators to the 
leukotriene-induced bronchoconstriction. Preclinical and clinical studies have shown that 
montelukast, zafirlukast and pranlukast differ in terms of potency and pharmacokinetics, but possess 
comparable pharmacodynamic profiles (reviewed by Aharony 1998, Hay 1997). In Europe, 
leukotriene receptor antagonists (LTRA) are considered as third-line treatment and are intended as 
add-on therapy for patients already taking inhaled corticosteroids (reviewed by Capra et al. 2007).  
Interestingly, the CysLT1 antagonists, montelukast and pranlukast were shown to functionally 
counteract LTD4-activated GPR17 signaling pathways. These observations were based on in vitro 
analyses of human (short and long isoform), rat and mouse GPR17 using [35S]GTPγS binding and 
Gαi/o-cAMP assays as well as patch-clamp electrophysiological studies measuring receptor coupling 
to potassium channels (Ciana et al. 2006, Lecca et al. 2008, Pugliese et al. 2009, Fumagalli et al. 
2011).  
Furthermore, montelukast and pranlukast were reported to counteract calcium mobilization of 
nucleotide-activated P2Y receptors upon stimulation with UDP and UTP respectively (Mamedova et 
al. 2005).  
1.5.3.2 Role of GPR17 for cerebral dysfunctions 
Besides the reported role of GPR17 as a ligand-independent negative regulator of CysLT1R, GPR17 
was shown to play key roles during brain damages. In vivo inhibition of GPR17 achieved either by 
pharmacological agents able to antagonize it’s in vitro activation (e.g., montelukast or cangrelor) or 
by an anti-sense oligonucleotide specifically designed to knock-down the receptor, was examined in 
the middle cerebral artery occlusion (MCAo) model for ischemia, and resulted in an extensively 
reduced progression of cerebral ischemic damage (Ciana et al. 2006, Lecca et al. 2008). Likewise, the 
biotechnological knock-down of GPR17 by an antisense oligonucleotide strategy during spinal cord 
injury (SCI) clearly impaired tissue damages and ameliorated SCI-related motor deficits (Ceruti et al. 
2009).  
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Furthermore, induction of brain damage and SCI was associated with spatiotemporal-dependent 
upregulation of GPR17 expression (Lecca et al. 2008, Ceruti et al. 2009). Initially, 24 h after MCAo, 
GPR17 was transiently upregulated by dying neurons within the ischemic core, colocalized with the 
cellular stress, injury and death marker heat shock protein 70 (HSP70). At later times after ischemia 
(48-72h after MCAo) GPR17 immuno-labeling appeared on microglia/macrophages infiltrating the 
lesioned area, whereas it should be noted that microglia were shown to play a neuroprotective role 
after ischemic stroke (reviewed by Jin, Yang & Li 2010). GPR17 was also found to be expressed on 
adult oligodendrocyte precursor cells that began to proliferate and express myelin specific genes, 
probably initiating remyelination in the peri-lesioned area (Lecca et al. 2008). Pharmacological 
manipulation of GPR17 with its proposed ligands (UDP-glucose, LTD4) promoted progression of 
preoligodendrocytes toward mature myelinating cells, suggesting a role of GPR17 in the transition 
between immature and myelinating oligodendrocytes (Lecca et al. 2008). Similar time-dependent 
regulations of GPR17 expression were reported after SCI (Ceruti et al. 2009). Additionally GPR17 was 
also found to be expressed on ependymal cells, which started proliferating and expressing multi-
potential progenitor markers (GFAP and nestin), suggesting activation of repair mechanisms (Ceruti 
et al. 2009). Thus, GPR17 was claimed to play a dual and spatiotemporal-dependent role on the 
evolution of nervous system tissue damage and subsequent postinjury repair of damage in the brain 
and in spinal cord.  
The role of GPR17 as a ‘sensor’ for pathological situations and a sensitizer for cell death was 
additionally confirmed by Ceruti et.al., as they demonstrated that only GPR17 expressing 
oligodendrocytes underwent massive cell death when exposed to high ATP concentrations (Ceruti et 
al. 2011). 
Maisel et al. further have proven the potential role of GPR17 in long-term central nervous system 
(CNS) repair, since the receptor was identified as one out of three genes that are specifically 
expressed in adult hippocampal neuronal progenitor cells (NPCs), which are multipotent stem cells 
that can differentiate into all three types of the CNS (oligodendrocytes, neurons and astrocytes), thus 
possessing the potential to repair neurodegenerative disorders, such as stroke or multiple sclerosis 
(Maisel et al. 2007).  
Additional evidence that GPR17 plays a role in CNS repair and development was provided by Daniele 
et al. It was presented that nerve growth factor (NGF) treated rat pheocromocytoma cells (PC12) 
express GPR17, and its stimulation with proposed GPR17 agonists (UDP-glucose, LTD4) promoted 
pro-survival neurotrophic effects and neurite outgrowth (Daniele et al. 2010). 
Chen et al. also described GPR17 as an intrinsic regulator of oligodendrogliogenesis, but in contrast 
to the previously mentioned findings, they proposed that GPR17 might transmit extracellular signals 
to negatively regulate oligodendrocyte myelination (Chen et al. 2009). GPR17 was shown to be 
expressed in oligodendrocyte precursor cells (OPCs) in the developing mouse CNS with increasing 
expression levels until the beginning of the third postnatal week, but was down-regulated during the 
peak period of myelination and in adulthood. Over-expression of GPR17 either induced in vitro by 
transfection in primary wild type OPCs or in vivo by generation of transgenic mice with sustained 
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GPR17 over-expression, inhibited OPC differentiation into mature oligodendrocytes. Consequently, 
transgenic mice displayed typical features of CNS myelinating disorders such as generalized tremors, 
hind limb paralysis and seizures, and died early during the peak period of myelinogenesis at 3 weeks 
of age. Conversely, GPR17 knock-out mice revealed precocious onset of myelination and accelerated 
OPC differentiation (Chen et al. 2009). Furthermore, quantitative RT-PCR revealed that GPR17 was 
upregulated in demyelinating lesion induced by a mouse model of multiple sclerosis (experimental 
autoimmune encephalomyelitis (EAE)) and in human multiple sclerosis plaque tissue (Chen et al. 
2009).  
The role of GPR17 as a new timer for oligodendrogliogenesis was recently further proven by 
Fumagalli et.al., who explored the time-dependent changes of GPR17 during spontaneous in vitro 
OPC differentiation using purified OPCs isolated from rat cortex (Fumagalli et al. 2011). 
Immunocytochemistry as well as single cell real time PCR revealed that the presence of GPR17 was 
restricted to the first culture days, reaching a maximum around day 6 and was completely segregated 
from that of mature myelin. In contrast to postulations made by Chen et al., but in agreement with 
observations of Lecca et al., stimulation of OPCs with UDP-glucose promoted maturation of OPCs, 
whereas preincubation with cangrelor as well as biotechnological knock down of GPR17 with siRNAs 
delayed differentiation, thus establishing a mechanistic link between OPC differentiation and GPR17 
(Chen et al. 2009, Fumagalli et al. 2011, Lecca et al. 2008). 
Taken together, despite some controversial assertions, GPR17 can be regarded as a promising target 
for development of pharmacological inhibitors as anti-ischemic drugs able to counteract damage 
evolution in stroke and SCI, and as a new target for demyelinating diseases, such as multiple 
sclerosis.  
1.6 Intention of this work 
As mentioned above, deorphanization of GPR17 as a dual nucleotide/lipid receptor remains a 
controversial matter, and additional in vitro investigations are essential to probe GPR17 
pharmacology and function in more detail. By means of a high throughput pharmacogenomic 
approach, our group has identified a synthetic small molecule agonist for GPR17 (here referred to as 
RA-II-150) that represents a precious pharmacological tool for further characterizations of ligand-
dependent behaviors triggered by GPR17, especially as the postulated endogenous agonists remain 
disputable and likewise the previously uncovered signaling properties. Discovery of an activating 
ligand is a prerequisite to search for compounds that antagonize GPR17. Therefore, elucidation of 
the molecular mechanisms of signal transduction will not only help to better understand 
functionality of GPR17, but will additionally provide a basis for subsequent development of promising 
neuroprotective and regenerative drugs, which counteract GPR17-promoted signaling. 
A first aim was to characterize signaling patterns of GPR17 upon activation with our small molecule 
agonist. Traditional second messenger assays based on HTRF® technology (cAMP, IP1) had to be 
established to analyze G protein-dependent signaling including Gαi/o, Gαs and Gαq pathways. 
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Additionally, GPR17-induced dynamic mass redistribution in living cells had to be examined by use of 
the Epic® system, a novel label-free technology to study GPCR functionality in real time and in a 
pathway unbiased but pathway-sensitive manner. Furthermore mechanistic insights into recruitment 
of β-arrestin to the activated GPR17 had to be investigated using a bioluminescence resonance 
energy transfer (BRET2)-based approach. Since cell surface expression as well as internalization upon 
agonist-stimulation constitute further common features of GPCRs, two approaches had to be 
established, namely indirect enzyme-linked immunosorbent assays (ELISA) and immunofluorescence 
analyses, respectively, both based on fixed whole cells.  
Besides a CHO Flp-In™ T-REx™ cell line stably expressing the short isoform of GPR17, which was 
already available, additional GPR17 (short isoform) expressing cell lines had to be generated. Since 
no specific antibody for GPR17 was readily available, a sequence encoding a triple HA-epitope tag 
(haemagglutinin influenza virus epitope tag) had to be introduced in frame at the amino terminus of 
GPR17 to provide a useful tool for immunobiological analyses such as ELISA and 
immunofluorescence, respectively. Furthermore, to analyze β-arrestin recruitment, GPR17 had to be 
C-terminally tagged with Renilla luciferase (RLuc) using standard molecular biology techniques. 
Following the generation of distinct GPR17 expression plasmids (GPR17, 3xHA-GPR17, GPR17-RLuc, 
3xHA-GPR17-RLuc), HEK293 cell lines were chosen as host cells to be stably transfected. For BRET2 
analyses HEK293 cells stably expressing β-arrestin2 N-terminally tagged with GFP2, were generously 
provided by J. M. Mathiesen (Department of Medicinal Chemistry, University of Copenhagen). 
After elucidating GPR17 signaling patterns in recombinant over-expressing cell lines, it was the 
intention to find a native cell line endogenously expressing GPR17 using Epic® technology, 
accordingly providing data more closely related to native GPR17 characteristics. Additionally, mouse 
embryonic stem cells had to be modified by heterologous recombination to knock-out the GPR17 
gene, thus serving as a cellular tool for further differentiations into neuronal cells lacking GPR17. 
Another intention was to examine the influence of increasing β-arrestin amounts on GPR17-
mediated signaling patterns and internalization behavior upon agonist stimulation. Therefore, three 
HEK293 cell lines stably expressing varying amounts of β-arrestin2 (low, high and very high, 
generously provided by J. M. Mathiesen, Department of Medicinal Chemistry, University of 
Copenhagen) had to be stably cotransfected with GPR17, and subsequently investigated by means of 
all previously established functional assays (cAMP, IP1, Epic®, ELISA, immunofluorescence).  
A final task was to analyze antagonistic properties of the postulated CysLT1R antagonists 
(montelukast, pranlukast, zafirlukast, MK571) on RA-II-150-induced GPR17 functional responses. As 
pranlukast was shown to possess the most promising potential to counteract GPR17-promoted 
signaling, the compound had to be further characterized regarding its pharmacological profile in all 
the functional settings described above (cAMP, IP1, Epic®, ELISA, immunofluorescence, BRET2. 
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2 Materials 
2.1 Water purification 
Solutions and media were prepared with purified water. A Milli-Q® Water System (Millipore, 
Eschborn) was employed for water purification (demineralization, dH2O). For molecular and cell 
biological experiments, sterile UltraPureTM Distilled water (Gibco/InvitrogenTM) was used. 
2.2 Sterilization method 
All heat stable materials, equipments, solutions and media were autoclaved in a Varioklav® (H+P 
Labortechnik AG, Oberschleißheim) at 121°C and 1.2 bar for 21 min. Temperature sensitive solutions 
and buffers were sterilized using sterile filter pore width 0.2 µl.  
2.3 Chemicals 
Table 2 Chemicals employed in the present work 
abbreviation substance article number company 
C1 Agar 05040 Fluka 
C2 Agarose UltraPure 15510027 Invitrogen™ 
C3 Albumin bovine essential 
fatty acid free 
A6003 Sigma 
C4 Ampicillin sodium salt K029.1 Roth 
C5 ATP A6419 Sigma 
C6 Atropine monohydrate 
sulfate salt 
A0257 Sigma 
C7 Bromophenol blue 18030 Fluka 
C8 Calcium chloride, dihydrate 21097 Fluka 
C9 Carbachol 212385 Merck 
C10 Coelenterazine 400A C-320-10 Gold Biotechnology 
C11 DMSO 60153 Riedel-de Haen 
C12 DMSO (cell culture) A1584 AppliChem 
C13 Dry milk blotting grade 
blocker, Non-fat dry milk 
170-6404 Bio-Rad 
C14 Ethylendiamine tetra acetic 
acid (EDTA) 
CN06.3 Roth 
C15 Ethanol absolute 08-205 KMF 
C16 Ethidiumbromide 1% 2218.1 Roth 
C17 Forskolin 1099 Tocris 
C18 Gelatin G2500 Sigma 
C19 Glacial acetic acid 100% 00063.2511 Merck 
C20 D-(+)-glucose G7021 Sigma 
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abbreviation substance article number company 
C21 Glycerin 99% 11052 Grüssing GmbH 
C22 Goat serum S26-100ML Millipore 
(Chemicon®) 
C23 HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid) 
54457 Fluka 
C24 Hydrochloric acid min.37% 08-721 KMF 
C25 3-Isobutyl-1-methylxanthine 
(IBMX) 
2845 Tocris 
C26 Magnesium chloride, 
hexahydrate 
63072 Fluka 
C27 Magnesium sulphate, 
hexahydrate 
00627 Fluka 
C28 Manganese(II) chloride 
tetrahydrate 
T881.1 Roth 
C29 MK571 10029 Cayman / Biozol 
C30 Montelukast 10008318 Cayman / Biozol 
C31 MOPS, 4-
Morpholinepropanesulfonic 
acid 
1254 Sigma 
C32 Paraformaldehyde 0335.2 Roth 
C33 Pertussis toxin (PTX) 2980 Sigma 
C34 Poly-D-lysine hydrobromide P6407 Sigma 
C35 Potassium acetate 1.04820.1000 Merck 
C36 Potassium chloride 12008 Grüssing GmbH 
C37 Potassium dihydrogen 
phosphate 
1.04873.5000 Merck 
C38 Pranlukast 10008319 Cayman / Biozol 
C39 Propan-2-ol P-7507-15 Fisher Scientific 
C40 Prostaglandin E1 13010 Cayman / Biozol 
C41 Rubidium chloride R-2252 Sigma 
C42 Sodium acetate anhydrous 4555 Applichem 
C43 Sodium chloride 12123 Grüssing GmbH 
C44 Sodium dodecyl sulfate 
Pellets (SDS) 
CN30.0 Roth 
C45 Di-sodium hydrogen 
phosphate, anhydrous 
71640 Fluka 
C46 Sodium hydroxide 12156 Grüssing GmbH 
C47 D(+) sucrose 84105 Fluka 
C48 Sulfuric acid 95-97% 00731.2511 Merck 
C49 3,3’,5,5’-
Tetramethylbenzidine (TMB) 
T8665 Sigma 
C50 Tris A2264 AppliChem 
C51 Tris-HCl 90.90.3 Roth 
C52 Triton X-100 93420 Fluka 
C53 Tryptone A1553 AppliChem 
C54 Xylene cyanol X4126 Sigma 
C55 Yeast extract 2363.3 Roth 
C56 Zafirlukast 10008282 Cayman / Biozol 
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2.4 Chemicals not acquired by purchase 
Table 3 Chemicals not acquired by purchase 
substance function source/reference 
BIM-46187 (BIM) reported as G protein 
pan-inhibitor 
generous gift from 
Dr. Kaj Grandien, Sanofi Aventis 
(Ayoub et al. 2009) 
RA-II-150 GPR17 agonist synthesized by AK Müller, 
Pharmaceutical Chemistry, 
University of Bonn 
YM 254890 (YM) selective inhibitor of 
Gαq/11 
provided by Prof. Dr. G Milligan, 
Faculty of Biomedical & Life 
Sciences, University of Glasgow, 
within a collaborative effort 
(Taniguchi et al. 2003) 
2.5 Chemical structures of applied compounds 
2.5.1 Small molecule GPR17 agonist 
 
Figure 5 Chemical structure of RA-II-150 
(provided by AK Müller, Pharmaceutical Chemistry, University of Bonn) 
2.5.2 Potential GPR17 antagonists 
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Figure 6 Chemical structure of montelukast (C30, Cayman / Biozol) 
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Figure 7 Chemical structure of pranlukast (C38, Cayman / Biozol) 
 
 
Figure 8 Chemical structure of zafirlukast (C56, Cayman / Biozol) 
 
 
Figure 9 Chemical structure of MK571 (C29, Cayman / Biozol) 
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2.5.3 Pharmacological inhibitors 
 
 
 
Figure 10 Chemical structure of BIM-46187 (Ayoub et al. 2009) 
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Figure 11 Chemical structure of YM 254890 (Taniguchi et al. 2003) 
2.6 Buffer and solutions 
 
S1 Blotto (ELISA) 
 constituent amount  final concentration 
C13 Dry milk 1.5 g 3.0% 
C52 Triton X-100 50 µl 0.1% 
S22 Tris-HCl, 50 mM ad 50 ml - 
Prepare Blotto always freshly before use. Dry milk is added to Tris-HCl and triton X-100 only if cell 
permeabilization is required. 
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S2 2 M Calcium Chloride (calcium phosphate transfection) 
 constituent amount  final concentration 
C8 CaCl2 x 2H2O 14.7 g 2 M 
2.1 dH2O ad 50 ml - 
Sterilize via sterile filtration and store 10 ml aliquots at 2-8°C. 
 
S3 DNA Loading dye buffer 
 constituent amount  final concentration 
C7 Bromophenol blue 25 mg 0.25% 
C54 Xylene cyanol 25 mg 0.25% 
C47 Sucrose 4 g 4% 
2.1 dH2O ad 10 ml - 
Dissolve constituents in dH2O and store aliquots (1000 µl) at room temperature. 
 
S4 Doxycycline (1 mg/ml) 
 constituent amount  final concentration 
2.7.1 Doxycycline  1.0 mg 1 mg/ml 
2.1 dH2O ad 1.0 ml - 
Dissolve 1 mg doxycycline in 1 ml dH2O. Store at -20°C. 
Note: Final receptor expression induction concentration: 1 µg/ml 
 
S5 0.25 M / 0.5 M EDTA (pH 8.0) 
 constituent amount  final concentration 
C14 EDTA  93.05 g / 186.1 g 0.25M / 0.5M 
2.1 dH2O ad 1000 ml - 
C46 NaOH q.s. - 
Adjust pH to 8.0 with NaOH (~20 g of NaOH pellets). EDTA will dissolve at pH 8.0. Correct volume to 
1000 ml with dH2O. Sterilize by autoclaving and store at room temperature. 
 
S6 Ethanol (70%) 
 constituent amount  final concentration 
C16 Ethanol absolute (96%) 730 ml 70% 
2.1 dH2O ad 1000 ml - 
Store at RT. 
 
2 Materials  
 
25
S7 FIAU (1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-iodouracil, 0.2 mM) 
 constituent amount  final concentration 
2.7.1 FIAU 1.0 mg 0.2 mM 
2.7.1 UltraPureTM Distilled water ad 13.4 ml - 
Dissolve FIAU in cell culture grade water (UltraPureTM Distilled water) and sterilize via sterile 
filtration. Store aliquots (500 µl) at -20°C. 
 
S8 Gelatin solution (ES cell cultivation) 
 constituent amount  final concentration 
C18 Gelatin 2.0 g 1.0% 
2.7.1 UltraPureTM Distilled water ad 200 ml - 
Dissolve gelatin in cell culture grade water (UltraPureTM Distilled water). After autoclaved once, 
autoclave for a second time on the following day. Store stock solution at 4-8°C and freshly prepare 
working dilution (0.1% in UltraPureTM Distilled water). 
 
S9 Goat serum blocking solution (immunofluorescence) 
 constituent amount  final concentration 
C22 Goat serum 1.0 ml .0 
C3 BSA 100 mg 1% 
C52 Triton X-100 50 µl 0.5% 
S15 PBS ad 10 ml - 
Prepare blocking solution always freshly before use. Goat serum and BSA are added to PBS and triton 
X-100 only if cell permeabilization is required. 
 
S10 2X HBS (calcium phosphate transfection) 
 constituent amount  final concentration 
C23 HEPES 5.95 g 50 mM 
C43 NaCl 8.18 g 280 mM 
C45 Na2HPO4 0.133 g 1.5 mM 
2.1 dH2O ad 500 ml - 
Dissolve all constituents in 500 ml dH2O. Sterilize via sterile filtration and store 50 ml aliquots at -
20°C. 
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S11 10X HBS (ES cell electroporation) 
 constituent amount  final concentration 
C20 D-Glucose 2.0 g 1.0% 
C23 HEPES 10.0 g 20 mM 
C36 KCl 0.74 g 50 mM 
C43 NaCl 16.0 g 280 mM 
C45 Na2HPO4 0.252 g 1.5 mM 
2.7.1 UltraPureTM Distilled water ad 200 ml - 
Dissolve all constituents in 180 ml UltraPureTM Distilled water and adjust pH to 7.2. Bring up to 
200 ml and sterilize via sterile filtration. Store at -20°C. To prepare 1xHBS dilute with UltraPureTM 
Distilled water (1:10) to reach a pH of 7.05. 
 
S12 1 M HEPES 
 constituent amount  final concentration 
C23 HEPES 23.8 g 1 M 
2.1 dH2O ad 10 ml - 
C46 NaOH q.s. - 
Adjust pH to 7.2 with NaOH. Sterilize via sterile filtration and store 10 ml aliquots at -20°C. 
 
S13 Lysis buffer (DNA isolation from murine stem cells) 
 constituent amount  final concentration 
S22 1 M Tris-HCl 10 ml 0.1 M 
S5 0.25 M EDTA 2 ml 0.025 M 
S19 10% SDS 2 ml 1.0% 
S18 1 M NaCl 20 ml 0.1 M 
2.1 dH2O ad 100 ml - 
Dissolve all constituents in 80 ml dH2O and adjust pH to 7.2 with NaOH (C46). Bring up to 100 ml and 
sterilize via sterile filtration and store 10 ml aliquots at -20°C. 
 
S14 Paraformaldehyde solution (fixation solution for ELISA and immunofluorescence) 
 constituent amount  final concentration 
C32 paraformaldehyde 8.0 g 4.0% 
S15 PBS ad 200 ml - 
C46 NaOH q.s. - 
Add paraformaldehyde in 100 ml PBS (S15) and heat up to 60°C under a safety cabinet. Add NaOH to 
the white suspension and wait short period of time to dissolve the PFA. If solution does not clear add 
more NaOH and wait again. Repeat this procedure until solution is clear. Bring up to a total volume of 
200 ml and store 10 ml aliquots at -20°C. 
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S15 Phosphate buffered saline (1X PBS)  
 constituent amount  final concentration 
C36 KCl 0.2 g 2.7 mM 
C37 KH2PO4 0.2 g 1.76 mM 
C43 NaCl 8.0 g 137 mM 
C45 Na2HPO4 1.44 g 10.0 mM 
2.1 dH2O ad 1000 ml - 
C24 HCl q.s. - 
Dissolve all constituents in 980 ml dH2O and adjust pH to 7.4 with HCl. Correct volume with dH2O up 
to 1000 ml. Sterilize by autoclaving. Store at RT. 
 
S16 Poly-D-lysine solution (fixation solution for cell culture) 
 constituent amount  final concentration 
C34 Poly-D-lysine 5.0 mg 0.1 mg / ml 
2.1 dH2O ad 50 ml - 
Dissolve poly-D-lysine (PDL) in 50.0 ml dH2O. Sterilize via sterile filtration and store at 2-8°C. 
 
S17 3 M Sodium acetate (precipitation of linearized plasmid DNA) 
 constituent amount  final concentration 
C42 Sodium acetate anhydrous 2.46 g 3 M 
2.1 dH2O ad 10 ml - 
Dissolve sodium acetate in 8.0 ml dH2O and adjust pH up to 5.1 with glacial acetic acid (C19). Sterilize 
via sterile filtration and store at RT. 
 
S18 1 M Sodium chloride (NaCl) 
 constituent amount  final concentration 
C43 NaCl 5.85 g 1 M 
2.1 dH2O ad 100 ml - 
Dissolve NaCl in dH2O. Store at RT. 
 
S19 10% Sodium dodecyl sulphate (SDS) 
 constituent amount  final concentration 
C44 SDS 10.00 g 10.0% 
2.1 dH2O ad 100 ml - 
Dissolve SDS in dH2O. Store at RT. 
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S20 TE buffer (calcium phosphate transfection) 
 constituent amount  final concentration 
C51 Tris-HCl 0.61 g 10 mM 
C14 EDTA 0.19 g 1 mM 
2.1 dH2O ad 500 ml - 
Dissolve constituents in dH2O and sterilize via sterile filtration. Store aliquots of 50 ml at -20°C. 
 
S21 Tris-Acetate-EDTA (50X TAE-buffer) 
 constituent amount  final concentration 
C50 Tris 242 g 2 M 
C19 Glacial acetic acid 57.1 ml 5.71% 
S5 0.5 M EDTA (pH 8.0) 100 ml 0.05 M 
2.1 dH2O ad 1000 ml - 
Mix Tris base with stir bar to dissolve in about 600 ml of dH2O. Add EDTA and glacial acetic acid and 
bring up to a final volume of 1000 ml with dH2O. Store at RT. 
Note: Final (1x) working concentration: 0.04 M Tris-acetate and 0.001 M EDTA 
 
S22 50 mM / 1 M Tris-HCl  
 constituent amount  final concentration 
C50 Tris 0.605 g / 12.11 g 50 mM / 1 M 
2.1 dH2O ad 100 ml - 
C24 HCl (37%) q.s. - 
Dissolve Tris in 80 ml dH2O and adjust pH with HCl up to 7.4. Store at RT. 
2.7 Media and solutions for cell culture 
2.7.1 Buffer, media and supplements 
Table 4 Cell culture buffer, media and supplements 
name article number source 
Blasticidin ant-bl-1 InvivoGen 
Dulbecco’s Modified Eagle Medium (DMEM) 41965 Gibco/Invitrogen™ 
Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) 
21331 Gibco/Invitrogen™ 
Doxycycline hyclate D9891 Sigma 
ES cell qualified fetal bovine serum (Mexiko) 10439024 Gibco/InvitrogenTM 
ESGRO® (107 Units) LIF= leukemia inhibitory factor ESG1107 Chemicon® 
FIAU 1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-
iodouracil 
M251 Moravek Biochemicals 
G418, liquid (Geneticin, 100mg/ml) Ant-gn-5 InvivoGen 
Hank’s balanced salt solution (HBSS) 14025050 Gibco/InvitrogenTM 
Hygromycin B, liquid 10687010 Gibco/InvitrogenTM 
2 Materials  
 
29
name article number source 
L-Glutamine, 200 mM, liquid 25030 Gibco/InvitrogenTM 
2-Mercaptoethanol, 50 mM 31350010 Gibco/InvitrogenTM 
Minimum Essential Medium (MEM) 31095029 Gibco/InvitrogenTM 
MEM Non Essential Amino Acids Solution 11140035 Gibco/InvitrogenTM 
Nutrient Mixture Kaighn’s Modification 
(F-12K) 
21127022 Gibco/InvitrogenTM 
Penicillin-Streptomycin solution 15140130 Gibco/InvitrogenTM 
RPMI 1640 21875034 Gibco/InvitrogenTM 
Sera Plus special processed FBS 3702-P290616 PANTM Biotech GmbH 
Sodium pyruvate, 100 mM, liquid 11360 Gibco/InvitrogenTM 
Trypsin / EDTA (0.05%/0.02%) P10-02318P PANTM Biotech GmbH 
Trypsin, 0.25% (1x) with EDTA 4 Na, liquid 25200 Gibco/InvitrogenTM 
UltraPureTM Distilled water 10977 Gibco/Invitrogen™ 
ZeocinTM R25001 Invitrogen 
 
2.7.2 Cell specific culture Media 
Table 5 CHO-K1 cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12) 
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Split ratio: 1:5 to 1:20 every 2-5 days 
 
Table 6 CHO-FITR-GPR17 cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12) 
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Blasticidin 1.7 30 µg/ml 
Hygromycin 2.75 500 µg/ml 
Split ratio: 1:5 to 1:20 every 2-5 days 
The Flp-In T-Rex (FITR) system allows the generation of stable mammalian cell lines exhibiting 
tetracycline-inducible expression of a gene of interest from a specific genomic location. GPR17 
expression is induced by addition of doxycycline (S4, final induction concentration: 1 µg/ml) into the 
culture medium for 14-20 h. 
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Table 7 COS-7 cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Split ratio: 1:3 to 1:10 every 2-4 days 
 
Table 8 HaCat cell culture medium 
constituent volume [ml] final concentration 
RPMI 1640  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Split ratio: 1:2 to 1:10 every 2-5 days (0.25% trypsin needed) 
 
Table 9 HEK293 cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Split ratio: 1:3 to 1:20 every 2-4 days 
 
Table 10 HEK-GFP2-β-arrestin2 cell culture medium (HEK-BRET) 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
G418 2.5 2.2 mg/ml 
Split ratio: 1:2 to 1:20 every 2-4 days 
 
2 Materials  
 
31
Table 11 HEK-3xHA-GPR17 / HEK-3xHA-GPR17-RLuc cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Zeomycin 0.31 56 µg/ml 
Split ratio: 1:2 to 1:20 every 2-4 days 
 
Table 12 HEK-GFP2-β-arrestin2-3xHA-GPR17-Rluc (HEK-BRET-GPR17) 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
G418 2.5 2.2 mg/ml 
Zeomycin 0.31 56 µg/ml 
Split ratio: 1:2 to 1:20 every 2-4 days 
 
Table 13 Jurkat cell culture medium 
constituent volume [ml] final concentration 
RPMI 1640  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Sodium pyruvate 5 2 mM 
Split ratio: 1:2 to 1:3 every 2-3 days 
 
Table 14 PC-3 cell culture medium 
constituent volume [ml] final concentration 
Nutrient Mixture Kaighn’s Modification 
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Split ratio: 1:3 to 1:10 every 3-5 days 
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Table 15 SK-N-MC cell culture medium 
constituent volume [ml] final concentration 
Minimum Essential Medium (MEM) 
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Sodium pyruvate 5 2 mM 
Split ratio: 1:3 to 1:6 every 3-5 days 
 
Table 16 U2OS cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM)  
500  
Fetal calf serum (FCS) 50 ~10% 
Penicillin-Streptomycin  5 ~100 U/ml Penicillin, 
0.1 mg/ml Streptomycin 
Sodium pyruvate 5 2 mM 
MEM non-essential amino acids solution 5 0.1 mM 
Split ratio: 1:3 to 1:6 every 2-4 days 
2.8 Characteristics of analyzed cell lines 
Table 17 Cell lines used in the present work 
name characteristics reference number 
A431 Human epidermoid carcinoma 
Adherent epithelial cells 
CRL-1555 
ACHN Human renal adenocarcinoma 
Adherent epithelial cells 
CRL-1611 
CHO-GPR17 Chinese hamster ovary 
Stable, inducible GPR17 expression cell line 
based on Flp-InTM T-RexTM system 
Generously provided by 
A. Spinrath (AK Kostenis) 
CHO-K1 Chinese hamster ovary 
Adherent epithelial cells 
CCL-61 
COS-7 Green African Monkey kidney  
Adherent fibroblastoid cells 
CRL-1651 
DU-145 Human prostate carcinoma derived 
from brain metastasis 
Adherent epithelial cells 
HTB-81 
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name characteristics reference number 
Hacat Human keratinocytes 
Adherent epithelial cells 
CCL-228 
HEL-299 Human lung 
Adherent fibroblastoid cells 
CCL 137 
HEK293 Human embryonic kidney 
Adherent fibroblastoid cells  
CRL-1573 
HFF-1 Human skin / foreskin 
Adherent fibroblastoid cells 
SCRC-1041 
HUVEC-2 Human umbilical cord 
Adherent epithelial cells 
354151 
Jurkat Human T cell leukemia 
Suspension lymphoblastoid cells 
CRL-2063 
Keratinocytes Human primary skin cells kindly provided by Ralf 
Schröder (AK Kostenis) 
Neutrophils Human primary suspension cells kindly provided by Stefanie 
Blättermann (AK Kostenis) 
NHI 3T3L1 Murine embryonic cells 
Adherent fibroblastoid cells 
CL-173 
PC-3 Human prostate adenocarcinoma 
Adherent epithelial cells 
CRL-1435 
RMS13 Human muscle rhabdomyosarcoma 
Adherent fibroblastoid cells 
CRL-2061 
SW-620 Human lymph node colorectal 
adenocarcinoma 
Adherent epithelial cells 
CCL-227 
SW-872 Human liposarcoma 
Adherent fibroblastoid cells 
HTB-92 
U2OS Human bone osteosarcoma 
Adherent epithelial cells 
HTB-96 
U-87MG Human glioblastoma/astrocytoma 
Adherent epithelial cells 
HTB-14 
UMR-106 Rat bone osteosarcoma 
Adherent epithelial cells 
CRL-1661 
 
2 Materials  
 
34
2.9 Media and solutions for bacteria culture 
2.9.1 Generation of rubidium chloride competent bacteria 
 
RB1 Rubidium chloride solution 1 
 constituent amount  final concentration 
C35 KAc 0.088 g 30 mM 
C28 MnCl2 x 4 H2O 0.297 g 50 mM 
C41 RbCl 0.363 g 100 mM 
C8 CaCl2 x 2 H2O 0.044 g 10 mM 
C21 Glycerin 4.5 ml 15.0% 
2.1 dH2O ad 30 ml - 
Adjust pH to 5.8 with HCl (C24). Sterilize via sterile filtration and store at RT. 
 
RB2 Rubidium chloride solution 2 
 constituent amount  final concentration 
C41 RbCl 0.012 g 10 mM 
C8 CaCl2 x 2 H2O 0.110 g 75 mM 
C31 MOPS 0.021 g 10 mM 
C21 Glycerin 1.5 ml 15.0% 
2.1 dH2O ad 10 ml - 
Adjust pH to 6.8 with HCl (C24). Sterilize via sterile filtration and store at RT. 
 
RB3 1 M MgCl2 
 constituent amount  final concentration 
C26 MgCl2 x 6 H2O 2.033 g 1 M 
2.1 dH2O ad 10 ml - 
Sterilize by autoclaving. Store at 2-8°C 
 
RB4 1 M MgSO4 
 constituent amount  final concentration 
C27 MgSO4 x 6 H2O 2.285 g 1 M 
2.1 dH2O ad 10 ml - 
Sterilize by autoclaving. Store at 2-8°C 
 
2 Materials  
 
35
RB5 Super optimal broth (SOB medium) 
 constituent amount  final concentration 
C53 Tryptone 6.0 g 2.0% 
C55 Yeast extract 1.5 g 0.5% 
C43 NaCl 0.175 g 10 mM 
C36 KCl 0.055 g 2.5 mM 
RB3 1 M MgCl2 3.0 ml 10 mM 
RB4 1 M MgSO4 3.0 ml 10 mM 
2.1 dH2O ad 300 ml - 
Dissolve tryptone, yeast extract, NaCl and KCl in Milli-Q water and sterilize by autoclaving. Store at 2-
8°C. Add MgCl2 and MgSO4 solutions directly before use. 
2.9.2  Transformation and cultivation 
 
T1 1000 x Ampicillin 
 constituent amount  final concentration 
C4 Ampicillin 1.0 g 0.1 µg/µl 
2.1 dH2O ad 10 ml - 
Sterilize via sterile filtration and store 1 ml aliquots at -20°C. 
 
T2 LB agar (Luria Bertani agar) 
 constituent amount  final concentration 
C53 Tryptone 10 g 1.0% 
C55 Yeast extract 5 g 0.5% 
C43 NaCl 10 g 1.0% 
C1 Agar 15 g 1.5% 
2.1 dH2O ad 1000 ml - 
C46 NaOH q.s.  
Dissolve tryptone, yeast extract and NaCl in 800 ml in Milli-Q water and adjust pH to 7.5 with NaOH. 
Add agar into solution in a microwave and adjust volume to 1000 ml with Milli-Q water. Sterilize by 
autoclaving 
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T3 LB medium (Luria Bertani medium) 
 constituent amount  final concentration 
C53 Tryptone 10 g 1.0% 
C55 Yeast extract 5 g 0.5% 
C43 NaCl 10 g 1.0% 
2.1 dH2O ad 1000 ml - 
C46 NaOH q.s.  
The LB-medium according to Luria Bertani is a complex or undefined medium. The exact composition 
is not known, as its constituents are for itself complex mixtures. Tryptone provides mainly amino 
acids and small peptides, whereas yeast extract contains nitrogen, sugar as well as organic and 
anorganic nutrients. Additionally sodium chloride is added. 
Adjust the pH to 7.4 with NaOH and fill it up to 1000 ml with Milli-Q water. Sterilize by autoclaving. 
 
T4 S.O.C. medium (Invitrogen
TM
 #15544.034) 
 2% tryptone 
0.5% yeast extract 
10 mM sodium chloride 
2.5 mM potassium chloride 
10 mM magnesium chloride 
10 mM magnesium sulfate 
20 mM glucose 
 
2.10 Bacterial strains 
Table 18 Bacterial strains employed in the present work 
name function company 
NEB 10-beta Competent E. 
coli 
Chemically competent E. coli 
cells suitable for high 
efficiency transformation 
(targeting vector) 
New England BioLabs 
# C3019I 
XL1-Blue Competent Cells Host strain for routine 
cloning applications using 
plasmids 
Agilent Technologies 
#200249 
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2.11 Consumables 
Table 19 Consumables 
consumable article number source 
cAMP assay plate 
(low volume, 384 well) 
784080 Greiner 
Cell culture flasks  
25 / 75 / 175 cm2, TC 
430168 / 430729 / 431079 Corning 
Centrifuge tubes 
15 ml / 50 ml 
430791 / 430829 Corning 
Combitips plus 
2.5 / 5.0 / 10.0 / 25.0 ml 
0030 069. 447/455/463/390 Eppendorf 
Costar® 6 / 12 / 24 / 48 well 
clear TC-treated multiple well 
plates 
3506 / 3512 / 3527 / 3548 Corning 
Cryogenic vials (2.0ml) 5000-1020 Nalgene® 
Thermo Fisher Scientific 
Culture dishes  
21 / 55cm2, TC 
430166 / 430167 Corning 
Disposable filter unit 0.2 µl FB30/0.2 CA-s Whatman® 
ELISA microplate (96 well) 9017 Corning 
Epic compound plate 
(384 well) 
3657 Corning 
Filter tips SSNC 
10 / 20 / 200 / 1000 µl 
B95012 / B95020 / B 90222 / 
B95210 
Bioplastics BV 
Gene Pulser® cuvette 0.4 cm 
electrode 
165-2088 Bio-Rad 
Immunofluorescence 
microplate (96well) 
6005050 Perkin Elmer® 
Incubation tube, PP 294718727 Labomedic 
Microtubes snap-lock   
1.5 ml 115105 Labomedic 
2.0 ml 115106 Labomedic 
ParafilmTM 1447011 Labomedic 
Pasteur pipettes, glass 447016 Labomedic 
Pasteur pipettes, PP, sterile 297804239 Labomedic 
PCR tubes, 200 µl 0030 124.332 Eppendorf 
Pipette tips   
Oxygen crystal tips 10 µl 110727 Labomedic 
Yellow 200 µl tips 70.760.002 Sarstedt 
Blue 1000 µl tips 686290 Greiner bio-one 
Ritips professional  
0.1 / 0.5 ml 
40007 – 0000 / 0003 Ritter GmbH 
Reagent reservoirs 4870 Corning 
Stripette® serological 
pipettes,  
2 / 5 / 10 / 25 / 50 ml 
4486 – 4490 Corning 
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2.12 Enzymes and molecular weight markers 
Table 20 Molecular biology enzymes and molecular weight markers 
enzyme product number manufacturer 
Antarctic Phosphatase M0289S NEB 
BamHI R0136S NEB 
EcoRI R0101S NEB 
GoTaq Flexi DNA Polymerase M8305 Promega 
HindIII R0104S NEB 
10xLong PCR buffer with 
MgCl2 
Out of K0201 Fermentas 
NcoI R0193S NEB 
NheI R0131S NEB 
NotI R0189S NEB 
1 kb DNA Ladder N3232 NEB 
100 bp DNA Ladder N3231 NEB 
Pfu DNA Polymerase M7741 Promega 
Proteinase K 82560 Fluka 
PstI R0140S NEB 
SacI R0156S NEB 
SalI R0138S NEB 
StuI R0187S NEB 
T4 DNA Ligase M0202S NEB 
XbaI R0145S NEB 
XhoI R0146S NEB 
2.13 Molecular and cellular biological Kits 
Table 21 Kits applied in this work 
abbreviation Kit article number company 
K1 QIAquick® Gel Extraction Kit 28706 QIAGEN GmbH 
K2 QIAprep® Spin Miniprep Kit 27106 QIAGEN GmbH 
K3 NucleoBond® Xtra Maxi 740414.50 Macherey-Nagel 
K4 cAMP dynamic 2 HTRF® 
assay kit 
62AM4PEC Cisbio Bioassays 
K5 IP-One HTRF® assay kit 62P1APEB Cisbio Bioassays 
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2.14 Oligonucleotides 
All applied oligonucleotide primers were synthesized by Invitrogen/Illumina collaboration. The 
deoxynucleotides were reconstituted in UltraPureTM Distilled water to obtain 100 µM stock solutions.  
2.14.1 Cloning primers 
abbreviation sequence (5’-3’) function 
PC1 GAAGGATCCCGGAGTGCCTGACTTGTGGT short arm BamHI forward 
(TV) 
PC2 CAAGAATTCGTTCTTACTTTTGAGAATTA short arm EcoRI reverse (TV) 
PC3 GAATTGCGGCCGCGAGCATGTGGGGTATCCG long arm NotI forward (TV) 
PC4 GAATTCTCGAGCACCGTTCAGTCTATGTG long arm XhoI reverse (TV) 
PC5 CTGAAGCTTATGAATGGCCTTGAA hGPR17 HindIII forward 
PC6 CTTCTCGAGTCACAGCTCTGACTT hGPR17 XhoI reverse 
PC7 GAAGCTAGCGACTCTAGAATGTAC 3xHA-tag NheI forward 
PC8 CACTTCAAGGCCATTGTTTTGCTGACTCGA 3xHA-tag hGPR17 reverse 
2.14.2 Sequencing primers (targeting vector) 
abbreviation sequence (5’ to 3’) function 
PS1 AACCCTCACTAAAGGGAACA long arm forward 1 
PS2 TCAGCCACCATCTGAAGCTT long arm reverse 1 
PS3 TACCGCCCAGACTTTGCTTA long arm forward 2 
PS4 ATTCGCCAACTTAAAACTCC long arm reverse 2 
PS5 CTTTGGGGGACAGAAGCTT long arm forward 3 
PS6 AGCATGTGGTGACCGCTCTA long arm reverse 3 
PS7 CCTTCATCTTAAGACTCAGT long arm forward 4 
PS8 GCCTTGGGAAAAGCGCCTCC long arm reverse 4 
PS9 CTTCATTCTCAGTATTGTTT short arm forward 1 
PS10 GCAAGCCAACACTAAAAGAC short arm reverse 1 
PS11 AAACGACTCCCCATAGGTC short arm forward 2 
PS12 AAGCGCATGCTCCAGACTGC short arm reverse 2 
2.14.3 Screening primers (homologous recombination) 
abbreviation sequence (5’ to 3’) function 
PScr1 CGGAACTTCTCAGCCACAA long arm forward 1st 
PScr2 ACCCTGTCAAGTCCCTCAAG wild type reverse 1st 
PScr3 TCCATCTTGTTCAATGGCCG knock-out reverse 1st 
PScr4 TCAAGAGACCGGGTGCAGGTG outside of homologous 
regions forward 
PScr5 CAGCTCATTCCTCCCACTCATGAT neomycin resistance 
(knock-out) reverse 
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2.15 Antibodies 
Table 22 Employed antibodies in the present work 
abbreviation antibody article number source 
A1 Anti-HA (0.4 mg/ml) 
Mouse monoclonal antibody (clone 12CA5) to a 
peptide epitope derived from the haemagglutinin 
protein of human influenza virus 
11583816001 Roche 
A2 Anti-Mouse IgG (whole molecule) horse 
radish peroxidase antibody produced in 
goat (affinity isolated antibody) 
A4416 Sigma 
A3 Alexa Fluor 546 goat anti-mouse IgG 
(y2b), 2 mg/ml 
A 21143 InvitrogenTM 
 
2.16 Recombinant plasmid maps of hGPR17 
These plasmid maps represent hGPR17-expression plasmids, which were self-engineered during the 
present thesis. 
 
Figure 12 Self-constructed hGPR17 expression plasmid maps 
Plasmid maps were designed with the use of bioinformatic software Vector NTI 8. For detailed information 
about molecular biology procedures used to generate the plasmids see 3.3.3.2 and 3.3.4.2.1. 
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2.17 Vector plasmids 
Table 23 Vectors applied in the present work 
vector resistance/selection size [bp] promoter reference 
pcDNA3.1 
zeo (+) 
ampicillin/zeomycin 5015 CMV 
Phage T7 
SV40 
InvitrogenTM 
pPNT ampicillin/neomycin/ 
thymidine kinase 
7331 mPKG-1 
E. coli lac operon  
Phage T3  
(Thomas & 
Capecchi 1987) 
(Tybulewicz et al. 
1991) 
 
2.18 Laboratory instruments and equipment 
Table 24 Laboratory instruments and equipment 
function type company 
Autoclave Varioklav® H+P Labortechnik 
Balances TE64  
(precision balance) 
Sartorius 
 TE6101 Sartorius 
 BL310 Sartorius 
Centrifuges MiniSpin Eppendorf 
 Galaxy Mini VWR 
 Centrifuge 5810 Eppendorf 
CO2 incubator 
(cell culture) 
Heraeus®HERAcell® 240 Thermo Fisher 
Scientific 
Counting chamber Fuchs-Rosenthal Labomedic 
Dry block heater Thermomixer® comfort Eppendorf 
 QBT2 Grant Instruments 
Electronic pipet filler Easypet® Eppendorf 
Electrophoresis chambers Mini-Sub® cell GT BIO-RAD 
 Wide Mini-Sub® cell GT Bio-Rad 
Fluorescence microscope DM IL LED Fluo Leica 
camera DFC 360 FX Leica 
objectives HI PLAN I 10x/0.22 PH1 Leica 
 HI PLAN I 20x/0.30 PH1 Leica 
 HI PLAN I 40X/0.50 PH2 Leica 
Freezer (-80°C) Heraeus®Herafreeze® Thermo Fisher 
Scientific 
Freezer (liquid nitrogen) MVE 815P-190 Chart BioMedical 
Ltd. 
 System monitor MVETec 3000 Chart BioMedical 
Ltd. 
Microplate readers Mithras LB940 Multimode 
reader 
Berthold 
Technologies 
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function type company 
 Sunrise-Basic Tecan Austria GmbH 
Microscopes CKX31SF Olympus 
 Leica DM IL LED Fluo Leica 
Microwave Intello Wave LG 
Multichannel pipettes Genex Alpha 12 channel 
25-250 µl / 5-100 µl 
Genex Lab 
PCR cyclers GeneAmp® PCR System 9700 Applied Biosystems 
 2720 Thermal Cycler  
pH electrode InLab Sciences pro, Academia Mettler Toledo 
pH-meter SevenEasy™ Mettler Toledo 
Photo documentation systems De Vision DBOX Decon Sience Tec 
Pipettes 0.5-10 µl; 10-100 µl; 100-
1000 µl 
physiocare concept pipettes 
Eppendorf 
Power supplies (agarose gel 
electrophoresis) 
PowerPac HC™ BIO-Rad 
Safety cabinets HeraSafe HS12 Thermo Electron 
UV/VIS spectrophotometer SmartSpecTM Plus  BIO-RAD 
Vacuum pump system AP 15 Membrane Vacuum 
Pump 
HLC BioTech 
Vortex Reax Top Heidolph 
 
2.19 Software 
name company 
Application Suite 3.3.1 Leica 
DeVision G v1.0 Decon Science Tec GmbH 
Microplate Analyzer v1.5 modified for Excel 
2002 
Corning® Incorporated 
MikroWin2000 Berthold Technologies GmbH & Co. KG 
Office Excel 2007 Microsoft® Corporation 
Office Picture Manager Microsoft® Corporation 
Office PowerPoint® Microsoft® Corporation 
Office Word 2007 Microsoft® Corporation 
Prism® 4.02 GraphPad Software 
Vector NTI 8 InvitrogenTM 
XFluor4 Microsoft® Corporation/Tecan sunrise 
 
2.20 Manufacturer 
Agilent Technologies D-76337 Waldbronn 
Applichem D-64291 Darmstadt 
Applied Biosystems CA 92008, USA 
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Berthold technologies D-75323 Bad Wildbad 
Bioplastics BV 6374 XW Landgraaf, NL 
Bio Rad CA 94547, USA 
Biozol D-85386 Eching 
Cayman Chemical Company MI 48108, USA 
Chemicon® (Millipore) MA 01821, USA 
Cisbio Bioassays BP 84175, France 
Corning® Incorporated NY 14831, USA 
CyBio D-07745 Jena 
Decon Science Tec GmbH D-37318 Hohengandern 
Enzo Life Sciences PA 19462-1202, USA 
Eppendorf D-22339 Hamburg 
Fermentas D-68789 St. Leon-Rot 
Fisher Scientific Leicestershire LE11 5R6, UK 
Fluka D-21147 Hamburg 
Genex Lab Torquay TQ2 8JG, UK 
Gibco Paisley PA4 9RF, UK 
Gold Biotechnology MO 63132, USA 
GraphPad Software, Inc CA 92037, USA 
Greiner bio one 4550 Kremsmünster, Austria 
Grüssing GmbH Analytika D-26849 Filsum 
Heraeus D-63450 Hanau 
HLC BioTech D-37120 Bovenden 
Invitrogen™ D-64293 Darmstadt 
KMF Laborchemie Handels GmbH D-53785 Lohmar 
Labomedic GmbH D-53115 Bonn 
Leica D-35578 Wetzlar 
Merck D-64293 Darmstadt 
Mettler Toledo D-35353 Giessen 
Microsoft® Corporation D-85716 Unterschleißheim 
Moravek Biochemicals CA 92821, USA 
New England BioLabs® (NEB) MA 01938-2723, USA 
Olympus D-20097 Hamburg 
PerkinElmer Life Sciences MA 02451, USA 
Promega WI 53711, USA 
QIAGEN GmbH D-40724 Hilden 
Riedel-de Haen D-30926 Seelze 
Ritter GmbH D- 86830 Schwabmünchen 
Roth D-76231 Karlsruhe 
SAFC Supply Solutions MO 63103, USA 
Sarstedt D-51582 Nümbrecht 
Sartorius D-37075 Göttingen 
Sigma D-21147 Hamburg 
Thermo Fisher Scientific Germany Ltd. & Co. KG. D-53113 Bonn 
Tocris Bristol BS11 0QL, UK 
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3 Methods 
3.1 Methods in molecular biology 
3.1.1 Transformation of chemically competent bacteria 
The term transformation describes insertion of external DNA into host cells. Bacteria are transformed 
with plasmid DNA in order to increase its production along with the bacteria genome. Therefore host 
cells need to be prepared to enable permeation of DNA. This was done by chemical pretreatment 
with rubidium chloride and a subsequent heat shock. The transformation efficiency depends on 
plasmid size, since big plasmids are harder to transform than smaller ones. 
3.1.1.1 Preparation of rubidium chloride competent E.coli 
At first, a preparatory culture was arranged by inoculating 5 ml of SOB medium (RB5) with 5 µl of 
either XL-1 blue or NEB-10beta (Table 18). These suspensions were incubated over-night at 37°C and 
vigorously shaking (220 rpm). The following day 100 ml of SOB medium (RB5) were inoculated with 
1 ml of preparatory culture and grown at 37°C with 220 rpm. When the OD550 reached 0.5 (takes 
~2.5 hours), the cells were placed on ice for 10 min and then pelleted at 2800 g for 10 min in ice-cold 
50 ml tubes at 4°C. The supernatant was removed and the bacteria resuspended gently in 25 ml of 
ice-cold rubidium chloride solution 1 (RB1) followed by incubation on ice for 10 min. The bacteria 
were centrifuged again at 2800 g (4°C), and gently resuspended in 8 ml rubidium chloride solution 2 
(RB2). Finally, the bacteria were aliquoted (100 µl), immediately frozen in liquid nitrogen and stored 
at -80°C. 
3.1.1.2 Transformation by heat shock 
Aliquots (100 µl) of chemical competent bacteria, either XL-1 blue or NEB-10beta (Table 18), were 
thawed on ice (3-5 min). Approximately 50 ng of DNA were added and mixed gently by pipetting 
carefully up and down once. The bacteria were incubated for 30 min on ice, followed by a 30-60 
seconds heat-shock (42°C) in the water bath. Afterwards the suspensions were transferred onto ice 
again and left there for 2 min before 300 μl of room temperature SOC medium (T4) were added. The 
tubes were then put into the incubator (37°C), shaking (220 rpm) for 60 min, so that encoded 
antibiotic resistance could develop. Thereafter, various amounts (mostly 100 and 200 µl) from each 
transformation were spread on a prewarmed LB agar plates (T2) containing an appropriate antibiotic 
(mostly ampicillin, T1) for selection and incubated overnight at 37°C. 
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3.1.2 Isolation of plasmid DNA 
The isolation of plasmid DNA was performed with plasmid isolation kits (Table 21, K2, K3), which are 
based on the principle of basic lysis (Birnboim & Doly 1979). In a first step, bacteria are lysed by 
addition of NaOH and SDS, where DNA, RNA and proteins are precipitated by denaturation and the 
supplementation of RNAse-A degrades the RNA. The second step is neutralization with potassium 
acetate. The small renaturated plasmid DNA stays in solution, whereas the genomic bacterial DNA 
stays denaturated and remains, together with the proteins and other cellular components, 
precipitated and can be separated by centrifugation.  
The subsequent purification of plasmid DNA by phenol extraction is substituted by chromatographic 
purification. 
3.1.2.1 Analytical plasmid-isolation (mini-preparation) 
To analyze the plasmids for inserts by restriction analysis, the plasmid DNA was isolated on a small 
scale using QIAprep® Spin Miniprep Kit (Table 21, K2). Typically, 10 colonies were picked and cultured 
overnight in 8 ml of LB medium (T3) containing 100 μg/ml ampicillin (T1) at 37°C.  
The plasmid DNA isolation procedure: 2 ml of bacteria were pelleted, lysed and neutralized. The 
dispensable cell fragments were separated from the rest by centrifugation. The clarified supernatant 
contained plasmid DNA in an appropriate high-salt binding buffer and was centrifuged through a 
QIAprep® spin column where the DNA bound to the silica-gel membrane. Impurities were washed 
away, and pure DNA was eluted in a small volume of water.  
The remaining bacteria suspension was used to generate a glycerol stock (see 3.1.3). 
3.1.2.2 Preparative plasmid isolation (maxi-preparation) 
To obtain high-purity and high-concentration plasmid DNA for transfection experiments, the DNA 
was isolated on a larger scale using NucleoBond® Xtra Maxi (Macherey-Nagel, Table 21, K3) according 
to the manufacturer’s recommendations.  
For that purpose, 300 ml of LB medium (T3) containing 100 μg/ml ampicillin (T1) were inoculated 
with the bacteria harboring the appropriate plasmid, either one colony from the LB agar plate (see 
3.1.1.2) or bacteria culture left over from the mini preparation (see 3.1.2.1) or from a glycerol stock 
(see 3.1.3). The suspension was cultured overnight with vigorous shaking (220 rpm) at 37°C. The maxi 
preparation kit (Table 21, K3) works according to the same principle as the mini preparation kits, 
except that instead of silica-gel matrix the columns contain an anion exchanger matrix and the eluted 
DNA is precipitated with isopropanol (C39). Typical yield was ~0.3-1 mg. 
3.1.3 Cryoconservation of bacterial strains 
In order to have permanent stocks of bacterial strains that are harboring a desired plasmid, the 
respective bacteria were cryopreserved. 800 μl of bacterial suspension (see 3.1.2.1) were mixed with 
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200 µl of glycerin (C21) and stored at -80°C. For reactivation, a pipette tip was dipped into the 
glycerin culture and used to inoculate a LB-medium for preparative plasmid isolation (see 3.1.2.2). 
3.1.4 Determination of nucleic acid concentration 
Nucleic acid concentrations were determined photometrically by measurement of the optical density 
(OD) at a wavelength at 260 nm. Following equation was used for calculations:  
 [/ ] =       
c concentration 
OD260 Optical density at 260 nm 
D Dilution factor 
F Multiplication factor (for DNA 50) 
1 absorbance corresponds to 50 µg DNA per ml water 
The quotient of OD260/OD280 is a determinant of the purity and should be between 1.6 and 2.0 (in 
water), so that protein impurities can be disregarded.  
3.1.5 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a rapid procedure for in vitro enzymatic amplification of 
specific DNA sequences (Mullis & Faloona 1987). The discovery of a heat-stable bacterium Thermus 
aquaticus and its DNA polymerase (Taq polymerase) firstly enabled efficient polymerase chain 
reactions (Saiki et al. 1988). It is an enzyme with high efficiency through a fast DNA synthesis, but it 
causes a high error rate of approximately 1 × 10–5 errors per base (approximately one incorrectly 
integrated base per 10.000 nucleotides). Another utilized thermostable DNA polymerase is the Pfu 
polymerase, isolated from Thermococcus species. This polymerase shows lower rate of DNA 
synthesis in comparison to Taq polymerase, but offers 3’5’-exonuclease activity, which allows a 
correction of wrongly incorporated nucleotides (also referred to as proofreading). 
For routine screening PCR, where simple detection of an amplification product was important, GoTaq 
Flexi® DNA polymerase was chosen. Whereas, if the amplified product was to be cloned or expressed 
in eukaryotic cell systems, the Pfu DNA polymerase was applied, as this enzyme exhibits a lower error 
rate. If long fragments with high accuracy were to be amplified, a mixture of Pfu and Taq polymerase 
was applied. 
PCR reactions were performed in an automated thermal cycler (see 2.18).  
PCR products were electrophoresed on an agarose gel appropriate for the PCR product size expected 
(see 3.1.7), isolated and purified via agarose gel electrophoresis using Gel Extraction-Kit from Qiagen 
(Table 21, K1, see 3.1.8). 
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3.1.5.1 Amplification of human GPR17 
In order to amplify the sequence of human GPR17 (hGPR17, GenBank accession no. U33447), a 
plasmid vector (MSP70) containing the appropriate sequence was used, which was kindly provided 
by Andreas Spinrath (AK Kostenis, University of Bonn). The obtained PCR product was flanked by 
HindIII and XhoI restriction sites. 
Table 25 PCR reaction conditions of hGPR17 amplification 
PCR reaction mixture Temperature program 
1.0 µl template (MSP70)  Time Temperature 
1.0 µl "sense" primer, PC5, 100 µM  [min] [°C] 
1.0 µl "antisense" primer, PC6, 100 µM initial denaturation 
35 cycles of 
2:00 95 
 
5.0 µl 10x Pfu buffer (with MgSO4) denaturation 0:30 95 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 58 
0.5 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 2:30 72 
2.0 µl DMSO final extension 5:00 72 
38.5 μl  UltraPureTM Distilled water    
 
3.1.5.2 Amplification of 3xHA tagged hGPR17 
For amplification of 3xHA epitope tag of hGPR17, two PCR reactions were consecutively performed. 
The first reaction was made to amplify an oligonucleotide primer, which was necessary for the 
second reaction. The applied template was pcDNA3.1/Neo (+) vector containing the sequence of a 
3xHA-tagged GPCR (GPR55) that was already available in our group. 
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Table 26 PCR reaction conditions of 3xHA-hGPR17 primer amplification 
PCR reaction mixture Temperature program 
1.0 µl template (pcDNA3.1-3xHA-GPR55)  Time Temperature 
1.0 µl "sense" primer, PC7, 100 µM  [min] [°C] 
1.0 µl "antisense" primer, PC8, 100 µM initial denaturation 
35 cycles of 
2:00 95 
 
5.0 µl 10x Pfu buffer (with MgSO4) denaturation 0:30 95 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 55 
1.0 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 1:00 72 
2.0 µl DMSO final extension 5:00 72 
38.0 μl  UltraPureTM Distilled water    
The second amplification was performed to obtain the 3xHA epitope tagged hGPR17, flanked by NheI 
(5’) and XhoI (3’) restriction sites. 
Table 27 PCR reaction conditions of 3xHA-hGPR17 amplification 
PCR reaction mixture Temperature program 
1.0 µl template (pcDNA3.1-hGPR17)  Time Temperature 
1.0 µl "sense" primer, PCR product  [min] [°C] 
1.0 µl "antisense" primer, PC6, 100 µM initial denaturation 
35 cycles of 
2:00 95 
 
5.0 µl 10x Pfu buffer (with MgSO4) denaturation 1:00 95 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 60 
0.5 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 3:00 72 
2.0 µl DMSO final extension 5:00 72 
38.5 μl  UltraPureTM Distilled water    
 
3.1.5.3 Targeting vector 
The amplification of 5’ and 3’ homology regions of mouse GPR17 (mGPR17) gene (GenBank accession 
no NM_001025381) for generation of the targeting construct was performed in two PCR reactions 
with the use of genomic ES cell DNA derived from mouse strain Ola/SC129 as template, which was 
kindly provided by Daniel Schulz (AK Kostenis, University of Bonn).  
The amplification of short homologous 3’ region (short arm) was performed with the following 
conditions. Primers were designed to contain mGPR17 sequence flanked by artificial restriction 
enzyme sites (5’ BamHI and 3’ EcoRI). 
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Table 28 PCR reaction conditions of short arm amplification 
PCR reaction mixture Temperature program 
1.0 µl template (ES cell DNA)  Time Temperature 
1.0 µl "sense" primer, PC1, 100 µM  [min] [°C] 
1.0 µl "antisense" primer, PC2, 100 µM initial denaturation 
35 cycles of 
2:00 94 
 
5.0 µl 10x Long PCR buffer denaturation 0:30 94 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 55 
0.5 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 2:00 70 
0.5 µl Taq DNA Polymerase (5 U /µl) final extension 5:00 70 
2.0 µl DMSO    
38.0 μl  UltraPureTM Distilled water    
 
The amplification of long homologous 5’ GPR17 sequence (long arm) was performed with slightly 
varied PCR conditions (see Table 29). Primers were designed to contain GPR17 sequence flanked by 
artificial restriction enzyme sites (5’ NotI and 3’ XhoI). 
Table 29 PCR reaction conditions of long arm amplification 
PCR reaction mixture Temperature program 
1.0 µl template (ES cell DNA)  Time Temperature 
1.0 µl "sense" primer, PC3  [min] [°C] 
1.0 µl "antisense" primer, PC4, 100 µM initial denaturation 
35 cycles of 
2:00 94 
 
5.0 µl 10x Long PCR buffer denaturation 0:30 94 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 56 
0.25 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 6:00 70 
0.75 µl Taq DNA Polymerase (5 U /µl) final extension 10:0 70 
2.0 µl DMSO    
38.5 μl  UltraPureTM Distilled water    
 
3.1.5.4 Genotyping of genetically modified ES cells 
For the screening of recombination events in targeted ES cells, a PCR-based genotyping was 
designed, which distinguished between wild type and heterozygous modified GPR17 gene.  
Preliminary PCR screening was performed to check, whether targeting-construct was integrated, 
disregarding the fact, where recombination took place. The presence of wild type allele was proven 
3 Methods  
 
50
by an amplicon of 511bp, whereas the occurrence of heterozygous modification of GPR17 gene was 
shown by the appearance of a PCR product of 721bp. 
Table 30 PCR reaction conditions of preliminary screening of ES cell clones 
PCR reaction mixture Temperature program 
1.0 µl Isolated ES cell DNA   Time Temperature 
1.0 µl "sense" primer, PScr1, 100 µM  [min] [°C] 
1.0 µl "antisense" primer, PScr2-WT or 
PScr3-KO, 100 µM 
initial denaturation 
28 cycles of 
2:00 95 
 
5.0 µl 5x Taq buffer  denaturation 0:30 95 
2.0 µl MgCl2 hybridization 0:30 62 
1.0 µl dNTP-Mix, 2.5 mM each extension 0:30 72 
0.3 µl Taq DNA Polymerase (5 U /µl)    
1.0 µl DMSO final extension 6:00 72 
12.7 μl  UltraPureTM Distilled water    
 
A second PCR genotyping was performed with the ES cell DNA, which was formerly proven in the 
preliminary analyses to possess heterozygous modified GPR17 allele. This more specified PCR 
reaction was carried out to check whether the recombination was homologous, and targeting 
construct was integrated in the accurate location. The presence of targeted GPR17 allele was proven 
by an amplicon of 1832bp. 
Table 31 PCR reaction conditions of specified screening of ES cell clones 
PCR reaction mixture Temperature program 
1.0 µl Isolated ES cell DNA   Time Temperature 
1.0 µl "sense" primer, PScr4, 100 µM  [min] [°C] 
1.0 µl "antisense" primer, PScr5, 100 µM initial denaturation 
28 cycles of 
2:00 94 
 
5.0 µl 10x Long PCR buffer denaturation 0:30 94 
1.0 µl dNTP-Mix, 2.5 mM each hybridization 0:30 61 
0.2 µl Taq DNA Polymerase (5 U /µl)    
0.2 µl Pfu DNA Polymerase  
(2-3 U/μl) 
extension 3:00 70 
1.0 µl DMSO    
17.9 μl  UltraPureTM Distilled water final extension 6:00 70 
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3.1.6 Sequencing of cloned PCR products 
GATC Biotech AG, Konstanz, analyzed all PCR-derived products. Thus, the correct sequence and 
especially the absence of point mutations were ensured. 
3.1.7 Agarose gel electrophoresis 
Agarose gel electrophoresis is a simple and highly effective method for separating and purifying DNA 
fragments of different sizes (Vogelstein & Gillespie 1979). The molecules migrate through the 
agarose-matrix with varying speed, depending on their size and charge. The electrophoresis buffer 
(1xTAE, S21) enables the charge migration and due to its pH of 8, the DNA stays negatively charged. 
These anions migrate in the electric field to the positively charged anode. Smaller fragments travel 
faster than bigger ones through the network, because they do not interfere as much with the 
surrounding agarose gel matrix. 
The gels were made of 0.6 – 1.0 % agarose in 1xTAE (S21) supplemented with 0.5 μg/ml ethidium 
bromide (C16). With this method, fragments of 0.5–15 kb can be sufficiently separated. Prior to 
loading, the samples were supplemented with DNA gel loading buffer (S3). Dependent on the size of 
the gel and the fragments, the electrophoresis was performed at 50-120 V. The addition of ethidium 
bromide allows a visualization of DNA fragments under UV-light. Ethidium bromide intercalates with 
the DNA helix, which induces an intensification of the fluorescence properties. The DNA fragments 
appear in a red color through UV illumination (302 nm), whereas other parts of the gel stay dark. 
Banding patterns were photographically documented. For determination of fragments size, a DNA 
marker was always separated in parallel.  
3.1.8 DNA-elution from agarose gels 
DNA fragments were purified using Gel Extraction-Kit from Qiagen (Table 21, K1) following 
manufacturer’s instructions. 
In brief: the gel slice containing the band of interest was removed from the gel and this agarose slice 
was solubilized at 55°C for 10 min by mixing it with the appropriate high-salt binding buffer and then 
applied to the spin column where DNA binds to the silica gel membrane. Impurities were washed 
away, and pure DNA was eluted in a small volume of water (30-100 µl). 
3.1.9 Restriction endonuclease digestion  
3.1.9.1 Analytical restriction enzyme cleavage 
For analytical purposes, plasmids from mini preparations (see 3.1.2.1), were cut with restriction 
enzymes to identify positive clones with the correct insert. Approximately 500 ng of respective 
plasmid were digested in a mixture of 1 x appropriate restriction buffer, 1x BSA and 10 U of each 
restriction enzyme at 37°C for 1 h. The fragment pattern was visualized in a 1% agarose / ethidium 
bromide gel. Positive plasmids were sent to sequencing (see 3.1.6). 
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Restriction endonuclease cleavage was accomplished by incubating the enzyme(s) with the DNA in 
appropriate reaction conditions. The amounts of enzyme and DNA, the buffer and ionic 
concentrations, and the temperature and duration of the reaction were adjusted to the specific 
application according to the manufacturer´s recommendations. 
3.1.9.2 Preparative restriction enzyme cleavage 
For preparative purposes, respective vector DNA (pcDNA 3.1 / pPNT) and PCR products were cut with 
similar restriction enzymes to obtain compatible, sticky ends. PCRs were prepared (see 3.1.5) and 
PCR products were isolated from agarose gels (see 3.1.8). Afterwards, fragments and linearized 
vector were digested in a mixture of 1 x appropriate restriction buffer, 1x BSA and 10 U of each 
restriction enzyme at 37°C for 1h. Subsequently, fragments or vector were purified again with an 
agarose / ethidium bromide gel. These obtained digested products were used for further ligations 
(see 3.1.12). 
3.1.9.3 Linearization of plasmids for stable transfection 
In order to prepare plasmid DNA for stable transfection of eukaryotic cells (see 3.2.6.2), the DNA was 
linearized in advance. Approximately 50 µg of plasmid DNA were cleaved with 50 U of restriction 
enzyme (PvuI for pcDNA3.1 / NotI for pPNT) in a mixture of 1 x appropriate restriction buffer and 1 x 
BSA for 3 h at 37°C. 
3.1.10 Precipitation of plasmid DNA 
This method was applied to precipitate linearized plasmid DNA out of the reaction mixture (see 
3.1.9.3). The digested DNA was mixed with 1/10 volume of sterile sodium acetate (S17, 3M, pH 5.1) 
and precipitated by addition of the double volume of absolute ethanol (C15). DNA was pelleted for 5 
min at 13000 rpm and supernatant was discarded. The pellet was washed with 500 µl ethanol (S6, 
70%) and centrifuged once more for 5 min at 13000 rpm. The supernatant was decanted and after 
the DNA pellet was dried under a safety cabinet, it was dissolved in 100 µl of UltraPureTM distilled 
water. 
3.1.11 Dephosphorylation of cleaved vector DNA 
In this work the Antarctic Phosphatase was applied to catalyze the removal of 5´ phosphate groups 
from restriction enzyme digested vector DNA prior to ligation reactions. Phosphatase-treated 
fragments lack the 5´ phosphoryl termini required by ligases, so that the effect self-ligation is 
diminished. The digested vector DNA (~2 µg) was incubated in a mixture of 1x Antarctic Phosphatase 
reaction buffer and 5 U of Antarctic Phosphatase at 37°C for 15 min. This reaction was heat-
inactivated at 65°C for 5 min. 
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3.1.12 Ligation of DNA fragments 
T4 DNA Ligase catalyzes the formation of a phosphodiester bond between juxtaposed 5'-phosphate 
and 3'-hydroxyl termini in duplex DNA. Digested (see 3.1.9.2) and dephosphorylated (see 3.1.11) 
vector DNA (50-400 ng) and respective insert DNA were mixed, where up to 5-fold molar excess of 
insert DNA over vector DNA was used. This reaction mixture was supplemented with 10 X ligation 
buffer and UltraPureTM distilled water to a total volume of 10 μl and 2 U of T4 DNA Ligase. The 
mixture was incubated over-night at 16°C and then either used directly for transformation or stored 
at –20°C. 
3.2 Cell biological methods 
All cells were grown under the same culture requirements in cell incubators, which were set to 37°C 
with an atmosphere of 5% CO2 and 96% humidity. Applied cell culture solutions and media were 
prewarmed in a water bath (37°C). Every operation was carried out under aseptical conditions in 
safety cabinets with laminar air flow. 
3.2.1 Passaging cell lines 
Cells were splitted routinely at least twice a week (for detailed cell type specific information see 2.8). 
They were harvested either by trypsinization (adherent cell cultures) or by centrifugation at 800 g for 
4 min (suspension cell cultures). 
For trypsinization, the growth medium was removed from the flask and cells were washed carefully 
with prewarmed PBS (S15, 37°C) to remove remaining medium. Depending on the flask size, 0.5-3.0 
ml of prewarmed trypsin (37°C) were added to the flask and incubated at 37°C until cells have 
detached (1-5 min). Trypsinization was stopped by addition of respective growth medium (see2.7.2). 
Cells were resuspended in an appropriate volume and transferred into a new culture flask, which was 
already filled with growth medium (5-25 ml, depending on flask size). 
3.2.2 Cryopreservation of cell lines 
In order to have permanent stocks of the utilized cell lines, cells were expanded until they nearly 
reached confluence (80-95%), using 1-5 cell culture flasks (175 cm2). Cells were washed with PBS 
(S15, 37°C) to remove residual medium and then trypsinized with prewarmed trypsin (37°C) until 
they have detached (as brief exposure as possible). After resuspension in normal growth medium, 
cell suspensions were combined and centrifuged at 800 g (4 min). In the meantime freezing medium 
was freshly prepared by adding 20% FCS and 10% DMSO (C12) to the respective plain medium (see 
2.7.2). Addition of DMSO serves as an antifreezing agent. Subsequent to centrifugation growth 
medium was removed. After resuspending the pellet with freezing medium (4-8°C), aliquots of 1 ml 
cell suspension (3-5 x 106 adherent cells or 5-10 x 106 suspension cells) were transferred into labeled 
freezing vials and placed into a -80°C freezer. This allowed freezing of the cells at an approximate 
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rate of 1°C/min. The following day freezing vials were transferred into a liquid nitrogen tank for long-
term storage. One vial of frozen cell stocks was tested before discarding the cell line. 
3.2.3 Revitalization of cell lines 
For cell thawing after long-term storage, a vial of frozen cells was removed from the liquid nitrogen 
tank and rapidly unfrozen in a 37°C water bath. In order to remove the cell toxic DMSO from the 
freezing medium, the cell suspension was promptly transferred into a centrifuge tube containing 10 
ml of prewarmed growth medium (without antibiotics) and pelleted at 800 g. After 4 min of 
centrifugation, the supernatant was discarded; cells were resuspended in fresh growth medium 
(without antibiotics) and transferred into a culture flask. Cells were incubated overnight under their 
usual culture conditions, and the next day the medium was replaced by complete growth medium, 
including antibiotics. Usually cells were cultured at least for one week before they were used for 
further analyses. 
3.2.4 Counting cells with a hemocytometer 
The hemocytometer is a device, as the name suggests, originally used to count blood cells, whereas 
in this work the Fuchs-Rosenthal chamber was used to determine the number of respective cells, 
which were needed for further analyses. The hemocytometer consists of 2 chambers, which are 
divided into 9 squares (1 x 1 mm). The cover glass is situated 0.1 mm over these squares so that the 
total volume over each square is 0.1 mm3, which equals 1 ml. After cells were detached by 
trypsinization (see 3.2.1), a small amount of cell suspension was diluted (1:2 - 1:6) in PBS (S15) and 
placed onto the chamber. With the help of capillary forces, the chamber was completely filled with 
the sample. By use of a microscope, the number of cells was determined by manual counting. The 
cell concentration per ml is the average count per square times 104. Further dilutions were taken into 
account and usually cells were diluted, so that each square had between 20-60 cells.  
3.2.5 Coating cell culture dishes with poly-D-lysine 
In order to reduce cell detachment from shear stress in washing steps associated with cell labeling 
(see 3.3.4, 3.3.5) and to improve cell vitality, surfaces of cell culture dishes were pretreated with 
poly-D-lysine, which improves adhesive properties by altering the charge on the vessel surface from 
negative to positive and leads to a uniform net positive charge.  
Culture plate surfaces were completely covered with PDL solution (S16, 50 µl per well in a 96 well 
plate) and incubated at 37°C for 30 min. After the redundant PDL was aspirated, surfaces were 
thoroughly rinsed three times with PBS (S15) and then dried in the safety cabinet. These prepared 
plates were directly used or sealed with parafilm and kept at 2-8°C until further usage. 
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3.2.6 Transfection of eukaryotic cells 
The DNA transfer into eukaryotic cells can be divided into transient and stable transfections. While 
the transient method leads to a temporally limited DNA incorporation, stable transfection results in a 
permanently expression of the introduced gene, by integration of the plasmid DNA into the cell 
genome. The applied calcium phosphate transfection method according to Chen and Okayama (Chen 
& Okayama) was used for both kinds of transfection, stable and transient. This method is based on 
the formation of DNA/calcium phosphate coprecipitates, which first settle onto the cells and are then 
taken up by endocytosis. These precipitates should be formed freshly at the time of transfection. 
According to Orrantia and Chang (Orrantia & Chang 1990) it is thought that small DNA/calcium 
phosphate particles are taken up by endocytosis and transported to the nucleus, where some DNA 
escapes the precipitate and can be expressed. 
 
Figure 13 Diagram of transient and stable transfection of host cells with plasmid DNA 
Expression of the gene of interest can be achieved by integration of a plasmid vector containing the respective 
sequence of interest (here receptor) into a host cell (e.g. HEK293 cells): Initially, for transient transfection, the 
gene of interest has to be introduced into the cell. Finally, for a stable transfection the gene has to be 
integrated into genomic DNA. The transiently transfected DNA is not passed from generation to generation 
during cell division and therefore the genetic alteration is not permanent, whereas in a very low number of 
cases, the exogenous DNA randomly integrates into chromosomal DNA of the recipient, which allows the 
transfected DNA to be carried stably from generation to generation. The incorporation of selectable markers, 
such as antibiotic resistances (e.g. neomycin, blasticidin or hygromycin), allows selection for cells that have 
integrated this exogenous DNA into their genomic DNA. While transient transfection is useful for fast analyses 
of genes, stable transfection enables long-term, reproducible, and defined gene expression.  
3.2.6.1 Transient calcium phosphate–mediated transfection  
Cells (3.8 – 4.4 x 106) were seeded onto 60 cm2 tissue culture dishes one day prior to transfection, so 
that they were ~50-60% confluent at the time of transfection. Initially the plasmid DNA (20 µg) was 
carefully mixed with TE-buffer (S20, 500 µl) and CaCl2 (S2, 60 µl). The DNA/calcium phosphate 
precipitates were formed via drop-by-drop addition of this DNA/CaCl2 solution into round bottomed 
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falcon tubes prefilled with 2x HEPES-buffered saline (S10, 500 µl). Followed by incubation at room 
temperature for 20 min, the freshly formed precipitates were carefully pipetted drop-by-drop onto 
the dishes containing the adherent cultured cells and growth medium. The dishes were slewed 
carefully to achieve an even distribution. After the cells have been exposed to the precipitates for 
approximately 5 h in the incubator, the medium containing the transfection reagents was removed 
and fresh medium was added to prevent toxicity. Transiently transfected cell were usually analyzed 
48 h after transfection. 
3.2.6.2 Stable calcium phosphate–mediated transfection  
Stable transfections were performed according to the transient protocol mentioned above (see 
3.2.6.1) with some specific changes. First the plasmid DNA was linearized (see 3.1.9.3) prior to 
transfection to simplify its stable integration into the genome. 24 h after transfection cells were 
splitted (1:3 – 1:5) to avoid confluence and 48 h later medium was exchanged by medium containing 
selection antibiotics encoded on the transfected plasmids (see Table 23 for information about 
respective antibiotics). In this work only pooled clones were generated, meaning selective medium 
was exchanged every 2-3 days until every not stably transfected cell was dead and all surviving cells 
were combined to one pooled clone. These generated cells were always kept under selection 
pressure. 
By use of this method, five different HEK293 cell lines stably expressing human GPR17 were 
generated: 
• HEK-3xHA-hGPR17 
• HEK-3xHA-hGPR17-RLuc 
• HEK-β-ARR2-GFP2-3xHA-hGPR17-RLuc 
also referred to as HEK-BRET-GPR17  
(three distinct β-arrestin2 GFP2 expression levels: low, high and very high) 
3.3 Cell-based experiments 
In order to elucidate receptor function, selective and efficacious pharmacological tool ligands are 
required. As for the orphan GPR17 receptor neither endogenous ligands nor other pharmacological 
tools are available, our selective GPR17 agonist RA-II-150 was used for further functional 
investigations. 
3.3.1 Dynamic mass redistribution assays 
Conventional assay technologies applied for analyses of GPCR mediated signaling are mainly based 
on the use of dyes, antibodies or fusion gene constructs, which may influence the actual cellular 
physiology of the receptor. In addition they are usually focused on one specific cellular event, ranging 
from second messenger generation (e.g. cAMP, IP1) to the translocation of a particular target labeled 
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with a fluorescent tag (e.g. β-arrestin) or expression of a reporter gene. Furthermore, many of these 
traditional assays are end point assays, so that a sustained monitoring of cell signaling is not possible.  
In order to circumvent these problems and provide greater biological insight, a label-free technique 
with a holistic and pathway-independent screening method was applied. For the detection of whole 
cell pleiotropic signaling events a beta version of the Corning®Epic® system was used. This biosensor 
consists of a temperature-control unit, an optical resonant waveguide grating (RWG) detection unit 
and an on-board robotic liquid handling device. 
3.3.1.1 Principle of resonant waveguide sensing 
Ligand induced activation of GPCRs leads to a series of spatial and temporal events that govern cell 
responses (Kholodenko 2006), which involve modulation of the cytoskeleton, and relocation of 
proteins, vesicles or organelles. This dynamic redistribution of cellular contents also referred to as 
dynamic mass redistribution (DMR), lead to a change of local optical density (Fang et al. 2005). The 
application of optical biosensors, which utilize waveguide grating surfaces embedded in the bottom 
of every well of special 384-well microtiter plates, enable detection of these redistributions.  
Figure 14 Principle of RWG sensing by means of the Epic® system (modified from Fang et al. 2005, 
Fang et al. 2006) 
Cells are seeded onto microplates containing optical biosensors (resonant waveguide grating, RWG) at the 
bottom of each well. Stimulation-induced relocation of cellular constituents, also referred to as dynamic mass 
redistribution (DMR), influence the refractive index in an area up to 150 nm distance from the biosensor. This 
change leads to a relative shift of reflected wavelength. (for more details please refer to the text) 
A broadband and polarized light is used to illuminate the waveguide and to pass polarized light 
through the bottom portion of cells. The grating surfaces reflect a very narrow band of light, which is 
characteristic of the refractive index near the sensor surface, which is sensitive to changes in the 
concentration of biomolecules. The relative shift of reflected resonant wavelength is proportional to 
changes in local mass density within the penetration depth of the biosensor, which is approximately 
150 nm (Fang et al. 2005, Fang et al. 2006, Fang, Ferrie & Tran 2009, Lee et al. 2008). The resulting 
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optical trace can be recorded for minutes up to hours after ligand induced activation of GPCRs, which 
provides a real-time readout of pharmacologically mediated changes in cellular mass. 
3.3.1.2 Experimental procedure of DMR analyses 
Cells were seeded in a density of 12.500-20.000 cells per well in 384-well in fibronectin-coated 
microplates with 30 µl of growth medium and cultured at 37°C in an atmosphere of 5% CO2 for about 
16-24 hours to obtain confluent monolayers. If CHO-GPR17 were analyzed, the growth medium 
contained doxycycline (S4, 1 µg/ml) to induce receptor expression. If necessary, cells were treated 
over-night (16-20 h) with PTX (C33, 50 ng/ml) to elucidate particular GPCR coupling patterns.  
 
Figure 15 Experimental procedure of DMR assay (refer to the text for detailed information) 
On the day of experiment cell culture medium was removed and cells were washed twice with assay 
buffer (HBSS + 20 mM HEPES (S12), pH 7.0). Supernatant was removed up to 10 µl by use of an eight 
channel manifold and cells were allowed to rest in 30 µl of assay buffer for at least 60 min in the 
Epic® reader at a constant temperature of 28°C. In prestimulation experiments with YM or BIM-
46187, they were added in the appropriate concentration after the washing procedure and 
incubated for 2.5 h prior to addition of test compounds. After an initial baseline read of 300 s, 10 µl 
test compound diluted in assay buffer and dispensed in a microtiter source plate were added into the 
sensor plate by means of the liquid handling device. Induced DMR responses were monitored for at 
least 3600 s. As some compound stock solutions were prepared in DMSO (C11), assay buffer was 
always adjusted to obtain similar DMSO concentration during a measurement. In order to avoid 
unspecific responses due to DMSO, the concentration did never exceed 0.4%, which was proven to 
have no detectable effects on the cells.  
3.3.1.3 Data evaluation of DMR analyses 
For a computer-based evaluation of recorded wavelength shifts, data were opened in table form with 
the help of „Microplate Analyzer v2.0“ software and were transferred to GraphPad Prism4 software 
for further evaluation. Optical signatures were depicted as representative figures of one individual 
experiment performed in triplicates. Each experiment shown was repeated at least three times 
gaining comparable results (detailed information is given in respective legends of results). For 
generation of concentration-response curves (CRC) the maximum response (0-1800 s) and area 
under curve (AUC, 0-3600 s), respectively, were plotted against agonist concentrations, depending on 
the respective optical signature shape.  
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The illustrated optical recordings in the present thesis are all baseline corrected, meaning the ligand-
induced wavelength shifts were corrected for signals obtained by addition of a compound-free assay 
buffer control. Buffer signal usually ranged between 0 and 40 pm. 
Concentration-effect curves were fitted by least squares, non-linear sigmoidal regression based on 
Hill equation with the use of GraphPad Prism4 software. Curve fitting was checked by application of 
F-test, whether fitted curve was sufficiently described with a constant Hill-coefficient of nH= 1 or if 
application of variable slope showed significantly better fitting. Pharmacological parameters of 
plotted sigmoidal CRC such as EC50 value (inflection point dedicating the agonist-concentration 
inducing half maximal effect) and Emax value (indicator of the intrinsic activity of a tested compound) 
were calculated by the GraphPad Prism4 software. Each data point of a depicted experiment 
represents a mean of at least three independent experiments performed in triplicates. 
3.3.2 Homogeneous time resolved fluorescence (HTRF®) technology 
Regulation (activation/inhibition) of cyclic AMP concentration and stimulation of inositol 
phospholipid hydrolysis constitute two major mechanisms by which GPCRs affect the cell 
metabolism. In order to analyze Gαs, Gαi/o and Gαq protein mediated signal transduction and their 
subsequent impact on effector proteins, such as adenylate cyclase (AC) and phospholipase C (PLC), 
cAMP and IP1 Kits (Table 21, K4, K5) from Cisbio were applied, which are based on the HTRF® 
technology. This non-radioactive dual labeling technique is based on the time-resolved fluorescence 
resonance energy transfer (reviewed by Degorce et al. 2009). TR-FRET combines standard FRET 
chemistry by application of lanthanoids as fluorescence donors, which are characterized by a very 
long emission half life (Selvin 2000). The HTRF® technology combines the advantages of FRETs 
homogeneity and the low background of TR-FRET. 
3.3.2.1 Theoretical background of HTRF® technology 
In the applied HTRF®-method the lanthanoid europium was used as fluorescence donor, which is 
complexed with three molecules bispyridin to a cryptate (Degorce et al. 2009, Trinquet & Mathis 
2006). The bispyridin molecules form a three dimensional cage around the lanthanoid and serve as a 
light-collection device, thus transferring the absorbed excitation energy on the europium. The very 
long emission half life of the lanthanoids allows a delayed detection, which guarantees that only the 
persistent FRET based fluorescence signal will be measured and the non-specific short-lived 
background fluorescence can be neglected. The applied acceptor is the so-called d2, a modified 
allophycocyanin organic molecule with a relatively low molecular weight from about 1.000 DA 
(Trinquet et al. 2001).  
When fluorescence donor (europium cryptate) and acceptor (d2) get into close proximity while 
simultaneously excitated with 320 nm, fluorescence resonance energy transfer (FRET) occurs. The 
maximum of the d2 emission spectrum is measured at 665 nm and a part of the energy captured by 
the europium has its maximum at 620 nm. A ratiometric measurement of these two emission 
wavelength enables corrections of well variability, signal quenching from assay components and 
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medium variability. Emissions at 665 nm (acceptor fluor) indicate the investigated biological reaction, 
whereas emissions at 620 nm (donor fluor) are used as an internal reference. In addition, the 
ratiometric readout can minimize the system errors caused by liquid handling instruments and 
detectors. To ensure a simultaneous detection of the cryptate donor emission at 620 nm and the d2 
acceptor transmission at 665 nm, the multimode reader Mithras LB940 (Berthold) was utilized. 
 
Figure 16 HTRF® cAMP / IP1 assay principle (modified from Degorce et al. 2009) 
The underlying method is a competitive immunoassay between endogenously accumulated second messengers 
and added d2-labeled second messengers. Specific monoclonal antibodies (Mab) labeled with europium 
cryptate (depicted as yellow cloud), which are targeted against either cAMP (A) or IP1 (B), serve as fluorescence 
donor. The respective second messengers are labeled with the dye d2 and serve as acceptor. The binding of the 
labeled Mab to its appropriate labeled second messenger (cAMP / IP1) results in a fluorescence resonance 
energy transfer (FRET) from the europium cryptate to the d2. This induces light emissions at 620 and 665 nm. 
The endogenously produced cAMP / IP1 binds as well to the specific labeled Mab, which leads to compensation 
of FRET and a decrease of the emission signal. Thus the resulting specific signal is inversely proportional to the 
endogenously available cAMP / IP1.  
3.3.2.2 Generation of cyclic AMP 
The observation of intracellular cAMP accumulation enables investigations of two distinct G protein 
mediated signal transductions, Gαs and Gαi/o (reviewed by Williams 2004, Gabriel et al. 2003). 
Generation of cAMP is controlled through the adenylate cyclase (AC) family of enzymes, which 
convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP) and inorganic 
pyrophosphate (PP). Two distinct heterotrimeric GTP binding proteins, Gαs and Gαi/o, have an 
impact on AC activity. Gαs primarily induces activation of AC, whereas Gαi/o shows inhibitory 
influences. Since the basal cyclic AMP production is usually low in a living cell, it is not possible to 
observe the inhibitory effect of receptors on the AC activity without prior stimulation of the enzyme. 
This was avoided by simultaneous addition of a constant forskolin concentration to the compound 
dilutions to activate the AC in a G protein-independent manner (Seamon, Padgett & Daly 1981). 
Furthermore the phosphodiesterase inhibitor IBMX (C25) was added to the assay buffer in order to 
inhibit degradation of accumulated cAMP.  
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3.3.2.3 Generation of IP1 
Signal transduction via Gαq subunit induces, amongst others, activation of PLC, which hydrolyzes 
phosphatidylinositol 4,5-phosphate into diacylglycerol and D-myo-inositol 1,4,5-triphosphate (IP3). 
IP3 will be further degraded into D-myo-inositoldiphosphate (IP2) and D-myo-
inositolmonophosphate (IP1) and finally D-myo-inositol. Since the half life of IP3 is extremely short, 
but degradation of IP1 can be prevented by the presence of LiCl, the intracellular IP3 concentrations 
can be measured indirectly via detection of accumulated IP1 (Trinquet et al. 2006, Zhang et al. 2010), 
thus giving information about Gαq mediated signaling. 
3.3.2.4 cAMP HTRF® assay experimental procedure 
Agonist induced changes in cAMP accumulation were measured according to manufacturer’s 
instructions unless otherwise specified (summarized in Figure 17). 
The required amount of cells was harvested and washed once in HBSS (20 mM HEPES (S12)), 
involving one centrifugation step for 15 s at 2700 rpm. Pelleted cells were resuspended in 
appropriate volume of assay buffer (HBSS, 20 mM HEPES (S12), 1 mM of IBMX (C25)) and dispensed 
at 50.000 cells/5 µl/well in 384-well microtiter plates on the day of experiment. After 30 min of 
preincubation at 37°C, cells were stimulated by addition of 2-fold concentrated agonist (5 µl) in the 
presence or absence of forskolin (C17), diluted in assay buffer. If the effects of antagonists were 
analyzed, they were added 30 min prior to agonist addition and incubated at 37°C. Following a 
30 min incubation at 37°C, the reaction was stopped by the addition of 5 µl of IP-d2 followed by 5 μl 
of europium(Eu)-cryptate-labeled cAMP Mab diluted (1:20) in lysis buffer (50 mM phosphate buffer 
(pH 7.0), 1 M KF and 1.25% triton X-100).  
The plates were allowed to incubate for 60 min at RT and were then read after excitation at 320 nm 
using the multimode reader Mithras LB940 (Berthold) with 100 μs delay and 200 μs window time.  
 
Figure 17 Schematic HTRF® cAMP assay protocol diagram (please refer to the text above for detailed 
information) 
3.3.2.5 IP1 HTRF® assay experimental procedure 
Agonist induced IP1 accumulation was determined similar as described for cAMP (see 3.3.2.4) 
according to manufacturer’s instructions (summarized in Figure 18).  
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On the day of experiment the required amount of cells was harvested and washed twice in HBSS 
(20 mM HEPES (S12)), including two centrifugation step for 15 s at 2700 rpm. Pelleted cells were 
resuspended in appropriate volume of stimulation buffer (containing LiCl) and dispensed at 100.000 
cells/7 µl/well in 384-well microtiter plates. Following incubation at 37°C for 30 min, cells were 
stimulated by addition of 7 µl 2-fold concentrated agonists diluted in stimulation buffer. If the impact 
of antagonists was investigated, they were added 30 min prior to agonist addition and incubated at 
37°C. After another 30 min incubation at 37°C, the reaction was terminated by addition of 3 μl of IP-
d2 followed by 3 μl of europium(Eu)-cryptate-labeled IP1 Mab diluted (1:20) in lysis buffer. The 
plates were allowed to incubate for 60 min at room temperature and were then read by Mithras 
LB940 (Berthold) with 100 μs delay and 200 μs window time.  
 
Figure 18 Schematic HTRF® IP1 assay protocol diagram (please refer to the text above for detailed 
information) 
3.3.2.6 Data evaluation of second messenger HTRF® assay 
The evaluation of HTRF® data was performed according to manufacturer’s instructions. Data analyses 
were made based on the HTRF® ratio given as 10,000 × [emission (665 nm)/emission (615 nm)], 
meaning light emitted by labeled IP1/cAMP over the light emitted by the europium cryptate-labeled 
anti-IP1 / anti-cAMP. Levels of cAMP were normalized to the amount of cAMP elevated by forskolin 
and levels of IP1 were normalized to the maximum amount of IP1 generated by ligand-induced GPCR 
activation. In some analyses, data were presented as arbitrary units, meaning amount of cAMP or IP1 
related to the examined basal levels ((buffer HTRF® ratio subtracted by agonist-induced HTRF® ratio) 
+buffer HTRF® ratio). 
In order to generate concentration-response curves (CRCs), accumulated cAMP / IP1 or 
representative values were plotted against agonist concentrations. Each data point of a single 
experiment represents a mean of at least three independent experiments performed in duplicates or 
triplicates. CRCs were fitted as described in 3.3.1.3. 
3.3.3 Bioluminescence Resonance Energy Transfer (BRET) 
Bioluminescence resonance energy transfer (BRET) was discovered in marine organisms and is a 
naturally occurring physical phenomenon with non-radiative energy transfer from a donor enzyme to 
a suitable acceptor molecule after substrate oxidation. Renilla luciferase (RLuc), isolated from the sea 
pansy Renilla reniformis, is traditionally used as a bioluminescence donor (Ward & Cormier 1979). 
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The enzyme generates bioluminescence through oxidation of its substrate coelenterazine h and thus 
excites the fluorescence acceptor YFP (Yellow Fluorescent Protein). A further development of this 
classical BRET technique is the here applied BRET2 method, which is based on the application of 
coelenterazine 400A (DeepBlue C) as the substrate, while the Green Fluorescent Protein 2 (GFP2) is 
used as the acceptor protein (Bertrand et al., Hamdan et al. 2005, Ramsay et al. 2002, Vrecl et al. 
2004, Vrecl et al. 2009, reviewed by Pfleger & Eidne 2006). Coelenterazine are small, hydrophobic 
molecules that can easily cross cell membranes. This chemical property enables analyses of intact 
living cells (Xu, Piston & Johnson 1999).  
By use of the BRET technique a few practical problems occurring with FRET can be circumvented. 
Unlike FRET, BRET avoids the need for excitation, thus avoiding problems associated with auto 
fluorescence, photo bleaching and cell damage (Tsien, Bacskai & Adams 1993, Tsien 1998, reviewed 
by Milligan 2004). One main disadvantage of BRET method is the need of heterologous expression of 
fusion proteins, either C-terminally with RLuc or N-terminally with GFP2, which may alter the 
physiological and mechanistic function of proteins of interest.  
3.3.3.1 Theoretical background of BRET2 technique 
In principle many intracellular protein-protein-interactions can be examined by means of BRET 
technology. In the field of GPCR research the method was mainly applied to analyze homo- and 
heterodimerization of receptors, but the analyses of β-arrestin recruitment induced by an activated 
GPCR gets more and more into the focus of interest (Angers et al. 2000, Bertrand et al., Hamdan et 
al. 2005, Vrecl et al. 2004, Vrecl et al. 2009, reviewed by Milligan 2004, Pfleger & Eidne 2005, Pfleger 
& Eidne 2006, Pfleger et al. 2007). In the year of 2000 Angers et al. were the first to report about the 
application of BRET to observe and quantify agonist-induced β-arrestin2 recruitment to the β2-
adrenergic receptor in living cells (Angers et al. 2000). This opened up new possibilities of analyzing 
GPCR activation, independent of its preferred G protein-coupling, as agonist-mediated arrestin 
translocation by GPCRs is an almost universal event. Furthermore, Hamdan et al. showed that use of 
BRET for analyses of GPCR-β-arrestin interactions is applicable for High Throughput Screening (HTS) 
of GPCR-specific ligands (Hamdan et al. 2005). 
In order to elucidate GPR17 mediated β-arrestin2 recruitment by means of BRET2, the receptor was 
C-terminally fused to Renilla Luciferase (RLuc) and β-arrestin2 was N-terminally tagged with the 
Green Fluorescent Protein (GFP2). These two fusion proteins were stable coexpressed in HEK293 
cells. In the presence of oxygen, RLuc catalyzes the oxidation of its substrate coelenterazine 400A 
into coelenteramide while emitting blue light at 400 nm. If ligand-mediated activation of GPR17 
induces recruitment of β-arrestin2 to the activated receptor, an energy transfer will occur between 
RLuc and GFP2 as the two molecules are brought into close proximity (within 100 Å, Xu, Piston & 
Johnson 1999). The GFP2 molecule will then emit green light at 515 nm. The effectiveness of energy 
transfer between RLuc/Coelenterazine 400A and GFP2 is demonstrated in the ratio of acceptor 
energy emission (515 nm) relative to the donor emission (400 nm). This quotient is also referred to as 
BRET ratio and is a degree for proximity of GFP2 to RLuc (Pfleger & Eidne 2006). 
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Figure 19 Analysis of β-arrestin2 recruitment by means of BRET2 
In unstimulated cells, the receptor resides in the plasma membrane, whereas β-arrestin2 is located in the 
cytosol. During ligand-induced stimulation β-arrestin2, N-terminally fused to green fluorescent protein 2 
(GFP2), translocates to the plasma membrane and forms a complex with the activated receptor, which is C-
terminally fused to Renilla luciferase (RLuc) The spatial proximity of the two proteins brings RLuc and GFP2 
close together, which, upon addition of coelenterazine 400A (C10), leads to bioluminescence resonance energy 
transfer (BRET). 
3.3.3.2 Generation of BRET2 fusion constructs 
HEK293 cells stably expressing various amounts of β-arrestin2, N-terminally tagged with GFP2, were 
kindly provided by Jesper Mosolff Mathiesen (Department of Medicinal Chemistry, University of 
Copenhagen). The C-terminally tagged RLuc-GPR17 construct was made using standard molecular 
biology techniques employing fragment replacement strategies. A plasmid (pcDNA3.1 (+), neomycin) 
containing the human GPR17 (GenBank accession no. U33447) fused in-frame to the coding 
sequence of RLuc already existed in our group. Nevertheless, it was necessary to subclone the 
sequence into a zeomycin resistant expression vector, as the provided stable β-arrestin2-GFP2 
HEK293 cells possessed neomycin resistance. Therefore a pcDNA3.1(+) Zeo expression vector 
comprising the Protease Activated Receptor 1 (PAR1) fused in-frame to the coding sequence of RLuc 
was cut with the restriction enzymes HindIII and EcoRI (see 3.1.9.2) and replaced by hGPR17 (see 
3.1.12), which previously has been cut with the same restriction enzymes (HindIII and EcoRI) out of 
its pcDNA3.1(+) Neo-RLuc expression vector.  
For functional validations of the fusion protein (hGPR17-RLuc), the wild type GPR17 was additionally 
subcloned into pcDNA3.1 (+) Zeo. The coding sequence of GPR17 was PCR amplified from a plasmid 
template (MSP70, kindly provided by Andreas Spinrath, AK Kostenis, University of Bonn), containing 
the required sequence of human GPR17 (GenBank accession no. U33447). By use of specific 
oligonucleotide PCR primers (see 2.14.1) external to the GPR17 cDNA, a product of 1020bp was 
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amplified (see 3.1.5.1) and inserted (see 3.1.12) into the pcDNA3.1 (+) Zeo expression vector via 5‘ 
HindIII and 3’XhoI (see 3.1.9.2). 
 
Figure 20 Agarose gel electrophoresis of hGPR17 PCR product detected with ethidium bromide under 
UV light. 
The PCR reaction revealed a product of a size slightly bigger than 1.0 kb, thus certainly representing the 
expected size of hGPR17 cDNA (1020bp). For detailed information about PCR conditions see 3.1.5.1. 
The completed vectors were transformed into XL1-blue (see 3.1.1.2) and, following a primary 
analytical screening by restriction endonuclease digest (see 3.1.2.1 and 3.1.9.1), sufficient amounts 
of vector DNA were obtained by preparative plasmid isolation (see 3.1.2.2). Restriction cleavage of 
GPR17-RLuc construct with HindIII and EcoRI resulted in linearized pcDNA3.1 vector (4947bp) 
including the RLuc sequence (936bp) and the smaller fragment verified the correct insertion of 
GPR17 sequence without its stop codon (1017bp) due to in frame fusion with RLuc sequence. The 
wild type GPR17 plasmid was cut with HindIII and XhoI (B), resulting in one fragment of 4.9kb, 
illustrating the linearized pcDNA3.1 vector, and one fragment of 1020bp, verifying the correct 
insertion of GPR17 sequence. Due to very low rate of successful transformation, the wild type GPR17 
plasmid was additionally proven by cleavage with SalI and NcoI, respectively (C). Restriction analysis 
resulted in expected fragments, as depicted in Figure 21. 
The sequence identity of both constructs was further verified by sequencing in both directions with 
the use of standard oligonucleotide primers T7 and BGH reverse (see 3.1.6). 
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0.5kb
1020bp
3 Methods  
 
66
 
Figure 21 Analytical cleavage of pcDNA3.1-hGPR17-RLuc and pcDNA3.1-hGPR17 
A, Restriction endonuclease digest with HindIII and EcoRI of pcDNA3.1/Zeo(+)-hGPR17-RLuc resulted in two 
fragments: 5883 bp of vector DNA (4947 bp) including the RLuc sequence (936 bp) and 1017 bp of hGPR17 
sequence exclusive of its stop codon B, Restriction endonuclease digest with HindIII and XhoI of 
pcDNA3.1/Zeo(+)-hGPR17 resulted in two fragments: 4947 bp of vector DNA and 1020 bp of hGPR17 sequence 
C, restriction endonuclease digest of pcDNA3.1/Zeo(+)-hGPR17 with SalI lead to two main fragments (3.7 kb 
and 2.2 kb) and one not visual band of 30 bp. The restriction enzyme NcoI cut the plasmid into 5 fragments 
(3.4 kb, 1.2 kb, 0.8 kb, 0.3 kb and 0.2 kb). For detailed information about plasmid maps see 2.16. 
3.3.3.3 Experimental procedure of BRET2  
Functional BRET2 (here also referred to as BRET) assays were performed on HEK293 cells stably 
expressing human GPR17-Rluc and GFP2-β-arrestin2. 
Cells were detached by trypsinization, counted and washed once in assay buffer (HBSS, 20 mM HEPES 
(S12), pH 7.0). After centrifugation at 800 rpm for 4 min, the pelleted cells were resuspended in an 
appropriate volume of assay buffer to a density of 1 x 106 cells per ml. In order to stabilize readings, 
cells were allowed to incubate at 28°C for 30 min while slowly shaking (180 rpm), prior to 
experiments. 
The coelenterazine 400A stock solution (C10, 1 mM in ethanol) was freshly diluted (3:100) in PBS 
(S15) containing 20% of ethanol (C15) to obtain a 30 µM solution, which was always kept in the dark, 
due to its light-sensitivity. 
 
Figure 22 Experimental procedure of agonist BRET2 (please refer to the text for detailed information) 
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3.3.3.3.1 Agonist assay 
As a first step, the agonist solutions were prepared and 10 µl of each 8-fold dilution was dispensed in 
the 384-well assay plate. DMSO (C11) concentrations were adjusted and did not exceed 0.1% in final 
concentrations.  
Harvested and stabilized cells were manually distributed (70 µl, 70.000 c/well) to the assay plate 
containing the agonist dilutions. Cells were stimulated at 28°C at 450 rpm for 5 min or a respective 
time period for long adhesion kinetic measurements(1, 5, 10, 15, 30 or 60 min). Following cell 
stimulation, Coelenterazine 400A (C10, 10 µl) was injected by the Mithras injector 3 at a final 
concentration of 3.3 µM (10 µl of 30 µM solution). Two seconds after the injections, the light output 
from the well was measured at 400 and 515 nm by use of Mithras LB 940 plate reader, which allows 
the sequential integration of light signals detected with two filter settings. The BRET signal, 
milliBRET ratio, was calculated by the quotient of the fluorescence emitted by GFP2-β-arrestin2 (515 
nm) over the light emitted by the GPR17-Rluc (400 nm).  
For BRET2 experiments in the presence of Pertussis toxin, cells were preincubated over-night in the 
presence of the toxin at a final concentration of 50 ng/ml. 
3.3.3.3.2 Measurement of recruitment kinetics 
For recruitment kinetic analyses (0-140 s) of GPR17-RLuc and GFP2-βarrestin2 interactions, cells were 
seeded in empty 384-well assay plate. Coelenterazine 400A (C10) was added (Mithras injector 3, final 
concentration 3.3 µM) 20 s before injection of the agonist (10 µl, 9-fold) with the Mithras injector 1. 
Readings were performed immediately at 1.0 s intervals and during 140 s using the Mithras LB 940 
plate reader. 
3.3.3.3.3 Antagonist assay 
Antagonists (5 µl, 15-fold) were preincubated with the cells for 30 min (28°C, 450 rpm) before agonist 
dilutions (5 µl, 16-fold) were manually added. Following 5 min of agonist-stimulation at 28°C and 
450 rpm, Coelenterazine 400A (C10, 10 µl) was injected by the Mithras injector 3 at a final 
concentration of 3.3 µM (10 µl). Two seconds after the injection, the light emission was measured at 
400 and 515 nm by use of Mithras LB 940 plate reader. 
3.3.3.4 Data evaluation of BRET2 
Data were collected using the MikroWin200 software. For concentration-response data, curves were 
fitted with nonlinear regression equation using Prism software. Results were calculated as the ratio 
of GFP2 emitted light over RLuc catalyzed light emission. Agonist-promoted net BRET was calculated 
by subtracting the BRET ratio obtained in the absence of agonist from the one obtained in the 
presence of an agonist.  
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3.3.4 Enzyme-linked immunosorbent assay (ELISA) 
ELISA, enzyme-linked immunosorbent assay, is a technique based on the reaction of antigens and 
antibodies. In this work the indirect ELISA method was applied to quantitate cell surface expression 
of the N-terminally 3xHA-tagged GPR17 receptor as well as investigate its internalization behavior. 
3.3.4.1 Theoretical background of indirect ELISA 
The method involves an unlabeled primary antibody (Table 22, A1) targeted against the desired 
antigen (N-terminally 3xHA-tag labeled GPR17) in conjunction with an enzyme-labeled (horseradish 
peroxidase, HRP) secondary antibody (Table 22, A2), which is directed against all antibodies of a 
given species (here e.g. anti-goat).  
 
Figure 23 Indirect ELISA principle (for detailed information please refer to the text) 
A, Blue circles represent fixed cells expressing 3xHA-tagged GPR17. B, Specific antibody (yellow) binds to 
antigen (3xHA) C Enzyme-linked antibody (pink) binds to specific antibody (yellow). D, Substrate (tetramethyl 
benzidine, TMB) is added and converted by the enzyme (horseradish peroxidase, HRP) into a color product 
(blue). Rate of color formation is proportional to the amount of 3xHA-tagged GPR17. 
3.3.4.2 Experimental procedure of indirect ELISA 
3.3.4.2.1 Generation of 3xHA tagged hGPR17 
Since no specific antibody for GPR17 was readily available, a sequence (102 bp) encoding a 3xHA-
epitope tag (haemagglutinin influenza virus epitope tag) was introduced in frame by PCR at the 
amino terminus of the GPR17. As there are commercially available antibodies directed against this 
tag, the genetically engineered GPR17 provided a useful tool for immunobiological analyses (ELISA 
and immunofluorescence). The uniqueness of the epitope in the genome and the use of monoclonal 
antibodies assure a high-affinity, specific and abundant antibody binding (Kolodziej & Young 1991). 
In order to generate these constructs, two PCR reactions were consecutively performed. At first an 
oligonucleotide primer consisting of a 3xHA tag sequence and additionally in-frame the 5’ start 
sequence of human GPR17 was amplified by PCR. Therefore a plasmid containing the sequence of a 
3xHA tagged GPCR (GPR55) was used as the template (for further information about PCR conditions 
see 3.1.5.2). The PCR product was separated by agarose gel electrophoresis (Figure 24) and purified 
with gel extraction kit (see 3.1.8).  
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Figure 24 Agarose gel electrophoresis of 3xHA tag primer PCR product detected with ethidium 
bromide under UV-light. 
PCR primers were designed to obtain a PCR product (147bp) consisting of 3xHA tag sequence in frame with the 
5’ start sequence of hGPR17 and flanked by an artificial NheI restriction site (5’). Please refer to Table 26 for 
details of the PCR conditions. 
With a second PCR reaction the 3xHA-tagged GPR17 sequence was amplified. Therefore, the 
preliminarily amplified PCR product was used as forward primer and pcDNA3.1/zeo-GPR17 plasmid 
as the template (see 3.1.5.2 for further information about PCR conditions). The resulting construct 
was inserted in-frame via 5‘NheI and 3‘XhoI into pcDNA3.1/zeo. In order to obtain a 3xHA-epitope 
tagged GPR17 C-terminally fused to Renilla Luciferase (RLuc), the resulting fragment was inserted in-
frame via 5’NheI and 3’PstI into pcDNA3.1/zeo-GPR17-RLuc. 
 
Figure 25 PCR amplicon of 3xHA tagged hGPR17 envisaged by agarose gel electrophoresis 
PCR primers were designed to obtain a PCR product consisting of 3xHA tag sequence (102bp) in frame with the 
5’ hGPR17 sequence (1017bp) without its start codon, and flanked by artificial restriction sites (5’ NheI, 3’ 
XhoI). Please refer to Table 27 for details of the PCR conditions. 
The sequence identity of the constructs was verified by restriction endonuclease cleavage and the 
expected fragments were detected by agarose gel electrophoresis, as depicted in Figure 26. The 
sequence identity of both constructs was further verified by sequencing in both directions with the 
use of standard oligonucleotide primers T7 and BGH reverse (see 3.1.6). 
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Figure 26 Restriction endonuclease cleavage of 3xHA tagged GPR17 constructs 
A, Restriction endonuclease cleavage of pcDNA3.1-3xHA-GPR17 with XhoI and NheI resulted in two fragments, 
pcDNA3.1 vector consisting of 4954bp and 3xHA-GPR17 sequence (1119bp), respectively. B, Restriction 
endonuclease cleavage with NheI and PstI of pcDNA3.1-3xHA-GPR17-RLuc showed two main fragments, 
whereat 6331bp represented pcDNA3.1 vector (4954bp) including sequence of RLuc (936bp) and a part of 
GPR17 sequence (441bp), and a fragment of 673bp belonging the other part of 3xHA-GPR17. C, Restriction 
endonuclease digest with XbaI of pcDNA3.1-3xHA-GPR17-RLuc resulted in two bands, one of 4952bp 
(pcDNA3.1) and one of 2052bp (3xHA-GPR17-RLuc). For more information about constructed plasmids and 
respective restriction sites, see Figure 12. 
 
3.3.4.2.2 Quantification of receptor expression levels 
Whether for quantification of receptor expression levels or for examination of internalization 
behavior, cells stably expressing 3xHA-tagged GPR17 (50.000 cells/well) were seeded onto PDL 
coated 96 well plates and grown in the incubator (37°C, 5%CO2) 24 h prior to analyses. On the day of 
experiment medium was carefully aspirated and cells were fixed with 4% paraformaldehyde (S14, 
100 µl/well) for 25 min at RT. After washing three times with PBS (S15, 200 µl/well), cells were 
blocked with non-fat dried milk (blotto, S1, 100 µl/well) for 60 min at 37°C. If permeabilization was 
required for quantification of total receptor expression, triton X-100 (0.5%, C52) was added to 
blocking solution. After aspirating the blocking solution, cells were incubated with goat anti-HA 
antibody (Table 22, A1, diluted 1:400 in blotto, S1) for 45 min at RT. Following three washes with PBS 
(S15), the cells were incubated for 45 min at RT. The cells were washed again and incubated with 
tetramethyl benzidine liquid substrate (TMB, C49, 100 µl/well) for up to 5 min. The reaction was 
stopped by addition of sulfuric acid (C48, 0.5 M H2SO4, 50 µl/well) to a final concentration of 
approximately 0.17 M and the optical density (OD) of the supernatant was measured at 450 nm with 
the Tecan Sunrise-Basic. Cells without transfection were similarly treated and used as negative 
control.  
3.3.4.2.3 Quantification of internalization 
In addition to the protocol of expression analyses, the cells were initially stimulated for various time 
periods (15, 30, 60 and 120 min) at 37°C to induce receptor internalization. After washing once 
carefully with PBS (S15), cells were fixed with PFA (4%). It was then preceded as described for 
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receptor expression analyses (see 3.3.4.2.2). The degree of internalization was expressed as percent 
(%) relative to cells without ligand stimulation. 
3.3.4.3 Data evaluation of ELISA 
The respective OD450 values were collected using the XFluor2 software and evaluated with the help of 
Prism software. The OD450 value for the negative control was subtracted from all other samples.  
3.3.5 Immunofluorescence microscopy 
The generated 3xHA-epitope tagged GPR17 (see 3.3.4.2.1) allowed studying its subcellular 
localization by immunofluorescence microscopy. HEK293 cell lines stable expressing the epitope 
tagged GPR17 were used for analyses. 
3.3.5.1 Theoretical background of immunofluorescence 
The immunofluorescence analyses were based on an indirect fluorescent technique, similar to the 
applied ELISA method (see 3.3.4.1). An unlabeled primary antibody (Table 22, A1) targeted against 
the desired antigen (N-terminally 3xHA-tag labeled GPR17) is utilized in conjunction with an 
fluorescence-labeled (Alexa Fluor 546) secondary antibody (Table 22, A3), which is directed against 
antibodies of a given species (here e.g. anti-goat). 
3.3.5.2 Experimental procedure immunofluorescence 
For immunocytochemical studies of subcellular localization of unstimulated 3xHA-GPR17, stable 
transfected HEK293 cells (30.000 cells/well/100 µl) were plated onto poly-D-lysine coated 96well 
plates (black with clear bottom) 20-24 h prior to analyses. On the day of experiment, cells were 
washed once with PBS (S15, 200 µl) and then fixed with 4% paraformaldehyde in PBS (S14, 100 µl) 
for 30 min at RT. The fixed cells were washed three times with PBS (S15, each 200 µl, 10-15 min 
at RT), and then incubated with goat serum blocking solution (S9, containing goat serum, BSA, 
and triton X-100 for permeabilization) for 60 min at RT. Subsequent to the blocking procedure, 
cells were incubated with the primary anti-HA antibody (Table 22, A1, diluted 1:500 in blocking 
solution) (100 µl) for 60 min at 37°C. Following three washes with PBS (S15, 200 µl, 10 min each, 
37°C), cells were incubated with the secondary antibody Alexa Fluor 546 goat anti-mouse (Table 22, 
A3, diluted 1:2000 in blocking solution) for 60 min at 37°C. After three last washing steps with PBS 
(S15, 200 µl, 10 min each, 37°C), wells were completely filled with PBS (S15), and sealed with self-
sticky foil. Plates were kept at 2-8°C for further analyses. 
3.3.5.2.1 Internalization 
For immunocytochemical studies of subcellular localization of agonist-stimulated and -internalized 
3xHA-GPR17, stable transfected HEK293 cells (30.000 cells/well/100 µl) were plated onto black poly-
D-lysine coated 96well plates (with clear bottom) 20-24 h prior to analyses. On the day of 
experiment, the 3xHA-epitope tagged GPR17 on the plasma membrane was labeled by incubation 
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with anti-HA antibody (Table 22, A1, diluted 1:200 in cell medium without FCS) for 60 min for at 37°C. 
Afterwards cells were treated with ligands (diluted in cell medium without FCS to avoid unspecific 
blocking reactions) for the indicated time periods. The stimulated cells were then washed once in 
PBS (S15, 200 µl), and then fixed in 4% paraformaldehyde (S14) for 30 min at RT. After three 10 min 
washes with PBS (S15) the cells were permeabilized, and nonspecific binding was blocked with goat 
serum blocking solution (S9, containing 0.5% triton X-100) for 60 min at RT. Following three washing 
steps (each 10 min) with PBS (S15), cells were stained with goat anti-mouse Alexa Fluor 546-
conjugated secondary antibody (Table 22, A3, 1:2000 in blocking solution) for 1 h at 37°C. After three 
last washing steps with PBS (S15, 200 µl, 10 min, 37°C), wells were completely filled with PBS (S15), 
and sealed with self-sticky foil. Plates were kept at 2-8°C for further analyses. 
3.3.5.3 Data evaluation 
Cells were examined by immunofluorescence microscopy on a Leica DM IL LED Fluo fluorescence 
microscope using a 20 or 40X objective and the received pictures with a resolution of 1.4 megapixels 
were pseudo-colored using the Leica DFC 360 FX. Images were collected using 
Leica Application Suite 3.3.1 imaging software and were processed with Microsoft Office Picture 
Manager. All experiments were confirmed at least three times, and a representative image is shown. 
3.3.6 Schild regression analysis 
In order to evaluate antagonistic potencies as well as to determine antagonistic behaviors, Schild 
regression analyses were performed, which represent the major pharmacological tool used to 
quantify affinities of antagonists. Antagonist Ki values could be calculated from their IC50 values from 
competition binding experiments; provided that the radioligand’s Kd value was known. As for GPR17 
no radioligand is readily available, the method developed by Schild and coworkers (ARUNLAKSHANA 
& SCHILD 1959) was utilized to obtain antagonist KB values with functional studies. Utilizing this 
method, a system-independent estimate of the affinity of an antagonist can be made in a functional 
system. Furthermore, the method can also compare the pattern of antagonism, thereby allowing 
definition of the mechanism of action of the antagonist.  
The method is based on the fact that competitive antagonists produce a parallel rightward shift of 
the agonist concentration-response curve, which is measured in the presence of increasing, constant 
concentrations of the antagonist. Dose ratios (DR), which are usually defined as the ratio of EC50 
values in presence and absence of the antagonist, were calculated. Accordingly, for every 
concentration of antagonist there will be a corresponding DR value. The next step is to plot the 
common logarithm of the DR subtracted by 1 (log DR-1) against the common logarithm of the applied 
antagonist concentration (log M). This plot is referred to as Schild plot, and it reflects that, when 
log DR subtracted by 1 equals 0, the plot intercepts with the abscissa and, in this situation, log KB is 
equal to log M.  
 −  =   –   
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Thus, the concentration of antagonist that produces a log (DR-1) = 0 value will be equal to the log KB, 
the equilibrium dissociation constant of the antagonist-receptor complex. The antagonist’s log KB can 
be easily calculated by linear regression of Schild Plot according to Arunlakshana and Schild 
(ARUNLAKSHANA & SCHILD 1959). Since KB values are obtained from a logarithmic plot, they are log 
normally distributed and are therefore conventionally reported as pKB values. The negative logarithm 
to base 10 of the molar concentration of an antagonist that makes it necessary to double the 
concentration of the agonist needed to elicit the original submaximal response obtained in the 
absence of antagonist (SCHILD 1997). The negative logarithm of this concentration is often referred 
to as the pA2. Hence, the pA2 value is formally the pKB for simple competitive antagonists, but 
furthermore also approximates the pKB for insurmountable antagonists if a parallel rightward shift of 
the curve occurs concomitant with depression of maximal response. Instead of utilizing EC50 values 
for calculation of dose ratios (DR), the DR values are calculated from values of response below where 
depression of response occurs, for example at 20% maximal response level, whereas curves should 
be fitted to a common slope (Kenakin, Jenkinson & Watson 2006). As the model of simple 
competitive antagonism predicts that the slope of the Schild regression should be unity, statistical 
estimation of the 95% confidence limit of the slope were used to determine whether the sample data 
revealed a unit slope, thus describing simple competitive antagonism. 
3.4 Homologous recombination in embryonic stem cells 
In 1981, Evans and Kaufman (Evans & Kaufman 1981) and Martin (Martin 1981) were the first to 
isolate and cultivate murine pluripotent embryonic stem cells. This was a prerequisite for the 
generation of gene-modified animals or pluripotent cells with the ability for further differentiations. 
The switch-off of a specific gene enables the analysis of its coded protein and investigations of its 
physiological role. Therefore, foreign DNA molecules (targeting vector) are transfected into 
embryonic stem cells, where they can integrate into the host genome, which is also referred to as 
crossing over.  
3.4.1 Targeting vector 
A first step for a successful gene targeting is the generation of an appropriate targeting construct.   
The murine GPR17 (mGPR17, GenBank accession no. NM_001025381) consists of two exons 
(exon1: 0.18 kb, exon2: 5.0 kb) and is located on chromosome 18. The protein coding region is 
situated in the first segment of exon 2. The transcript length is 1020 bp, and the translated protein 
consists of 339 amino acids.  
In principle a targeting construct consists of four segments: two homologous regions (one 5’ of the 
respective gene and one 3’), which are inserted in a plasmid vector (here pPNT) and separated by the 
neomycin resistance cassette. The homologous regions are also referred to as ‘arms’ (short and long 
arm). Following linearization and electroporation, they attach to their respective homologous regions 
in the genomic DNA (heteroduplex formation), and replace the particular DNA segments, due to the 
3 Methods  
 
74
crossing-over (Thomas, Folger & Capecchi 1986). The possibility of a homologous recombination 
increases with the size of these homologous regions (Hasty, Rivera-Pérez & Bradley 1991). Optimal 
sizes were found to be in between 5 and 10 kb, as the application of even bigger sequences increases 
efficiency of recombination, but especially the cloning strategies were no longer feasible.  
For generation of the targeting vector, a homologous genomic sequence (6.2 kb), including a part of 
intron 1 and exon 2, was chosen. In order to knock-out the functionality of the 7TM receptor GPR17, 
the sequence of its transmembrane domains 2-6 (TM2-6, 564 bp) was replaced by neomycin-
resistance-cassette (1.8 kb). Since the transmembrane domains 3 and 6 are essential for a correct 
transition of GPCRs to its full active state (Hulme et al. 1999), their knock-out leads to a loss of 
complete function.  
 
Figure 27 Knock-out strategy  
Murine GPR17 (wild type) locus encompassing two exons (light blue bars), whereat the coding region (1020bp, 
red bar) is situated on Exon2. Experimental construct design of the targeted mouse GPR17 allele, based on 
homologous recombination with a targeting vector comprising the bacterial neomycin-resistance cassette (neo, 
yellow bar), which disrupts the coding sequence of the mouse GPR17 gene (transmembrane domains 2 until 6 / 
TMD2-TMD6) (please refer to the text for more information). 
3.4.1.1 Cloning procedure 
For amplification of homologous regions (short and long arm), PCR reactions were performed with 
the use of genomic ES cell DNA (HM-1, kindly provided by Daniel Schulz, AK Kostenis, University of 
Bonn) as template, as well as appropriate oligonucleotide primers and a mixture of Taq and Pfu 
polymerases (for further information about PCR conditions see 3.1.5.3). As shown in Figure 28, PCR 
products were purified by agarose gel electrophoresis (see 3.1.7) and isolated by subsequent gel 
extraction (see 3.1.8). 
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Figure 28 Agarose gel electrophoresis of homologous sequence PCR products detected with ethidium 
bromide under UV-light 
PCR primers were designed to obtain a PCR product consisting of homologous sequence 5’and 3’ of mGPR17. 
Both amplicons were flanked by artificial restriction sites (long arm 5’ NotI, 3’ XhoI; short arm 5’ BamHI, 3’ 
EcoRI). 1kb DNA ladder was applied for size estimations. Please refer to Table 28 and Table 29 for detailed 
information about respective PCR conditions. 
The short arm sequence was firstly introduced into the pPNT vector via 5’ BamHI and 3’ EcoRI. Prior 
to insertion of the remaining long region, the sequence identity of the hitherto existing construct 
(pPNT vector – short arm) was verified by restriction endonuclease digests (see 3.1.9.1), as presented 
in Figure 29. 
 
Figure 29 Verification of the introduction of the short homologous sequence in pPNT vector by 
restriction endonuclease cleavage and envisaged by agarose gel electrophoresis. 
A, Endonuclease restriction cleavage with BamHI and EcoRI revealed fragments of the accurate inserted short 
arm (1529bp) and pPNT vector (8211bp). B, Linearization with BamHI resulted in one DNA fragment (9760bp). 
C, Endonuclease restriction cleavage with SacI showed the expected 3 visible bands (4424bp, 2347bp and 
2068bp). D, Restriction enzyme StuI cut plasmid into two fragments with the expected size (5515bp and 
3342bp). 1kb DNA ladder was applied for size estimations. For further information about endonuclease 
restriction sites see Annex Figure 1. 
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The long arm PCR product was subcloned into the pPNT vector-short arm construct with the use of 
5’NotI and 3’XhoI. The correct insertion of the long homologous region was verified by restriction 
endonuclease digestion (XhoI and NotI, see Figure 30). Sequencing by GATC Biotech (see3.1.6) 
revealed no mutations. 
 
Figure 30 Analytical cleavage of the inserted long homologous sequence in pPNT-short-arm vector by 
endonuclease restriction cleavage and envisaged by agarose gel electrophoresis  
Three out of four isolated plasmids revealed correct DNA band pattern (+) after restriction with XhoI and NotI 
(8.9kb of pPNT-short-arm, 4.7kb of inserted long arm), whereas one revealed unknown fragments (-). 1kb DNA 
ladder was applied for size estimations. For further information about endonuclease restriction sites see Annex 
Figure 1. 
3.4.2 Cultivation of murine embryonic stem cells 
In general stem cells are cells that are not yet differentiated, meaning they are not yet specialized 
regarding their cellular functions. Since they derive from the inner cell mass of embryo blastocytes 
(3.5 days post coitum), they are also referred to as embryonic stem cells (ES cells). These ES cells are 
able to differentiate into virtually all kinds of cell types, tissue or organs, due to their pluripotent 
capability. As they are isolated from inner cell mass, they are not able to differentiate into external 
cell mass as e.g. umbilical cord or placenta, thus they are not totipotent. In order to maintain their 
pluripotency and to prevent untimely differentiation, it is necessary to cultivate them under special 
conditions.  
The applied embryonic stem cells, which derive from mice with Ola/SV129 strain, were kindly 
provided by Dr. Jesús Gomeza (AK Kostenis, University of Bonn). 
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Figure 31 Flow chart for the experimental procedures of gene targeting in ES cells  
This figure represents a schematic overview of the performed methods to generate gene modified ES cells, as 
described in detail in text.  
3.4.2.1 ES cell culture media and solutions 
ES cell culture medium 
One main supplement of the stem cell culture medium is the myeloid leukemia inhibitory factor (LIF). 
LIF is a polypeptide-cytokine and was discovered as an essential factor to prevent differentiation und 
thus helps to maintain the pluripotent state of the stem cells (Smith et al. 1988, Williams et al. 1988). 
LIF acts as a ligand at LIF-receptor-complex (Davis et al. 1993, Gearing et al. 1991). The ES cell culture 
medium additionally contains sodium pyruvate, non-essential amino acids, L-glutamine, heat-
inactivated fetal bovine serum (30 min, 56°C) and 2-mercaptoethanol. The latter prevents oxidation 
and subsequent inactivation of LIF and represents a sulfur source for the ES cells. In order to obtain 
ideal culture conditions, a daily change of culture medium is inevitable.  
Table 32 ES cell culture medium 
constituent volume [ml] final concentration 
Dulbecco’s Modified Eagle Medium (DMEM) 500  
Fetal bovine Serum ES Cell-qualified 56 10% 
l-Glutamine, 200 mM 5.6 2 mM 
Sodium pyruvate 5.6 2 mM 
Non-Essential Amino Acids 5.6 0.1 mM 
2-Mercaptoethanol, 50 mM 1.1 0.1 mM 
ESGRO® (107 units/ml) 
LIF= leukocyte inhibitory factor 
0.05 1000 units/ml 
Medium was always freshly prepared once a week and unnecessary warm-up cycles in water bath 
were avoided. 
Preparation of feeder cells
Seeding of feeder cells
Thawing and breeding of ES cells
Transfection of stem cells (electroporation)
Positive-negative selection (G418 / FIAU)
Picking and expansion of clones
Analyses of isolated DNA by means of PCR
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ES cell freezing medium (2x) 
ES cell freezing medium was freshly prepared by addition of fetal bovine serum (40%) and DMSO 
(C12, 20%) to complete ES cell culture medium. The respective final concentrations after 1:1 dilution 
with cell suspension were 20% fetal bovine serum and 10% DMSO (C12). 
ES cell positive-negative selection medium 
The medium for positive-negative selection was prepared by addition of 2000 µl of G418 (f. c. 
360 µg/ml) and 500 µl of FIAU (S7, f. c. 0.2 µM). 
Feeder cell medium 
Feeder cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (10%), L-glutamine (f. c. 2 mM) and sodium pyruvate (f. c. 2 mM). 
3.4.2.2 Preparation of feeder cells 
Mouse Embryonic Fibroblast (MEF) cells are required to provide nutrients, including cytokines such 
as LIF, to ES cells and to support the growth of undifferentiated ES cells, thus they are also referred to 
as feeder cells. MEF cells are isolated from mouse embryos and are used at their early passages. In 
order to prevent cell death due to treatment with selection antibiotics (G418, positive-negative 
selection), cells were isolated from mouse embryos containing transgene bacterial neomycin-
resistance-gen. These cells were kindly provided by Dr. Jesús Gomeza (AK Kostenis, University of 
Bonn). 
3.4.2.2.1 Thawing and cultivation of MEFs 
Frozen MEFs were quickly thawed in a water bath (37°C), then transferred to 10 ml of warm MEF 
medium, and pelleted by centrifugation (4 min, 800 rpm) in order to remove the DMSO contained in 
the freezing medium. The supernatant was soaked off; cells were resuspended in warm MEF medium 
and plated out. The time required until cells were grown to confluence depended on the splitting 
ratio (1:1 to 1:5).  
Before generating feeder layers from the MEFs, cells were expanded several times, letting the cells 
grow to confluence (see 3.2.1).  
3.4.2.2.2 Gamma ray treatment of feeder cells 
Feeder layer fibroblasts need to be mitotically inactivated prior to addition of ES cells. Applied cells 
were treated by irradiation to stop them from growing, while maintaining the abilities to secrete 
growth factors. The gamma ray treatment of 96 Gray for 5.53 min has been performed by Dr. Stefan 
Garbe (Radiology, University Medical Center of Bonn). 
These radiated cells were directly frozen after the radiation (see 3.2.2). 
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3.4.2.2.3 Seeding of feeder cells 
Embryonic stem cells are usually grown on a layer of mitotically inactivated primary mouse 
embryonic fibroblasts to promote growth and prevent differentiation.  
In general, one day before ES cells were plated, cell culture dishes were gelatinized with 3-10 ml of 
gelatin working solution (S8, 0.1%), so that surface was completely covered with gelatin. After 10 min 
incubation at RT, gelatin solution was aspirated and an appropriate amount of thawed feeder cells 
was seeded (see 3.2.3) on gelatin-coated dishes. The feeder layers were used for one week after 
plating.  
3.4.2.3 Thawing and plating ES cells 
Frozen ES cells were revitalized (see 3.2.3) and plated on cell culture dishes, which were coated with 
gelatin (S8) and feeder cells (see 3.4.2.2.3). In order to expand cells for electroporation, ES cells were 
passaged twice a week, splitting them 1:3 to 1:10, depending on their growth rate, when they 
reached approximately 70% confluence (see 3.2.1). Cells were incubated with ES cell trypsin at 37°C 
for up to 5 min, and large cell clumps were avoided by pipetting cell suspension up and down against 
dish wall about 10-20 times with varying distances. After each round of trypsinization, fresh feeder 
cells were added in advance, so that ES cells were grown on confluent feeder layers. Medium 
exchange was performed daily and cultures were never allowed to become over-confluent, as this 
triggers cell differentiation. Typical doubling time was about 24 h.  
3.4.3 Electroporation of murine embryonic stem cells 
Electroporation constitutes an efficient technique to transfect eukaryotic cells (Neumann et al. 1982). 
Short impetuses of high voltage induce a disturbance of cell membrane potential. This leads to 
formation of pores in the membrane und foreign DNA can be incorporated into the cell (Sukharev et 
al. 1992). 
For electroporation a densely grown 10 cm (55 cm2) cell culture dish, with approximately 10-20 x 106 
ES cells, was used. ES medium was aspirated, cells were washed with PBS (S15), and detached with 2 
ml of Trypsin/EDTA. Trypsinization was stopped by addition of ES medium, and cell number was 
determined in a counting chamber (see 3.2.4). Cells were centrifuged (4 min, 800 rpm) and 
resuspended in 10 ml of fresh ES medium. In order to get rid of the feeders, cells were dissolved by 
gently shaking and centrifuged once more (4 min, 800 rpm). Pelleted cells were resuspended in 
980 µl of electroporation buffer (S11, 1xHBS) and 20 µl (25 µg) of linearized targeting construct (NotI, 
see 3.1.9.3) were added. Suspension was mixed carefully by pipetting up and down, and after 5 min 
incubation at RT, transferred into an electroporation cuvette (0.4 cm). Electroporation was carried 
out with one pulse by 500 µF and 230 V, and the time constant was 117.2 ms. After the suspension 
was allowed to stand for 10 min at RT, cells were resuspended in appropriate amount of ES medium 
(1-2x106 cells per 10 ml per 55 cm2) on dishes covered with feeder cells.  
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3.4.4 Positive-negative selection 
The targeting construct contains the bacterial neomycin-resistance gene, which disrupts the coding 
sequence of the mouse GPR17 gene (TM2-TM6). When the linearized plasmid is introduced into the 
ES cells via electroporation, a few cells gain resistance against the aminoglykoside antibiotic 
Geneticin (G418), independent on the fact, where exactly the construct was integrated. Since during 
this type of selection only cells survive that stably integrated the resistance gene, it is also referred to 
as positive-selection. Besides the desired homologous recombination it happens more frequently, 
that the plasmid is randomly integrated.  
 
Figure 32 Plasmid map of constructed targeting vector  
(designed by use of bioinformatic software Vector NTI 8) 
In order to exclude these randomly integrated clones, a second selection marker (herpes-simplex-
virus thymidine-kinase-gen, HSV-TK), besides the positive selection (neomycin resistance gene), is 
applied. The thymidine-kinase is a viral enzyme, which converts prodrug analogs such as aciclovir, 
ganciclovir or fialuridine (FIAU) into nucleoside monophosphates. Subsequently, the monophosphate 
form is further phosphorylated into the active triphosphate form by cellular kinases. Thereby the 
analogs serve as wrong substrates for the polymerase; they are integrated into the DNA and inhibit 
its synthesis by induction of chain termination. If the selection medium is supplemented with 
ganciclovir or FIAU, it can only be activated when thymidine-kinase is present in the cell. When 
recombination takes place at the correct location, the HSV-TK sequence that is located 3’ outside the 
homologous regions falls away. Accordingly, only cells expressing this marker, due to non-
homologous recombination, do not survive the negative-selection (Mansour, Thomas & Capecchi 
1988). 
pPNT
13570 bp
HSV-TK (1127bp)
neo (804bp)
long arm (4713bp)
short arm (1523bp)
Not I (56)
Xho I (4776)
EcoRI (1272)
Eco RI (8137)
BamHI (1424)
BamHI (3317)
BamHI (4654)
Bam HI (6608)
3 Methods  
 
81
3.4.4.1 Picking of G418 and FIAU resistant clones 
One day after electroporation of ES cells, ES medium was exchanged by ES cell selection medium, 
containing G418 (360 µg/ml). On day number two after electroporation, selection with FIAU (S7, 
0.2 µM f.c.) was started. After 3 days of selection, medium was exchanged once more and following 
another 3 days (in total 6 days) the FIAU selection was stopped by addition of ES medium containing 
G418 but not FIAU.  
First colonies appeared 8 days subsequent to electroporation and after 9 days, sharply-bounded 
clones, resistant to G418 and FIAU, were isolated. Prior to clone isolation, the ES medium was 
replaced by prewarmed PBS (S15). Cell clones were picked under a microscope with the use of a 
200 µl pipette, which was prefilled with 100 µl ES cell trypsin. Each colony was soaked up with the 
pipette and transferred together with the 100 µl ES trypsin into an empty 24 well-plate cell culture 
dish. Following trypsinization at RT for 5-10 min, cells were singularized by pipetting up and down 3-
5 times and were transferred into 24-well plate cell culture dishes, previously coated with feeder 
cells, and filled with 1 ml of selective ES cell medium.  
As a whole, 120 colonies, resistant to G418 and FIAU, were picked and further cultivated. 
3.4.4.2 Cryopreservation of G418 and FIAU resistant clones 
When the isolated cell clones reached a confluence of approximately 80-90%, two-thirds of the cells 
were frozen, whereas the rest was kept in culture for further DNA isolation purposes (see 3.4.5). For 
cryopreservation, cells were washed with PBS (S15) and detached with 100 µl of ES trypsin (3-5 min, 
37°C). Trypsinization was stopped with 500 µl of ES medium and cells were singularized by pipetting 
10-20 times up and down against the dish wall. Two-thirds of the resuspended cells (400 µl) were 
transferred into labeled cryovials, which were prefilled with 400 µl of 2xfreezing medium (see 
3.4.2.1). After a short mixing, cells were briefly cooled at -20°C (1 h) and then frozen over-night at -
80°C. The following day cryovials were transferred into a liquid nitrogen tank for long-term storage at 
-210°C. 
3.4.5 Isolation of genomic ES cell DNA 
Isolation of genomic DNA from eukaryotic cell material is a far more delicate issue than preparation 
of plasmid DNA (see 3.1.2), due to its vast molecular size. Big DNA molecules easily disrupt into small 
fragments due to shear forces like pipetting, shaking or centrifugation. Therefore isolation has to be 
performed with adequate care.  
The lysis buffer (S13) contains SDS as a detergent to solubilize cell membranes and the supplemented 
proteinase K denaturates and degrades proteins. EDTA, as a chelating agent, is added in order to 
sequester divalent cations, such as Mg2+ or Ca2+, thus diminishing activity of present DNAses. 
Afterwards, DNA is purified via ethanol and NaCl precipitation. Monovalent cations (Na+) replace the 
hydration shell that is keeping DNA dissolved by ionic (salt bonds) and the DNA molecule is knocked 
out of solution (precipitates). Ethanol has a lower dielectric constant than water, so when mixed with 
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pure water, it effectively lowers the dielectric constant of the solution. Electrical attraction between 
negatively charged phosphate groups of DNA backbone and supplemented Na+ becomes strong 
enough to form stable ionic bonds and the DNA precipitates. 
Prior to addition of lysis buffer (S13, 300 µl), medium of confluent grown ES cells was aspirated. Cells 
were scratched from 24-well-plate and transferred into microliter tubes (1.5 ml) for incubation at 
55°C for 2 h. Following a supplement of saturated NaCl solution (150 µl), DNA was precipitated by 
addition of 900 µl of absolute ethanol (C15). The thin precipitated DNA threads were transferred into 
reaction tubes (1.5 ml), which already contained 500 µl of ethanol (S6, 70%). After centrifugation at 
12000 rpm for 5 min, the pelleted DNA was dissolved in 100 µl of cell culture grade water. Isolated 
genomic DNA was stored at 4-8°C. 
3.4.6 PCR genotyping of targeted ES cell clones 
The occurrence of recombination at the correct location is relatively rare, only in approximately 0.1-
1% of transfected cells an accurate insertion can be found (Thomas, Folger & Capecchi 1986). In the 
rest of the transfected cells, the construct can be randomly integrated or it happens not at all. 
Therefore, besides the positive-negative selection, an appropriate screening method is necessary to 
identify the clones, who integrated the targeting construct into the genome and furthermore to spot 
the ones, who integrated the linearized plasmids the correct location by homologous recombination. 
For this reason two PCR screenings were performed.  
The PCR screening strategy used to analyze the genotype of isolated DNA from targeted and 
positively-selected ES cell clones is presented in Figure 33. The sequences of the respective screening 
primers are listed in 2.14.3.  
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Figure 33 PCR genotyping strategy  
Primers were designed to anneal a part of 3’homology region (PScr1, long arm, Exon2), desired knock-out 
coding sequence (PScr2, Exon2), Neomycin resistance cassette (Neo, PScr3, PScr5) and 5’homolgy region 
(PScr4, short arm, Intron1). In the preliminary PCR analyses in the case of wild type allele, primer pairs PScr1 
and PScr2 give rise to a band of 511bp, whereas primer pairs PScr1 and PScr3 amplify amplicons of 721bp. In 
the case of the more specified PCR analyses, the primer pair PScr4 and PScr5 gives rise to a band of 1832bp, 
indicating the correct homologous recombination. See Figure 34 and Figure 35 for the utility of the designed 
genotyping. Please refer to Annex Figure 1 for detailed information about respective primer binding sites in the 
targeting vector.  
A first preliminary screening was made to identify clones, which integrated the construct. Both 
oligonucleotide primers were designed to bind inside the sequence of the targeting construct, so that 
independent from the fact where the construct was integrated, targeted clones were identified. 
 
Figure 34 Preliminary PCR analyses of genomic DNA from targeted ES cells 
PCR screening revealed amplicons of 551bp for wild type (wt) and 721bp for the targeted allele (neo). 1 kb DNA 
ladder was applied for size estimations. For detailed information about PCR conditions see Table 30 and for 
further information about PCR strategy see Figure 33. 
The second performed PCR was more specified regarding the correct homologous recombination. 
The choice of PCR oligonucleotide primers were made based on a forward primer that binds outside 
of the homologous sequence (5’) of the targeting construct and a reverse primer that binds to the 
Exon 2Exon 1
coding
sequence
PScr1PScr2
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neomycin resistance gene. Consequently, PCR products amplified by this reaction indicate an 
accurate homologous recombination. 
 
Figure 35 PCR analyses of genomic DNA from correctly targeted ES cells 
PCR screening revealed a fragment of 1832bp for the targeted allele (neo), whereas wild type allele did not 
result in any amplification, which has already been checked in preliminary PCR screening (see Figure 34). 1 kb 
DNA ladder was applied for size estimations. Please refer to Table 31 for detailed information about PCR 
conditions and see Figure 33 for further information about PCR strategy.  
Following incorporation of the linearized targeting construct into Ola/SV129 ES cells by 
electroporation, 120 G418- and FIAU-resistant colonies were picked. Due to slow and bad cell 
expansion, only 93 of these clones were screened for homologous recombination by PCR. The first 
preliminary screening revealed 28 wild type clones (~30%) and 65 clones (~70%) who integrated the 
targeting construct. Since this PCR only proved stable incorporation of the vector, but no 
homologous recombination, the second PCR was performed with these 65 clones. The more specified 
PCR uncovered three clones (~3%), in which the targeting construct was inserted by homologous 
recombination, thus leading to heterozygous modification of GPR17.  
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4 Results 
By means of a high throughput pharmacogenomic approach, our group has identified a synthetic 
small molecule agonist for GPR17, here referred to as RA-II-150, which has not been published yet. 
As the reported endogenous ligands (Ciana et al. 2006) did not display functional activity in our 
laboratory (data not shown, Ph.D. thesis of Andreas Spinrath, AK Kostenis), as well as in other 
independent laboratories (Benned-Jensen & Rosenkilde 2010, Maekawa et al. 2009, Wunder et al. 
2010), the identification of an activating ligand was the prerequisite to analyze signaling patterns of 
GPR17, and to further evaluate inhibiting properties of potential antagonists. 
4.1 Uncovering signaling patterns of GPR17 
Regarding the fact that recent studies revealed a ligand-independent regulatory role for GPR17, 
suppressing CysLT1 receptor function (Maekawa et al. 2009, Maekawa et al. 2010), it was a goal of 
this work to elucidate that GPR17 does not lack the common features of GPCR signaling upon 
stimulation with a small molecule agonist (RA-II-150). Analyses were performed in two different 
cellular backgrounds (CHO and HEK293 cells) generated to stably express GPR17. Untransfected wild 
type cells were used as negative controls. 
4.1.1 GPR17 mediates promiscuous G protein-coupling 
Traditional second messenger assays were performed to evaluate the GPR17 mediated cellular 
events upon agonist stimulation, and the focus was set on quantification of cAMP and IP1 
generation, respectively.  
4.1.1.1 GPR17 inhibits cAMP accumulation via Gαi/o-coupling 
In the original deorphaning publication, GPR17 was shown to act via coupling with Gαi/o protein, 
based on 35[S]GTPγS binding and cAMP inhibition assays (Ciana et al. 2006). Thus, a functional assay 
was established to analyze the ability of our GPR17 agonist RA-II-150 to inhibit adenylate cyclase in 
intact cells. As presented in Figure 36, RA-II-150 revealed inhibition of forskolin-stimulated cAMP 
accumulation in a concentration-dependent manner, in both analyzed cellular backgrounds 
(CHO-GPR17, HEK-GPR17). The determined pharmacological parameters are summarized in Table 33. 
As the inhibition effect mediated by the agonist-stimulated GPR17 was hardly detectable in HEK-
GPR17 cells, data from challenged untransfected HEK293 cells were plotted in parallel to illustrate 
the significant differences. The concentration-response curve of RA-II-150 using CHO-GPR17 cells was 
shifted to the right with an EC50 value more than six times higher in comparison with the one 
obtained with HEK-GPR17 cells (CHO-GPR17: 15.5 nM; HEK-GPR17: 2.4 nM). It should be noted, that 
the CRC in CHO-GPR17 cells was determined in the presence of 10 µM forskolin, whereas in HEK-
GPR17 only 0.3 µM forskolin were employed. Thus, the different forskolin concentrations might have 
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an impact on the respective agonist pharmacology in both cell lines. Nevertheless, for the purpose of 
this work, it is sufficient to conclude, that agonist-mediated stimulation of GPR17 leads to 
concentration-dependent inhibition of cAMP accumulation, in both examined cellular backgrounds. 
 
Figure 36 Concentration-dependent effect of GPR17 agonist RA-II-150 on forskolin-stimulated cAMP 
production in CHO-GPR17 and HEK-GPR17 cells, respectively. 
Cells stably expressing GPR17 (A: CHO, B: HEK293) were stimulated with increasing concentrations of RA-II-150 
in the presence of 10 and 0.3 µM forskolin, respectively. GPR17-mediated decrease of intracellular cAMP was 
calculated as percent inhibition of adenylate cyclase stimulated with forskolin (10 and 0.3 µM, respectively). A, 
Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 18 h) completely abolished inhibition of FSK induced cAMP 
accumulation B, HEK293 cells were taken as control. All data are means (+/- s.e.m.) of at least three 
experiments. B, For statistical analyses, individual concentrations were compared by two-way ANOVA with 
Bonferroni’s correction for multiple comparisons (**p < 0.01). 
Table 33 Parameters of averaged RA-II-150 concentration-effect curves determined by Gαi/o-cAMP 
assays, as depicted in Figure 36 (± s.e.m.) 
cell line pEC50 bottom value (%) top value (%) nH n 
CHO-GPR17 7.81 ± 0.05 71.5 ± 1.0 97.9 ± 0.9 -1,8 ± 0.3 4-5 
HEK-GPR17 8.62 ± 0.54 83.1 ± 3.0 97.6 ± 4.1 1.0 (fixed) 5 
 
Pertussis toxin (PTX) that inhibits the Gαi/o subunit by catalyzing its irreversible ADP-ribosylation 
(Katada & Ui 1982) was utilized to uncover Gαi/o-dependence of the GPR17-mediated inhibiting 
effect in CHO-GPR17 cells (Figure 36, A). Pertussis toxin pretreatment (50 ng/ml, 18 h) completely 
diminished the concentration-dependent response, thus demonstrating that Gαi/o subunit was 
essential for the observed response. Due to the barely detectable Gαi/o activity in HEK-GPR17 cells 
by means of traditional cAMP inhibition assays, PTX sensitivity and thereby Gαi/o-mediated signaling 
of HEK-GPR17 cells was further elucidated with the use of Epic® system (Figure 37). The monitored 
optical traces induced by challenge of GPR17 with RA-II-150 (0.3 and 0.1 µM) in the presence and 
absence of PTX pretreatment (50 ng/ml, 18 h), revealed Gαi/o-dependence of the dynamic 
redistribution, since the optical signatures were almost completely abrogated in the presence of PTX. 
Consequently these analyses verified the results obtained by cAMP inhibition assays, namely that 
agonist-stimulated GPR17 inhibits cAMP synthesis via Gαi/o-coupling, in both analyzed cellular 
backgrounds. 
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Figure 37 Verification of Gαi/o-coupling in HEK-hGPR17 cells via DMR analyses 
A, HEK293 cells stably expressing hGPR17 were stimulated with the indicated concentrations of RA-II-150 and 
the effect of the Gαi/o inhibitor PTX (50 ng/ml, 18 h) on the optical signatures elicited by RA-II-150 was 
analyzed. Wavelength shift (pm) was monitored as a measure of receptor activation. Representative data 
(mean + s.e.m.) of at least three independent experiments performed in triplicates. B, Bar chart resulting from 
DMR traces of validation by PTX pretreatment (50 ng/ml, 18 h) of RA-II-150 (1 and 3 µM) induced Gαi/o 
activation. Data are represented as means +/- s.e.m. normalized to the maximum response elicited by 0.3 µM 
RA-II-150 of four independent experiments, performed in triplicates. For statistical analyses, paired t-tests with 
two-tailed p values and 95% confidence interval were applied and revealed significant differences of RA-II-150 
induced responses in PTX pretreated cells compared to untreated ones (*p < 0.05; **p < 0.01). 
4.1.1.2 GPR17 activates adenylate cyclase 
While analyzing inhibition of forskolin-stimulated cAMP accumulation by agonist-activated GPR17, an 
additional stimulatory effect on adenylate cyclase was observed. Reverse bell-shaped concentration-
response curves in both cellular backgrounds (A: CHO-GPR17, B: HEK-GPR17) uncovered, that by 
application of higher RA-II-150 concentrations the induced stimulatory signaling cascade prevailed 
the inhibiting effect (Figure 38). The reverse bell-shaped concentration–response curves induced by 
RA-II-150 were analyzed by dividing them into one inhibitory and one stimulatory curve (bell-shaped 
concentration-response curve equation by GraphPad Prism4). In both cellular backgrounds maximum 
inhibition of cAMP synthesis (CHO-GPR17: ~30%; HEK-GPR17: ~11%) was reached with 0.3 µM 
RA-II-150, while further increases of the agonist concentration reversed the inhibitory effect and 
increased cAMP production. Whereas in CHO-GPR17 cells maximum of cAMP level was similar to the 
one obtained with 10 µM forskolin (Emax ~102%), the maximum in HEK-GPR17 cells outranged the 
cAMP concentration induced by 1 µM of forskolin (Emax ~124%). The differences in the maximum 
effect can be explained by the varying concentration of forskolin (10 µM versus 1 µM), and it should 
be regarded that RA-II-150 showed higher opposing efficacy via Gαi/o protein in CHO-GPR17 cells, 
observable in higher percentage inhibition (Emax 30% ↔ 11%). The stimulatory response was about 
50-fold less potent (EC50 values: 17.0 nM ↔ 851.1 nM) than the inhibitory response in CHO-GPR17 
cells, whereas in HEK-GPR17 cells the Gαs mediated pathway was approximately 75-fold less 
sensitive (EC50 values: 17.7 nM ↔1 259.9 nM). The pharmacological parameters are summarized in 
Table 34.  
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Figure 38 Reverse bell-shaped CRCs reveal concentration-dependent modulation of intracellular 
cAMP levels  
Cells stably expressing GPR17 (A: CHO, B: HEK293) were stimulated with varying concentrations of RA-II-150 in 
the presence of 10 (A) and 1 µM (B) forskolin, respectively. GPR17-mediated change of intracellular cAMP was 
calculated as percent inhibition of adenylate cyclase stimulated with forskolin (10 and 1 µM, respectively). All 
data are means (+/- s.e.m.) of three to five experiments performed in duplicates. 
Table 34 Parameters of averaged reverse bell-shaped RA-II-150 concentration-effect curves 
determined by Gαi/o-cAMP assays, as depicted in Figure 38 (± s.e.m.) 
cell line pEC50 bottom value (%) top value (%) nH n 
CHO-GPR17 
inhibitory 
7.77 ± 0.07 70.0 ± 2.2 98.0 ± 0.9 -1.6 ± 0.3 4-5 
CHO-GPR17 
stimulatory 
6.07 ± 0.04 70.0 ± 2.2 102.2 ± 1.2 2.8 ± 0.9 4-5 
HEK-GPR17 
inhibitory 
7.77 ± 0.67 88.7 ± 8.6 98.1 ± 3.1 -2.0 ± 4.4 5 
HEK-GPR17 
stimulatory 
5.90 ± 0.23 88.7 ± 8.6 123.7 ± 4.5 1.4 ± 1.4 5 
 
As the reverse bell-shaped concentration-response curves were obtained in the presence of 
forskolin, further analyses were performed to evaluate the unbiased GPR17-mediated increase of 
cAMP, avoiding simultaneous stimulation of adenylate cyclase by forskolin. Furthermore, the 
inhibitory component was eliminated by pretreatment of cells with PTX (50 ng/ml, 18 h), for a more 
accurate assessment of the stimulatory effect. Stimulation of GPR17 with increasing RA-II-150 
concentrations resulted in an elevated synthesis of cyclic AMP. As presented in Figure 39, effects 
were concentration-dependent, and CRC obtained in CHO-GPR17 cells was shifted to the right in 
comparison to the one determined in HEK-GPR17 cells (see Table 35 for pharmacological 
parameters). The stimulatory response was about 110-fold less potent (15.5 nM ↔ 1.7 µM) than the 
inhibitory response in CHO-GPR17, whereas in HEK-GPR17 the Gαs mediated pathway was 
approximately 350-fold less sensitive (2.4 nM ↔ 0.8 µM), when comparing the inhibition in 
untreated cells (Figure 36) with the stimulation in PTX-pretreated cells. 
Since the stimulatory effects on adenylate cyclase were not eliminated by preincubation with Gαi/o 
inhibitor PTX, whereas the inhibitory effects were completely blunted (see 4.1.1.1), a bifurcation 
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between both G proteins in the transduction can be neglected. Thus, the observed reverse bell-
shaped behavior was mediated by a promiscuous interaction by agonist-activated GPR17 with both 
proteins, Gαi/o and Gαs, in an independent manner. 
 
Figure 39 Concentration-response-curves of cAMP accumulation in CHO-GPR17 and HEK-GPR17 cells 
determined in the presence of Gαi/o inhibitor PTX 
Cells stably expressing GPR17 (CHO and HEK293) were pretreated with Gαi/o inhibitor PTX (50 ng/ml, 18 h), 
and stimulated with increasing concentrations of RA-II-150. GPR17-mediated increase of intracellular cAMP 
was normalized and expressed as percent of maximum activation induced by a saturating concentration of RA-
II-150 (100 µM). All data are means (+/- s.e.m.) of three to four experiments performed in duplicates.  
Table 35 Parameters of averaged RA-II-150 concentration-effect curves determined by Gαs-cAMP 
assays, as depicted in Figure 39 (± s.e.m.) 
cell line pEC50 bottom value (%) top value (%) nH n 
CHO-GPR17  5.74 ± 0.04 0.0 fixed 100.0 fixed 1.0 fixed 4 
HEK-GPR17  6.07 ± 0.03 0.0 fixed 100.0 fixed 1.0 fixed 3 
 
4.1.1.3 GPR17 raises intracellular IP-One concentrations 
Following elucidation of dual G protein-coupling via Gαi/o and Gαs, and regarding the fact that 
nucleotide-activated GPR17 was reported to elevate intracellular calcium levels, based on single cell 
calcium imaging (Ciana et al. 2006), a functional assay to analyze potential Gαq protein coupling was 
established. Therefore, the ability of our GPR17 agonist RA-II-150 to raise intracellular IP1 
concentrations in intact cells was evaluated. 
As depicted in Figure 40 stimulation of stably transfected cells (CHO-GPR17, HEK-GPR17) yielded 
concentration-dependent increases of intracellular IP1 levels. The CRC of RA-II-150 obtained in CHO-
GPR17 cells was shifted to the left in comparison to the one determined in HEK-GPR17 cells. The 
GPR17-mediated increase of IP1 synthesis in HEK-GPR17 cells was about 3-fold less potent than the 
response in CHO-GPR17 (EC50 values: 288.4 nM ↔ 85.3nM), a phenomenon which was observed 
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inversely in cAMP accumulation assays, where CRC obtained in CHO-GPR17 cells were shifted to the 
right for both inhibitory and stimulatory effects (see 4.1.1.1, 4.1.1.2).  
 
Figure 40 Concentration-dependent raise of intracellular IP1 by agonist-activated GPR17 in CHO-
GPR17 and HEK-GPR17 cells 
Cells stably expressing GPR17 (CHO-GPR17, HEK-GPR17) were stimulated with varying concentrations of RA-II-
150. GPR17-mediated increase of intracellular IP1 was normalized and expressed as percent of maximum 
activation induced by a saturating concentration of RA-II-150 (100 µM). All data are means (+/- s.e.m.) of three 
to four experiments performed in duplicates.  
Table 36 Parameters of averaged RA-II-150 concentration-effect curves determined by IP1 assays, as 
depicted in Figure 40 (± s.e.m.) 
cell line pEC50 basal value (%) Emax (%) nH n 
CHO-GPR17 7.07 ± 0.05 0.0 (fixed) 100.0 (fixed) 1.0 (fixed) 3-4 
HEK-GPR17 6.54 ± 0.04 0.0 (fixed) 100.0 (fixed) 1.0 (fixed) 3 
 
4.1.2 Agonist-activated GPR17 triggers dynamic mass redistribution in a PTX-sensitive 
manner 
After uncovering promiscuous G protein-coupling of agonist-activated GPR17 via Gαi/o, Gαs and Gαq 
proteins, the cell lines stably expressing GPR17 were analyzed by the label-free dynamic mass 
redistribution technology, which has been proven to be a powerful means for interrogating GPCR 
function in non-disturbed cellular settings without the need of labels (Fang, Frutos & Verklereen 
2008, Fang, Ferrie & Tran 2009, Schröder et al. 2010). The term ‘signature’ is used to describe the 
dynamic response profile displayed over time following ligand stimulation.  
Our GPR17-agonist RA-II-150 was analyzed according to its ability to trigger dynamic mass 
redistribution in cells stably transfected with GPR17 (CHO-GPR17, HEK-GPR17), thus signaling 
capability of agonist-activated GPR17 was monitored in real time. Representative experiments are 
depicted in Figure 41. Following stimulation with varying RA-II-150 concentrations, CHO-GPR17 cells 
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responded with a rapid positive DMR event, followed by a short negative DMR phase with a decay in 
signal and finally, especially with higher concentrations (1-100 µM), a slow positive DMR event was 
monitored that lead to another elevated plateau (Figure 41, A). HEK-GPR17 cells responded as well 
with specific optical signatures when exposed to increasing concentrations of RA-II-150 (Figure 41, C). 
Higher concentrations (10 and 100 µM) induced a rapid positive DMR followed by an elevated 
plateau, whereas lower concentrations did trigger a rapid positive DMR, followed by a short DMR 
decline and ending in another elevated plateau.  
 
Figure 41 Dynamic mass redistribution analyses reveal PTX-sensitive functional activity of GPR17 by 
activation with RA-II-150 
A-D, The cell lines stably expressing GPR17 were stimulated with the indicated concentrations of RA-II-150 and 
wavelength shift [pm] over time [s] was monitored as a measure of functional activity. Signatures were 
baseline-corrected by subtraction of buffer traces from the DMR response after receptor activation. 
Representative optical trace experiment (mean + s.e.m.) of at least three independent experiments performed 
in triplicates. A,B, CHO cells stably expressing GPR17 (CHO-GPR17). C, D, HEK293 cells stably transfected with 
GPR17 (HEK-GPR17). B,D, The effect of the Gαi/o inhibitor PTX (50 ng/ml, 18 h) on the optical signatures 
elicited by RA-II-150 in CHO-GPR17 cells (B) and HEK-GPR17 cells (D).  
Since the integrated response monitored in real time by use of the Epic® system is a complex 
phenomenon, which reflects multiple overlapping cellular events downstream of the agonist-
activated receptor, the data interpretation remains challenging especially regarding the promiscuous 
G protein-coupling of GPR17. To further determine whether heterotrimeric G proteins are 
responsible for initiating the monitored temporal response profiles, pertussis toxin was applied to 
pharmacologically silence Gαi/o signaling. As suspected from previously performed second 
messenger assays, PTX pretreatment did result in a shape change of the optical signatures, verifying 
promiscuous G protein-coupling including Gαi/o mediated signal transduction (Figure 41, B and D). 
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Regarding the data obtained by second messenger assays, the remaining optical signatures should be 
induced at least by Gαs and Gαq/11 mediated signaling pathways.  
The optical signatures induced by agonist-stimulated GPR17, in the presence and absence of PTX 
pretreatment, were transformed into concentration-response curves for RA-II-150 using area under 
curve (AUC) for CHO-GPR17 and maximum response for HEK-GPR17 (Figure 42), and normalized to 
respective response obtained in the absence of PTX.  
 
Figure 42 Concentration-dependency and PTX-sensitivity of RA-II-150 induced DMR 
Transformation of optical signatures into concentration-response curves for the GPR17 agonist RA-II-50 using 
the AUC values between 0 and 3600 s time points for CHO cells stably expressing GPR17 (A, CHO-GPR17), and 
maximum response (B) for HEK293 cells stably transfected with GPR17 (HEK-GPR17), respectively. All data are 
normalized to the AUC (A) or the maximum response (B) obtained in the absence of PTX. All data are means 
(+/- s.e.m.) of three to nine experiments performed in triplicates. For statistical analyses, individual 
concentrations were compared by two-way ANOVA with Bonferroni’s correction for multiple comparisons 
(*p < 0.05; **p < 0.01; ***p < 0.001). 
Table 37 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 42 (± s.e.m.) 
cell line pEC50 basal value (%) Emax (%) nH n 
CHO-GPR17 6.30 ± 0.14 1.8 ± 3.5 117.3 ± 7.6 0.51 ± 0.08 3-9 
CHO-GPR17 + PTX 5.69 ± 0.13 0.4 ± 4.0 130.0 ± 10.5 0.74 ± 0.13 3-8 
HEK-GPR17 5.85 ± 0.09 1.0 ± 2.8 96.3 ± 4.0  1.0 (fixed) 4 
HEK-GPR17 + PTX 5.70 ± 0.08 2.1 ± 2.4 86.5 ± 3.7 1.0 (fixed) 4 
 
The concentration-response curve of RA-II-150 obtained in CHO-GPR17 cells without PTX 
pretreatment was slightly shifted to the left in comparison to the one determined in HEK-GPR17 cells 
(EC50 values: 0.5 µM ↔ 1.4 µM). The PTX preincubation triggered a slight, but not significant 
(p > 0.05) rightward shift of concentration-response curves, in both analyzed cellular backgrounds. 
Especially with lower agonist concentration a significant inhibition effect of PTX preincubation was 
monitored, which is in agreement with data obtained in second messenger assays, where stimulatory 
effect on cAMP synthesis prevailed with application of higher RA-II-150 concentrations (see 4.1.1.2). 
A sigmoidal curve fitted for RA-II-150 response in CHO-GPR17 cells exhibited a shallow Hill slope 
(nH= 0.51 +/- 0.08), whereas pretreatment with PTX was accompanied by a small increase (nH= 0.74 
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+/- 0.13). The observed shallow Hill slope probably was due to crosstalk between signaling pathways, 
as EC50 values obtained by means of second messenger assays differed amongst each other, and 
depending on RA-II-150 concentration signaling preferences of GPR17 changed. Since holistic 
measurement of the Epic® system reflects multiple overlapping cellular events downstream of the 
agonist-activated receptor, these heterogeneous signaling events might cause such shallow Hill 
coefficients. Another proof for this hypothesis was the fact, that exclusion of one signaling pathway 
(Gαi/o) with PTX rather steepened curve slope closer to unity. Concentration-response curves 
explored in HEK-GPR17 cells were fitted with a constant Hill slope (nH= 1), thus in this cellular system 
crosstalk between involved signaling pathways did not result in dampened curve slopes. 
4.1.3 GPR17 internalizes upon ligand activation 
In order to evaluate whether GPR17 internalizes upon agonist activation, HEK293 cells stably 
expressing triple HA-tagged GPR17 (HEK-3xHA-GPR17) were examined by fluorescence microscopy 
and ELISA assays. Fusion of GPR17 with the haemagglutinin (HA) epitope tag did not impair its 
functionality as monitored by use of the Epic® technology (Figure 43). The GPR17 agonist RA-II-150 
concentration-dependently elicited dynamic mass redistribution (DMR), and the monitored optical 
signatures did slightly differ in magnitude but not in shape, indicating comparable signaling 
properties of the analyzed fusion receptor.  
 
Figure 43 GPR17 fused to epitope tag haemagglutinin retains functionality 
HEK293 cells transiently transfected (calcium phosphate precipitation) with distinct GPR17 constructs (GPR17: 
wild type and 3xHA-GPR17: N-terminally fused with haemagglutinin) were challenged with the indicated 
concentrations of the GPR17 agonist RA-II-150 and 10 µM ATP. The resulting picometer-shifts of reflected light 
wavelength over time [s] were monitored as a measure of functional activity. Presented data are means + 
s.e.m. from a representative optical trace experiment of two independent experiments performed in 
triplicates.  
The examination of HA-immunoreactivity gives information about the subcellular localization, 
whereas cell surface ELISA measurements allow monitoring of the quantitative changes in surface-
expressed GPR17. As seen in Figure 44, immunofluorescence analyses revealed that under control 
conditions GPR17 was predominantly located on the cell surface (A), but upon activation with 
10 µM RA-II-150 for 1 h, GPR17 internalized from the cell surface into the cytoplasm with a punctate 
distribution into intracellular vesicles (B). To verify these observed data and further characterize the 
agonist-induced internalization of GPR17, HEK-3xHA-GPR17 cells were treated with 10 µM RA-II-50 
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for various time periods, and cell surface GPR17 was quantitatively detected by ELISA. The agonist 
treatment induced endocytosis within 15 min, and the GPR17 continued to internalize, leading to 
~26.2% (+/- 2.3%) loss of cell surface expression (Figure 44, C). Thus, the data obtained from 
immunofluorescence microscopy and surface ELISA exhibit equivalent patterns, namely that GPR17 
internalizes from the cell membrane into the intracellular membrane compartments of the cell in a 
time-dependent manner upon agonist challenge. 
 
Figure 44 Agonist-induced internalization of GPR17 
A-C, Receptor expression was imaged by immunofluorescence microscopy (A-B), and quantitated by indirect 
cellular ELISA. HEK293 cells stably expressing GPR17 fused to an N-terminal 3xHA tag were pre-labeled with 
anti-HA antibody (Table 22, A1), and after agonist-induced stimulation, all cells were permeabilized and 
immunostained. A-B, Fluorescence images of cell surface and intracellular 3xHA-GPR17 immunoreactivity. Cells 
were treated for 1 h at 37°C with 0.1% DMSO (A, C11) or 10 µM RA-II-150 (B). A, Control cells showed primarily 
plasma membrane localization of GPR17 and less internalized receptor. B, RA-II-150 induced distinguishable 
endocytosis. The following settings were used for Alexa Fluor 546 recordings: 400 fold magnification, 100 ms 
exposure time, 0.99 γ and 2-22 histogram. Representative cells from at least three independent experiments 
are shown. After indirect immunofluorescence staining, no specific fluorescence was observed in untransfected 
HEK293 cells. Scale bars = 20 µM. C, Colorimetric ELISA measurements of RA-II-150 (10 µM) induced GPR17 
sequestration for the indicated time period. The amount of internalized receptor was calculated from the 
decrease in the level of surface-expressed receptor after agonist treatment compared with untreated, control 
cells (HEK293). Each data point represents mean (+/- s.e.m.) of four to five independent experiments 
performed in triplicates.  
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4.1.4 GPR17 agonist RA-II-150 shows no activity on untransfected CHO-K1 and HEK293 
cells 
In order to ensure that the results obtained with the stably transfected cells (CHO-GPR17, HEK-
GPR17) were specifically due to an activation of GPR17, the corresponding untransfected cells (CHO-
K1, HEK293) were analyzed by means of DMR, cAMP and IP1 assays, after challenging with GPR17 
agonist RA-II-150. As presented in Figure 45, RA-II-150 did not induce any visible dynamic mass 
redistribution, neither in CHO-K1 (A) nor in HEK293 (B) cells. The functional capability of assay 
conditions and viability of examined cell lines was controlled by stimulation with ATP (A) and 
carbachol (B), respectively, whereby ATP stimulates endogenous purinergic receptors in CHO-K1 cells 
(P2Y1 and P2Y2, Iredale & Hill 1993, Marcet et al. 2004) and carbachol activates muscarinic receptors 
endogenously expressed in HEK293 cells (M1 M3, Estacion et al. 2004, Mundell & Benovic 2000).  
 
Figure 45 GPR17 agonist RA-II-150 does not trigger dynamic mass redistribution in untransfected 
CHO-K1 and HEK293 cells, respectively. 
A-B, The untransfected cell lines (A:CHO-K1, B:HEK293) were challenged with 10 and 100 µM of RA-II-150, and 
ATP (A) or carbachol (B) were used as controls of assay conditions by activation of endogenously expressed 
purinergic (P2Y) and muscarinic receptors (M3). Wavelength shift [pm] over time [s] was monitored as a 
measure of functional activity by use of the Epic® system. Representative optical trace experiment 
(mean + s.e.m.) of at least three independent experiments performed in triplicates are shown.  
The results from DMR analyses were further corroborated in cAMP and IP1 assays, where GPR17 
agonist RA-II-150 did not reveal any activity, both conducted with CHO-K1 and HEK293 cells, 
respectively (Figure 46). Neither cAMP levels were elevated after stimulation with RA-II-150 nor 
forskolin-stimulated cAMP accumulation was inhibited (A). The increase of cAMP by addition of 
forskolin revealed good assay conditions as well as appropriate cell viability. In addition, activation of 
untransfected cells did not result in an increase of intracellular IP1 levels, but rather a little non-
significant decrease, whereas ATP and carbachol, used as positive controls, did reveal significant 
elevations. Purinergic (P2Y1 and P2Y2) as well as muscarinic (M1 and M3) receptors are known to 
couple via Gαq protein leading to an increase in intracellular IP1 concentrations. 
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Figure 46 GPR17 agonist RA-II-150 shows no activity in untransfected CHO-K1 and HEK293 cells, 
respectively, analyzed by cAMP and IP1 assays. 
A-B, Untransfected cell lines (CHO-K1, HEK293) were challenged with indicated RA-II-150 concentrations and 
analyzed by cAMP (A) and IP1 (B) assays, respectively. Forskolin (A), carbachol (B) and ATP (B) were used as 
positive controls. All data are means (+/- s.e.m.) of three to six experiments performed in duplicates. For 
statistical analyses, unpaired t-tests with two-tailed p values and 95% confidence interval were applied and 
revealed no significant differences of RA-II-150 induced values compared to unstimulated ones, whereas 
positive controls were significant (**p < 0.01, ***p < 0.001). 
4.1.5 GPR17 is not a constitutively active receptor 
Beyond these classical features, a number of additional functional paradigms of GPCRs are of 
importance, including constitutive activity (Costa & Cotecchia 2005, Milligan, Bond & Lee 1995). By 
raising the number of receptors present in a system, the number of spontaneously active receptors 
can be augmented until a threshold is reached where the resulting functional response from a 
spontaneously active receptor can be observed. This explains why in recombinant systems, over-
expressed receptors are capable of showing constitutive activity, resulting in a receptor-mediated 
increase in basal activity without any agonist intervention (Bond et al. 1995, Milligan, Bond & Lee 
1995, Newman-Tancredi et al. 1997). Regarding the fact that GPR17 was demonstrated to be 
constitutively active through Gαi/o (Benned-Jensen & Rosenkilde 2010), the cell lines applied in this 
work, engineered to stably express GPR17, were analyzed with respect to constitutive activity by 
means of cAMP and IP1 assays.  
In order to evaluate the intrinsic activity via Gαi/o or Gαs, the G protein-independent stimulation of 
adenylate cyclase with increasing concentrations of forskolin (Seamon, Padgett & Daly 1981) was 
examined in untransfected cells (CHO-K1, HEK293) and compared to the data obtained in stably 
transfected cell lines (CHO-GPR17, HEK-GPR17). Thus, a rightward shift of the forskolin 
concentration-response curve obtained in cells engineered to stably express GPR17 would indicate a 
constitutive Gαi/o activity. As presented in Figure 47 (A and B), neither in CHO nor in HEK cells, 
ligand-independent activity of GPR17 was observed, concentration-response curves did not 
significantly differ from each other. Furthermore the determined basal IP1 levels, again 
untransfected cells (CHO-K1, HEK293) were compared with stably transfected cells (CHO-GPR17, 
HEK-GPR17), did not significantly vary, but recombinant GPR17 cells showed rather slightly lowered 
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basal IP1 levels (Figure 47, C). Thus, indicating that GPR17 is not constitutively active through Gαq 
protein. 
 
Figure 47 GPR17 does not show constitutive activity 
A-B, Comparison of G protein-independent activation of adenylate cyclase with increasing forskolin 
concentration in untransfected (A: CHO-K1, B: HEK293) and stably transfected cell lines (A: CHO-GPR17, B: HEK-
GPR17). Data were normalized to cAMP accumulation induced in untransfected cells by 100 µM forskolin. All 
data are means (+/- s.e.m.) of two to four experiments performed in duplicates. Calculated pEC50 values are: 
CHO-K1: -6.55 +/- 0.05, CHO-GPR17: -6.33 +/- 0.04, HEK293: -6.42 +/- 0.04, HEK-GPR17: -6.55 +/- 0.05. C, 
Comparison of basal IP1 concentrations in untransfected cells (CHO-K1, HEK293) and stably transfected cells 
(CHO-GPR17, HEK-GPR17). Data were expressed as arbitrary units and are all means (+/- s.e.m.) of three to five 
experiments performed in duplicates. A-C, For statistical analyses, paired t-tests with two-tailed p values and 
95% confidence interval were applied and revealed no significance (cAMP: p= 0.1146 for CHOs and p= 0.0666 
for HEKs; IP1: p= 0.1325 for CHOs and p= 0.1581 for HEKs). 
4.1.6 GPR17 recruits β-arrestin2 upon ligand activation 
After elucidating the G protein-dependent signaling properties of GPR17 and its internalization 
behavior, the agonist-induced translocation of β-arrestin2 to the activated receptor was analyzed, 
which has been shown to occur for the vast majority of GPCRs independent of their G protein 
signaling pathways (Claing et al. 2002, Perry & Lefkowitz 2002). Therefore the BRET2 methodology 
was employed with the use of a double stable cell line that constitutively expressed β-arrestin2 N-
terminally fused to GFP2 and GPR17 C-terminally tagged with Renilla luciferase (RLuc). This cell line 
will be further referred to as HEK-BRET-GPR17. 
4.1.6.1 GPR17-RLuc-fusion construct retains functional activity 
Functional validation of fusion proteins is essential for subsequent BRET2 data to be interpreted as 
precisely reflecting cellular function (Pfleger & Eidne 2006). Therefore, in a first series of experiments 
the pharmacological properties of GPR17 C-terminally fused to Renilla luciferase (RLuc) were 
investigated, with the focus on the cellular localization (ELISA, immunofluorescence), the 
internalization behavior (ELISA), as well as the functional characteristics (DMR, cAMP, IP1). To 
facilitate analyses of the fusion protein GPR17-RLuc behavior in subsequent experiments, a HEK293 
cell line stably expressing 3xHA tagged GPR17 C-terminally fused to RLuc (HEK-GPR17-RLuc) was 
generated and compared to wild type 3xHA labeled GPR17 expressing HEK293 cells. 
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4.1.6.1.1 Cell surface expression of GPR17-RLuc is diminished 
As presented in Figure 48 (A), ELISA analyses of cell surface expression revealed a significant 
decrease of GPR17-RLuc in comparison with the wild type GPR17. The relative surface expression of 
wild type GPR17 (mean +/- s.e.m.: 99.91 +/- 0.11%) expressed on the cell surface exceeded more 
than three times the surface expression level of the fusion protein GPR17-RLuc (mean +/- s.e.m.: 
29.55 +/- 2.36%). Importantly, decrease in cell surface expression of GPR17-RLuc in comparison to 
wild type GPR17 was not due to deficient cellular expression, as similar total cellular levels of WT and 
fusion protein were detected by ELISA. In agreement with the obtained ELISA data, 
immunofluorescence studies using the same cell lines showed that GPR17-RLuc was expressed at the 
cell surface (C), but at reduced levels as compared with wild type GPR17 (B), and with discrete 
accumulation in the cytosol of the cells.  
 
Figure 48 Cell-surface expression of 3xHA-GPR17 C-terminally fused to Renilla luciferase (RLuc) is 
diminished 
A, The levels of surface and total GPR17 expression were determined by indirect ELISA. Immunological 
detection of an N-terminal 3xHA-epitope allowed a quantification of receptor proteins at the plasma 
membrane (dark grey bars). Permeabilization with triton X-100 (C52) enabled a determination of total receptor 
expression (light grey bars). The non-specific OD surface value was A450 nm: 0.051 +/- 0.009 and the OD 
surface value of the wild type HA-tagged GPR17 was A450 nm: 0.217 +/- 0.011. ELISA data are given as mean 
+/- s.e.m. of four to five independent experiments, each carried out in triplicate. Specific optical density (OD) 
readings were normalized to OD value of wild type 3xHA-tagged GPR17 cell surface expression. B, Fluorescence 
microscopy images on HEK293 cells stably expressing 3xHA tagged hGPR17 (wt), and 3xHA tagged hGPR17 C-
terminally fused to Renilla luciferase (RLuc) are shown. The following settings were used for Alexa Fluor 546 
recordings: 400 fold magnification, 100 ms exposure time, 0.99 γ and 2-22 histogram. Representative cells from 
at least three independent experiments are shown. After indirect immunofluorescence staining, no specific 
fluorescence was observed in untransfected HEK293 cells. Scale bars = 20 µM. 
4.1.6.1.1.1 GPR17-RLuc fusion protein internalizes upon agonist activation 
Internalization assay was used as an additional means to measure expression of fusion receptor 
GPR17-RLuc at the cell surface as well as receptor function compared to the wild type. In order to 
evaluate endocytosis of agonist-activated GPR17-RLuc, HEK293 cells stably expressing 3xHA-tagged 
GPR17-RLuc (HEK-GPR17-RLuc) were examined by indirect cellular ELISA, which enabled evaluation of 
HEK-GPR17 HEK-GPR17-RLuc
0
20
40
60
80
100 cell surface
total
ex
pr
es
sio
n
(%
 
of
 
HE
K-
G
PR
17
)
A B
C
20 µm
20 µm
4 Results  
 
99
the quantitative changes of surface expressed GPR17-RLuc upon agonist activation (10 µM RA-II-150) 
for indicated time periods. The agonist treatment induced receptor endocytosis within 15 min, and 
GPR17-RLuc continued to internalize, leading to ~32.2 +/- 4.7% (mean +/- s.e.m.) loss of cell surface 
expression (Figure 49). The extent of GPR17-RLuc internalization was slightly increased in comparison 
to wild type GPR17 (~26.2 +/- 2.3%). This relative enhancement does not regard the fact, that the 
fusion receptor GPR17-RLuc showed lower cell surface expression (Figure 48), which might lead to a 
mistakable, relatively higher internalization extent, although the total amount of internalized 
receptor might be similar. If precise information about respective internalization extent was needed, 
cell lines expressing equal amounts of receptors, wild type and RLuc fusion protein, would be 
necessary. For the present thesis, this information was negligible, as it was only important to see, 
that the fusion construct remains competent to internalize upon agonist stimulation, and this 
conclusion was undoubtedly possible. However, in addition this assay revealed, that the fusion 
receptor showed a more rapid endocytosis, as after 15 min already 18.2 +/- 6.1% of surface receptors 
were internalized, which relates to over 30% of the receptor internalized after 120 min. In 
comparison, the wild type showed lower rate of endocytosis (7.0 +/- 2.8%, 15 min), which represents 
only 26.7% of the internalized receptor at 120 min. Nevertheless, this information is likewise not 
crucial for subsequent BRET2 experiments.  
 
Figure 49 Time-dependent internalization behavior of agonist-activated GPR17-RLuc 
Colorimetric ELISA measurements of RA-II-150 (10 µM) induced GPR17 sequestration for the indicated time 
period. The amount of internalized receptor was calculated from the decrease in the level of surface-expressed 
receptor after agonist treatment compared with untreated, control cells. Each data point represents mean (+/- 
s.e.m.) of three to five independent experiments performed in triplicates. Data from HEK-GPR17 are shown in 
light grey color, as these data have already been presented before in Figure 44. 
4.1.6.1.2 GPR17-RLuc fusion protein maintains coupling via Gαq and Gαi/o 
After GPR17 C-terminally fused to Renilla luciferase (RLuc) has been proven to be expressed at the 
cell surface, even though in a reduced extent compared to wild type, and internalization analyses 
revealed no significant differences to the wild type receptor, the functional characteristics of agonist-
activated receptor were determined based on cAMP and IP1 assays.  
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As presented in Figure 50, the BRET2 fusion receptor retains its capability to couple via Gαq/11 and 
Gαi/o proteins. Challenging of GPR17-RLuc with increasing RA-II-150 concentrations revealed 
concentration-dependent IP1 accumulation (A) as well as inhibition of forskolin-stimulated cyclic 
AMP synthesis (B). As the latter effect was completely blunted by preincubation with PTX, the 
involvement of Gαi/o protein was proven. Both concentration-response curves were shifted to the 
right in comparison to curves obtained with analyses of wild type HEK-GPR17 cells. Whereas the 
potency to induce IP1 synthesis was only ~7-fold less (EC50 values 2.1 µM ↔ 0.3 µM), the potency to 
inhibit cAMP accumulation was ~500-fold decreased (EC50 values 1.0 µM ↔ 0.002 µM). Even more 
impressive was the fact, that the BRET2 fusion protein completely lost its ability to couple via Gαs 
proteins, since neither reverse bell-shaped CRCs were monitored, nor any increase of cAMP synthesis 
by stimulation with RA-II-150 concentrations, as high as possible, was detected. The loss of the 
stimulatory signaling pathway (Gαs) might be the reason for the stronger efficacy of the inhibitory 
(Gαi/o) effect on cAMP synthesis (Emax RLuc: 37.6 +/- 3.0% ↔ WT: 16.9 +/- 3.0%).  
 
Figure 50 GPR17-RLuc remains signaling competent via Gαq and Gαi/o proteins 
A-C, HEK293 cells stably expressing GPR17 C-terminally fused to Renilla luciferase were challenged with varying 
RA-II-150 concentrations. A-B, Data of wild type HEK-GPR17 were included for comparison. A, GPR17-mediated 
increase of intracellular IP1 was normalized and expressed as percent activation induced by 10 µM RA-II-150. B, 
Stimulation of GPR17 with increasing concentrations of RA-II-150 in the presence of 1 µM forskolin. GPR17-
mediated decrease of intracellular cAMP was calculated as percent inhibition of adenylate cyclase stimulated 
with forskolin (1 µM). Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 18 h) completely abolished inhibition 
of FSK induced cAMP accumulation C, Stimulation of GPR17 did not increase intracellular cAMP synthesis, 
whereas 1 µM forskolin elevated basal cAMP levels. Data were expressed as arbitrary units. For statistical 
analyses, paired t-tests with two-tailed p values and 95% confidence interval were applied and revealed no 
significant differences of RA-II-150 induced values compared to basal levels, whereas forskolin induced 
elevation was significant (*p < 0.05). A-C, All data are means (+/- s.e.m.) of three to four experiments 
performed in duplicates.  
Table 38 Parameters of averaged RA-II-150 concentration-effect curves determined by IP1 and cAMP 
assays with the BRET2 fusion receptor GPR17-RLuc, as depicted in Figure 50 (± s.e.m.) 
assay pEC50 bottom value (%) top value (%) nH n 
IP1 5.68 ± 0.09 -1.8 ± 2.9 103.2 ± 4.2 1.0 (fixed) 3-6 
cAMP 6.00 ± 0.16 62.4 ± 3.0 100.9 ± 1.8  1.0 (fixed) 3-4 
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4.1.6.1.3 BRET2 fusion receptor GPR17-RLuc induces dynamic mass redistribution upon 
agonist activation 
The resonant waveguide grating biosensor technology was employed to resolve signaling capability 
of the BRET2 fusion receptor GPR17 C-terminally fused to RLuc in real time. The stable HEK-GPR17-
RLuc cells responded with specific optical signatures when exposed to increasing concentrations of 
GPR17 agonist RA-II-150 (Figure 51). The obtained signature profile resembled the one observed for 
Gαi-coupled CRTH2 receptor in HEK293 cells (Schröder et al. 2009, Schröder et al. 2010). As it is 
known, that the major G protein signaling pathways engaged by receptors from different coupling 
classes yield pathway-specific optical traces dependent on the cellular background (Fang, Frutos & 
Verklereen 2008, Lee et al. 2008, Schröder et al. 2010), one could conclude that GPR17-RLuc couples 
via Gαi protein. This assumption was further proven, as the pretreatment with the Gαi/o inhibitor 
PTX resulted in a partial inhibition of the optical traces (B).  
The optical signatures of GPR17-RLuc virtually overtopped those of the wild type receptor (see Figure 
41 for comparison), despite the fact that the fusion receptor showed significantly lower cell surface 
expression (Figure 48). Thus the fusion receptor GPR17-RLuc turned out to be superior in real time 
DMR assays, regarding the maximum response. As Gαs-induced DMR signals might begin with a 
negative DMR event (Fang, Li & Ferrie, Kebig et al. 2009, Schröder et al. 2010), the loss of this 
pathway, which has been reported in 4.1.6.1.2, could be the reason for the observed amplification of 
DMR response. 
 
Figure 51 Agonist-induced activation of GPR17-RLuc triggers DMR in a PTX-sensitive manner 
A-B, HEK293 cells stably expressing GPR17-RLuc were challenged with the indicated concentrations of the 
GPR17 agonist RA-II-150 in the absence (A) or presence (B) of the Gαi/o inhibitor PTX (50 ng/ml, 18 h). The 
resulting picometer-shifts of reflected light wavelength over time [s] were monitored as a measure of 
functional activity. Presented data are means + s.e.m. from a representative optical trace experiment of five to 
six independent experiments performed in triplicates.  
The transformation of the GPR17-RLuc optical signatures into concentration-response curves for 
RA-II-150 using maximum response (pm) revealed an EC50 value of 1.5 µM (Figure 52), which is very 
similar to the one obtained from wild type GPR17 DMR assays (1.4 µM, see Figure 42 for 
comparison). Thus, despite the apparent higher efficacy of GPR17-RLuc in DMR assays in comparison 
to the wild type receptor, the potency of RA-II-150 is virtually identical at both receptors, 
demonstrating that the BRET2 fusion receptor retains its proper functional characteristics. 
Furthermore it could be concluded that the EC50 value determined by use of DMR assays (1.5 µM) 
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represents a mean value of both EC50 values obtained with the second messenger assays (Gαi/o 
~1.0 µM; Gαq ~2.1 µM), thus both pathways seem to contribute with the same impact on DMR 
responses. PTX pretreatment caused a significant (student t-test, p= 0.0006) rightward shift of 
concentration-response curve, and individual data points revealed higher PTX-sensitivity than data 
points determined with wild type HEK-GPR17 cells (Figure 42). The increase of PTX-sensitivity is most 
likely caused due to the loss of Gαs-mediated signal transduction. Based on performed second 
messenger analyses, the remaining DMR is most likely caused by Gαq-mediated transduction. 
However, the EC50 value of PTX pretreated cells does not resemble the EC50 value determined in 
IP1 assays.  
 
Figure 52 Concentration-dependence and partial PTX-sensitivity of RA-II-150 induced DMR 
Comparison of concentration-effect curves resulting from DMR assays of HEK-GPR17-RLuc cells challenged with 
indicated concentrations of GPR17 agonist RA-II-150 in the presence or absence of the Gαi/o inhibitor PTX 
(50 ng/ml, 18 h). Data are presented as maximum response of wavelength shift and all data points represent 
mean (+/- s.e.m.) of five to six independent experiments performed in triplicates. For statistical analyses, 
individual concentrations were compared by two-way ANOVA with Bonferroni’s correction for multiple 
comparisons (***p < 0.001). 
Table 39 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 52 (± s.e.m.) 
cell line pEC50 bottom value (pm) top value (pm) nH n 
HEK-GPR17-RLuc  5.82 ± 0.10 18.2 ± 13.4 450.3 ± 19.6 1.0 (fixed) 5-6 
HEK-GPR17-RLuc 
+ PTX 
4.84 ± 0.09 -3.7 ± 6.5 363.6 ± 20.6 1.0 (fixed) 5-6 
 
4.1.6.2 Rapid recruitment of β-arrestin2 to the agonist-activated GPR17 and sustained 
protein-protein interaction 
Since fusion of GPR17 to Renilla luciferase (RLuc) did not impair its ability to promote agonist-
stimulated inositol phosphate accumulation and cyclic AMP inhibition, respectively, as well as the 
rate of internalization, a BRET2 assay was established for further analyses of the generated construct.  
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The kinetic analyses of the ligand induced BRET signal between GPR17-RLuc and β-arrestin2-GFP2 
was performed on two time windows. The recruitment kinetic was determined on a time window of 
120 s after RA-II-150 injection, whereas the sustained receptor-arrestin interaction was evaluated on 
a time window from 1 to 60 min after RA-II-150 injection. As depicted in Figure 53, RA-II-150-induced 
BRET increase occurred rapidly without any lag time and half maximum BRET ratio was already 
reached after 20.9 +/- 2.0 s (A). This rapid translocation of β-arrestin2-GFP2 to the agonist-activated 
GPR17-RLuc, followed by a constant rise, was further substantiated with endpoint kinetic assays (B), 
as already after one minute the maximum BRET ratio was reached and persisted for the next 5 min. 
The β-arrestin2-GFP2 and GPR17-RLuc association declined only slowly, with a 18% decrease after 
10 min and 66% decrease after 60 min (*p < 0.05). 
 
Figure 53 Kinetic analyses of RA-II-150-induced BRET increase between GPR17 and β-arrestin2 
A-B, HEK293 cells stably coexpressing GPR17-RLuc and β-arrestin2-GFP2 were used for BRET2 experiments, and 
repetitive signals were recorded before and after the injection of RA-II-150 (1 µM) during 140 s (A) and 60 min 
(B), respectively. A, BRET measured every 2.4 s. BRET signal was fitted with GraphPad Prism4 (plateau than 
increase to top equation). B, Data were normalized and expressed as percent of maximum recruitment induced 
by RA-II-150 (5 min). A-B, Each data point represents mean (+/- s.e.m.) of three to five independent 
experiments performed in triplicates. For statistical analyses, paired t-tests with two-tailed p values and 95% 
confidence interval were applied (*p < 0.05). 
4.1.6.3 Recruitment of β-arrestin2 to agonist-activated GPR17 in a concentration-
dependent and partially PTX-sensitive manner 
After determination of translocation and adhesion kinetics of β-arrestin2 recruitment to the 
RA-II-150-activated GPR17, a time window of 5 min was chosen for agonist stimulation to analyze 
concentration-dependence. The BRET2 signal was measured in the absence and presence of 
increasing concentrations of the GPR17 agonist RA-II-150. As presented in Figure 54, RA-II-150 
promoted a concentration-dependent increase in BRET2, indicative of an association between 
GPR17-RLuc and β-arrestin2-GFP2. The absolute EC50 value calculated for this agonist-induced 
interaction was ~0.4 µM, thus the potency determined by BRET2 assays was 2.5- up to 5.5-fold 
higher in comparison with the data obtained in second messenger and DMR assays. Preincubation 
with Gαi/o inhibitor PTX induced a slight rightward shift of the concentration-response curve. Even 
though this effect was not statistically significant (p < 0.05), this phenomenon was in good 
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agreement with previous data obtained with PTX preincubation (DMR analyses, Figure 52), and 
indicated participation of Gαi/o-mediated signaling in β-arrestin2 recruitment.  
 
Figure 54 Concentration-dependent β-arrestin2 recruitment to agonist-activated GPR17 
HEK293 cells stably transfected with β-arrestin2-GFP2 and GPR17-RLuc (HEK-BRET-GPR17) were exposed to 
indicated concentrations of RA-II-150, and agonist-induced increases in BRET ratio were monitored. 
Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 18 h) did not have a significant influence (p < 0.05). Each data 
point represents mean (+/- s.e.m.) of three to six independent experiments performed in triplicates. For 
statistical analyses, paired t-tests with two-tailed p values and 95% confidence interval were applied. 
Table 40 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 54 (± s.e.m.) 
cell line pEC50 bottom value 
(net BRET ratio) 
top value 
(net BRET ratio) 
nH n 
HEK-BRET-GPR17  6.38 ± 0.12 3.0 ± 4.0 130.3 ± 5.2 1.0 (fixed) 6 
HEK-BRET-GPR17 + PTX 6.01 ± 0.14 3.1 ± 4.8 126.6 ± 7.3 1.0 (fixed) 3 
 
4.1.6.4 Mechanistic insights into the β-arrestin2 recruitment to GPR17 upon stimulation 
with RA-II-150 
Now that β-arrestin2 recruitment to activated GPR17 upon RA-II-150 stimulation has been proven by 
BRET2 assays, it was the aim to further investigate the underlying mechanism of this translocation. 
Especially the impact of the heterotrimeric G proteins was of interest, as at least for some receptors, 
β-arrestin-mediated functions, such as internalization or signaling, have been demonstrated to occur 
independent of prior G protein-coupling (reviewed by Defea 2008, DeWire et al. 2007, Violin & 
Lefkowitz 2007). 
4.1.6.4.1 BIM-46187: a suitable tool to analyze G protein independent recruitment of β-
arrestin? 
The analyses of GPR17 C-terminally fused to Renilla luciferase (RLuc) revealed its capability to couple 
via Gαi/o and Gαq proteins (see 4.1.6.1). Thus, a small molecule modulating both pathways in 
parallel was needed to further analyze whether the observed β-arrestin-recruitment occurs in a 
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G protein independent manner. As no such compound exists, the small molecule BIM-46187 was 
chosen for further analyses. BIM-46187 was published as a small molecule pan-inhibitor of G protein 
signaling, that prevents the accurate interaction of receptors with the G protein heterotrimer 
through a direct binding to the Gα subunit, consequently promoting inhibition of the agonist-induced 
GDP/GTP exchange (Ayoub et al. 2009).  
4.1.6.4.1.1 Label-free dynamic mass redistribution technology unsuitable to characterize 
pan G protein inhibition by BIM-46187 
As a first attempt, the impact of BIM-46187 was analyzed using dynamic mass redistribution (DMR) 
technology, since this method is able to analyze both G protein pathways of interest simultaneously.  
 
Figure 55 BIM-46187 induces prominent negative dynamic mass redistribution 
A-B, HEK293 cells stably coexpressing β-arrestin2-GFP2 and GPR17-RLuc were challenged with the indicated 
concentrations of BIM-46187 in the absence (A) or presence (B) of forskolin (10 µM). Wavelength shift [pm] 
over time [s] was monitored by use of the Epic® system. Representative optical trace experiment 
(mean + s.e.m.) of at least three independent experiments performed in triplicates are shown. 
HEK293 cells stably co-expressing β-arrestin2-GFP2 and GPR17-RLuc (HEK-BRET-GPR17) were 
challenged with three different BIM-46187 concentrations (10, 30 and 100 µM), and cells responded 
with a strong negative DMR, in a concentration-dependent manner (Figure 55, A). Furthermore, the 
influence of BIM-46187 on forskolin induced DMR was investigated for control purposes. Therefore 
HEK-BRET-GPR17 cells were preincubated (2.5h) with the indicated BIM-46187 concentrations, 
followed by stimulation with forskolin (Figure 55, B). As this diterpene is known to act directly via 
stimulation of the adenylate cyclase, independent of G proteins, BIM-46187 should not have any 
impact on forskolin-triggered DMR. However, preincubation with BIM-46187 resulted in 
concentration-dependent inhibition of forskolin-mediated wavelength shifts. The negative DMR 
induced by BIM-46187 probably compensated the forskolin-triggered positive DMR, thus resulting in 
a neutralized optical signature, even though the actual signaling event might not be influenced. 
Regarding these results, it was concluded that DMR technology does not represent an appropriate 
method to analyze the impact of BIM-46187 on GPR17-mediated signaling. 
4.1.6.4.1.2 Cell type dependent properties of BIM-46187 
Subsequent to the analyses of BIM-46187 in Epic® assays, traditional second messenger assays were 
performed to further elucidate suitability of this small molecule. Therefore, first of all, the influence 
on forskolin-stimulated cAMP accumulation was examined. As presented in Figure 56 (A), 
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preincubation with increasing BIM-46187 concentrations did not result in reduction of forskolin-
induced synthesis of cAMP. Thus, these data support the conclusion that inhibition of forskolin-
induced DMR, monitored with the Epic® system (see 4.1.6.4.1.1), was due to compensation effects of 
negative and positive DMR events and not mediated by direct inhibition of adenylate cyclase.  
 
Figure 56 Influence of BIM-46187 on cAMP accumulation analyzed in HEK293 cells stably 
coexpressing GPR17-RLuc and β-arrestin2-GFP2 
A-C, HEK293 cells stably coexpressing β-arrestin2-GFP2 and GPR17-RLuc were analyzed by cAMP assays. A, 
Stimulation of adenylate cyclase with constant forskolin concentration (10 µM), preincubated (2.5h, 37°C) with 
increasing BIM-46187 concentrations. Forskolin induced increase of intracellular cAMP was calculated as 
percent of cAMP determined by stimulation with forskolin (10 µM) in the absence of BIM-46187. B, Cells were 
stimulated with increasing concentrations of RA-II-150 in the presence of 0.3 µM forskolin. GPR17-mediated 
decrease of intracellular cAMP was calculated as percent inhibition of adenylate cyclase stimulated with 
forskolin (0.3 µM). Pretreatment with BIM-46187 (30 and 100 µM) did not significantly influence GPR17-
mediated inhibition. C, Cells, endogenously expressing prostanoid receptors (EP2 and EP4) were challenged 
with 10 µM forskolin (FSK) as a control, as well as with 0.1 µM prostaglandin E1 (PGE1, C40) without (w/o) or 
with preincubation of increasing BIM-46187 concentrations. Elevation of intracellular cAMP was normalized 
and expressed as percent of maximum activation induced by 0.1 µM PGE1. B-C, For statistical analyses, paired 
t-tests with two-tailed p values and 95% confidence interval were performed. A-C, All data are means 
(+/- s.e.m.) of three to five experiments performed in duplicates. 
Based on SRE-Luc gene reporter assays applied to COS-7 cells transiently expressing PAR1 (protease-
activated receptor 1), which is known to activate many different G proteins including Gαi/o, Gαq and 
Gα12/13, BIM-46187 has been reported to diminish Gαi/o-mediated effects (Ayoub et al. 2009). 
Based on this information, the influence of BIM-46187 on GPR17-induced inhibition of cAMP 
accumulation was investigated. However, preincubation with two BIM-46187 concentrations 
(30 and 100 µM) did not significantly influence RA-II-150-induced concentration-response curves, 
thus contrary to expectations; BIM-46187 did not inhibit GPR17-mediated Gαi/o-induced effect on 
adenylate cyclase (Figure 56, B).  
Ayoub et al. further observed the effects of BIM-46187 in whole cells, monitored by cAMP 
production. COS-7 cells, transiently expressing GPCRs known to couple via Gαs (V2, β2-AR and 5-
HT4a), were preincubated with BIM-46187, that dramatically inhibited Gαs-mediated cAMP 
production in a concentration-dependent manner. Despite their observation, preincubation of 
HEK293 cells, endogenously expressing Gαs-linked prostanoid receptors (EP2R and EP4R, Willoughby 
et al. 2007), with BIM-46187, did not significantly alter prostaglandin E1 (PGE1) mediated increase of 
intracellular cAMP (Figure 56, C). 
-11 -10 -9 -8 -7 -6 -5 -4 -3
0
25
50
75
100
125
10 µM Forskolin
buffer
BIM-46187 (log M)
cA
M
P
(%
 
o
f 1
0 
µM
 
FS
K)
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
125
150
w/o
30   µM BIM
100 µM BIM
RA-II-150 (log M)
In
hi
bi
tio
n
 
of
 
FS
K-
st
im
ul
at
ed
cA
M
P 
ac
cu
m
u
la
tio
n
(%
 
of
 
0.
3 
µM
 
FS
K)
bu
ffe
r 
10 
µM
 
FS
K
w/o
+ 
10
 
µM
 
BIM
+ 
30
 
µM
 
BIM
+ 
10
0 µ
M 
BIM
0
20
40
60
80
100
120
cA
M
P
(%
 
o
f 0
.
1 
µM
 
PG
E1
)
0.1 µM PGE1
A B C
4 Results  
 
107
Furthermore, Ayoub et al. reported inhibition effects of BIM-46187 in COS-7 cells, transiently 
expressing GPCRs known to couple via Gαq (PAR1, LPAR1 and 5-HT2ca), monitored by means of IP1 
assays. Similar to cAMP analyses, preincubation with BIM-46187 dramatically inhibited Gαq-
mediated IP1 production in a concentration-dependent manner. Regarding this information, HEK293 
cells stably expressing GPR17-RLuc were analyzed according to inhibition effects of BIM-46187 on 
RA-II-150-induced intracellular IP1 accumulation. Interestingly, preincubation with the small 
molecule (30 and 100 µM) did significantly and almost completely diminish the GPR17-mediated IP1 
production in a concentration-dependent manner (Figure 57, A). This apparent pathway-specific 
inhibition was further proven, as carbachol-induced IP1 production through activation of 
endogenously expressed muscarinic receptors (M1 and M3, Estacion et al. 2004, Mundell & Benovic 
2000) was likewise inhibited by preincubation with BIM 46187. To control that observed inhibition 
effects on Gαq-mediated IP1 increase were not due to any peculiar effects of BIM-46187, the 
influence on basal IP1 levels was examined and did not reveal any significant unspecific impact 
(Figure 57, B). 
 
Figure 57 Influence of BIM-46187 on IP1 accumulation analyzed in HEK293 cells stably coexpressing 
GPR17-RLuc and β-arrestin2-GFP2 
A-B, HEK293 cells stably coexpressing β-arrestin2-GFP2 and GPR17-RLuc were analyzed by IP1 assays. 
Intracellular IP1 levels were expressed as arbitrary units. For statistical analyses, paired t-tests with two-tailed 
p values and 95% confidence interval were applied (*p < 0.05, **p < 0.01, ***p < 0.001). All data are means 
(+/- s.e.m.) of three to four experiments performed in duplicates. 
Based on the results with BIM-46187 preincubation, one could conclude that, despite the reported 
information about this small molecule as a pan-inhibitor of G protein-dependent signaling (Ayoub et 
al. 2009) it only acts as a pathway specific inhibitor by diminishing Gαq-mediated signaling events. 
Since all so far observed results presented in this thesis were obtained in HEK293 cells stably 
coexpressing β-arrestin2-GFP2 and GPR17-RLuc, and regarding the fact that Ayoub et al. mainly 
investigated BIM-46187 in COS-7 cells transiently transfected with appropriate GPCRs, it was a next 
aim to further evaluate the small molecule and its inhibition effects in COS-7 cells.  
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Figure 58 Influence of BIM-46187 on cAMP accumulation in COS-7 cells 
Untransfected COS-7 cells, endogenously expressing prostanoid receptors were challenged with forskolin 
(1 and 10 µM FSK) as a control, as well as with prostaglandin E1 (0.1 and 1 µM PGE1, C40), both without (w/o) 
or with preincubation of increasing BIM-46187 (BIM) concentrations (30 and 100 µM). Elevation of intracellular 
cAMP was normalized and expressed as percent of maximum activation induced by 10 µM forskolin. For 
statistical analyses, unpaired t-tests with two-tailed p values and 95% confidence interval were performed 
(*p < 0.05, **p < 0.01). All data are means (+/- s.e.m.) of three experiments performed in triplicates. 
Therefore PGE1 was chosen to stimulate cAMP accumulation via endogenously expressed prostanoid 
receptors. Similar to the results obtained in HEK293 cells, elevation of forskolin-induced cAMP levels 
were not inhibited by preincubation with BIM-46187, confirming its absence of nonspecific AC 
inhibition. However interestingly, in COS-7 cells preincubation with BIM-46187 resulted in a 
significant inhibition of PGE1-induced Gαs-mediated cAMP accumulation. Both applied PGE1 
concentrations, 0.1 and 1 µM, did increase intracellular cAMP concentrations in a concentration-
dependent manner (without preincubation, w/o), and both utilized BIM-46187 concentrations 
(30 and 100 µM, respectively) did inhibit this effect (Figure 58). Regarding the fact that BIM-46187 
did also significantly decrease the basal intracellular cAMP level (buffer values in Figure 58), one 
could conclude that these examined inhibition effects were some unspecific artifacts, but as 
preincubation with BIM-46187 did not have any impact on forskolin-induced cAMP elevation, it 
should be reliable, that inhibition effects of the small molecule were due to its ability of inhibiting 
Gαs-initiated intracellular effects on adenylate cyclase. The decrease of the basal cAMP level could 
be explained by the presence of constitutively active GPCRs endogenously expressed in COS-7 cells, 
thus inhibiting these receptors would result in a lowered basal cAMP level. Similar effects are known 
for YM-254890, as preincubation with the specific Gαq/11 inhibitor might result in a lowered IP1 
concentration (Figure 59, and Schröder et al. 2010).  
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4.1.6.4.2 GPR17 acts as a balanced receptor 
After uncovering Gαi/o and Gαq as the G protein-dependent signaling pathways of the BRET2 fusion 
construct GPR17-RLuc upon stimulation with RA-II-150 (see 4.1.6.1.2), and evaluation of the small 
molecule BIM-46187 to not represent a suitable tool to diminish both pathways simultaneously in 
HEK293 cells (see 4.1.6.4.1), it was the next goal to assess, whether combination of the Gαi/o 
inhibitor pertussis toxin (PTX) and the Gαq inhibitor YM-254890 would be a feasible method to 
analyze whether G protein-independent β-arrestin2-recruitment upon GPR17 activation occurs.  
Initially, as depicted in Figure 59 (A-C), the pharmacological inhibitors were examined by means of 
second messenger assays (cAMP and IP1) and dynamic mass redistribution technology (DMR, Epic® 
system) by use of HEK293 cells stably expressing GPR17 C-terminally fused to RLuc and β-arrestin2 N-
terminally labeled with GFP2 (HEK-BRET-GPR17). Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 
18 h) completely abolished the concentration-dependent inhibition of forskolin-induced cAMP 
accumulation initiated by RA-II-150-activated GPR17 (Figure 59, A). Likewise, the Gαq inhibitor 
YM-254890 (300 nM, 2.5h) completely diminished the RA-II-150 induced IP1 accumulation (B). These 
results were further confirmed in Epic® assays (C), as the optical DMR signatures triggered with 
RA-II-150 (1 µM) were partly sensitive to pretreatment with PTX (50 ng/ml, 18 h) and YM-254890 
(300 nM, 2.5 h), respectively, but completely abrogated in the presence of a combination of both 
pharmacological modulators (PTX and YM). Thus, simultaneous incubation with PTX and YM-254890 
of HEK-BRET-GPR17 cells prior to β-arrestin-translocation assays (BRET2) enables analyses of 
G protein-independent recruitment to the activated receptor. In addition, the influence of BIM-
46187 that has been shown to inhibit GPR17-mediated IP1 accumulation (Figure 57) on β-arrestin2-
recruitment has been analyzed.  
The obtained results, as depicted in Figure 59 (D), revealed that GPR17 acts as a balanced receptor, 
meaning that even though the G protein-mediated signaling pathways were completely abrogated, 
β-arrestin2 was still partly recruited to the agonist-activated GPR17, thus in a G protein-independent 
manner. The Gαi/o inhibitor revealed a superior inhibition on GPR17-mediated β-arrestin2 
translocation in comparison to the Gαq inhibitor YM-254890 (PTX: 34.2 +/- 6.2 % ↔ YM: 17.4 +/-
 8.4 %), comparable to the results obtained by means of DMR analyses. Whereas the additive effect 
of both inhibitors resulted in a complete abrogation of GPR17-induced optical signatures, the β-
arrestin2-recruitment was only decreased slightly above the half (55 +/- 7 %), which is consistent 
with the calculated theoretical sum of each inhibitor (~51.6 %), thus confirming that it was an 
additive effect. Preincubation with BIM-46187 resulted in comparable results as obtained with YM-
254890, whereas 30 µM revealed slightly lower (13.9 +/- 9.9 %) and 100 µM a slightly bigger 
(23.3 +/- 5.8 %) inhibition effect. Likewise, additive effects were monitored by simultaneous 
preincubation with PTX, causing strongest inhibition (63.7 +/- 5.7 %) with PTX and 100 µM BIM-
46187. These findings further prove the previously postulated Gαq-selective inhibition of BIM-46187 
in HEK293 cells.  
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Figure 59 GPR17-mediated β-arrestin2 recruitment is only partly G protein-dependent 
A-D, HEK293 cells stably coexpressing GPR17 C-terminally fused to Renilla luciferase (RLuc) and β-arrestin2 N-
terminally fused to GFP2 (HEK-BRET-GPR17 low) were challenged with indicated concentrations of GPR17-
agonist RA-II-150. A, Cells were stimulated with increasing RA-II-150 concentrations in the presence of 10 µM 
forskolin (FSK). GPR17-mediated decrease of intracellular cAMP was calculated as percent inhibition of 
adenylate cyclase stimulated with forskolin (10 µM). Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 18 h) 
completely abolished inhibition of FSK induced cAMP accumulation. B, RA-II-150 (1 µM) induced IP1 production 
was completely abrogated in the presence of Gαq inhibitor YM-254890 (YM, 300 nM, 2.5h). Intracellular IP1 
levels were expressed as arbitrary units. C, The optical DMR signature obtained with RA-II-150 (1 µM) was 
partly sensitive to pretreatment with PTX (50 ng/ml, 18 h) and YM-254890 (300 nM, 2.5 h), respectively, but 
completely abolished in the presence of a combination of both modulators (PTX + YM). D, Influences of Gαi/o 
inhibitor PTX (50 ng/ml, 18 h), Gαq inhibitor YM-254890 (300 nM, 2.5h) and BIM-46187 (30 and 100 µM, 2.5h) 
on agonist-induced increases in BRET2 ratio were monitored. Data were normalized and expressed as percent 
of maximum activation induced by RA-II-150 (1 µM) without (w/o) pretreatment. A-D, Each data point 
represents mean (+/- s.e.m.) of three to six independent experiments performed in triplicates. For statistical 
analyses, unpaired t-tests with two-tailed p values and 95% confidence interval were applied. A-D, All data are 
means (+/- s.e.m.) of three to nine experiments performed in triplicates.  
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4.1.7 Receptor panning of multiple cell systems with GPR17 agonist 
The strategies applied so far to elucidate signaling patterns of GPR17, such as over expression into 
host cells (here CHO and HEK) and / or receptor labeling, offer benefit in sensitivity of detection, but 
do not inevitably exhibit biological relevance or predictability of physiological importance. GPCRs are 
able to activate different signaling pathways depending on their cellular surroundings, thus the 
ability of a ligand to trigger functional responses is dependent on cellular background, receptor 
expression levels and coupling efficiencies (Eglen 2005, Kenakin 2002, Kenakin 2005, Milligan 1993). 
The previous results, as determined before, verified that the potency and efficacy of RA-II-150 
showed differences between the two analyzed cellular backgrounds as well as between different 
signaling pathways. In order to obtain more insight into the physiological importance of the 
described signaling pathways, it was the aim to identify a cellular system endogenously expressing 
GPR17. Therefore various cell systems, including mostly immortalized but also primary cell lines, 
were analyzed by use of the Epic® system, which enables whole-cell and label-free detection of 
endogenously expressed GPCRs with high sensitivity (Fang, Li & Ferrie, Fang & Ferrie 2007, Schröder 
et al. 2010). Thus, a panning of the GPR17 agonist RA-II-150 against cell systems by means of DMR 
analyses was used to map endogenously expressed GPR17. Part of the panning was generously 
provided by Dr. Ye Fang (Corning® Company, NY, USA). 
Unfortunately, as depicted in Figure 60, none of the analyzed cell lines responded to the stimulation 
with the GPR17-agonist RA-II-150, whereas the applied positive controls always revealed that assay 
conditions were properly chosen as well as cell viability was highly sufficient. Even HUVEC cells 
(human umbilical vein endothelial cells), which have been reported to express GPR17 (Ciana et al. 
2006), did not reveal any detectable DMR after challenge with RA-II-150.  
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Figure 60 Receptor panning with GPR17-agonist RA-II-150 by DMR assays 
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Figure 60 Native cell lines were challenged with the GPR17-agonist RA-II-150 (10 µM) and the indicated positive 
controls (10 µM adenosine triphosphate / ATP, 10 µM adenosine-5-N-ethylcarboxamide / NECA, 10 µM 
nicotinic acid, 10 µM phorbol myristate acetate / PMA and 10 µM forskolin). Wavelength shift [pm] over time 
[s] was monitored as a measure of functional activity. Signatures were baseline-corrected by subtraction of 
buffer traces from the DMR responses after receptor activation. Data kindly provided by Dr. Ye Fang are 
indicated with *. Representative optical trace experiment (mean + s.e.m.) of one to five independent 
experiments performed in triplicates.  
4.1.7.1 Generation of a GPR17-deficient cellular tool for further cell differentiations 
derived from murine embryonic stem cells  
Since all the efforts finding an appropriate cell system, which endogenously expresses GPR17 by 
means of DMR analyses failed, it was the aim to generate a cellular tool, which offers the capability 
to be differentiated into a desired cell system, especially of neural cell type such as cortical neurons 
(Gaspard et al. 2009) or spinal cord motor neurons (Wichterle et al. 2002). Therefore murine 
embryonic stem cells were modified by gene targeting to obtain pluripotent cells with heterozygous 
knocked-out GPR17 (see 3.4). The homologous recombination was verified by PCR screening and 
revealed three clones where TM2-TM6 of GPR17 were heterozygously knocked-out (Figure 35), 
discerned by the presence of an integrated neomycin-resistance cassette. The proceeding 
modifications of the heterozygous modified embryonic stem cells, such as homologous knock-out 
and differentiation into the desired neural cell type, were beyond the scope of the present thesis, 
and will be conducted in the future. 
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4.2 The influence of β-arrestin2 coexpression on GPR17-mediated signaling 
patterns upon agonist-induced activation 
Following the elucidation of GPR17-mediated signaling patterns, the focus was set on β-arrestin 
coexpression and its impact on the receptor’s signaling outcome. As described in chapter 1.3 and 
reviewed by many authors (e.g. Lefkowitz & Shenoy 2005, Luttrell & Lefkowitz 2002), β-arrestins 
possess multiple functions regarding regulation of agonist-activated GPCR signaling, particularly 
desensitization of subsequent G protein-coupling, promotion of receptor trafficking, and stimulation 
of signaling cascades in a G protein-independent manner. To analyze whether increasing β-arrestin 
expression levels exhibit an influence on GPR17-induced signaling, HEK293 cells stably expressing 
distinct β-arrestin2 amounts (kindly provided by J. M. Mathiesen, Department of Medicinal 
Chemistry, University of Copenhagen) were stably transfected with GPR17-RLuc fusion protein 
labeled with 3xHA tag to enable further expression analyses. Thus, one single and three double 
stable cell lines, initially generated for β-arrestin-recruitment studies (BRET2 assay), were analyzed: 
• HEK293 cells + 3xHA-hGPR17-RLuc 
→ endogenous 
• HEK293 cells + 3xHA-hGPR17-RLuc + low amounts of β-arrestin2-GFP2 
→ low 
• HEK293 cells + 3xHA-hGPR17-RLuc + high amounts of β-arrestin2-GFP2 
→ high 
• HEK293 cells + 3xHA-hGPR17-RLuc + very high amounts of β-arrestin2-GFP2 
→ very high 
The HEK293 cells stably transfected with fusion protein β-arrestin2-GFP2 were sorted based on 
respective fluorescence intensity caused by the autofluorescent tag GFP2 by use of FACS analyses 
(fluorescence activated cell sorting, kindly conducted by J. M. Mathiesen, Department of Medicinal 
Chemistry, University of Copenhagen), and photos of respective cell lines obtained by fluorescence 
microscopy are depicted in the appendix of this thesis (Annex Figure 2). Cell lines will be further 
referred to as endogenous, low, high and very high, based on their β-arrestin2 expression levels. 
The impact of β-arrestin2 coexpression on GPR17-mediated signaling outcome was analyzed 
regarding the previously determined G protein-dependent signaling events. 
4.2.1 No linear correlation between coexpression of β-arrestin2 and GPR17 cell surface 
expression 
Initially, self-engineered stable HEK293 cell lines were analyzed concerning their GPR17 expression 
levels, to determine whether these pooled clones were suitable for further comparative analyses.  
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As already presented in Figure 48, the fusion of the receptor C-terminally to the Renilla luciferase 
(RLuc) did result in a significantly lowered cell surface expression in comparison to the total receptor 
expression, determined by permeabilization with triton X-100 (Figure 61).  
In contrast to a suspected lowered cell surface expression due to enhanced β-arrestin2-mediated 
internalization, data obtained with indirect ELISA analyses revealed a slight, but significant increase 
of relative cell surface expression with low (115.7 +/- 4.0%) and high (136.7 +/- 4.9%) amounts of β-
arrestin2 coexpression in comparison to the endogenous levels present in HEK293 cells, which was 
set as 100 percent (100.4 +/- 0.2%) (Figure 61). Only the GPR17 surface expression in HEK293 cells 
comprising very high amounts of β-arrestin2 was significantly lowered by 83.4 +/- 5.3%. 
 
Figure 61 Cell-surface expression of 3xHA-GPR17 C-terminally fused to Renilla luciferase (RLuc) 
coexpressed with increasing β-arrestin2 amounts 
The levels of surface and total GPR17 expression were determined by indirect ELISA. Immunological detection 
of an N-terminal 3xHA-epitope allowed quantification of receptor proteins at the plasma membrane (dark grey 
bars). Permeabilization with triton X-100 (C52) enabled determination of total receptor expression (light grey 
bars). The non-specific OD surface value was A450 nm: 0.057 +/- 0.007 and the OD surface value of the 3xHA-
tagged GPR17-RLuc expressed in native HEK293 cells (endogenous) was A450 nm: 0.105 +/- 0.008. ELISA data 
are given as mean +/- s.e.m. of three to seven independent experiments, each carried out in triplicate. Specific 
optical density (OD) readings were normalized to OD value of 3xHA-tagged GPR17-RLuc cell surface expression 
in native HEK293 cells (endogenous). For statistical analyses, paired (low and high) and unpaired (very high), 
respectively, t-tests with two-tailed p values and 95% confidence interval were applied (*p < 0.05, **p < 0.01, 
***p < 0.001). 
This might be caused by the assumed higher internalization rate, but as well simply due to the total 
very high amount of proteins necessarily synthesized by the cell, which could be seen as well in the 
lowered total amount of GPR17 protein in the very high cells, whereas the three remaining cells 
(endogenous, low and high) did not differ significantly in their total GPR17 expression levels, 
indicating an insufficient protein synthesis in the very high cells.  
Thus, it was concluded, that three (endogenous, low and high) of the four generated cell lines 
represented appropriate tools to analyze the impact of increasing β-arrestin2 concentrations on 
GPR17 signaling patterns, whereas the very high cells turned out to be not as suitable, due to a 
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strongly decreased GPR17 expression level, but nevertheless might be a useful device to give some 
hints about β-arrestin2 influences. 
4.2.2 Effect of β-arrestin2 over-expression on RA-II-150-promoted GPR17 endocytosis 
Since β-arrestin2 is known for its role in mediating agonist-promoted G protein-coupled receptor 
trafficking (reviewed by Claing et al. 2002, Ferguson et al. 1996, Luttrell & Lefkowitz 2002), it was the 
aim to study whether increasing amounts of β-arrestin2 reveal some influence on RA-II-150-induced 
endocytosis of GPR17. The observation that β-arrestin2 was recruited to the RA-II-150 activated 
GPR17, revealing a strong and long lasting association (see 4.1.6.2), further highlighted potential 
influence on GPR17 trafficking.  
For that reason colorimetric cell surface ELISA analyses were performed utilizing three of the four 
generated cell lines stably expressing GPR17-RLuc and differing amounts of β arrestin2 (endogenous, 
low and high), whereas very high cells were disregarded due their very low GPR17 expression levels. 
In agreement with previous results (Figure 49) GPR17-RLuc was internalized from the cell surface 
following agonist application in all three cell lines. Equilibrium between surface and internalized 
receptors was reached after 60 min of permanent agonist exposure with the estimated intracellular 
pool of receptors being around 30%. GPR17 revealed a slightly enhanced endocytosis in high cells 
compared to receptor behavior in endogenous cells (32.2 +/- 4.7% ↔ 37.3 +/- 0.8% after 120 min), 
but this increase, probably caused by coexpression of β-arrestin2, was not significant as computed by 
two-way ANOVA with Bonferroni’s correction for multiple comparisons. Internalization rate 
determined in low cells appeared to be unchanged (31.4 +/- 3.0% after 120 min) in comparison to 
endogenous cells. Nevertheless, it should be regarded that high and low cells revealed a higher cell 
surface GPR17 expression than endogenous, thus, although the calculated relative internalization 
rate was not significantly increased, the total amount of internalized receptor, which was not 
examined, could be potentially even higher, as receptor number needed to obtain similar relative 
endocytosis needs to be higher when surface expression is higher.  
In agreement with expression analyses using colorimetric ELISA analyses (Figure 61), visualization of 
3xHA-GPR17 by immunofluorescence microscopy revealed predominant distribution in cytosolic 
vesicles devoid of agonist application (Figure 62, B). As a consequence, attempts to visualize GPR17 
internalization upon agonist-stimulation from cell membrane into the cytosol following receptor 
stimulation by immunofluorescence microscopy proved unsuccessful, as no clear visible change was 
detectable (data not shown).  
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Figure 62 Influence of β-arrestin2 coexpression on agonist-induced GPR17 internalization behavior 
A, Colorimetric ELISA measurements of RA-II-150 (10 µM) induced GPR17 sequestration for the indicated time 
period. The amount of internalized receptor was calculated from the decrease in the level of surface-expressed 
receptor after agonist treatment compared with untreated, control cells (HEK293). Each data point represents 
mean (+/- s.e.m.) of three to five independent experiments performed in triplicates. B, Receptor localization 
was imaged by immunofluorescence microscopy. HEK293 cells stably expressing GPR17-RLuc fused to an N-
terminal 3xHA tag were pre-labeled with anti-HA antibody (Table 22, A1), permeabilized with triton X-100 (C52) 
and immunostained with fluorescence antibody (Alexa Fluor 546 goat anti-mouse IgG, Table 22, A3). The 
following settings were used for Alexa Fluor 546 recordings: 400 fold magnification, 100 ms exposure time, 
0.99 γ and 2-22 histogram. Representative cells from at least three independent experiments are shown. After 
indirect immunofluorescence staining, no specific fluorescence was observed in untransfected HEK293 cells. 
Scale bars = 20 µm. 
4.2.3 Impact of β-arrestin2 coexpression on GPR17 initiated dynamic mass redistribution 
upon agonist stimulation 
As a first attempt to examine whether the increasing β-arrestin2 levels exhibit some influence on 
GPR17-mediated signaling, the dynamic mass redistribution (DMR) assay was chosen, since this 
method enables real time monitoring of the overall agonist-activated receptor signaling outcome.  
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4.2.3.1 Overall DMR induced by GPR17 is decreased in the presence of elevated β-
arrestin2 amounts while potencies are increased 
All analyzed cell lines (endogenous (A), low (B), high (C) and very high (D), see 4.2) responded with 
specific optical signatures when exposed to increasing concentrations of GPR17 agonist RA-II-150 
(Figure 63). The obtained signature profiles showed a rapid positive DMR event followed by an 
almost equally fast negative DMR episode, resulting in a spiky elevation, which might be also referred 
to as a ‘Gαi-nose’, as they resemble signatures observed for Gαi-coupled receptors in HEK293 cells, 
such as CRTH2 (Schröder et al. 2009, Schröder et al. 2010). Whereas the endogenous cells yielded a 
slower decreasing plateau after the sharp rise, and at least the highest concentrations 
(10 and 100 µM) did remain positive after 3600 s, the β-arrestin2 coexpressing cells (low, high and 
very high) showed less of this constant elevated plateau and all signatures were nearly at the basal 
level after the monitored time (3600 s).  
 
Figure 63 Influence of β-arrestin2 expression levels on GPR17-mediated dynamic mass redistribution 
optical signatures  
HEK293 cells stably expressing GPR17-RLuc (A) and HEK293 cells stably cotransfected with increasing amounts 
of β-arrestin2-GFP2 (B: low, C: high, D: very high) were challenged with the indicated concentrations of the 
GPR17 agonist RA-II-150. The resulting picometer-shifts of reflected light wavelength over time [s] were 
monitored by use of the Epic® system as a measure of functional activity. Presented data are means + s.e.m. 
from a representative optical trace experiment of three to nine independent experiments performed in 
triplicates. 
Thus, out of these optical signatures it was concluded, that GPR17 retains at least its capability to 
couple preferentially via Gαi/o-protein in the presence of increasing β-arrestin2 amounts, but 
additionally some change in signaling was suspected due to the changes of the signature shape.  
Even more interesting was the fact, that the optical signatures induced by GPR17-RLuc in HEK293 
cells without cotransfection of β-arrestin2 (endogenous, A) virtually overtopped all three double 
stable cell lines (low (B), high (C) and very high (D)), despite the fact that the endogenous cell line 
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showed significantly lower cell surface expression than low and high, respectively (Figure 61). Hence, 
increasing β-arrestin2 concentrations exhibited a repressive effect on the overall DMR response 
initiated by RA-II-150-activated GPR17. Only the decreased optical signatures monitored with 
very high cells might be as well diminished due to very low receptor expression levels (Figure 61). 
In order to draw further conclusions out of this assay, the optical traces were transformed into 
concentration-response curves, where maximum response (pm) was plotted against increasing 
RA-II-150 concentrations (Figure 64, A). In addition, the determined pharmacological parameters 
(relative efficacy (B) and pEC50 (C)) were represented as bar charts for a clear illustration of obtained 
differences (Figure 64).  
 
Figure 64 Influence of β-arrestin2 coexpression on RA-II-150-induced concentration-dependent 
dynamic mass redistribution 
A, Comparison of concentration-effect curves resulting from DMR assays of HEK293 cells stably expressing 
GPR17-RLuc (endogenous) and HEK293 cells stably cotransfected with GPR17-RLuc and increasing β-arrestin2-
GFP2 amounts (low, high and very high) challenged with indicated concentrations of GPR17 agonist RA-II-150. 
Data are presented as maximum response of wavelength shift [pm]. B-C, Bar diagrams derived from 
concentration-response curves (A) presenting Emax (B) and pEC50 values (C), respectively. Emax values were 
normalized and expressed as percent of Emax  determined with endogenous cells. For statistical analyses 
unpaired t-tests with two-tailed p values and 95% confidence interval were applied (*p < 0.05, **p < 0.01, 
***p < 0.001). A-C, All data points represent mean (+/- s.e.m.) of three to nine independent experiments 
performed in triplicates. 
Table 41 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 64 (± s.e.m.) 
β-arrestin2 level pEC50 basal value (pm) Emax (pm) nH n 
endogenous 5.82 ± 0.09 18.2 ± 13.4 450.3 ± 19.6 1.0 (fixed) 5-6 
low 6.38 ± 0.18 29.8 ± 12.0 285.5 ± 19.2 1.0 (fixed) 3-9 
high 6.78 ± 0.16 17.6 ± 11.9 237.3 ± 13.6  1.0 (fixed) 3-9 
very high 7.61 ± 0.27 12.8 ± 16.2 134.1 ± 12.1 1.0 (fixed) 3-4 
 
These data agree very well with the conclusions that were drawn from the optical signatures, 
especially insofar as the Emax value (maximum response) decreases with increasing β-arrestin2 
amounts. The relative efficacy obtained with low cells was reduced by 38.9% (+/- 6.9%) and high cells 
revealed an even stronger reduction of the maximum overall DMR effect with 44.6% (+/- 4.0). 
Regarding the fact, that both cell lines (low and high) were shown to express higher amounts of 
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GPR17 on the cell surface (Figure 61), one could conclude that similar expression levels would result 
in even higher reduction of the maximum effect, due to lower receptor densities. Even though very 
high cells revealed the highest repression of the overall response, data need to be taken into account 
with care, due to the already mentioned low cell surface expression of GPR17 (Figure 61).  
In addition to the decreased relative efficacy by coexpression of increasing β-arrestin2 
concentrations, another interesting phenomenon was observed, as the concentration-response 
curves were significantly shifted to the left in the presence of rising β-arrestin2 amounts (Figure 64, 
A). These mounting pEC50 values indicate a rise of the overall RA-II-150 potency mediated by GPR17. 
The absolute EC50 values determined with low cells were 3.6 times lower (0.42 µM), and with high 
cells even 8.8 times decreased (0.17 µM) in comparison to the endogenous (1.5 µM). The highest 
potency increase by the factor 75 was determined with very high cells (0.02 µM).  
In conclusion, these findings indicated that increasing amounts of coexpressed β-arrestin2 caused a 
diminishment of efficacy but elevation of potency elicited by GPR17-agonist RA-II-150, highlighted by 
decreased maximum effects and leftward shifts of concentration-response curves.  
4.2.3.2 Increased β-arrestin2 expression levels enhance pertussis toxin sensitivity of 
GPR17 initiated DMR 
Besides the unmodified real time monitoring of GPR17-induced dynamic mass redistribution upon 
agonist stimulation, the influence of PTX-pretreatment was examined to uncover whether β-
arrestin2 coexpression shows additional effects on GPR17-induced signaling, independent of the 
Gαi/o-mediated cascades.  
Therefore, HEK293 cells stably expressing GPR17-RLuc and differing β-arrestin2 concentrations (low, 
high and very high) were preincubated with the Gαi/o inhibitor pertussis toxin (PTX, 50 ng/ml, 18 h) 
prior to DMR analyses. As shown in Figure 65, stimulation of the cells with increasing RA-II-150 
concentrations revealed optical signatures, which were similar in shape, but partly obliterated in 
comparison to the untreated investigations (Figure 63), thus establishing an essential role for Gαi/o-
proteins in GPR17 response, which is in agreement with the previously determined signaling patterns 
of GPR17. Nevertheless, a difference between the four analyzed cell lines was detectable, as PTX-
sensitivity increased with increasing amounts of β-arrestin2 concentrations, mounting in an almost 
complete abrogation of DMR response in very high cells. Hence, coexpression of increasing β-
arrestin2 concentrations seemed to shift G protein-coupling preferences from dual coupling (Gαi/o 
and Gαq) to interaction with a single G protein (Gαi/o). 
4 Results  
 
121
 
Figure 65 Influence of β-arrestin2 expression levels on GPR17-mediated dynamic mass redistribution 
optical signatures in the presence of Gαi/o inhibitor PTX 
HEK293 cells stably expressing GPR17-RLuc (A) and HEK293 cells stably cotransfected with increasing amounts 
of β-arrestin2-GFP2 (B: low, C: high, D: very high) were challenged with the indicated concentrations of the 
GPR17 agonist RA-II-150 in presence of the Gαi/o inhibitor PTX (50 ng/ml, 18 h). The resulting picometer-shifts 
of reflected light wavelength over time [s] were monitored by use of the Epic® system as a measure of 
functional activity. Presented data are means + s.e.m. from a representative optical trace experiment of three 
to six independent experiments performed in triplicates.  
When data were transformed into concentration-response curves (Figure 66, A), the potencies of all 
four cell lines did not differ significantly, in contrast to the previously monitored values without PTX 
pretreatment (Figure 64, A). This observable fact was further demonstrated by the bar charts, in 
which calculated pEC50 values were plotted against the respective cell line, clearly highlighting that 
the significant differences between pEC50 values were not present anymore. The pharmacological 
parameters are summarized in Table 42.  
The already mentioned capability of elevated β-arrestin2 levels to decrease the maximum effect of 
overall DMR response, despite the fact that endogenous cells revealed lower receptor surface 
expression levels (Figure 61), was still present when cells were preincubated with PTX (Figure 66, B). 
The coexpression of low amounts of β-arrestin2 yielded in a 2 times lower relative efficacy (46.3 +/-
 9.1%), whereas high amounts resulted even in a 3 fold decrease (31.1 +/- 4.8%). The 10 times lower 
Emax value (10.5 +/- 1.8%) monitored with very high cells should be again regarded with care, due to 
the previously mentioned low receptor surface expression (Figure 61). 
To summarize these DMR investigations using Gαi/o inhibitor PTX, maximum responses were 
decreased due to increasing β-arrestin2 concentrations, whereas potencies of RA-II-150 remained 
comparable and did not differ significantly between all four analyzed cell lines.  
0 600 1200 1800 2400 3000 3600
-100
0
100
200
300
400
500
-4
-5
-5.5
-6
-6.5
-7
-8
-9
buffer
(0.4%DMSO)
R
A-
II-
15
0 
(lo
g 
M
)
time (s)
0 600 1200 1800 2400 3000 3600
-100
0
100
200
300
400
500
-4
-5
-5.5
-6
-6.5
-7
-8
-9
buffer
(0.4%DMSO)
R
A-
II-
15
0 
(lo
g 
M
)
time (s)
re
sp
o
n
se
 
(p
m
)
0 600 1200 1800 2400 3000 3600
-100
0
100
200
300
400
500
-4
-5
-5.5
-6
-6.5
-7
-8
-9
buffer
(0.4%DMSO)
R
A-
II-
15
0 
(lo
g 
M
)
time (s)
re
sp
o
n
se
 
(p
m
)
0 600 1200 1800 2400 3000 3600
-100
0
100
200
300
400
500
-11
-10
-9
-8
-7
-6
-5
buffer
(0.4% DMSO)
R
A-
II-
15
0 
(lo
g 
M
)
time (s)
A B
C D
endogenous low
high very high
4 Results  
 
122
 
Figure 66 Influence of β-arrestin2 coexpression on RA-II-150-induced concentration-dependent 
dynamic mass redistribution in the presence of Gαi/o inhibitor PTX 
Concentration-effect curves transformed from DMR assays of HEK-293 cells stably expressing GPR17-RLuc 
(endogenous) and HEK293 cells stably cotransfected with GPR17-RLuc and increasing β-arrestin2-GFP2 
amounts (low, high and very high) challenged with indicated concentrations of GPR17 agonist RA-II-150. Cells 
were preincubated with Gαi/o inhibitor PTX (50 ng/ml, 18 h) A, Data are presented as maximum response of 
wavelength shift [pm] and all data points represent mean (+/- s.e.m.) of three to six independent experiments 
performed in triplicates. B-C, Bar charts derived from concentration-response curves (A) presenting Emax (B) and 
pEC50 values (C), respectively. C, Emax values were normalized and expressed as percent of Emax determined with 
endogenous cells. For statistical analyses unpaired t-tests with two-tailed p values and 95% confidence interval 
were applied (**p < 0.01; ***p < 0.001). 
Table 42 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 66, A (± s.e.m.) 
β-arrestin level pEC50 basal value (pm) Emax (%) nH n 
endogenous 4.84 ± 0.09 -3.7 ± 6.5 363.6 ± 20.6 1.0 (fixed) 5-6 
low 4.96 ± 0.13 5.7 ± 6.5 244.4 ± 23.3 1.0 (fixed) 3-6 
high 4.79 ± 0.12 5.2 ± 3.2 149.7 ± 13.6  1.0 (fixed) 3-6 
very high 5.52 ± 0.52 12.1 ± 2.4 41.4 ± 10.5 1.0 (fixed) 3 
 
4.2.3.2.1 Coexpression of β-arrestin2 reveals different impacts on GPR17-mediated 
signaling depending on available Gα-proteins 
In order to gain a better insight into the effects of β-arrestin2 coexpression on GPR17-initiated 
optical signatures, pharmacological parameters (pEC50, relative efficacy) determined by DMR assays 
(4.2.3.1, 4.2.3.2) were summarized, so that differences monitored between unmodified and PTX 
pretreated cells are clearly highlighted.  
Obviously, as presented in Figure 67 (A), the significantly enhanced potencies, caused by increasing 
amounts of β-arrestin2 concentrations, determined with unmodified cells (w/o), were completely 
abolished when preincubated with PTX, resulting in lowered potencies with increasing significance 
between calculated pEC50 values of one cell line. Consequently, these investigations indicated that 
differences of determined potencies caused by increasing β-arrestin2 concentrations were mainly 
due to Gαi/o-protein-mediated signaling events, establishing an essential role for Gαi/o proteins 
concerning this phenomenon.  
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Furthermore, as depicted Figure 67 (B), the relative repression of GPR17-induced DMR was even 
stronger after elimination of Gαi/o-mediated signaling. Especially regarding the high cells, where 
relative efficacy was more than half (55.4 +/- 4.0%) without pretreatment, but by preincubation with 
PTX the repression was even stronger (31.1 +/- 4.8%). Thus, indicating a relatively higher PTX 
sensitivity of GPR17-mediated signaling when coexpressed with increasing β-arrestin2-
concentrations. 
These observations suggested that the preference of G protein-coupling seems to be shifted to the 
most preferred one, which was previously determined to be the Gαi/o-protein for GPR17. 
 
Figure 67 Summary and comparison of pharmacological parameters pEC50 and Emax determined by 
DMR assays in HEK293 cells stably expressing GPR17-RLuc and varying amounts of β-arrestin2 
Bar charts derived from concentration-response curves (Figure 64, Figure 66) comparing pEC50 (A) and Emax 
values (B), respectively, determined in the absence (w/o) or presence of PTX pretreatment (PTX, 50 ng/ml, 
18 h) by RA-II-150 stimulation of HEK293 cells stably expressing GPR17-RLuc and increasing amounts of β-
arrestin2 (endogenous, low, high and very high). B, Emax values were normalized and expressed as percent of 
Emax determined with endogenous cells. For statistical analyses two-way ANOVA with Bonferroni’s correction 
for multiple comparisons was applied (ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001). A-C, All data are means 
(+/- s.e.m.) of three to nine experiments performed in triplicates. 
 
4.2.4 Coexpression of β-arrestin2 induces enhanced potency but decreased efficacy of 
GPR17-induced inhibition of cAMP accumulation 
Since DMR assays revealed that coexpression of increasing β-arrestin2 amounts causes changes in 
GPR17-mediated signaling, especially highlighting the essential role of Gαi/o-mediated events, it was 
the next aim to determine whether this hypothesis can be further confirmed by means of cAMP 
inhibition assays.  
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Figure 68 Influence of increasing β-arrestin2 coexpression levels on GPR17-mediated inhibition of 
cAMP accumulation 
A, HEK293 cells stably expressing GPR17 C-terminally fused to Renilla luciferase in the absence (endogenous) or 
presence of varying amounts of β-arrestin2 coexpression N-terminally fused to GFP2 (low, high and very high) 
were stimulated with increasing concentrations of RA-II-150 in the presence of 1 µM forskolin (FSK). GPR17-
mediated decrease of intracellular cAMP was calculated as percent inhibition of adenylate cyclase stimulated 
with FSK (1 µM). For statistical analyses, individual concentrations were compared by two-way ANOVA with 
Bonferroni’s correction for multiple comparisons (*p < 0.05, ***p < 0.001). B-C, Bar charts derived from 
concentration-response curves (A) presenting Emax (B) and pEC50 values (C), respectively. B, Emax values were 
normalized and expressed as percent of Emax determined with endogenous cells. B-C, For statistical analyses 
paired t-tests with two-tailed p values and 95% confidence interval were applied (*p < 0.05).A-C, All data are 
means (+/- s.e.m.) of three to four experiments performed in triplicates. 
Table 43 Parameters of averaged RA-II-150 concentration-effect curves determined by cAMP assays, 
as depicted in Figure 68 (± s.e.m.) 
β-arrestin2 level pEC50 top value (%) bottom value 
Emax (%) 
nH n 
endogenous 6.00 ± 0.16 100.9 ± 1.8 62.4 ± 3.0 1.0 (fixed) 3-4 
low 6.53 ± 0.19 103.4 ± 2.3 69.7 ± 2.5 1.0 (fixed) 3-4 
high 6.92 ± 0.25   99.3 ± 1.6 84.9 ± 1.4 1.0 (fixed) 3-4 
very high 7.82 ± 0.53 101.9 ± 1.5 97.2 ± 0.6 1.0 (fixed) 3-4 
 
Therefore concentration-dependent effects of RA-II-150 on forskolin-induced cAMP accumulation 
were analyzed in parallel in all four cell lines, stably coexpressing GPR17-RLuc and increasing β-
arrestin2 amounts (endogenous, low, high and very high). In agreement with the previously stated 
hypothesis, elevated amounts of β-arrestin2 exhibited a strong impact on GPR17-initiated Gαi/o-
signaling (Figure 68). Concentration-effect curves (A) were clearly distinguishable amongst each 
other, in relation to maximum effects as well as potencies. Similar to the data obtained from DMR 
assays, the relative efficacy (B) was depressed along endogenous to very high cells. Low cells gave 
rise to 76.6 +/- 13.2% and high cells induced 35.0 +/- 6.7%, presented as percent of Emax determined 
with endogenous cells (100.1 +/- 10.3%). The lack of response from very high cells (8.1 +/- 2.5%) 
needs to be regarded again with care, due to low GPR17 surface expression (Figure 61). Additionally, 
pEC50 values were significantly increased with rising β-arrestin2 amounts (Figure 68, C), yielding 
comparable potencies as determined with the Epic® system.  
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Thus, investigations of Gαi/o-mediated signaling by cAMP analyses provided further evidence, that 
coexpression of increasing β-arrestin2 amounts exhibits alterations of GPR17-initiated signaling, 
since maximum effects were depressed while potencies were increased.  
4.2.5 Increased β-arrestin2 quantities diminish GPR17 mediated IP-One accumulation 
In order to further prove the previously observed findings, the impact of β-arrestin2 on GPR17-
induced IP1 accumulation was investigated. Therefore, all four stably generated HEK-GPR17 cell lines 
(endogenous, low, high and very high) were challenged with increasing concentrations of RA-II-150. 
Elevated IP1 concentrations were expressed as arbitrary units and corrected by respective basal 
values to facilitate comparison of CRCs.  
Interestingly, the presence of augmented β arrestin2 amounts exhibited a strong impairment on 
GPR17-initiated IP1 accumulation, as depicted in Figure 69 (A). Whereas in endogenous cells 
stimulation with RA-II-150 yielded a concentration-dependent IP1 elevation, the challenge of β-
arrestin2-coexpressing cells (low, high and very high) almost completely impaired IP1 detection. In 
fact, only the highest applied RA-II-150 concentration (100 µM) induced an increase of IP1 level 
above basal, making it impossible to compute appropriate CRCs. These results may reflect insufficient 
Gαq protein-coupling due to an increased desensitization rate caused by the elevated β-arrestin2 
amounts. Consequently, to possibly increase or sensitize the Gαq-coupled signaling events, the 
simultaneously occurring and potentially competing Gαi/o-mediated signaling and subsequent 
desensitization was interrupted by preincubation with the Gαi/o-inhibitor pertussis toxin (PTX, 
50 ng/ml, 18 h). Interestingly, the preincubation with PTX enhanced RA-II-150-promoted 
IP1-accumulation in cells over-expressing GPR17 and distinct β-arrestin2 amounts (low, high and very 
high), whereas CRC determined in HEK-GPR17 cells with endogenous β-arrestin levels did not reveal 
significant changes (Figure 69, B), neither in potency (pEC50) nor in efficacy (Emax) (summarized in 
Table 44). These findings additionally highlighted that IP1-accumulation occurred independently of 
Gαi/o proteins. Furthermore, CRCs determined in PTX-pretreated cells (endogenous, low and high) 
did not differ significantly from each other, which was in agreement with data observed with the 
Epic® system (Figure 66). Additionally it should be noted, that almost no response was observable 
with very high cells (Figure 69), even preincubation with PTX only slightly increased GPR17-induced 
IP1-accumulation, but due to high variations no significant and reliable CRCs could be computed. The 
lack of response might correlate with very high amounts of β-arrestin2 inducing an amplified 
desensitization rate, but likewise be due to very low GPR17-expression levels observed in this cell line 
(Figure 61). The latter would be in agreement with findings observed using the Epic® system (Figure 
65, D), as pretreatment with PTX fully obliterated RA-II-150-induced DMR in very high cells, thus 
establishing an essential if not exclusive role for Gαi/o proteins in GPR17 response examined in this 
cell line.  
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Figure 69 Increased amounts of β-arrestin impair GPR17-induced IP1 accumulation 
A-B, HEK293 cells stably expressing GPR17 C-terminally fused to Renilla luciferase in the absence (endogenous) 
or presence of increasing amounts of β-arrestin2 N-terminally fused to GFP2 (low, high and very high) were 
challenged with increasing concentrations of RA-II-150, in the absence (A) or presence (B) of PTX (50 ng/ml, 
18 h). GPR17-mediated increase of intracellular IP1 was expressed as arbitrary units and corrected for baseline 
values obtained with buffer. All data are means (+/- s.e.m.) of three to ten experiments performed in 
duplicates and triplicates, respectively. 
Table 44 Parameters of averaged RA-II-150 concentration-effect curves determined by IP1 assays, as 
depicted in Figure 69 (± s.e.m.) 
β-arrestin2 
level 
pEC50 bottom value 
(arbitrary units) 
top value (arbitrary 
units) 
nH n 
endogenous 5.61 ± 0.20 53.7 ± 57.6 875.2 ± 82.6 1.0 (fixed) 3-7 
endogenous 
+ PTX 
6.07 ± 0.30 0.51 ± 95.4 729.4 ± 89.5 1.0 (fixed) 3 
low 3.93 ± 1.92 0.1 ± 118.9 - 1.0 (fixed) 4-10 
low           + PTX 6.53 ± 0.19 0.1 ± 66.2 705.2 ± 74.8 1.0 (fixed) 4 
high 4.06 ± 1.04 0.1 ± 74.0 - 1.0 (fixed) 3-4 
high          + PTX 6.92 ± 0.25 0.1 ± 144.4 695.5 ± 163.3 1.0 (fixed) 3 
very high - 11.5 ± 95.5 - - 3-4 
very high + PTX 4.94 ± 1.68 0.5 ± 79.8 194.1 ± 202.2 1.0 (fixed) 3 
Taken together, presence of increasing β-arrestin2 amounts diminishes GPR17-mediated IP1-
accumulation, probably caused by an elevated desensitization rate initiated by the simultaneously 
occurring and possibly preferred Gαi/o-mediated signaling, as elimination of this pathway reversed 
the observed phenomenon resulting in comparable CRC.  
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4.3 Analyses of potential GPR17 antagonists 
Due to the claimed physiological role of GPR17 (see 1.5.3.2), the development of specific antagonists 
would have a therapeutic value to prevent cell death in stroke/ischemia as well as to restore deficits 
in myelination. GPR17 activation has been shown to be counteracted by treatment with already 
marketed ‘specific’ CysLT1 receptor antagonists pranlukast and montelukast (Ciana et al. 2006, 
Fumagalli et al. 2011, Lecca et al. 2008, Pugliese et al. 2009).  
Since the inhibition properties of the published CysLT1 receptor antagonists have been analyzed 
based on LTD4-activated GPR17 signaling, mainly in recombinant 1321N1 cells (Ciana et al. 2006, 
Lecca et al. 2008, Pugliese et al. 2009) as well as in native OPCs (Fumagalli et al. 2011), it was the aim 
to examine the antagonistic properties with regard to GPR17 activation by our small molecule 
agonist RA-II-150. Therefore a set of various functional assays were performed by application of 
recombinant CHO cells engineered to stably express GPR17. Additionally, HEK293 cells stably 
coexpressing GPR17 C-terminally fused to Renilla luciferase (GPR17-RLuc) and β-arrestin2 N-
terminally labeled with green fluorescent protein 2 (GFP2) were utilized for analyses of β-arrestin2 
recruitment. 
4.3.1 Preliminary screening of cysteinyl leukotriene receptor antagonists as inhibitors for 
GPR17-initiated signaling 
Initially, the two published antagonists (montelukast, pranlukast) and two additional potent CysLT1 
receptor inhibitors (zafirlukast, MK571) were investigated to determine the compound with the most 
promising antagonistic potencies on RA-II-150-activated GPR17 signaling.  
4.3.1.1 Investigation of antagonistic properties by Epic® DMR technology 
As a first attempt, the inhibiting properties of pranlukast, montelukast and zafirlukast on GPR17 
functionality were studied by the holistic dynamic mass redistribution technology.  
GPR17-expressing CHO cells were preincubated with the indicated antagonist for 60 min prior to 
stimulation with RA-II-150 (3 µM). As depicted in Figure 70, all three tested antagonists (pranlukast 
(A), montelukast (B) and zafirlukast (C)) diminished the agonist-induced optical signatures in a more 
or less concentration-dependent manner. Especially pranlukast counteracted GPR17-triggered DMR 
in a highly significant way; resulting in an almost complete inhibition with the highest applied 
concentration (30 µM). Results from four to twelve independent DMR experiments were summarized 
as bar charts (Figure 70, D) that clearly highlight pranlukast as the most promising GPR17 antagonist, 
whereas data obtained with montelukast were not consistent with previous published data (Ciana et 
al. 2006), as almost no constant inhibition was detectable. Zafirlukast, whose antagonistic potencies 
regarding GPR17 have not been investigated before, as well revealed significant and concentration-
dependent repression of the optical signatures, but not as strong as pranlukast and furthermore with 
higher variations. Consequently, the following rank order based on maximum percent inhibition of 
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GPR17-induced DMR was determined: pranlukast (86.5 +/- 5.5%) > zafirlukast (43.1 +/-
 18.3%) > montelukast (30.3 +/- 16.1%). 
Taken together, DMR technology uncovered pranlukast as the most potent GPR17-antagonist 
amongst the three analyzed CysLT1 receptor antagonists. 
 
Figure 70 Inhibition effects of cysteinyl leukotriene receptor antagonists on GPR17-induced dynamic 
mass redistribution upon stimulation with 3 µM RA-II-150 
A-C, CHO cells stably expressing GPR17 were challenged with 3 µM RA-II-150 in absence (w/o) and presence of 
the indicated cysteinyl leukotriene receptor antagonist (pranlukast (A), montelukast (B) and zafirlukast (C)). 
Cells were preincubated with antagonists for 60 min at 28°C. Agonist-induced relative wavelength shift [%] over 
time [s] was monitored as a measure of functional activity. Responses were normalized and expressed as 
percent of wavelength shift induced by 3 µM RA-II-150 determined in the absence of antagonist (w/o). 
Signatures were baseline-corrected by subtraction of buffer traces from the DMR response after receptor 
activation. Representative optical trace experiment (mean + s.e.m.) of at least four independent experiments 
performed in triplicates. D, Bar chart representing summarized DMR analyses normalized and expressed as 
percent of wavelength shift induced by 3 µM RA-II-150 determined in the absence of antagonist. For statistical 
analyses unpaired t-tests with two-tailed p values and 95% confidence interval were applied (*p < 0.05, 
**p < 0.01, ***p < 0.001). A-C, All data are means (+/- s.e.m.) of four to twelve independent experiments 
performed in triplicates. 
4.3.1.2 Evaluation of inhibition effects on IP-One accumulation 
In order to further confirm the results obtained by DMR analyses, a classical second messenger assay 
was chosen to evaluate the antagonistic impact on GPR17-induced elevation of intracellular IP1 
accumulation. Additionally, the effect of MK571 as a fourth CysLT1 receptor antagonist was 
examined. 
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First of all, the four antagonists, pranlukast, montelukast, zafirlukast and MK571 were tested for their 
agonistic effects in GPR17-expressing CHO cells (Figure 71, A). Whereas pranlukast and montelukast 
were devoid of any significant agonist effect, zafirlukast and MK571 revealed some increase of the 
basal intracellular IP1 concentration, although it was shown to be non significant (p > 0.05, unpaired 
t-tests with two-tailed p values and 95% confidence interval). Functionality of GPR17 was proven by 
application of RA-II-150, which significantly increased the basal IP1 level. 
Preincubation (30 min, 37°C) of GPR17-expressing CHO cells with the four potential GPR17 
antagonists, followed by a subsequent stimulation with RA-II-150 (0.3 µM), uncovered pranlukast 
once more as the most potent antagonist. As depicted in Figure 71 (B), pranlukast caused a complete 
inhibition of GPR17-induced IP1 accumulation, whereas MK571, zafirlukast and montelukast 
exhibited only partial effects, resulting in the following potency rank order, based on maximum 
percent inhibition of GPR17-induced IP1 synthesis: pranlukast (105.0 +/- 3.9%) > MK571 (57.8 +/-
 11.2%) > zafirlukast (51.3 +/- 18.4%) > montelukast (16.5 +/- 6.3%). Thus again, montelukast, which 
has been published several times as a potent GPR17 antagonist with an IC50 value in the nanomolar 
range counteracting LTD4-induced responses (Ciana et al. 2006, Fumagalli et al. 2011, Lecca et al. 
2008), surprisingly showed the worst inhibition properties amongst the four analyzed antagonists.  
In agreement with previous observations, pranlukast was uncovered as the most potent and most 
promising GPR17-antagonist and was therefore chosen for further examinations. 
 
Figure 71 Agonistic and antagonistic effects of cysteinyl leukotriene receptor antagonists analyzed by 
IP1 assays using GPR17-expressing CHO cells  
A, CHO cells stably expressing GPR17 were stimulated with cysteinyl leukotriene receptor antagonists and 
GPR17 agonist RA-II-150. Increase of intracellular IP1 was normalized and expressed as percent of maximum 
activation induced by RA-II-150 (10 µM). For statistical analyses unpaired t-tests with two-tailed p values and 
95% confidence interval were applied (***p < 0.001). B, Concentration-dependent inhibition by cysteinyl 
leukotriene receptor antagonists of the IP1 accumulation in CHO cells stably expressing GPR17 stimulated by 
0.3 µM RA-II-150. Cells were preincubated with antagonists for 30 min at 37°C. Data were expressed as percent 
of IP1 levels induced by 0.3 µM in the absence of an antagonist. A-B, All data are means (+/- s.e.m.) of three to 
six independent experiments performed in duplicates.  
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4.3.2 Pranlukast exhibits biased partial agonistic properties at GPR17 
Subsequent to preliminary screening analyses of cysteinyl leukotriene receptor antagonists, which 
uncovered pranlukast as the most suitable compound to diminish RA-II-150-induced GPR17 signaling, 
it was the next aim to examine the agonistic properties of pranlukast in order to determine whether 
pranlukast acts as a pure neutral antagonist, as an inverse agonist or even as a partial agonist. 
Therefore the effects of pranlukast on cells (CHO and HEK293 cells) stably expressing GPR17 were 
investigated by means of distinct functional assays.  
4.3.2.1 Detection of the agonistic nature via DMR technology 
As a first attempt the effect of pranlukast at GPR17 was examined in real time by use of the Epic® 
system, in order to directly measure the complete cell response. Stimulation of CHO cells stably 
expressing GPR17 with increasing pranlukast concentrations (3, 10 and 30 µM) elicited dynamic mass 
redistribution (Figure 72, A) in a concentration-dependent manner, highlighting an agonistic effect of 
pranlukast at GPR17. Interestingly, preincubation with the Gαi/o inhibitor PTX (50 ng/ml, 18 h) 
partially diminished pranlukast-induced optical signatures, indicating the involvement of Gαi/o-
protein-mediated signaling cascades. To further illustrate this phenomenon, a theoretical DMR 
signature plot was calculated by subtraction of the data obtained in the presence of PTX from the 
data determined in the absence of PTX. Since the signatures elicited in the presence of PTX represent 
every DMR event except for Gαi/o-protein-mediated signaling, subtraction of the overall response 
represents DMR triggered by Gαi/o-proteins. The theoretical optical signatures, as presented in 
Figure 72 (B), clearly reveal concentration-dependent DMR induced by pranlukast via Gαi/o-protein. 
 
Figure 72 Pranlukast-induced optical DMR signatures on CHO cells stably expressing GPR17 reveal 
PTX sensitivity 
A, CHO cells stably expressing GPR17 were challenged with the indicated concentrations of pranlukast in the 
absence and presence of Gαi/o inhibitor PTX (50 ng/ml, 18 h). Wavelength shift [pm] over time [s] was 
monitored as a measure of functional activity. Signatures were baseline-corrected by subtraction of buffer 
traces from the DMR response after receptor activation. Representative optical trace experiment 
(mean + s.e.m.) of at least three independent experiments performed in triplicates. B, Theoretical DMR optical 
signatures determined by subtraction of data obtained in the presence of PTX from data obtained without 
pretreatment, thus representing the theoretical signature elicited by Gαi/o protein. 
In order to ensure that DMR elicited by pranlukast in GPR17-expressing CHO cells was specific due to 
activation of GPR17, untransfected CHO-K1 cells were stimulated with pranlukast (3 µM (A), 10 µM 
(B) and 30 µM (C)) and monitored by DMR technology. CHO-GPR17 cells were analyzed in parallel, 
both in the absence and presence of PTX. Unfortunately, pranlukast additionally induced DMR in 
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untransfected CHO-K1 cells, but obviously with a smaller extent than in GPR17-expressing cells, thus 
confirming at least a partial GPR17-mediated effect (Figure 73). In contrary to GPR17-expressing 
cells, optical signatures monitored in CHO-K1 cells were not influenced by preincubation with PTX, 
indicating an independence of Gαi/o-mediated signaling. Interestingly, the shapes of the optical 
signatures elicited by pranlukast in CHO-K1 cells resembled the ones obtained in CHO-GPR17 cells in 
the presence of PTX (Figure 73, A-C).  
These investigations demonstrate that DMR induced by pranlukast in CHO-GPR17 cells is partly due 
to activation of Gαi/o-protein-mediated signaling through stimulation of GPR17, whereas the 
remaining part of the overall DMR response is caused by some unspecific, PTX-resistant events, 
which similarly appear in untransfected CHO-K1 cells. This conclusion further suggests that 
stimulation of GPR17 with pranlukast only activates the Gαi/o-mediated pathway, although the 
receptor has been shown to mediate promiscuous G protein-coupling, including Gαi/o, Gαs and 
Gαq proteins (see 4.1.1), thus pranlukast seems to act as a biased ligand at GPR17. 
 
Figure 73 Comparison of optical DMR signatures elicited by pranlukast in untransfected CHO-K1 and 
CHO cells stably expressing GPR17 
Untransfected CHO-K1 (K1) and CHO cells stably expressing GPR17 were challenged with increasing pranlukast 
concentrations (3 µM (A), 10 µM (B), 30 µM (C) in the absence and presence of Gαi/o inhibitor PTX (50 ng/ml, 
18 h). Wavelength shift [pm] over time [s] was monitored by use of the Epic® system as a measure of functional 
activity. Signatures were baseline-corrected by subtraction of buffer traces from the DMR response after 
receptor activation. Representative optical trace experiment (mean + s.e.m.) of at least three independent 
experiments performed in triplicates 
4.3.2.2 Pranlukast partially inhibits forskolin-induced cAMP synthesis  
To further probe the assumption that pranlukast acts as a biased agonist at GPR17 via Gαi/o-
coupling, its inhibition effect on forskolin-stimulated cAMP accumulation was investigated using a 
traditional cAMP assay. Therefore GPR17-expressing CHO cells as well as HEK-BRET-GPR17 cells 
(= HEK293 cells stably cotransfected with GPR17 C-terminally fused to Renilla luciferase and β-
arrestin2 N-terminally labeled with GFP2) were challenged with increasing pranlukast concentrations 
in the presence of 10 µM forskolin. In agreement with previous hypothesis, pranlukast induced a 
concentration-dependent inhibition of forskolin-stimulated adenylate cyclase (Figure 74), even 
though not with the same extent as the full agonist RA-II-150. Inhibition of cAMP accumulation was 
expressed as percentage inhibition of adenylate cyclase stimulated with forskolin (10 µM). Emax and 
potency values are summarized in Table 45. In CHO cells (A) efficacy of pranlukast yielded 
approximately one third (35.2 +/- 3.8%), whereas in HEK293 cells efficacy was reduced by half 
(9.3 +/- 1.2%) relative to RA-II-150 (28.3 +/- 1.0%). Furthermore, indicated by rightward shifts of 
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CRCs, potency of pranlukast was reduced in both cell lines, 185-fold less potent in CHOs (absolute 
EC50 values 3.72 µM ↔ 0.02 µM) and 40-fold less potent in HEKs (absolute EC50 values 2.40 µM ↔ 
0.06 µM). Whereas pranlukast exhibited slightly higher potency in HEK-BRET-GPR17 cells, RA-II-150 
was more potent in CHO-GPR17 cells.  
Taken together, these observations uncovered pranlukast as a partial agonist with decreased 
potency in comparison to our GPR17 agonist RA-II-150. The intrinsic activity and potency of 
pranlukast for the GPR17-mediated inhibition of cAMP accumulation was cell line-dependent, since 
the compound showed weak partial agonist activity in the CHO-GPR17 cell line, but enhanced partial 
agonist activity in HEK-BRET-GPR17 cells. 
 
Figure 74 cAMP assays reveal concentration-dependent partial agonistic effects of pranlukast 
analyzed in cells stably expressing GPR17 
CHO cells stably expressing GPR17 (A) and HEK293 cells stably cotransfected with GPR17-RLuc and β-arrestin2-
GFP2 (B, HEK-BRET-GPR17 low) were stimulated with increasing concentrations of pranlukast and RA-II-150, 
respectively, in the presence of 10 µM forskolin. GPR17-mediated decrease of intracellular cAMP was 
calculated as percent inhibition of adenylate cyclase stimulated with FSK (10 µM). All data are means 
(+/- s.e.m.) of at least three experiments performed in duplicates.  
Table 45 Parameters of averaged pranlukast and RA-II-150 concentration-effect curves determined 
by Gαi/o-cAMP assays, as depicted in Figure 74 (± s.e.m.) 
cell line pEC50 bottom value / Emax 
(%) 
top value (%) nH n 
CHO-GPR17 
Pranlukast 
5.43 ± 0.18 90.7 ± 1.2 99.6 ± 0.8 -1.9 ± 0.3 4-6 
CHO-GPR17 RA-II-150 7.81 ± 0.05 71.7 ± 1.0 97.8 ± 0.8 -1.9 ± 0.3 5 
HEK-BRET-GPR17 
Pranlukast 
5.62 ± 0.26 97.3 ± 0.3 100.1 ± 0.3 1.0 (fixed) 3-4 
HEK-BRET-GPR17 
RA-II-150 
7.20 ± 0.27 94.5 ± 0.5 99.0 ± 0.4 1.0 (fixed) 4 
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4.3.2.3 Stimulation of GPR17 with pranlukast does neither elevate intracellular cAMP nor 
IP-One concentrations 
Based on the analyses performed with the Epic® system, it was concluded that pranlukast stimulation 
of GPR17 only results in coupling with Gαi/o. To further prove this functional selectivity, the ability of 
pranlukast to elevate intracellular cAMP and IP1 levels, respectively, was examined. As presented in 
Figure 75, stimulation of cells stably expressing GPR17 (CHO-GPR17, HEK-BRET-GPR17) with 
pranlukast did not cause an elevation of intracellular second messengers, neither cAMP (A) nor IP1 
(B). The cAMP levels in CHO-GPR17 cells were rather decreased, possibly due to partial Gαi/o-
agonism. To verify viability of the cells and functionality of the methods, RA-II-150 and forskolin were 
applied as positive controls for cAMP accumulation assays, and RA-II-150 and carbachol as controls 
for elevation of IP1. All control compounds did significantly increase the respective intracellular 
second messengers, thus confirming appropriate conditions. It should be noted that RA-II-150 was 
not applied on HEK-BRET-GPR17 cells, neither in cAMP nor in IP1 assays, because previously obtained 
data revealed lack of Gαs-mediated responses (Figure 50) and weak Gαq-initiated effects in HEK293 
cells stably coexpressing β-arrestin (Figure 69). Nevertheless, this cell line was additionally applied to 
examine effects of pranlukast, as these in formations were essential for subsequent analyses by 
means of BRET2 (Figure 77). 
Taken together, pranlukast behaved as a partial agonist for inhibition of cAMP accumulation, yet 
failed to stimulate cAMP and IP1 production, consequently these investigations further prove the 
conclusion that pranlukast acts as a functionally selective partial agonist. 
 
Figure 75 Stimulation of GPR17 with pranlukast does neither raise intracellular cAMP nor IP1 
concentrations 
CHO cells stably expressing GPR17 (CHO-GPR17) and HEK293 cells stably coexpressing GPR17-RLuc and β-
arrestin2-GFP2 (HEK-BRET-GPR17) were challenged with indicated concentrations of RA-II-150 and pranlukast, 
respectively. Changes of intracellular cAMP (A) and IP1 (B) were determined, whereas forskolin (A) and 
carbachol (B) were used as positive controls. Data are expressed as arbitrary units. All data are means 
(+/- s.e.m.) of three to four independent experiments performed in duplicates. For statistical analyses unpaired 
t-tests with two-tailed p values and 95% confidence interval were applied and revealed no significant 
differences of pranlukast induced values compared to unstimulated ones, whereas positive controls were 
significant (**p < 0.01, ***p < 0.001). 
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4.3.2.4 Pranlukast shows no activity on untransfected CHO-K1 and HEK293 cells neither in 
cAMP nor in IP1 assays 
As analyses of pranlukast by means of the Epic® system revealed some unspecific DMR events in 
untransfected CHO-K1 cells, the impact of stimulation with pranlukast was additionally analyzed 
using second messenger assays (cAMP and IP1) to further characterize unspecific influences in 
untransfected cells (CHO-K1 and HEK293 cells). 
The data presented in Figure 76 obviously demonstrate, that pranlukast caused no significant 
changes of basal second messenger levels, neither cAMP (A) nor IP1 (B). Furthermore, the elevation 
of cAMP by forskolin was not inhibited by pranlukast preincubation (A). Carbachol and ATP were 
applied as positive controls, and they significantly elevated intracellular IP1 levels via stimulation of 
endogenous Gαq-coupled muscarinic acetylcholine receptors (Mundell & Benovic 2000) and 
purinergic P2Y1 / P2Y2 receptors (Iredale & Hill 1993, Marcet et al. 2004), respectively (B). 
The lack of response clearly demonstrates that on the one hand inhibition of cAMP accumulation in 
GPR17-expressing cells via Gαi/o coupling can be regarded as a specific response due to stimulation 
of GPR17, and on the other hand the remaining unspecific effects monitored by use of the Epic® 
system in untransfected as well as in PTX-pretreated CHO-GPR17 cells were neither elicited by Gαs 
nor Gαq/11 protein-coupling events, and remain elusive so far.  
 
Figure 76 Pranlukast shows no activity on untransfected CHO-K1 or HEK293 neither in cAMP nor in 
IP1 assays 
A-B, Untransfected cell lines (CHO-K1, and HEK293 cells) were challenged with indicated pranlukast 
concentrations and analyzed by cAMP (A) and IP1 (B) assays, respectively. Forskolin (A), carbachol (B) and ATP 
(B), respectively, were used as positive controls. All data are means (+/- s.e.m.) of three to six experiments 
performed in duplicates. For statistical analyses, unpaired t-tests with two-tailed p values and 95% confidence 
interval were applied and revealed no significant differences of pranlukast induced values compared to 
unstimulated ones, whereas positive controls were highly significant (***p < 0.001). 
4.3.2.5 Stimulation of GPR17 by pranlukast elicits translocation of β-arrestin2 in a PTX-
sensitive manner 
Since at least for some receptors it is known that β-arrestin recruitment occurs independent of 
G protein-coupling (reviewed by Defea 2008, DeWire et al. 2007, Violin & Lefkowitz 2007) and the 
GPR17 agonist RA-II-150 was shown to promote both G protein-dependent and -independent β-
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arrestin2 translocation, it was the next intention to investigate whether pranlukast is able to trigger 
β-arrestin2 recruitment to the activated GPR17 and whether this protein-protein-interaction is Gαi/o 
protein-dependent.  
Therefore the established bioluminescence resonance energy transfer method (BRET2) was applied 
using HEK293 cells stably coexpressing GPR17 C-terminally fused to Renilla luciferase (RLuc) and 
β-arrestin2 N-terminally labeled with green fluorescent protein 2 (GFP2). These HEK-BRET-GPR17 
cells were challenged with increasing pranlukast concentrations in the presence and absence of 
Gαi/o-inhibitor PTX (50 ng/ml, 18 h).  
 
Figure 77 Pranlukast partially recruits β-arrestin2 in a PTX-sensitive manner 
HEK293 cells stably transfected with β-arrestin2-GFP2 and GPR17-RLuc (HEK-BRET-GPR17) were exposed to 
indicated concentrations of pranlukast, and agonist-induced increases in BRET ratio were monitored. 
Pretreatment with Gαi/o inhibitor PTX (50 ng/ml, 18 h) completely abolished partial recruitment. Data of full 
agonist RA-II-150 were included for clear comparison. Each data point represents mean (+/- s.e.m.) of three to 
six independent experiments performed in triplicates. 
Table 46 Parameters of averaged RA-II-150 concentration-effect curves determined by DMR assays, 
as depicted in Figure 77 (± s.e.m.) 
agonist pEC50 bottom value 
(net BRET ratio) 
Emax 
(net BRET ratio) 
nH n 
Pranlukast 5.72 ± 0.30 4.0 ± 3.8   41.7 ± 4.6 1.0 (fixed) 6 
Pranlukast + PTX - 3.3 ± 4.6    7.0 ± 2.3 - 3 
RA-II-150  6.38 ± 0.12 3.0 ± 4.0 130.3 ± 5.2 1.0 (fixed) 6 
RA-II-150 +PTX 6.02 ± 0.18 2.9 ± 8.6 126.6 ± 8.5 1.0 (fixed) 3 
 
Stimulation with pranlukast resulted in a concentration-dependent β-arrestin2 recruitment to the 
activated GPR17 (Figure 77), measured as an increase of BRET ratio. To help clarify the agonist 
efficacy, the data obtained with RA-II-150 were included in the figure. In agreement with previous 
results (see 4.3.2.2), pranlukast behaved as a partial agonist with decreased potency relative to 
RA-II-150. The efficacy was reduced by approximately 32% (Emax values: 41.7 +/- 4.6 mBRET ↔ 
130.3 +/- 5.2 mBRET), and the potency was ~4.5-fold lower (absolute EC50 values: 
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1.91 µM ↔ 0.42 µM). Interestingly, inhibition of Gαi/o protein-mediated signaling by preincubation 
with PTX completely abolished pranlukast-induced translocation of β-arrestin2 to the stimulated 
receptor, whereas, as previously reported, β-arrestin2 recruitment initiated by stimulation of GPR17 
with RA-II-150 was only partially diminished by blocking of G protein-dependent signaling (Figure 59). 
These observation further confirmed the assumption that pranlukast acts as a partial agonist at 
GPR17 with functional selectivity relative to RA-II-150. Furthermore, it was shown that translocation 
of β-arrestin2 to the stimulated receptor proceeds in a Gαi/o protein-dependent manner, whereas 
RA-II-150-induced recruitment furthermore occurs without the need of G protein activation (Figure 
59).  
4.3.2.6 GPR17 internalizes upon pranlukast activation 
In addition to functional analyses, the influence of pranlukast on GPR17 cell surface expression was 
studied, since the loss of cell surface receptor density might as well cause an inhibition of receptor 
mediated signaling. In order to examine endocytosis of GPR17 initiated by pranlukast application, 
HEK293 cells stably expressing 3xHA-tagged GPR17 were investigated by immunofluorescence 
microscopy and by indirect cell surface ELISA, which enabled evaluation of the quantitative changes 
of surface expressed GPR17 upon agonist activation for indicated time periods. The examination of 
HA-immunoreactivity using fluorescence microscopy gives information about the subcellular 
localization. 
Pranlukast treatment induced endocytosis within 15 min, and GPR17 continued to internalize, 
leading to ~11.2% (+/- 1.5%) loss of cell surface expression (Figure 78, A). In agreement with the 
previously described partial agonism, the extent of GPR17 endocytosis was decreased by the factor 
2.3 relative to RA-II-150 induced internalization rate (~26.2 +/- 2.3%). 
Immunofluorescence analyses of DMSO-treated HEK-3HA-GPR17 cells revealed that, under control 
conditions GPR17 was predominantly located on the cell surface (B). Stimulation with pranlukast 
(30 µM, 60 min) induced endocytosis of GPR17 from the cell surface into the cytoplasm with a 
punctate distribution into intracellular vesicles (Figure 78, C), again with a lower extent relative to 
RA-II-150 (Figure 44).  
Thus, the data obtained from immunofluorescence microscopy and surface ELISA exhibit equivalent 
patterns, explicitly that pranlukast stimulation of GPR17 induces partial internalization of the 
receptor from the cell membrane into the intracellular membrane compartments of the cell in a 
time-dependent manner upon stimulation with pranlukast. 
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Figure 78 Pranlukast induces partial endocytosis of GPR17 
GPR17 internalization behavior was quantitated by indirect cellular ELISA (A) and imaged by 
immunofluorescence microscopy (B) using HEK293 cells stably expressing GPR17 fused to an N-terminal 
3xHA tag. A, Colorimetric ELISA measurements of pranlukast (30 µM) induced GPR17 sequestration for the 
indicated time period. The amount of internalized receptor was calculated from the decrease in the level of 
surface-expressed receptor after agonist treatment compared with untreated, control cells (HEK293). Each data 
point represents mean (+/- s.e.m.) of four to five independent experiments performed in triplicates. B-C, 
Fluorescence images of cell surface and intracellular 3xHA-GPR17 immunoreactivity. Cells were treated for 1 h 
at 37°C with 0.1% DMSO (B, C11) or 30 µM pranlukast (C). B, Control cells primarily showed plasma membrane 
localization of GPR17 and less internalized receptor. B, Cells were pre-labeled with anti-HA antibody (Table 22, 
A1), and after agonist-induced stimulation, cells were permeabilized with triton X-100 (C52) and 
immunostained with fluorescence antibody (Alexa Fluor 546 goat anti-mouse IgG, Table 22, A3). The following 
settings were used for Alexa Fluor 546 recordings: 400 fold magnification, 100 ms exposure time, 0.99 γ and 2-
22 histogram. Representative cells from at least three independent experiments are shown. After indirect 
immunofluorescence staining, no specific fluorescence was observed in untransfected HEK293 cells. Scale 
bars = 20 µM. 
4.3.3 Functional analyses uncover pranlukast as a GPR17-antagonist with a versatile 
antagonistic profile  
To further characterize pranlukast as a GPR17 antagonist, functional consequences of preincubation 
with pranlukast on RA-II-150-induced responses were evaluated in a set of different functional 
assays. 
4.3.3.1 Determination of antagonistic potencies in various functional assays  
Since GPR17 revealed promiscuous G protein-coupling upon activation with RA-II-150, inhibition 
potencies of pranlukast were investigated by use of two second messenger assays (cAMP for Gαi/o 
and Gαs and IP1 for Gαq) as well as BRET2 technology to analyze repression of β-arrestin2 
recruitment. Due to the functionally selective partial agonistic effects that have been shown to be 
completely dependent on Gαi/o-mediated signaling, in certain assays (Gαs cAMP, BRET2) cells were 
pretreated with PTX (50 ng/ml, 18 h) to circumvent influences caused by this partial agonism. Hence, 
results obtained in Gαs cAMP, IP1 and BRET2 (+PTX) assays can be regarded as pure antagonistic 
properties.  
As presented in Figure 79, pranlukast concentration-dependently inhibited the RA-II-150-induced 
responses in all performed functional assays (cAMP (A-B), IP1 (C) and β-arrestin-recruitment (D)). 
Inhibition potencies (pIC50 values) and percentage efficacies (bottom values) are summarized in Table 
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47. At 30 µM, pranlukast completely blocked the RA-II-150-induced cAMP (B) as well as IP1 (C) 
accumulation, whereas both Gαi/o-mediated inhibition of forskolin-induced cAMP synthesis upon 
RA-II-150 stimulation (A) and β-arrestin2 recruitment to the activated GPR17 (D) were only partially 
inhibited. The partial inhibition of Gαi/o-mediated signaling observed by cAMP inhibition assays 
(56.6 +/- 4.7%) was probably due to a counteracting partial agonistic effect of pranlukast. Conversely, 
the incomplete repression of β-arrestin2-recruitment was not due to the partial agonistic property as 
its inhibition by PTX-pretreatment did not significantly change the maximum effect 
(Emax 82.2 +/- 2.9% ↔ Emax PTX 85.5 +/- 2.9%). Apparently, RA-II-150-induced translocation of 
β-arrestin2 cannot be completely blocked by pranlukast pretreatment.  
The determined absolute IC50 values were all in a micromolar range from 11.2 µM to 1.1 µM with the 
following rank order: Gαi/o-cAMP (11.2 µM) > IP1 (4.0 µM) > Gαs-cAMP (3.2 µM) > BRET2 (1.5 µM) > 
BRET2+PTX (1.1 µM).  
 
Figure 79 Concentration-dependence of inhibition by pranlukast of RA-II-150-induced functional 
responses in GPR17-expressing CHO cells 
CHO cells stably expressing GPR17 were challenged with RA-II-150 in the presence of increasing pranlukast 
concentrations (30 min preincubation, 37°C). A, Inhibition of RA-II-150 (0.3 µM) induced inhibition of forskolin-
stimulated cAMP accumulation. Data are expressed as percent of maximum inhibition induced by 
RA-II-150 (0.3 µM) in the absence of pranlukast. All data are means (+/- s.e.m.) of at least three experiments. 
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Table 47 Parameters of averaged pranlukast inhibition-concentration-effect curves determined 
various assay methods, as depicted in Figure 79 (± s.e.m.) 
assay pIC50 top value (%) bottom (%) nH n 
Gαi/o cAMP 4.95 ± 0.10 100.4 ± 2.8 43.4 ± 4.7 -1.8 (fixed) 3 
Gαs cAMP + PTX 5.49 ± 0.04 92.1 ± 2.0 0.1 ± 2.4 -1.8 ± 0.3 3 
IP1 5.45 ± 0.07 97.3 ± 3.4 -7.6 ± 4.8 -1.3 ± 0.3 3 
BRET2 5.81 ± 0.06 92.6 ± 3.0 17.8 ± 2.9 -1.7 ± 0.4 6 
BRET2 +PTX 5.96 ± 0.07 84.1 ± 3.4 14.5 ± 2.9 -2.0 ± 0.6 3 
 
4.3.3.2 Schild regression analyses using traditional second messenger assays and DMR 
technology reveals diverse antagonistic behavior 
To further characterize the mode of action, Schild analyses on the effects of pranlukast on GPR17-
initiated signaling events were performed. First, pranlukast was tested for its ability to antagonize 
GPR17-triggered dynamic mass redistribution. The activity of pranlukast was tested in the 
concentration range of 3 – 30 µM and cells were preincubated for 60 min at 28°C with the antagonist 
prior to stimulation with increasing concentrations of GPR17-agonist RA-II-150. 
 
Figure 80 Influence of pranlukast on RA-II-150-induced optical signatures monitored by means of the 
Epic® system 
CHO cells stably expressing GPR17 were challenged with the indicated concentrations of RA-II-150 in the 
absence (A) and presence of pranlukast (3 µM (B), 10 µM (C) and 30 µM (D)). Cells were preincubated with 
pranlukast for 60 min at 28°C prior to addition of RA-II-150. Wavelength shift [pm] over time [s] was monitored 
as a measure of functional activity. Signatures were baseline-corrected by subtraction of buffer traces from the 
DMR response after receptor activation. Representative optical trace experiment (mean + s.e.m.) of at least 
three independent experiments performed in triplicates.  
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Representative optical signatures are presented in Figure 80 (A-D), and clearly highlight a depression 
of overall response dependent on the applied pranlukast concentration (0 µM (A), 3 µM (B), 
10 µM (C) and 30 µM (D)). Interestingly, besides the clear inhibition of the RA-II-150-induced overall 
responses, the shape of the optical signatures remained unchanged. These observations suggest that 
all monitored signaling events were inhibited equally, which is in agreement with the findings 
previously observed by examination of pranlukast potencies in distinct functional assays, which 
revealed comparable IC50 values for all performed analyses (Figure 79). 
Furthermore, in accord with data obtained in BRET2 assays as well as in Gαi/o cAMP assays (Figure 
79, A, D), preincubation with 30 µM pranlukast did not result in a complete inhibition of RA-II-150 
induced response. 
In addition to DMR technology, Schild analyses were performed by cAMP and IP1 assays. Figure 81 
presents the curves of RA-II-150 concentration-dependent functional responses in the presence of 
increasing pranlukast concentrations. Concentration-response curves (CRCs) transformed from 
optical signatures obtained by DMR analyses were shifted to the right and simultaneously revealed a 
decrease of the maximal RA-II-150 response, indicating insurmountable antagonism (A). In contrary 
CRCs determined by use of IP1 assays were parallel shifted to the right without affecting the 
maximum response, indicating surmountable antagonism (B). Additionally, in cAMP accumulation 
analyses pranlukast induced clear rightward shifts of RA-II-150 CRCs in concentrations up to 10 µM; 
at a concentration of 30 µM, however, Emax of RA-II-150 seemed to be depressed, indicating 
insurmountable antagonism at the highest applied concentration (C). Examination of pranlukast in 
Gαi/o cAMP assays revealed a pattern of RA-II-150 curves with decreased baseline (due to partial 
agonism) shifted to the right of the control curve (due to antagonistic properties of the partial 
agonist) in concentrations up to 10 µM, and similar to results from Gαs cAMP assays, 30 µM 
depressed the maximum response of RA-II-150, indicating a mixed surmountable/insurmountable 
antagonism also in this assay (D). 
The decrease of the maximal level, observed in DMR and cAMP assays, was inconsistent with the 
possibility that pranlukast was a competitive antagonist of GPR17, as suggested from IP1 assays. In 
conclusion, functional data revealed that pranlukast concentration-dependently counteracted 
GPR17-mediated responses, but it seemed to exhibit surmountable and insurmountable antagonism, 
dependent on the respective functional assay, suggesting that the nature of antagonism is 
dependent on the cellular signaling pathway used by GPR17. Furthermore, it should be taken into 
account, that pranlukast slightly reduced the available number of GPR17 on the cell surface (Figure 
78), which may correlate to insurmountable inhibition of agonist responses in functional assays. 
4 Results  
 
141
 
Figure 81 Effects of pranlukast on the concentration-response curve induced by GPR17-agonist 
RA-II-150 evaluated in a set of different functional assays 
CHO cells stably expressing GPR17 were challenged with increasing concentrations of RA-II-150 in the absence 
(w/o) and presence of the indicated concentrations of pranlukast. A, Concentration-response curves (CRCs) 
transformed from optical traces monitored using DMR assays (Figure 80). Data are normalized and presented 
as percent of maximum area under curve (AUC, 0-3600 s) induced by a saturating concentration of 
RA-II-150 (10 µM) in the absence of pranlukast. B, CRCs analyzed by IP1 assays. Intracellular IP1 levels were 
expressed as percent of maximum IP1 amounts induced by RA-II-150 (10 µM) in the absence of pranlukast. C, 
Concentration-dependent stimulation of cAMP synthesis by RA-II-150 was normalized and expressed as 
percent of maximum activation induced by a saturating concentration of RA-II-150 (100 µM) in the absence of 
pranlukast. D, Cells were stimulated with increasing concentrations of RA-II-150 in the presence of 10 µM 
forskolin, besides indicated concentrations of pranlukast GPR17-mediated decrease of intracellular cAMP was 
calculated as percent inhibition of adenylate cyclase stimulated with forskolin (10 µM). A-D, All data are means 
(+/- s.e.m.) of at least three independent experiments performed in triplicates (A) and duplicates (B-C), 
respectively. Black lines highlight response levels that were used to calculate dose ratios (DRs) for subsequent 
Schild regression analyses. 
The pA2 values for pranlukast analyzed by IP1, Gαs- and Gαi/o-cAMP assays were computed by linear 
regression of dose ratios (DR), determined from EC50 values of the parallel shifted concentration-
response curves, whereas for Epic® analyses dose ratios at 20% maximal response were used to 
calculate pA2 values, as described by Kenakin et al. (Kenakin, Jenkinson & Watson 2006). By this 
means estimated pA2 values for pranlukast of the Schild regression amounted to 5.81 (5.56 to 6.17) 
for DMR, 5.92 (5.71 to 6.16) for IP1, 5.66 (5.55 to 5.79) for Gαs-cAMP and 5.82 (5.53 to 6.15) for 
Gαi/o-cAMP. Thus, calculated pA2 values were comparable in all performed assays, yielding a 
predicted functional antagonism in the micromolar range (1.2 to 2.2 µM), which agrees very well 
with previously observed IC50 values (Table 47).  
In addition, Schild plot analyses revealed steep slopes of 2.04 (+/- 0.23) for DMR, 2.21 (+/- 0.17) for 
IP1, 1.89 (+/- 0.10) for Gαs-cAMP and 1.55 (+/- 0.15) for Gαi/o-cAMP. In Schild regression analyses, if 
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pranlukast were a competitive antagonist, a perfect linear line with a slope of 1.0 would be expected. 
However, as the confidence intervals for the slopes did not include 1.0, in none of the performed 
functional assays, pranlukast is probably not a simple competitive antagonist, but rather acting in a 
non-competitive way. Whether this non-competitive antagonism is due to allosteric interactions or 
based on hemi-equilibrium assay conditions remains elusive so far.  
 
Figure 82 Schild plots corresponding to analyses presented in Figure 81 
Response levels applied to determine dose-ratios (DRs) are depicted in Figure 81. The pA2 values were 
determined as X-intercept when Y = 0.0. Statistical estimations of 95% confidence limits of the slope are 
presented as dotted lines. Further determined parameters are presented in the respective plot (pA2 values 
(95% confidence interval) and slope (+/- s.e.m.)). 
In conclusion, pranlukast concentration-dependently counteracted RA-II-150-induced 
GPR17-mediated functional responses in a mixed competitive/non-competitive manner. Hence, in 
contrast to the observed differing effects of pranlukast on the RA-II-150-induced CRC (Figure 81) in 
distinct functional assays, comparable results were noted in corresponding Schild plot analyses. 
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4.3.4 Pranlukast shows no unspecific inhibiting effects on carbachol-induced cAMP 
production in CHO cells stably expressing muscarinic receptor M2 
Control experiments using carbachol to stimulate cAMP accumulation via the M2 muscarinic 
acetylcholine receptor stably transfected in CHO cells demonstrated a lack of inhibition by 
pranlukast. Additionally the effect of atropine on carbachol-induced cAMP accumulation was 
investigated in parallel as positive control, and preincubation with 1 µM resulted in a clear rightward 
shift of carbachol CRC, indicating appropriate assay conditions.  
Thus, these data demonstrate that pranlukast functionally interacts with GPR17, independent of 
another adenylate cyclase-coupled receptor. 
 
Figure 83 Pranlukast shows no unspecific inhibition on carbachol induced cAMP accumulation 
CHO cells stably expressing the muscarinic M2 receptor were challenged with the indicated carbachol 
concentrations in the absence (w/o) and presence of atropine (1 µM) or pranlukast (30 µM), respectively. M2-
mediated increase of intracellular cAMP was normalized and expressed as percent of maximum activation 
induced by a saturating concentration of carbachol (1 mM). All data are means (+/- s.e.m.) of three 
independent experiments performed in duplicates.  
Table 48 Parameters of averaged carbachol concentration-effect curves determined by Gαs-cAMP 
assays, depicted in Figure 83 (± s.e.m.) 
antagonist pEC50 bottom value (%) Emax (%) nH n 
none (w/o)  5.49 ± 0.09 2.7 ± 3.4 101.0 ± 3.2 1.0 fixed 3 
pranlukast 5.94 ± 0.05 -4.8 ± 2.2 102 ± 1.8 1.0 fixed 3 
atropine  2.79 ± 0.12 4.2 ± 1.7 104.2 ± 7.7 1.0 fixed 3 
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5 Discussion 
5.1 GPR17 shows common features of GPCR signaling 
Deorphanization efforts revealed GPR17 as a dual nucleotide/lipid receptor with two distinct classes 
of signaling molecules: uracil nucleotides and cysteinyl-leukotrienes (Ciana et al. 2006). However, 
these postulated endogenous agonists and likewise the previously uncovered signaling properties 
remain disputable, as verification by independent laboratories has not yet been made. Furthermore, 
GPR17 was published as a ligand-independent negative regulator of CysLT1 receptor via GPCR-GPCR 
interaction (Maekawa et al. 2009). The identification of a synthetic small molecule GPR17 agonist 
(here referred to as RA-II-150) by means of a high throughput pharmacogenomic approach enabled 
in vitro pharmacological characterization of human GPR17. The observed experimental findings using 
RA-II-150 clearly demonstrate that GPR17 does not lack the common features of GPCR signaling.  
5.1.1 Stimulation of human GPR17 with the synthetic small molecule RA-II-150 promotes 
promiscuous G protein-coupling  
As the endogenous G protein-coupling profile of GPR17 has not yet been elucidated, a set of various 
functional assays was established using two different cellular backgrounds (CHO and HEK293 cells), 
self-engineered to stably express the short isoform of human GPR17. Traditional assays based on 
HTRF® technology enable examination of two major second messengers (cyclic adenosine 
monophosphate (cAMP) and inositol-monophosphate (IP1)), and thus facilitates exploration of 
signaling outcomes triggered by the three main G proteins (Gαi/o, Gαs and Gαq). These 
investigations uncovered that GPR17-initiated signaling upon activation with RA-II-150 is mediated 
via promiscuous G protein-coupling. In both analyzed cell lines, stimulation of cAMP- and IP1-
accumulation, as well as inhibition of forskolin-stimulated adenylate cyclase was observed upon 
activation with RA-II-150, whereas stimulation of untransfected cell lines was shown to lack a 
response. In the presence of forskolin, stimulation of GPR17 with low concentrations of RA-II-150 
induced significant concentration-dependent decrease of cAMP, indicative of GPR17 coupling to 
Gαi/o, whereas at higher concentrations RA-II-150 yielded a concentration-dependent elevation of 
cAMP highlighting coupling to stimulatory Gαs, resulting in a reverse bell-shaped concentration-
response curve.  
Pertussis toxin (PTX) is a bacterial toxin produced by certain Bordetella pertussis strains. PTX 
catalyzes an irreversible ADP-ribosylation of Gαi and Gαo subunits, leading to functional uncoupling 
of these proteins from GPCRs (Casey & Gilman 1988, Katada & Ui 1982). Thus, sensitivity to PTX can 
serve as an indication of the involvement of Gαi/o protein in a signal transduction pathway. Since 
application of PTX completely abrogated GPR17-mediated inhibition of forskolin-stimulated cAMP 
accumulation, a substantial need of the Gαi/o subunit for RA-II-150-induced inhibition of adenylate 
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cyclase has been proven. Conversely, the stimulatory effects on adenylate cyclase were neither 
diminished nor enhanced by preincubation with Gαi/o inhibitor PTX, which suggests that members of 
the Gαi/o family of G proteins were not involved in GPR17-mediated elevation of intracellular cAMP. 
Accordingly, a cross-talk between both G protein subunits in the signal transduction can be neglected 
and the determined reverse bell-shaped behavior observed in the presence of forskolin is promoted 
by a promiscuous interaction by agonist-activated GPR17 with both proteins, Gαi/o and Gαs, in an 
independent manner. Such U-shaped concentration-response curves were initially described by 
Fraser et al. while analyzing stimulation of human α2-adrenergic receptors with epinephrine (Fraser 
et al. 1989).  
To further verify the role of Gαs proteins, cholera toxin (CTX) has been shown to be an appropriate 
tool (Schröder et al. 2010). CTX, a secretory product of Vibrio cholerae, is commonly used as a 
modulator of Gαs protein activity. The subunit A of CTX catalyzes ADP-ribosylation of the α-subunit 
belonging to stimulatory Gαs protein that is associated with activation of adenylate cyclase and 
generation of cAMP. CTX-catalyzed ADP-ribosylation inhibits the intrinsic GTPase activity of Gαs, 
thereby prolonging its active state. This, in turn, leads to an extended activation of adenylate cyclase 
by Gαs (Casey & Gilman 1988, Gill & Meren 1978). Thus, CTX may be used for analysis of Gαs 
transduction, inducing a full activation of this Gα protein, which cannot be further increased by 
receptor stimulation. Since HTRF® technology is based on a competitive immunoassay between 
endogenously accumulated second messengers and added d2-labeled second messengers (see 
3.3.2), the elevation of endogenous cAMP through CTX preincubation hampers the subsequent 
measurement window of GPR17-induced increase of cAMP, independent of Gαs participation. 
Therefore, CTX could not be applied to further prove activation of Gαs subunit by agonist-activated 
GPR17.  
It should be further noted, that stimulation of IP1 formation through activation of GPR17 has been 
verified to be insensitive to PTX pretreatment, indicating that Gαi/o subunits, especially the 
dissociated βγ-subunit that is known to activate phospholipase C (Marinissen & Gutkind 2001, 
Woehler & Ponimaskin 2009) were not necessary for this signal transduction. The selective Gαq/11 
inhibitor YM-254890, isolated from the culture broth of Chromobacterium sp. (Takasaki et al. 2004), 
blocks the exchange of GDP for GTP in Gαq/11 activation, hence keeping the G protein in an inactive 
state. Due to limited access and thus very low available quantities, YM-254890 could not be applied 
in this part of the thesis to investigate the involvement of Gαq/11 protein. Nevertheless, subsequent 
investigations of the G protein-dependence of β-arrestin recruitment to the activated GPR17 
revealed that YM-254890 completely abrogated the RA-II-150-induced IP1 accumulation, indicating 
Gαq/11 protein as the responsible signal transducer.  
Taken together, the analyses by traditional second messenger assays demonstrated that GPR17 can 
couple to both Gαs and to PTX-sensitive Gαi/o to mediate activation and inhibition of adenylate 
cyclase, respectively, in a concentration-dependent manner. Furthermore, stimulation of GPR17 with 
RA-II-150 induced accumulation of IP1, resistant to PTX and sensitive to YM-254890, indicating 
involvement of Gαq/11. Consequently, activation of GPR17 with our small agonist RA-II-150 
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promotes promiscuous coupling with at least three distinct G protein subunits, namely Gαi/o, Gαs 
and Gαq/11.  
To further analyze GPR17-mediated signaling patterns, a very recently introduced technology was 
applied. The Epic® system is based on resonant waveguide grating (RWG) that makes use of subtle 
ligand-induced cellular rearrangements, thus enabling non-invasive, real-time and label-free 
investigations. Activation of GPCRs is known to cause translocation of multiple signaling molecules 
upon receptor stimulation, and this process of dynamic redistribution of cellular content, also 
referred to as dynamic mass redistribution (DMR), is captured as an optical signature. The term 
‘signature’ is used to describe the dynamic response profile displayed over time following ligand 
stimulation. The holistic nature of DMR measurements allows monitoring GPCR functionality along all 
four G protein signaling pathways: Gαi/o, Gαs, Gαq and Gα12/13 (Schröder et al. 2010). It unifies and 
quantifies whole cell effects or outcomes upon stimulation rather than resolving individual 
components contributing to the overall responses. Furthermore, ligand-induced signatures were 
reported to be indicative of signaling routes and accordingly can be applied to facilitate the 
evaluation of respective coupling preferences (Fang, Li & Ferrie, Schröder et al. 2009, Schröder et al. 
2010). As demonstrated in this thesis, stimulation of GPR17 with RA-II-150 triggers distinct DMR 
events. The optical signatures monitored in both cellular backgrounds (CHO and HEK293 cells) were 
comparable, as both cell lines responded with a positive DMR event, but not identical, which is in 
agreement with previously reported information that DMR responses can be cell type dependent. 
Whereas DMR responses induced by Gαi-linked receptors (e.g. CRTH2 or M2) were shown to be 
similar in HEK293 and CHO cells, respectively, Gαs-linked receptors (e.g. EP2 and β2AR) revealed 
diverse responses dependent on cellular background, namely downward reflected signatures in CHO 
cells and positive DMR signals in HEK293 cells (Schröder et al. 2010). Since optical signatures elicited 
by RA-II-150-activated GPR17 are initiated by at least three independent signaling cascades, including 
Gαi/o, Gαs and Gαq, it appears correct that signatures differ amongst both analyzed cell lines.  
Additional differentiations of signatures with selective pathway modulators turned out to be a 
challenging task, and so far no detailed elucidation of optical DMR signatures of any GPCR coupling to 
more than two independent G proteins has been reported. Inhibition of Gαi/o protein with PTX 
clearly induced shape changes of monitored optical signatures and diminished DMR responses 
elicited by low RA-II-150 concentrations (< 0.3 µM). Thus supporting the preference of Gαi/o-
mediated signaling when challenged with low agonist concentrations. Whereas cholera toxin (CTX) 
has been proven to be a suitable tool to investigate GPCR coupling simply via Gαs proteins by means 
of the Epic® system (Schröder et al. 2010), it was found out to be inappropriate to analyze signaling 
patterns of GPR17, which are composed of promiscuous G protein transduction pathways. As already 
described above, CTX preincubation promotes an extended activation of adenylate cyclase via Gαs 
protein, which cannot be further increased by receptor stimulation. The simultaneous activation of 
additional signaling pathways, in particular those that elevate cAMP, may possess a regulatory 
control over Ca2+ signaling pathways (DeBernardi & Brooker 1996, Hajnóczky et al. 1993, Volpe & 
Alderson-Lang 1990). Furthermore, Ca2+ can also modulate components of the cAMP signaling 
machinery by either activating or inhibiting different subtypes of adenylate cyclase (Cooper, Mons & 
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Karpen 1995, Mons et al. 1998). Consequently, changes in Ca2+ and cAMP cannot be simply separated 
into two isolated linear signaling pathways, but they actually interact at multiple levels to effectively 
form a signaling network (reviewed by Bruce, Straub & Yule 2003). Since CTX does not inhibit Gαs 
mediated cAMP synthesis, the involving cross-communication between separate signaling units 
(Gαs↔Gαq) prohibited appropriate interpretation of data obtained with CTX preincubation. 
Accordingly, that is the reason why this pharmacological tool was not applied in this thesis to unravel 
optical signatures elicited by GPR17.   
 
Figure 84 Comparison of pEC50 values determined in distinct functional assays in CHO-GPR17 and 
HEK-GPR17 cells, respectively.  
pEC50 values were determined by stimulation of CHO (dark grey) and HEK293 (light grey) cells, respectively, 
stably expressing GPR17, with increasing concentration of RA-II-150 by use of various functional assays (cAMP 
and IP1 to analyze traditional second messengers, Epic® system to monitor dynamic mass redistribution and 
BRET2 technology to investigate β-arrestin2 recruitment). For statistical analyses, unpaired t-tests with two-
tailed p values and 95% confidence interval were applied (ns p > 0.05, *p < 0.05, **p < 0.01). 
When comparing pEC50 values determined by varying functional assays, it is obvious that potencies of 
our GPR17 agonist differ in both analyzed cellular backgrounds (Figure 84). The potencies concerning 
the adenylate cyclase activity, determined as changes of cAMP levels, exceed in HEK293 cells, 
whereas the activation of phospholipase C, monitored as increase of intracellular IP1, was more 
efficient in CHO cells. The potencies determined with the Epic® system do not differ significantly, 
thus indicating an indistinguishable overall potency of RA-II-150 in both analyzed cell lines. While the 
pEC50 value assessed in CHO cells using DMR analyses represents a mean value of all three 
independent second messenger assays, this is not the case for HEK293 cells, where DMR analyses 
revealed the lowest potency. This underlines that the precise nature of how signals appear, and how 
individual signaling steps relate to monitored DMR signatures is not yet fully understood, and 
constitutes key areas of further investigation. The difference between CHO and HEK293 cells with 
respect to absolute potencies after GPR17 stimulation can most probably be attributed to different 
concentrations of the transduction partners involved in the response to RA-II-150. In general, the 
nature of the observed response not only depends on the nature of G protein preferentially 
recognized by the receptor, but may also depend on differential expression of signal transduction 
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components (e.g. receptors, G proteins, effectors and modulatory proteins such as receptor kinases) 
by different cells (Nasman et al. 2001, Schulte & Levy 2007), and might thus explain cell-dependent 
signaling differences.  
Disregarding the fact that RA-II-150 exhibits distinct potencies in both analyzed cell lines, it was 
clearly demonstrated that, independent of the cell line, potency of the GPR17 agonist varies 
considerably for individual G protein subtypes, as clearly illustrated by determined pEC50 values 
(Figure 84). Agonist potency for stimulation of both Gαq and Gαs is less than for Gαi/o, indicating 
that the latter is preferentially engaged by GPR17 upon stimulation with RA-II-150. Whereas 
stimulation of Gαq was ~5 and ~100 (CHO and HEK293 cells, respectively) fold less, the potency for 
Gαs-mediated responses was even stronger reduced by the factors ~115 and ~280 (CHO and HEK293 
cells, respectively), thus GPR17 is relatively weakly coupled to Gαs proteins. These observations are 
in agreement with previously reported findings, which demonstrated that potencies observed for a 
ligand could be different considering the different signaling pathways regulated by a unique receptor 
(Ashkenazi et al. 1987, Berg et al. 1998, Brink, Wade & Neubig 2000, Hall et al. 1999, Krueger et al. 
2005, Offermanns et al. 1994, Shoemaker et al. 2005). Multiple signaling and a shift between two 
response curves may be explained by a difference in the affinity of the ligand-receptor complex for 
each G protein, or by a difference in the relative concentrations of the G proteins (Kenakin 2003). 
Besides the described signaling properties of GPR17, the trafficking upon stimulation by RA-II-150 has 
been characterized, since agonist-promoted internalization represents a regulatory phenomenon 
common to most GPCRs to limit receptor activation (Ferguson 2001). An expression vector was 
constructed containing GPR17 fused with haemagglutinin (HA) to the amino-terminus to enable 
visualization of GPR17 localization and trafficking by use of immuno-labeling techniques, such as 
ELISA and immunofluorescence microscopy, in self-engineered stably transfected HEK293 cells. The 
epitope tag haemagglutinin has been widely used to label GPCRs in order to monitor expression and 
localization (e.g. Hall et al. 1999, Holliday et al. 2005, Oakley et al. 2001, Reiner et al. 2009, Vrecl et 
al. 1998) and Epic® analyses revealed proper functionality of HA-tagged GPR17 (Figure 43). 
Immunofluorescence analyses demonstrate that, under control conditions, GPR17 is predominantly 
located at the cell membrane, but upon activation with RA-II-150, the receptor internalizes from the 
cell surface into the cytoplasm with a punctate distribution into intracellular vesicles. This 
phenomenon has been further confirmed by quantitative surface ELISA measurements, which 
uncover a rapid reduction of GPR17 surface expression in a time-dependent manner upon RA-II-150 
challenge. The fate of internalized GPR17 and the underlying molecular mechanisms of the trafficking 
have not been of current interest for this thesis, but represent an interesting task for future 
investigations. 
Taken together, these findings provide direct evidence that stimulation of human GPR17 
recombinantly expressed in two different cell lines (rodent CHO and human HEK293 cells) with our 
small molecule agonist RA-II-150 leads to activation of multiple G protein subtypes including Gαi/o, 
Gαs and Gαq, with subsequent stimulation of at least two intracellular signaling cascades and 
agonist-induced endocytosis. Furthermore, these investigations demonstrate that GPR17 couples to 
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multiple signaling pathways with the activation of a specific pathway being dependent on the agonist 
concentration. Receptor coupling to multiple G proteins may provide regulation of different activities 
within the cell and may play an important role in adjusting the effectiveness of the signals in different 
tissues. Promiscuity of GPR17 might represent an important means of differentially regulating 
multiple physiological events by a single molecule interacting with a single receptor. 
5.1.2 Characterization of GPR17-BRET2-fusion protein 
Prior to examination of β-arrestin recruitment to the agonist-activated GPR17, the generated fusion 
receptors had to be investigated regarding their pharmacological properties, in order to ensure 
subsequent BRET2 data to be interpreted as precisely reflecting cellular function (Pfleger & Eidne 
2006). Labeling of the N-terminus with 3xHA-tag comprising 27 amino acids did not impair 
functionality of GPR17 as determined by use of DMR assays (Figure 43).To obtain detailed 
information of the pharmacological characteristics further functional validations were performed 
with stable engineered cell lines (HEK293 cells stably transfected with dual labeled human GPR17: 
3xHA and RLuc). The cellular localization of the receptor fusion protein was visualized by 
immunofluorescence microscopy and quantitated by indirect ELISA analyses. Furthermore, signaling 
properties and internalization behavior upon agonist-stimulation were evaluated and compared to 
results obtained with unmodified receptor. The investigations demonstrated that GPR17-RLuc retains 
its capability to couple with Gαi/o and Gαq proteins, promoting inhibition of adenylate cyclase and 
elevation of intracellular IP1 concentrations, respectively, but cell surface expression is diminished 
and even more surprisingly, fusion of the receptor to RLuc impairs its stimulatory character on 
intracellular cAMP levels mediated through Gαs proteins.  
Both, quantitative ELISA analyses as well as immunofluorescence microscopy, demonstrated that 
3xHA-GPR17-RLuc is expressed at the cell surface, but with a significantly diminished cell surface 
expression in comparison to wild type GPR17. The decrease in cell surface expression was not due to 
deficient cellular expression, as indistinguishable total cellular levels of wild type and RLuc-fusion 
receptor were detected using ELISA assays on permeabilized cells. The internalization rate 
determined by ELISA was slightly increased for RLuc-fusion GPR17, which could be related to the 
lowered cell surface expression levels, as it has been demonstrated for B2 bradykinin receptor 
(Faussner et al. 2003).   
In contrast to the data obtained with unmodified GPR17, the preferential activation of Gαi/o versus 
Gαq by RA-II-150 was diminished in the presence of GPR17-RLuc, as potencies of RA-II-150 did not 
differ amongst the distinct analysis methods (Figure 85). Although agonist potencies to activate 
Gαi/o- and Gαq-mediated signaling are significantly lowered when GPR17 is fused to RLuc, the 
potency to elicit the overall functional response, as determined with the Epic® system, does not 
differ significantly. This might be owing to the deficit of the least preferred Gαs-promoted signaling 
pathway, since no stimulating effect on cAMP synthesis was detectable upon challenge with 
RA-II-150. Another interesting observation is the extreme increase of the relative efficacy in 
inhibition of cAMP accumulation (Gαi/o-cAMP), despite significantly lower cell surface expression. 
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This phenomenon is further reflected in DMR analyses, as the optical signatures exceeded those of 
the unmodified receptor. These findings are probably related to the loss of the counteracting 
stimulatory Gαs-mediated pathway. 
 
Figure 85 Comparison of pEC50 values and relative efficacies of wild type GPR17 and GPR17 C-
terminally fused to Renilla luciferase (RLuc) stably transfected in HEK293 cells as determined in a set 
of distinct functional assays  
pEC50 values were determined by stimulation of HEK293 cells stably expressing wild type GPR17 (dark grey) and 
fusion receptor GPR17 C-terminally fused to Renilla luciferase (RLuc) (light grey) cells, respectively, with 
increasing concentration of RA-II-150 by various functional assays (cAMP and IP1 to analyze traditional second 
messengers and Epic® technology to monitor dynamic mass redistribution). No response (n.r.) was obtained for 
HEK-GPR17-RLuc cells in Gs-cAMP assay. For statistical analyses, unpaired t-tests with two-tailed p values and 
95% confidence interval were applied (ns p > 0.05, **p < 0.01), ***p < 0.001). 
Substantial body of evidence indicates that the C-terminus of GPCRs represents a critical region 
determining various aspects of receptor functionality, such as expression and trafficking (Delhaye et 
al. 2007, Pankevych et al. 2003), but as well G protein-dependent and -independent signaling (Hoare 
et al. 1999, Kang & Leeb-Lundberg 2002, Labasque et al. 2008, Pankevych et al. 2003, Schröder et al. 
2009). Consequently, the observed changes of GPR17 fusion protein in comparison to unmodified 
receptor properties might be induced through elongation of the GPR17 C-terminus. A change in the 
conformation of cytoplasmic receptor domain may have impaired receptor-G protein-coupling in 
general, most intensely uncoupling Gαs protein that interacts less efficiently with receptor, resulting 
in complete abrogation of only one signaling pathway (Gudermann, Schöneberg & Schultz 1997). 
Interestingly, to the best of my knowledge, so far no BRET fusion receptor has been reported to 
reveal different pharmacological properties in such an extent as presented here for GPR17. Usually 
appropriate functionalities of fusion receptors are examined by confocal microscopy, binding studies, 
internalization assays and second messenger analyses such as cAMP and IP1, and none of the 
reported fusion receptors (representative for 13 class A GPCRs) was significantly affected regarding 
its functionality (Angers et al. 2000, Ayoub et al. 2002, Hanyaloglu et al. 2002, Issafras et al. 2002, 
Kroeger et al. 2001, Ramsay et al. 2002, Terrillon et al. 2003, Vrecl et al. 2004).  
Another important aspect that should be noted concerning the remarkable change of signaling 
properties, is the fact that multiplicity in G protein-coupling was found to depend on the receptor 
expression level (Brink, Wade & Neubig 2000, Cordeaux et al. 2000, George et al. 1988, Thibonnier et 
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al. 1997, Zhu et al. 1994). For example Brink et al. reported that the full agonist UK-14,304 inhibits 
cAMP production in CHO cells expressing α2-adrenergic receptors at high as well as low densities. 
When the Gαi/o-mediated process is inhibited by preincubation with PTX, UK-14,304 stimulates 
cAMP accumulation, but this response is very low in CHO cells expressing low receptor densities and 
much higher in cells with high receptor abundance (Brink, Wade & Neubig 2000). Regarding the fact 
that cell lines stably expressing GPR17-RLuc were shown to display lower cell surface expression 
levels compared to wild type, it is tempting to hypothesize that after high abundance of GPR17, 
coupling of activated receptors to G proteins becomes less specific, leading to the recruitment of 
additional transducers that are not engaged at lower receptor densities. Accordingly, it could be 
concluded that the human GPR17 activates several signaling pathways via different G proteins, 
depending on the level of receptor expression. Under these conditions, the receptor level can control 
not only the quantity of observed response but also the quality of response. Additional studies would 
be necessary to further prove this phenomenon, such as gene dosing experiments with the wild type 
receptor to see whether increasing GPR17 densities are really responsible for pleiotropically G 
protein-coupling. Answering this question was beyond the scope of this work, as it was only 
important to characterize pharmacological properties of the fusion receptor to achieve precise 
interpretations of subsequent BRET2 analyses data. 
5.1.3 Classification of GPR17 as a class B receptor recruiting β-arrestin2 in a very rapid 
and partially G protein-independent manner 
As described in the introduction of this thesis, β-arrestins uncouple GPCRs from their cognate G 
proteins and promote their internalization, leading to desensitization and down-regulation, thus 
serving as negative regulators of G protein-dependent GPCR signaling. Additionally, β-arrestins 
function as scaffold proteins, interacting with several cytoplasmic proteins and linking GPCRs to 
intracellular signaling pathways such as the mitogen-activated protein kinase (MAPK) cascade, hence 
promoting agonist-induced signaling in their own right.  
The natural phenomenon of bioluminescence resonance energy transfer (BRET) is a powerful and 
increasingly popular tool for studying dynamic protein-protein interactions in intact living cells and 
real time (for review, see Pfleger & Eidne 2006, Pfleger et al. 2007). Using this technique, an assay 
was established, based on the observation that translocation of β-arrestin to GPCRs upon ligand-
stimulation is a hallmark of receptor activation, as the majority of GPCRs recruit β-arrestin 
independently of their signaling pathway (Angers et al. 2000, Hamdan et al. 2005, Vrecl et al. 2004, 
for review see Pierce & Lefkowitz 2001, Perry & Lefkowitz 2002). Using a GFP2-tagged β-arrestin2, it 
was possible to measure changes in the amount of β-arrestin2 that was in close proximity to the 
RLuc-tagged-GPR17. The analyses of β-arrestin recruitment upon receptor stimulation by means of 
BRET2 technology revealed that β-arrestin2 interacted with RA-II-150-activated GPR17 in a 
concentration-dependent manner, and the obtained pEC50 value corresponds well to previously 
determined values using other functional assays (Figure 85). Moreover the observed sustained signal 
disclosed stable and persistent association between both proteins. GPCRs can be classified into two 
distinct classes (class A and B) according to their stability of receptor/β-arrestin interactions (Oakley 
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et al. 2000, Freedman & Lefkowitz 1996). The members of class A possess higher affinity for β-
arrestin2 than β-arrestin1, and only interact in a transient manner, whereas the members of class B 
bind both β-arrestin1 and 2 with equivalent affinity and their interactions are more stable. Members 
of class A do not co-internalize with β-arrestin and are rapidly dephosphorylated and recycled back 
to the plasma membrane, whereas members of class B internalize together with β-arrestin into 
endosomes and are weakly dephosphorylated and recovered to the cell surface. The stability of the 
GPR17/β-arrestin2 association determined by BRET2 assays is in agreement with a class B phenotype 
where the receptor internalizes with β-arrestin in endosomes and slowly recycles back to the plasma 
membrane (Oakley et al. 1999, Oakley et al. 2000, Oakley et al. 2001, Tohgo et al. 2003). Accordingly, 
GPR17 would be classified as a class B receptor when stimulated with the small synthetic agonist 
RA-II-150. These findings are further proven, as the amplitude of the RA-II-150-induced BRET2 signal 
(~130 mBRET) is considerably high in comparison to other published findings (e.g. Hamdan et al. 
2005), an effect that could also be explained by the observation that the association of β-arrestin2 
with agonist-stimulated GPR17 is very stable. Another possibility is that the interaction of β-arrestin2 
with GPR17 favors optimal distance and relative orientation, respectively, between the energy 
acceptor and the donor, leading to larger BRET2 signals than seen for other receptors, which 
previously has been postulated for class B receptors (Hamdan et al. 2005).  
In addition to the described long-term receptor-arrestin interaction, real time readings over short 
time periods to investigate kinetic of RA-II-150-induced recruitment of β-arrestin2 to the activated 
GPR17 have been performed. Since the applied Renilla luciferase substrate coelenterazine 400A is 
not stable over time (t½ ~1 min, Hamdan et al. 2005), the assay time span was restricted to 140 
seconds, taking measurements every 2.4 seconds. The temporal setting of the measurement can 
exceed the half-life of the substrate since the assay is ratiometric, thus a decrease in luminescence 
does not necessarily influence the BRET signal as long the luminescence signal does not decline 
below the sensitivity of the detector used. Interestingly, RA-II-150-induced BRET increase occurs 
considerably rapid without any lag time and maximum β-arrestin2-association is already reached 
after ~60 s. In contrast to these findings, several reports indicate that the interaction between 
agonist-activated GPCR and β-arrestin occurs in a much slower rate. Neuropeptide Y receptors 
(NPY1, NPY2, NPY4 and NPY5 receptors) have been shown to reach maximal β-arrestin association 
not until 20 to 60 min after agonist activation as determined by BRET2 analyses (Berglund et al. 
2003). Similar to these observations, Ayoub et al. demonstrated by use of BRET1 technology that 
association of β-arrestin with the activated protease-activated receptor 1 reaches its maximum not 
until ~30 min after ligand stimulation (Ayoub et al. 2007). Further real time BRET1 examinations of 
agonist-promoted β-arrestin recruitment to GPCRs are given by Hamdan et al., who reported that 
V1a and V2 vasopressin receptor, β2-adrenergic receptor, chemokine receptor CCR5 and platelet-
activating factor receptor require at least 5 minutes to reach maximum of respective β-arrestin 
association (Hamdan et al. 2005).  
Kinetics of G protein-coupled receptor signaling and desensitization have been reviewed by Krasel et 
al, and they propose GRK phosphorylation as the time-limiting step in receptor–arrestin interaction. 
Receptor phosphorylation has been shown to be the slowest of all analyzed processes, including 
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receptor activation measured as conformational changes within the receptor, G protein activation 
measured as G protein subunit rearrangement, receptor phosphorylation by GRK, and β-arrestin-
recruitment. Subsequent binding of β-arrestin to the activated receptor is fairly rapid and may occur 
within a few seconds (reviewed by Krasel et al. 2004). Further BRET studies investigating the 
interaction between oxytocin receptor and GRK2 revealed that the time course for the interaction 
with β-arrestin lagged behind the interaction of GRK, with the GRK2 interaction occurring within 4 s, 
and the β-arrestin interaction occurring after a 10 s delay, which is consistent with the requirement, 
that GRK-catalyzed phosphorylation must precede arrestin binding (Hasbi et al. 2004). Moreover, 
FRET based analyses between β2-adrenoceptor and βarrestin2 revealed a rapid phosphorylation-
independent association followed by a slower phosphorylation-dependent phase (Violin, Ren & 
Lefkowitz 2006). Regarding the observed rapid β-arrestin recruitment kinetic to agonist-activated 
GPR17, one could conclude that receptor phosphorylation seems to play no essential part in 
β-arrestin translocation. Although the majority of GPCRs has been reported to be phosphorylated to 
enhance β-arrestin affinity, it is also clear that for some receptors, phosphorylation is not an absolute 
requirement for arrestin binding. Leukotriene B4 receptors (Jala, Shao & Haribabu 2005), protease-
activated receptor-1 (Chen, Paing & Trejo 2004), lutropin receptor (Mukherjee et al. 2002) and 
substance P receptor (Richardson et al. 2003) are examples of receptors whereby β-arrestin binding 
occurs independently of receptor phosphorylation. Additionally, β-arrestin binding is maintained in 
mutants of the orexin-1 (Milasta et al. 2005), dopamine D2 (Cho et al. 2010) and protease-activated 
receptor-2 receptors (Stalheim et al. 2005) despite the removal of the putative phosphorylation sites. 
However, where phosphorylation seems to be not obligatory for arrestin translocation, it seems that 
the interaction of the active conformation of the receptor with the β-arrestin itself is sufficient to 
provide a functional receptor–arrestin complex. Since these conclusions are only hypotheses based 
on real time β-arrestin2 recruitment kinetics, additional studies are absolutely essential to decipher 
the necessity of prior receptor phosphorylation. For example, analyses could be performed to see 
whether over-expression of GRKs and their dominant-negative mutants, respectively, or deactivation 
by small interfering RNA exhibit effects on β-arrestin recruitment (Hasbi et al. 2004, Violin, Ren & 
Lefkowitz 2006). The use of transgenic and knock-out mouse models represents another important 
tool to determine in vivo specifity of GRKs and β-arrestins (Kohout & Lefkowitz 2003).  
In addition to this phosphorylation-independent association, GPCRs have been demonstrated to 
interact with β-arrestins independent of heterotrimeric G protein-coupling. Furthermore, increasing 
evidence is emerging that this interaction is capable to elicit signals in its own right, as extensively 
reviewed by many authors, e.g. (Defea 2008), (DeWire et al. 2007), (Ferguson 2001), (Lefkowitz & 
Shenoy 2005), (Luttrell & Lefkowitz 2002), (Luttrell & Gesty-Palmer 2010), (Reiter & Lefkowitz). Thus, 
it was another aim to get more insight into the underlying mechanism of β-arrestin2 recruitment to 
the agonist-activated BRET2-fusion receptor GPR17-RLuc, and interestingly complete abolishment of 
present G protein-dependent signaling by pharmacological inhibitors reveals only partial inhibition of 
the GPR17-promoted β-arrestin2 translocation. At first the pharmacological tools have been tested 
for their property to inhibit GPR17-mediated G protein-dependent signaling, and investigations by 
traditional second messenger assays clearly demonstrate that preincubation with either PTX to 
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diminish Gαi/o-mediated cAMP inhibition or YM-254890 to abolish Gαq-triggered IP1 accumulation, 
completely abrogates RA-II-150-induced second messenger alterations. Additional Epic® analyses 
further support these conclusions, as application of individual inhibitors (PTX or YM-254890) partly 
diminishes GPR17-triggered DMR response, whereas simultaneous usage completely abrogates the 
monitored optical signatures elicited by RA-II-150. Subsequent BRET2 analyses clearly demonstrate 
that inhibition of G protein-dependent signaling, obtained by simultaneous preincubation with both 
PTX and YM-254890, does not completely impair translocation of β-arrestin2, since almost the half 
(45.2 +/- 6.6%) is still recruited to the RA-II-150-activated receptor. Consequently, GPR17 can be 
described as a ‘balanced’ receptor that features the capability to recruit the scaffolding protein β-
arrestin2 in a G protein-dependent as well as –independent manner. To demonstrate whether the 
latter behavior exhibits signaling properties in its own right, such as activation of mitogen-activated 
protein kinase (MAPK) cascade, further investigations are necessary, but not part of the present 
thesis and thus, up to now, remain so far elusive. 
Nevertheless, the Epic® analyses revealed further interesting conclusions: one, regarding signaling 
properties of GPR17 and the other one, revealing information about detection sensitivity provided by 
DMR analyses. Whereas second messenger assays are suitable to uncover activation of Gαi/o, Gαq 
and Gαs sensitive receptors, such assays do not exist to detect Gα12/Gα13 signaling, but DMR 
technology has been reported to identify signaling along the Gα12/Gα13 pathway (Schröder et al. 
2010). Since simultaneous preincubation with PTX and YM-254890 completely abrogated optical 
signatures elicited by RA-II-150 stimulation, it is clearly demonstrated that the Gα12/Gα13 pathway 
does not play a role in GPR17 signaling, at least for the BRET2-fusion receptor, which is investigated 
here. Another important aspect, based on the complete abolishment of GPR17-triggered DMR 
response through pharmacological inhibition of both involved G protein-dependent pathways (Gαi/o 
and Gαq), is the fact that although GPR17-mediated DMR is entirely prevented, BRET2 assays still 
reveal recruitment of β-arrestin2. Consequently, the Epic® technology is not able to detect the 
G protein-independent β-arrestin2 recruitment to the RA-II-150-activated GPR17, which is an 
important information that has not been reported before, especially regarding the existence of 
arrestin-biased ligands (e.g. Gao & Jacobson 2008, Wei et al. 2003, for review see Violin & Lefkowitz 
2007) that could be missed while screening with the Epic® system.  
Another important general aspect for future analyses is that the generated double stable BRET2 cell 
line represents a suitable tool to monitor and quantify GPR17 activation in a pathway unbiased 
manner, for G protein-dependent and -independent events, in real time and in living cells. 
Consequently, this cell line will be helpful for further universally applicable functional cell-based 
screening analyses to characterize ligand-GPR17 interactions, since the inclusion of G protein-
independent pathways represents a helpful tool for future deorphanization studies. 
5.1.3.1 Uncovering the postulated small molecule pan-G protein inhibitor BIM-46187 to 
act in a cell type-dependent manner 
While analyzing G protein-dependence of β-arrestin2 recruitment to the agonist-activated GPR17, 
the small molecule pan-inhibitor of GPCR signaling BIM-46187, published to inhibit all isoforms of Gα 
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proteins (Ayoub et al. 2009), has been shown to exhibit cell type-dependent inhibition properties. 
Recently, BIM-46187 was demonstrated to prevent the accurate interaction of receptors with the 
G protein heterotrimer through a direct binding to the Gα subunit, consequently promoting 
inhibition of the agonist-induced GDP/GTP exchange (Ayoub et al. 2009). Based on the reported 
information, BIM-46187 has been applied as a promising tool to simultaneously abrogate both 
GPR17-RLuc-activated signaling pathways (Gαi/o and Gαq), but surprisingly traditional second 
messenger analyses disprove the postulated characteristics. Preincubation of HEK293 cells stably 
expressing GPR17-RLuc with BIM-46187 does neither alter RA-II-150-induced decrease of adenylate 
cyclase activity nor significantly inhibit prostaglandin E1 mediated increase of intracellular cAMP via 
endogenously expressed Gαs-linked prostanoid receptors (EP2R and EP4R, Willoughby et al. 2007). 
However, IP1 analyses revealed that BIM-46187 significantly and almost completely diminishes the 
GPR17-mediated IP1 production in a concentration-dependent manner. This apparent pathway-
specific inhibition property has been further proven, as carbachol-induced IP1 production through 
activation of endogenously expressed muscarinic receptors (M1 and M3, Estacion et al. 2004, 
Mundell & Benovic 2000) is likewise inhibited by preincubation with BIM-46187, whereas the small 
molecule inhibitor exhibits no significant impact on basal IP1 levels of HEK293 cells. Further evidence 
of Gαq-selective inhibition has been provided by BRET2 analyses of β-arrestin recruitment, since both 
inhibitors YM-254890 (known as selective Gαq/11-inhibitor) and BIM-46187 reveal comparable 
results. Consequently, since BIM-46187 inhibits neither Gαi/o- nor Gαs- mediated modifications of 
intracellular cAMP accumulation, but rather exclusively prevents Gαq-promoted increase of IP1 
concentrations, the small molecule can be regarded as a pathway-selective inhibitor in HEK293 cells, 
despite the previously reported pan-inhibition properties. In contrary, subsequent analyses in COS-7 
cells, which have also been applied in the original report, support the results presented by Ayoub et 
al., since prostaglandin E1-stimulated cAMP accumulation via endogenously expressed Gαs-linked 
prostanoid receptors is significantly impaired by preincubation with BIM-46187, whereas forskolin-
stimulated cAMP accumulation is not sensitive to the pretreatment, indicating G protein-dependent 
modifications. This led to the conclusion, that BIM-46187 does not only exhibit pathway-selective 
inhibition properties, as demonstrated in HEK293 cells, but furthermore cell-type dependent action.  
A very recent report demonstrated that HEK293 cells express an almost full complement of mRNA 
encoding for G protein isoforms for each subunit, whereas Gαq was shown to be the least abundant 
subunit compared to Gαi/o and Gαs, as determined by means of microarray technology (Atwood et 
al. 2011). This lower expression could be a reason for the selective inhibition of Gαq-mediated 
signaling by BIM-46187 observed in HEK293 cells, since less substance would inherently be necessary 
to fully abrogate activity of this G protein subunit. If this would be the case, application of higher 
BIM-46187 amounts should diminish the remaining G protein-dependent signaling pathways, but due 
to poor solubility of the inhibitor no concentration higher than the applied (100 µM) could be added, 
thus it remains elusive whether the expression levels of G protein subunits are the reason for the 
selective inhibition. Furthermore, this consideration can be translated to differential inhibition 
behavior observed between both analyzed cell lines, HEK293 and COS-7. Similar to discrepancies of 
signaling properties that do not only depend on which G protein is preferentially recognized by the 
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receptor, but also based on differential expression of signal transduction components 
(e.g. G proteins) by different cells (Nasman et al. 2001, Schulte & Levy 2007), the observed cell type-
dependent inhibition potencies of BIM-46187 can be explained, assuming that COS-7 cells possess 
lower amounts of G protein subunits. 
As so far only one selective inhibitor for Gαq/11 has been reported (Taniguchi et al. 2003), which is 
not commercially available, BIM-46187 as a novel Gαq/11 inhibitor represents a valuable tool for 
signaling analyses of GPCRs, although to date restricted to HEK293 cells.  
5.1.4 In search of an appropriate cellular system to investigate natural occurring signaling 
pathways 
Several GPCRs are known to activate multiple signaling systems, such as corticotropin-releasing 
hormone receptor, metabotrophic glutamate receptor or the prostacyclin receptor to name but a 
few (Grammatopoulos et al. 2001, Hermans et al. 2000, Lawler, Miggin & Kinsella 2001, summarized 
in Table 1). The involvement of multiple G proteins may arise from differences in the expression 
levels of the participating G proteins (Nasman et al. 2001). Furthermore, it is known that the use of 
recombinant systems might produce results that depend on cell type, transducer or effector 
availability, especially when dealing with GPCRs (Kenakin 1997). Multiplicity is frequently observed in 
recombinant over-expression systems where elevated densities of receptors are present, suggesting 
that over-expression of the receptor might favor additional coupling with the most abundant G 
protein (Gudermann, Schöneberg & Schultz 1997). Controversially, sufficient studies have confirmed 
the pleiotropic nature of GPCRs in native tissues. One such example is given by the thyrotropin (TSH) 
receptor, which was found to simultaneously activate members of all four classes of G proteins (Gαs, 
Gαi/o, Gαq/11 and Gα12) in human thyroid membranes (Laugwitz et al. 1996). Another example is 
given by the CB1 cannabinoid receptor that has been demonstrated to couple both Gαs (Glass & 
Felder 1997, Bash et al.) and Gαq/11 (McIntosh et al. 2007) in models where cannabinoid receptors 
are endogenously expressed. 
To further verify demonstrated multiplicity of GPR17 observed in recombinant cell systems and 
elucidate naturally occurring signaling pathways of GPR17, an experimental approach was chosen to 
identify an appropriate cell system by means of the Epic® system, which enables whole-cell and 
label-free analyses of endogenously expressed GPCRs with high sensitivity (Fang, Li & Ferrie, Fang & 
Ferrie 2007, Schröder et al. 2010). Since none of the analyzed immortalized and primary cell lines 
responds to the stimulation with the GPR17-agonist RA-II-150, the natural occurrence of 
promiscuous coupling of GPR17 upon activation with RA-II-150 remains elusive at present. However, 
establishment and validation of primary cultures endogenously expressing GPR17 will be a task of the 
near future, especially oligodendrocyte precursor cells (OPCs), which have been reported to express 
GPR17 (Lecca et al. 2008, Chen et al. 2009, Fumagalli et al. 2011, Ceruti et al. 2011), represent an 
interesting cellular system to analyze influence of our synthetic agonist RA-II-150 on 
oligodendrogliogenesis.  
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The modification of murine embryonic stem cells by gene targeting to obtain pluripotent cells with 
heterozygous knocked-out GPR17 was successfully performed. Although a second modification is 
necessary to completely knock-out the GPR17 gene, these cells already represent a promising cellular 
tool lacking the desired receptor, and featuring the capability to be differentiated into a desired cell 
system, especially of neural cell type such as cortical neurons (Gaspard et al. 2009) or spinal cord 
motor neurons (Wichterle et al. 2002). Thus, pharmacological comparison of wild type and knock-out 
neural cells will provide further information about the physiological role of GPR17 without the need 
of animal experiments, as generation of transgenic knock-out mice can be circumvented. 
5.1.5 Fascinating dualistic role of GPR17 
Increasing evidence is emerging that heterodimerization between orphan and non-orphan GPCRs 
opens an interesting possibility that orphan receptors regulate the ligand binding, signaling and/or 
trafficking of GPCRs with known ligands. The first and best characterized heterodimer that is 
composed of an orphan and a non-orphan GPCR is the metabotrophic γ-aminobutyric acid B (GABAB) 
receptor heterodimer. The functional GABAB receptor is composed of two homologous subunits 
called GABAB1 and GABAB2 (Jones et al. 1998, Kaupmann et al. 1998, White et al. 1998). While the 
non-orphan GABAB1 provides ligand binding, the orphan GABAB2 subunit is obligatory for efficient 
transport of GABAB1 to the cell surface and promotes G protein-coupling (Pin et al. 2005). Further 
support for the role of orphan GPCRs in ligand-independent modulation of receptor signaling and 
internalization comes from the Mas-related gene (Mrg) family members that consist of orphan and 
non-orphan GPCRs. MrgD subtype, known to be activated by β-alanine and MrgE, which has not been 
matched with any known ligand, have been shown to form heterodimers when transfected in 
HEK293 cells (Milasta et al. 2006). Binding of β-alanine to MrgD, when expressed alone, activates the 
extracellular-signal-regulated kinase (ERK1 and 2) pathway and receptor internalization. 
Coexpression of MrgD with the orphan MrgE potentiates ß-alanine induced MrgD signaling and 
impairs ligand-promoted MrgD internalization in the MrgD/MrgE heterodimer (Milasta et al. 2006). 
Another example of the association between orphan 7TM proteins with non-orphan GPCRs shows 
that orphans can also negatively modify the signaling of their interacting partners. Engagement of the 
orphan GPR50 into heterodimers with melatonin receptor (MT1), known to bind the circadian 
neurohormone melatonin, drastically impairs ligand-induced MT1 functionality, namely inhibition of 
high-affinity agonist binding, heterotrimeric G protein-coupling and β-arrestin binding in cells 
expressing both proteins heterologously (HEK293 cells) and endogenously (human endothelial 
cerebral CMEC/D3 cells) (Levoye et al. 2006). Consequently, GPR50 can be considered as a natural 
negative modulator of MT1. 
One could consider that GPR17 provides similar characteristics as described for GPR50, since GPR17 
has been reported to act as ligand-independent negative regulator of CysLT1 receptor (Maekawa et 
al. 2009). Furthermore GPR17 has been demonstrated to be constitutively active through Gαi 
(Benned-Jensen & Rosenkilde 2010), thus proclaiming that GPR17 acts ligand-independent, but 
nonetheless exhibits functional activity. Whereas the ligand-independent functional activity of GPR17 
could not be verified, neither in stably (as presented in this work) nor in transiently (data not shown, 
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Lucas Peters, AK Kostenis) transfected HEK293 cells, the dominant negative ligand-independent 
inhibition of CysLT1 receptor has been further proven in our laboratory. Upon transient coexpression 
of both receptors in HEK293 cells, GPR17 silenced CysLT1 functionality as monitored by means of the 
Epic® system (data not shown, Lucas Peters, AK Kostenis). Conversely, CysLT1 did not impair signaling 
properties of GPR17, thus indicating that no reciprocal inhibition by CysLT1 of GPR17 took place. 
Having characterized GPR17 as a receptor featuring common properties like the majority of known 
GPCRs upon agonist-stimulation, such as G protein-dependent signaling events (Gαi/o, Gαs and Gαq), 
recruitment of β-arrestin2 to the activated receptor in G protein-dependent and -independent 
behavior, and internalization in a ligand- and time-dependent manner (Figure 86), leads to the 
conclusion that this receptor, in contrast to the above mentioned orphan GPCRs, exhibits a dualistic 
role, that to the best of my knowledge has not been described before. On the one hand a ligand-
independent function as negative-regulator of CysLT1 receptor, and on the other hand GPR17 
features signaling in its own right upon agonist stimulation.  
 
Figure 86 Multiple cellular events initiated by GPR17 upon stimulation with RA-II-150 
Activation of GPR17 with RA-II-150 causes endocytosis of the activated receptor and recruitment of β-arrestin2, 
the latter shown to be only partially G protein-dependent. The dependence of β-arrestin2 for GPR17 
endocytosis, the cellular response mediated by the βγ-subunit, as well as β-arrestin-mediated activation of 
mitogen-activated protein kinase (MAPK) remains elusive so far (indicated with a ?). RA-II-150-activated GPR17 
preferentially couples to pertussis toxin (PTX)-sensitive Gαi/o protein, which was demonstrated in the 
inhibition of adenylate cyclase leading to decrease of cyclic adenosine monophosphate (cAMP) synthesis. 
Furthermore, GPR17-induced activation of phospholipase C and the consequent synthesis of inositol 
monophosphate (IP1) was shown to be sensitive to YM-254890 and BIM-46187, indicating an involvement of 
Gαq/11. High concentrations of GPR17 receptor agonist RA-II-150 were also capable to mediate adenylate 
cyclase activation, indicating a possible coupling with Gαs proteins. This stimulatory effect was lost (broken 
arrow) in analyzed HEK-BRET-GPR17 cell lines (for detailed information see main text).  
It is conceivable that this phenomenon of dual activity may represent a currently underappreciated 
strategy of a wide range of liganded GPCRs to fine-tune cellular signaling with great implication for 
development of GPCR targeted drugs. 
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It should be further mentioned that high-level expression of GPCRs may induce artificial interactions 
that might not be present in a physiological environment. Therefore, the application of cells with 
endogenous receptor expression is of interest. Both GPR17 and CysLT1 have been demonstrated to 
be expressed in bone-marrow derived CD11c-positive dendritic cells (DC) by RT-PCR analyses (Itagaki 
et al. 2009). Dendritic cells are potent antigen-presenting cells (APCs), and are known to promote 
and modulate the immune response through a variety of mechanisms, whereby one major function 
is stimulation of quiescent, naïve and memory B and T lymphocytes (Banchereau & Steinman 1998). 
Furthermore, CysLTs (LTD4 and LTC4) were found to regulate DC migration (Robbiani et al. 2000), 
and Machida et al. reported that in vitro treatment with LTD4 modifies the cytokine profile (IL-10) of 
DCs pulsed with house dust mite allergens (Dermatophagoides farina) and enhance these DCs to 
induce a Th2 response in vivo (Machida et al. 2004). Additionally, CysLTs were reported to potentiate 
DC functions such as Ag-presenting capacity and cytokine production (Okunishi et al. 2004). 
Consequently, primary bone marrow-derived DCs or an immortal DC line termed JAWSII (ATCC® CRL-
11904TM), that exhibits similar immunobiological characteristics and functions (Jiang et al. 2008), 
could represent an appropriate cellular system for further investigations of the regulatory role of 
GPR17 on CysLT1 receptor and its physiological relevance, especially consequences of GPR17 
activation with our small molecule agonist on immunobiological responses represent an interesting 
task for future analyses.  
5.2 Emerging role for β-arrestin as a modifier of GPR17-triggered G protein-
dependent signaling 
In the present thesis four HEK293 cell lines were engineered to stably coexpress GPR17 and differing 
amounts of β-arrestin2 to uncover the impact of the scaffolding protein as a regulator for the 
agonist-activated GPR17. HEK293 cells stably transfected with β-arrestin2 were kindly provided by J. 
M. Mathiesen, and the amino-terminal fusion of β-arrestin2 with the autofluorescent epitope tag 
green fluorescent protein 2 (GFP2) allows determination of respective expression levels and was 
assessed by fluorescence activated cell sorting (FACS) analyses, as conducted by J. M. Mathiesen 
(Department of Medicinal Chemistry, University of Copenhagen). Imaging of the cells by use of a 
fluorescence microscope revealed an even distribution of β-arrestin2 within the cell cytosol (Annex 
Figure 2). 
5.2.1 Increase of β-arrestin2 levels reveal no obvious impact on RA-II-150-induced GPR17 
endocytosis in HEK293 cells 
Numerous studies to date have employed over-expression of either wild type or dominant negative 
arrestins with heterologously expressed GPCRs to elucidate the role of these scaffolding proteins for 
GPCR trafficking (e.g., Anborgh et al. 2000, Aramori et al. 1997, Ferguson et al. 1996, Kim et al. 2001, 
Ménard et al. 1997, Vrecl et al. 1998, Zhang et al. 1996). Further techniques to reduce endogenous 
arrestin levels, such as RNA interference (e.g., Ahn et al. 2003, Li et al. 2010), antisense strategies 
(e.g., Mundell, Loudon & Benovic 1999, Mundell & Benovic 2000) and generation of β-arrestin-
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deficient mice (e.g., Kohout et al. 2001, Vines et al. 2003) were employed to determine the impact of 
β-arrestins on internalization, desensitization and resensitization of GPCRs.  
In the present thesis the effect of increased β-arrestin2 amounts on GPR17 internalization was 
evaluated, and despite a suspected augmented endocytosis due to the previously determined long 
lasting association between GPR17 and β-arrestin, all three analyzed cell lines reveal 
undistinguishable internalization rates upon stimulation with RA-II-150, which might suggest a β-
arrestin-independent internalization mechanism. Although it is known that β-arrestin serves as 
trafficking molecule participating in agonist-promoted receptor internalization, it has been reported 
that GPCRs might react differently on arrestin-over-expression, amongst others depending on the 
respective cellular differences. The angiotensin AT1a receptor, for example, has been shown to 
significantly increase internalization upon agonist-stimulation due to elevated expression of 
β-arrestin1 amounts both in HEK293 and COS-7 cells (Zhang et al. 1996), and thyrotropin-releasing 
hormone (TRH) receptor was reported to show a significant higher sequestration rate in COS-7 cells 
when coexpressed with increased β-arrestin concentrations (Vrecl et al. 1998). In contrary, agonist-
induced endocytosis of gonadotropin-releasing hormone (GnRH) receptor was unchanged despite 
increased β-arrestin concentrations in COS-7 cells (Vrecl et al. 1998), whereas the β2 adrenergic 
receptor (β2AR) revealed cell dependent characteristics, as β-arrestin over-expression induced 
significantly increased sequestration in COS-7 cells (Zhang et al. 1996), but not in HEK293 cells 
(Ferguson et al. 1996, Ménard et al. 1997, Zhang et al. 1996). Cellular differences were claimed to be 
due to known higher endogenous β-arrestin expression levels in HEK293 cells compared to COS-7 
cells, which express about 70% less total β-arrestins/mg protein (Ménard et al. 1997). Consequently, 
under conditions chosen for the present thesis, β-arrestins probably do not represent the limiting 
factor necessary for the endocytotic machinery. Since influence of β-arrestin2 on RA-II-150-promoted 
GPR17 endocytosis was only examined in HEK293 cells, further investigations are necessary to 
determine whether agonist-induced internalization occurs independently of β-arrestin2-recruitment 
or whether sequestration rate already reaches its maximum in the presence of endogenous 
β-arrestin amounts present in HEK293 cells and other, recently unknown participants, represent the 
rate limiting factors.  
5.2.2 A novel role for β-arrestin as a fine-tuner of promiscuous G protein-dependent 
signaling 
For many GPCRs it has been shown that besides the mentioned effect on internalization, the 
presence of β-arrestins is required to quench receptor signal and to enhance the desensitization 
process (Wilden, Hall & Kühn 1986, Benovic et al. 1987, Schlador & Nathanson 1997, for review, see 
Ferguson et al. 1998, Ferguson 2001). Nevertheless, only little and partly controversial information is 
given about the direct effect of β-arrestin on G protein-triggered signaling events, especially 
regarding the formation of downstream signaling, such as modification of second messengers. 
However, over-expression of β-arrestins, which are known to accelerate the uncoupling of GPCRs 
from their cognate G proteins, would be expected to attenuate receptor-mediated signaling events. 
In agreement with this hypothesis, inhibition of endogenously expressed β-arrestin2 by means of 
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RNA interference (Ahn et al. 2003) and transgenic knock-out of β-arrestin1 and 2 (Kohout et al. 
2001), respectively, were shown to enhance cAMP elevation induced by agonist activation 
(isoproterenol) of Gαs-linked β2 adrenergic receptor (β2AR), whereas Mundell et al. reported that 
repression of both β-arrestins using an antisense strategy did not significantly alter β2AR-mediated 
cAMP accumulation (Mundell, Loudon & Benovic 1999). Application of the same antisense strategy 
further revealed that inhibition of β-arrestins enhanced neither somatostatin receptor- nor AT1a 
angiotensin receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity (Mundell 
& Benovic 2000). Furthermore, the calcium responses for Gαq-linked muscarinic M1 mACh, and 
purinergic P2Y1 and P2Y2 receptors were shown to be unchanged in antisense-expressing cells 
compared with vector transfected controls, whereas solely the IP1 accumulation mediated by M1 
mACh receptor, neither by P2Y1 nor by P2Y2 receptor, was enhanced via repression of endogenous 
β-arrestins (Mundell & Benovic 2000). Further contradictory examples demonstrate the positive 
effect of reduced β-arrestin levels on GPCR triggered calcium release, e.g. silencing of β-arrestin by 
means of RNA interference increased carbachol-induced calcium release via M3 mACh receptor (Luo, 
Busillo & Benovic 2008), and calcium mobilization promoted by the chemokine receptor CXCR2 was 
elevated in neutrophils obtained from transgenic β-arrestin2-deficient mice (Su et al. 2005). All the 
mentioned examples have only evaluated the effect of reduced β-arrestin levels on GPCR-mediated 
second messenger modifications, and just one possible signaling pathway has been considered, 
although the receptor might reveal dual coupling, as shown for the angiotensin AT1a receptor. 
Whereas Mundell et al. only investigated the Gαi/o-linked inhibition of adenylate cyclase (Mundell & 
Benovic 2000), Kohout et al. examined the Gαq-mediated IP1 accumulation (Kohout et al. 2001), and 
Tohgo et al. analyzed the effect of elevated β-arrestin levels on intracellular IP1 concentrations, all 
three investigating the effect of AT1a receptor upon stimulation with angiotensin II, but none of 
them evaluated reciprocal or overall influences of distinct β-arrestin amounts on the dual G protein-
dependent signaling pathways.   
In the present thesis the use of the Epic® technology enabled to analyze the effect of increased β-
arrestin levels on the overall DMR response that has been shown to be based on Gαi/o-and Gαq-
promoted signaling pathways. In agreement with the studies mentioned before, the overall relative 
efficacies determined by stimulation with RA-II-150 are diminished in the presence of increasing 
amounts of β-arrestin, whereas, surprisingly, the obtained data further demonstrate that the 
presence of elevated β-arrestin2 amounts boosts the potency of our small molecule agonist 
RA-II-150, as depicted by pEC50 values in Figure 87. Moreover, this enhanced potency is clearly 
diminished in the presence of PTX, highlighting an important role for Gαi/o protein-triggered 
signaling, which is further confirmed by an enhanced PTX-sensitivity of GPR17-induced DMR 
responses in the presence of elevated β-arrestin2 amounts, as illustrated by impaired relative 
efficacies (Figure 87). Consequently, these findings indicate that besides the expected inhibition of 
the overall response due to an accelerated uncoupling from the cognate G proteins, the preference 
of the promiscuous G protein-coupling mediated by agonist-activated GPR17 seems to be shifted to 
the most preferred one (here Gαi/o-protein), as manifested by elevated potencies.  
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This phenomenon was further investigated by traditional second messenger assays, namely by 
examination of intracellular cAMP and IP1 modifications. Interestingly, the results obtained by cAMP 
analyses clearly resemble the data determined by use of the DMR technology in the absence of PTX, 
as illustrated by similar ascending pEC50 values in the presence of increasing β-arrestin2 amounts. 
Thus, the Gαi/o protein-mediated signaling events can be regarded as major if not even sole initiator 
for GPR17-elicited DMR responses in the presence of elevated β-arrestin2 amounts. This conclusion 
is further supported by the fact that investigations of intracellular IP1 changes revealed, in all cell 
lines coexpressing β-arrestin2, an almost complete inhibition of GPR17-mediated increase of inositol-
1-phosphate (IP1), whereby only the highest applied RA-II-150 concentration (100 µM) triggered a 
measurable hydrolysis of inositol phospholipids. This lack of response agrees very well with the 
conclusions drawn from DMR analyses, namely that in the presence of augmented β-arrestin2 levels 
the optical signatures elicited by challenge of GPR17 are almost exclusively caused by downstream 
events of Gαi/o proteins. Further inhibition of the simultaneously occurring and probably competing 
Gαi/o-mediated signaling by use of PTX preincubation, prior to IP1 analyses, triggers a reversal of the 
observed phenomenon and sensitizes the Gαq-coupled signaling, resulting in similar magnitudes and 
potencies of determined concentration-response curves amongst all analyzed cell lines. Accordingly, 
the observed insufficient coupling with Gαq proteins is probably caused by an elevated 
desensitization rate due to increased β-arrestin2 amounts, and initiated by the concurrently 
occurring and preferred Gαi/o-mediated signaling.  
Another interesting aspect that should be noted is the fact that relative efficacies determined by 
DMR and cAMP assays are clearly impaired by coexpression of augmented β-arrestin2 levels, as it 
would be expected due to enhanced uncoupling mechanisms, but the relative efficacies observed by 
use of IP1 analyses, in the presence of PTX, were almost indistinguishable, with the exception of the 
very high cells revealing very low GPR17 expression levels. Thus, these findings somehow mirror the 
beforehand mentioned controversial effects of β-arrestin on GPCR-triggered signaling, since e.g. 
Tohgo et al. postulated a reduction of AT1a receptor-mediated IP1 accumulation by over-expression 
of β-arrestin2 (Tohgo et al. 2002), and Kohout et al. demonstrated that both single and double knock-
out of both β-arrestins increases AT1a receptor-triggered hydrolysis of phosphatidylinositol 
hydrolysis (Kohout et al. 2001), whereas Mundell et al. reported an increase of M1 mACh receptor-
induced IP1 response but neither of P2Y1- nor of P2Y2-mediated IP1 production via antisense 
strategy to silence β-arrestin1 and 2 (Mundell & Benovic 2000).  
Taken together, the observed findings demonstrate that over-expression of β-arrestin2 with 
heterologously expressed GPR17 not only exhibits the expected capability to impair the agonist-
induced response efficacies, but rather enhances the potency of the overall responses upon 
stimulation with RA-II-150, as confirmed by increased pEC50 values using the DMR technology. This 
potency boost has been shown to emerge from a preference shift of the promiscuous G protein-
coupling to the most preferred one, which has been previously determined to be the Gαi/o protein. 
Consequently, the Gαi/o protein-mediated signaling consequences gain more overall weight for 
GPR17-triggered responses.   
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Figure 87 Comparison of pEC50 values and relative efficacies determined in HEK293 cells stably 
coexpressing GPR17 and distinct amounts of β-arrestin2 upon stimulation with RA-II-150 
pEC50 values were determined by RA-II-150 challenge of HEK293 cells stably coexpressing fusion receptor 
GPR17 C-terminally fused to Renilla luciferase and increasing amounts of β-arrestin2 N-terminally labeled with 
GFP2 (endogenous, low, high and very high). Data were achieved by various functional assays (cAMP and IP1 to 
analyze traditional second messengers and Epic® technology to monitor dynamic mass redistribution (DMR)), in 
absence and presence of pertussis toxin (PTX, 50 ng/ml, 18 h). No data (n.d.) were obtained by IP1 assays in the 
presence of elevated β-arrestin levels, as no appropriate CRC could be computed. 
These observed functional response differences depending on the amount of β-arrestin2 expression 
levels, represent a new example of fine-tuning in G protein-dependent receptor signaling. These 
findings become even more important regarding the information that different cell types have been 
shown to express distinct amounts of β-arrestins, such as the immortalized cell lines A431 (human 
epithelial carcinoma cell line), CHO, CHW (chinese hamster fibroblast cell line), COS-7 and HEK293 as 
detected by use of western blot analyses (Ménard et al. 1997), or for AtT20 (murine pituitary 
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epithelial-like tumor cell line), BV2 (mouse microglial cell line), N18 (murine neuroblastoma cell line) 
and HEK293 cells as identified by means of microarray analyses (Atwood et al. 2011). Even more 
interesting, pertaining to a physiological relevance of this phenomenon, is the fact that although 
studies of arrestin expression levels in native tissues are still limited, there is evidence of changes in 
the expression amounts of this protein during neuronal development (Gurevich, Benovic & Gurevich 
2004). Moreover, alterations of β-arrestin expression levels have been correlated with 
neuropathological incidents, as shown for MPTP-treated (1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridin, a neurotoxin to induce dopaminergic degeneration) Macaque monkeys (Bezard et 
al. 2005), and for patients with Parkinson’s disease with dementia at postmortem using western 
blotting (Bychkov et al. 2008). Furthermore, immunopathological reactions were demonstrated to 
influence β-arrestin-expression levels, since during inflammation, an increased expression of β-
arrestins was observed in spleens and in inflamed peripheral tissue (Lattin et al. 2007), and 
decreased amounts of β-arrestin2 were detected on intravascular renal graft leukocytes during acute 
rejection of kidney allografts, where the decrease in β-arrestin2 protein levels was only observed in 
monocytes but not in T lymphocytes, further suggesting cell specific expression patterns (Zakrzewicz 
et al. 2010).  
Consequently, the reported tissue-dependent, developmental- and disease-regulated alterations of 
β-arrestin expression levels cannot only influence the trafficking and desensitization of GPCRs as 
postulated several times (e.g. Li et al. 2010, Vrecl et al. 1998, Ahn et al. 2003, Mundell & Benovic 
2000, reviewed by Luttrell & Lefkowitz 2002, Reiter & Lefkowitz, Shenoy & Lefkowitz 2003), but 
additionally might influence the coupling preference of GPCRs interacting with promiscuous 
G proteins, leading to a potency boost of the respective agonist for the most preferred signaling 
pathway, and a possible abrogation of a usually simultaneously occurring but less preferred signaling 
pathway. Accordingly, in addition to the known roles of β-arrestins for GPCR desensitization, 
trafficking and signaling in their own right, an additional function can be postulated, namely the fine-
tuning of promiscuous G protein-dependent signaling.  
5.3 Uncovering Pranlukast as a mixed agonist/antagonist for GPR17 
The already marketed ‘specific’ CysLT1 receptor antagonists pranlukast and montelukast (Brink et al. 
2003) were reported to abrogate functional responses of LTD4-activated GPR17, as determined by 
[35S]GTPγS binding, electrophysiological studies, kinase (ERK1/2) and cAMP assays using 1321N1 cells 
transiently transfected with short and long isoform of GPR17, PC-12 cells and primary OPCs 
endogenously expressing GPR17 (Ciana et al. 2006, Fumagalli et al. 2011, Lecca et al. 2008, Pugliese 
et al. 2009). Anyhow, it should be noted that inhibition properties of pranlukast to counteract 
GPR17-mediated functional responses were only demonstrated by use of [35S]GTPγS binding in 
1321N1 cells transiently overexpressing the short GPR17 splice variant (Ciana et al. 2006), whereas 
the other observations were obtained solely with montelukast. Since activation of GPR17 with LTD4 
so far could not be verified by independent laboratories (Benned-Jensen & Rosenkilde 2010, 
Maekawa et al. 2009, Wunder et al. 2010), the inhibition efficiency of the postulated antagonists 
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remains as well disputable. Furthermore, Benned-Jensen et al. published that montelukast was not 
able to counteract their observed constitutive activity of GPR17 (Benned-Jensen & Rosenkilde 2010). 
Consequently, it was the goal to examine the antagonistic properties regarding GPR17 activation 
with our small molecule agonist RA-II-150. Additionally, two more specific CysLT1 receptor 
antagonists, zafirlukast (Aharony 1998) and MK571 (Jones et al. 1989), which have not been tested 
yet on GPR17, were included in the investigations.   
Preliminary screening analyses by use of the Epic® system and IP1 assays clearly demonstrate that 
the previously reported observations of montelukast and pranlukast could not be confirmed. 
Although all four tested antagonists functionally inhibit GPR17 to some extent, pranlukast represents 
the most promising compound to interfere with RA-II-150-induced GPR17 signaling. On the contrary, 
montelukast, which has been published several times as a potent GPR17 antagonist with an IC50 
value in the nanomolar range (Ciana et al. 2006, Fumagalli et al. 2011, Lecca et al. 2008), surprisingly 
revealed the worst inhibition properties amongst the analyzed antagonists. Therefore pranlukast was 
chosen to be further characterized regarding its pharmacological properties.  
5.3.1 Pranlukast reveals ligand-biased agonism at GPR17 
First of all the agonistic effects of pranlukast at GPR17 were evaluated to determine whether the 
compound acts as a pure neutral antagonist, as an inverse agonist or even as a partial agonist. 
Surprisingly, the use of the Epic® system uncovered dynamic mass redistribution elicited by GPR17 
upon stimulation with pranlukast in a concentration-dependent and PTX-sensitive manner, 
establishing an essential role for Gαi/o-mediated signaling. Indeed, these findings were further 
confirmed by traditional second messenger analyses that revealed pranlukast-induced inhibition of 
forskolin-stimulated adenylate cyclase, sensitive to PTX preincubation in CHO and HEK293 cells stably 
expressing GPR17, whereas a lack of response was monitored in untransfected cells, thus clearly 
indicating a GPR17-mediated coupling with Gαi/o proteins. Further evidence was supplied by use of 
BRET2 technology, since stimulation of HEK293 cells stably expressing BRET2 fusion proteins (GPR17-
RLuc and β-arrestin2-GFP2) with pranlukast yielded in a significant increase of the BRET ratio, 
indicating a recruitment of β-arrestin2 to GPR17, which is known to be a convergent step of GPCR 
signaling (Barak et al. 1997). Similar to results obtained by use of cAMP assays, the translocation of β-
arrestin2 upon pranlukast-stimulation is completely abrogated in the presence of PTX, in contrast to 
the BRET2 results obtained with RA-II-150, highlighting a functional selectivity of GPR17 activation by 
pranlukast. This supposed ligand-biased agonism was further verified by second messenger analyses 
that revealed a lack of functionality in Gαs-cAMP and IP1 assays, although GPR17 has previously been 
shown to couple with promiscuous G proteins upon RA-II-150 challenge, including Gαi/o, Gαs and 
Gαq. The observed functional response of GPR17 upon stimulation with pranlukast is not only 
selective for Gαi/o-pathway but furthermore exhibits only partial agonism with lowered potencies in 
comparison to RA-II-150 as depicted by pEC50 values and relative efficacies in Figure 88. Thus, 
pranlukast represents a weak GPR17 agonist only stimulating the most sensitive pathway. 
Interestingly neither pEC50 values nor relative efficacies exhibited by pranlukast differ significantly 
amongst the evaluated cell lines (CHO and HEK293 cells) and the applied functional assays (cAMP and 
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BRET2), respectively, even analyses of internalization rate confirmed the partial agonism with a 
relative efficacy of ~40% compared to RA-II-150 (Figure 88, B).  
 
Figure 88 Comparison of pEC50 values and relative efficacies of the partial GPR17 agonist pranlukast 
A-B, pEC50 values and relative efficacies were determined by pranlukast challenge of CHO and HEK293 cells 
stably expressing GPR17, and HEK293 cells stably coexpressing fusion receptor GPR17 C-terminally fused to 
Renilla luciferase and β-arrestin2 N-terminally labeled with GFP2 (HEK-BRET-GPR17). Data were achieved by 
various functional assays (cAMP to analyze Gαi/o-mediated decrease of cAMP accumulation, BRET2 assays to 
investigate β-arrestin recruitment, and ELISA to determine GPR17 internalization upon agonist stimulation). For 
statistical analyses, unpaired t-tests with two-tailed p values and 95% confidence interval were applied and 
revealed no significant differences for pranlukast between cell lines and assays, respectively, but between 
pranlukast and RA-II-150 as presented in the plot (p > 0.05, **p < 0.01, ***p < 0.001). A, pEC50 values of full 
agonist RA-II-150 were included for better comparisons with partial agonist pranlukast (P). B, Relative efficacies 
were normalized to maximum effect achieved with RA-II-150.  
Taken together, pranlukast not only counteracts GPR17-mediated functional responses as postulated 
by Ciana et al. (Ciana et al. 2006) and demonstrated in the present thesis, but rather induces 
signaling in its own right by activation of only one G protein-dependent signaling pathway (Gαi/o) of 
the versatile repertoire of possible modification as shown for activation by RA-II-150. This 
phenomenon was not controlled by the cell system, since it was observed in two different cellular 
backgrounds (CHO and HEK293 cells) with comparable extent, indicating dependence on the ligand-
related receptor conformation. Consequently, it could be referred to as a “true receptor active state 
based selectivity” (Kenakin 2007), revealing both partial agonist and pure antagonist actions at 
different functions mediated via a single receptor. Although this is the first time describing 
pranlukast as an agonist at GPR17, Pugliese et al. were not able to examine antagonistic properties of 
pranlukast on LTD4-stimulated GPR17 in electrophysiological studies due to a significant increase 
“per se” in outward currents (Pugliese et al. 2009). Consequently, even if not postulated as such by 
the authors and not knowing the underlying mechanism, this described ‘unspecific’ activity could be 
the regarded as a first hint for stimulating effects of pranlukast at GPR17 as demonstrated in the 
present thesis.  
5.3.2 Non-competitive antagonism of pranlukast at GPR17 
Due to promiscuous G protein-coupling of GPR17 observed upon stimulation with RA-II-150, 
inhibition potencies of pranlukast were examined by use of two traditional second messenger assays 
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to monitor the impact on G protein-dependent signaling (cAMP for Gαi/o and Gαs, IP1 for Gαq) as 
well as by means of BRET2 technology to evaluate repression of β-arrestin2 translocation. Whereas 
pranlukast exhibits functional selectivity for Gαi/o-coupled signaling in GPR17-activation, all 
observed RA-II-150-induced functional responses are concentration-dependently counteracted by 
prestimulation with pranlukast, even though inhibition potencies and relative efficacies differ 
according to the respective experimental approach (Figure 89). However, the observed findings did 
not agree with the previously published inhibition properties of pranlukast at GPR17, since IC50 values 
were reported to be in nanomolar range as examined by means of [35S]GTPγS binding assays in 
1321N1 cells expressing GPR17 (human and rat) (Ciana et al. 2006). Nevertheless, these controversial 
findings might be due to application of distinct GPR17 agonists, as Ciana et al. investigated inhibition 
potencies on LTD4-activated GPR17. Interestingly, their determined antagonistic properties resemble 
the ones obtained by inhibition of the LTD4-induced (33 nM) Ca2+ mobilization in HEK293 cells stably 
expressing CysLT receptor, with an IC50 value of 0.1 nM (Sarau et al. 1999). The effect of pranlukast on 
nucleotide-induced (UDP and UTP) increase of Ca2+ via nucleotide receptors in dU937 cells were 
similar to the data mentioned here, with IC50 values in micromolar range (Mamedova et al. 2005). 
Thus, although the antagonistic behavior of pranlukast has been demonstrated to be not as selective 
as originally assumed (Obata et al. 1992), the concentrations required to functionally counteract the 
effects of RA-II-150 in the present thesis are not comparable to the nanomolar amounts needed to 
inhibit the CysLT1 receptor.  
 
Figure 89 Comparison of pIC50 values and relative efficacies determined by preincubation with 
pranlukast prior to stimulation with RA-II-150  
Inhibition properties of pranlukast to impair RA-II-150-triggered (EC80) functional responses of CHO cells stably 
expressing GPR17 (cAMP and IP1 assays) and HEK293 cells stably transfected with GPR17-RLuc and β-arrestin2 
–GFP2 (= HEK-BRET-GR17 cells, low, for BRET2 analyses), expressed as pIC50 values and relative efficacies (%). 
Data were obtained by means of various functional assays (cAMP and IP1 to analyze traditional second 
messengers, BRET2 technology to monitor β-arrestin recruitment), in absence and presence of pertussis toxin 
(PTX, 50 ng/ml, 18 h).  
In agreement with the postulated partial Gαi/o-agonism of pranlukast at GPR17, the RA-II-150-
elicited inhibition of forskolin-stimulated cAMP accumulation is only partially diminished (~50%) by 
pranlukast prestimulation, whereas GPR17-mediated increase of intracellular IP1 and cAMP 
concentrations is completely abolished by the neutral antagonistic properties of pranlukast, provided 
4.0
4.5
5.0
5.5
6.0
6.5
pI
C
50
Gi
cAMP
Gs
cAMP
+ PTX
IP1 BRET2 BRET2
+ PTX
0
25
50
75
100
125
re
la
tiv
e
 
ef
fic
a
cy
 
(%
)
Gi
cAMP
Gs
cAMP
+ PTX
IP1 BRET2 BRET2
+ PTX
A B
5 Discussion  
 
168
by preincubation with PTX to circumvent influences caused by the partial Gαi/o-mediated agonism 
(Figure 89, B). Interestingly, the recruitment of β-arrestin2 to the agonist-activated GPR17 as well 
was only partially inhibited, but this time not due to the partial agonistic property, since it’s blocking 
by PTX-pretreatment does not significantly change the maximum inhibition effect (~75%), indicating 
a RA-II-150-induced translocation of β-arrestin2 that cannot be completely abolished by pranlukast 
pretreatment. The fact that previous data have revealed that approximately the half of RA-II-150-
induced β-arrestin2 recruitment occurs independently of activated G proteins, indicates that 
pranlukast partially inhibits G protein-independent-induced β-arrestin2 recruitment besides the 
demonstrated inhibition of G protein-dependent events. 
Control data clearly demonstrated that the observed inhibition properties of pranlukast are not due 
to any unspecific heterologous desensitization events and independent of another receptor 
stimulating the adenylate cyclase, since 30 µM pranlukast have no effect on the carbachol-mediated 
increase of intracellular cAMP in CHO cells stably expressing M2 muscarinic receptor.  
Having established antagonistic properties of pranlukast at GPR17, it was another goal to get some 
information about the underlying nature of antagonism. The performed Schild analyses revealed at 
first controversial results besides the common concentration-dependent parallel rightward shift of 
RA-II-150-induced concentration-response curves. Pranlukast was found to inhibit RA-II-150-induced 
IP1 accumulation in a surmountable manner, whereas GPR17-triggered DMR as monitored by the 
Epic® system was shown to be counteracted in an insurmountable nature, and both inhibition and 
stimulation of adenylate cyclase reveals a mixed mechanism as only application of the highest 
pranlukast concentration (30 µM) additionally suppresses the maximal responses. However, the plots 
of these Schild analyses revealed consistent steep slopes for all applied approaches (1.55-2.21), thus 
indicating not a simple competitive antagonism, but rather a non-competitive mechanism of action. 
Consequently, these data obtained by Schild analyses suggest that pranlukast most likely acts non-
competitively to inhibit receptor function and binds to an allosteric site, inducing a conformational 
change in GPR17 that compromises its interaction with RA-II-150 and/or its ability to elicit a 
response. Since besides these antagonistic effects on RA-II-150-activated GPR17, biased agonistic 
effects are demonstrated, pranlukast could be referred to as an “ago-allosteric modulator that is a 
ligand that functions both as an agonist on its own and as an allosteric modulator of the efficacy 
and/or potency of the orthosteric ligand” as described by Schwartz et al. (Schwartz & Holst 2007). 
Recent reports have postulated bitopic or dualsteric ligands, which simultaneously target both 
orthosteric and allosteric sites at the same time. Valant et al. demonstrated, using several different 
binding and functional assays, that McN-A-343, originally described as a selective M2 mAChR partial 
agonist, actually is a bitopic ligand binding to both allosteric and orthosteric binding sites on M2 
muscarinic receptors (Valant et al. 2008). Another recent report, as well using the mACh receptor as 
a template, presented a de novo design of dualsteric ligands by synthesis of hybrids fusing a highly 
potent orthosteric activator with M2-selective allosteric fragments. Radioligand binding analyses in 
wild type and mutant receptors supplemented by docking simulations studies revealed an M2-
selective and true allosteric/orthosteric binding. Furthermore, G protein activation was shown to be 
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mediated by the orthosteric site, and dualsteric hybrid compounds showed ligand-biased signaling 
properties activating only the most preferred Gαi/o pathways (Antony et al. 2009). Further evidence 
indicating that one bivalent ligand can simultaneously occupy both orthosteric and allosteric site is 
provided by Narlawar et al., who synthesized a series of bitopic hybrid ligands linking both the 
orthosteric and allosteric pharmacophores of the adenosine receptor A1 (A1AR) to locate the 
allosteric site on the A1AR (Narlawar et al. 2010). However, as the orthosteric binding site is defined 
as the site where the endogenous ligand binds and as the endogenous ligand of GPR17 has not been 
identified yet, no information is given about the “true” orthosteric binding site of GPR17. Thus, it is 
elusive and just speculation to describe our small molecule agonist RA-II-150 as an orthosteric 
activator and pranlukast as a potential bitopic ligand.  
 
 
Figure 90 Macroscopic view of three best configurations of pranlukast docked to GPR17 (adapted 
from Parravicini et al. 2010) 
The picture illustrates three potential binding poses (CI, CII and CIII) obtained for the antagonist pranlukast 
(stick representation) on GPR17 (cartoon representation), determined by means of docking studies and 
molecular dynamic simulations. The chance of pranlukast to assume different and energetically comparable 
configurations, as for CI, CII and CIII, probably is due to the high flexibility of the molecule yielding its high 
conformational freedom (Parravicini et al. 2010). 
Docking studies combined with molecular dynamic simulations unveiled three distinct potential 
binding sites for pranlukast, stabilizing three energetically favored conformations of GPR17 (Figure 
90, Parravicini et al. 2010), due to the high flexibility of the molecule, which already might be a hint 
for the observed multifaceted functional behavior in the present thesis. Thus, it can be hypothesized 
that the receptor conformations stabilized by pranlukast produce different changes in the various 
regions interacting with signaling proteins such as G protein and β-arrestins resulting in different 
modifications of one signaling pathway versus another, and potentially make GPR17 inaccessible to 
our small molecule agonist RA-II-150. Furthermore it can be hypothesized that the active receptor 
conformation state induced by RA-II-150 capable of interacting with multiple cellular components 
differs from the ones induced by pranlukast.  
Furthermore, it was suggested by Parravicini et al. that two different binding subsites are present on 
GPR17, and that intermolecular interactions with the ligands are different between UDP and 
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pranlukast (Parravicini et al. 2008, Parravicini et al. 2010). Hence, these observations could be 
another indication for allosteric interactions of pranlukast with GPR17, disregarding the fact that the 
postulated ligand UDP could not yet be verified as a GPR17-agonist, and thus the published results 
need to be regarded with care and further considerations about the nature of antagonism are only 
speculations at the moment, but represent an interesting task that will be addressed in future 
studies. To verify an allosteric interaction of pranlukast with GPR17, binding studies would be 
necessary to prove a displacement of our full agonist RA-II-150. Since no radiolabeled GPR17 agonist 
is readily available, the interaction remains elusive and can only be hypothesized.  
Additionally, it should be noted that the monitored insurmountability might be partially related to 
the disappearance of GPR17 cell surface receptors upon stimulation with pranlukast, since such 
phenomena of antagonists have been described previously (Perry et al. 2005, Roettger et al. 1997).  
An alternative explanation for the observed insurmountability could be the kinetic of pranlukast-
GPR17 interactions. Reversible but slow-dissociating competitive antagonists might also depress the 
maximal functional response if the chosen assay time window is insufficient to liberate the entire 
receptor site before agonist is added. Consequently, the insurmountable nature might be due to 
limited duration of the agonist challenge and insufficient readjustment of the receptor. This 
phenomenon is known as “hemi-equilibrium” conditions (Kenakin, Jenkinson & Watson 2006), and 
based on the demonstrated observations in the present thesis it cannot be excluded that this is the 
reason for insurmountability, although chosen time windows were quite long (30-60 min 
preincubation with pranlukast followed by a 60 min of agonist stimulation), but as no information is 
given about the dissociation kinetic of pranlukast for GPR17 it can just be speculated at the moment. 
5.3.3 Hypotheses of physiological relevance  
5.3.3.1 Does the clinical efficacy of pranlukast for the treatment of allergic respiratory 
diseases depend on GPR17 expression levels? 
Pranlukast was the first marketed leukotriene receptor antagonist, and actually is an orally 
administered, selective, competitive inhibitor of the cysteinyl leukotrienes (LTC4, LTD4 and LTE4), 
currently on the market only in Japan (Onon®, since 1995) and Latin America (Azlaire®, since 2002) 
launched by Ono Pharmaceutical Co., Ltd. (Osaka, Japan). The antagonist is applied in the treatment 
of inflammatory conditions of the respiratory system, such as asthma and allergic rhinitis (reviewed 
by Drazen, Israel & O'Byrne 1999, Lipworth 1999, Mastalerz & Kumik 2010, Riccioni et al. 2004). 
Many clinical studies have demonstrated that pranlukast acts as an anti-inflammatory and 
bronchodilator drug effective in reducing bronchial hyperresponsiveness and allergen-induced 
bronchoconstriction, and furthermore exhibits an adverse event profile similar to that of the placebo, 
indicating a good tolerance (Barnes & Pujet 1997, O'Shaughnessy et al. 1997 , reviewed by Hay 1997). 
Since other selective CysLT1 receptor antagonists, such as montelukast or zafirlukast, exhibit similar 
in vitro and in vivo profiles, and only differ in terms of relative potency (Aharony 1998, Hay 1997), the 
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above mentioned physiological effects induced by pranlukast are probably independent of its 
property to modify signaling of GPR17.  
Another interesting consideration regarding the relevance of pranlukast for the treatment of asthma 
and allergic rhinitis arises from the postulation that GPR17 acts as a negative regulator of the CysLT1 
receptor, which is known to trigger a range of proinflammatory effects (Maekawa et al. 2009, 
Maekawa et al. 2010). Unfortunately, no detailed information is available about GPR17 expression 
levels in peripheral blood leukocytes (e.g. monocytes, eosinophils, neutrophils, B lymphocytes), 
spleen or smooth muscle cells (lung, intestine), which are known to express high levels of CysLT1 
(Rovati & Capra 2007). Anyhow, it would be interesting to know whether asthmatic or allergic 
patients reveal distinct expression levels of GPR17 and whether these differences exert influence on 
the efficacy of the pranlukast treatment maybe in comparison to montelukast application. When 
GPR17 would be present and thus acting as down-regulator of the CysLT1-triggered inflammatory 
responses, the treatment with pranlukast could possibly counteract this repressive effect, 
consequently the actual inhibition effect on CysLT1 receptor could be compensated resulting in a 
lowered overall clinical efficacy. Maybe this could even be a reason for the restricted 
commercialization of pranlukast in comparison to montelukast for example. As already mentioned 
above, both receptors have been shown to be present in bone-marrow derived CD11c-positive 
dendritic cells (DC) by RT-PCR analyses (Itagaki et al. 2009), and therefore could represent an 
interesting cellular system to analyze not just the reciprocal effects of both receptors, but also the 
influence of pranlukast on both triggered immunobiological responses.  
Another consideration based on the postulated heterodimerization of GPR17 and CysLT1 receptor 
(Maekawa et al. 2009) could be that the observed effects of pranlukast at GPR17 are due to an 
allosteric regulation between these two proteins, since pranlukast originally was identified as a 
selective CysLT1R antagonist, and thus inhibition of CysLT1R-mediated responses could possibly 
modify signaling of GPR17. However, such considerations can be neglected as the CysLT1R is not 
present in the examined cellular systems (HEK293 and CHO cells). Recently published microarray 
analyses of HEK293 cells clearly demonstrate that neither CysLT1 nor CysLT2 mRNA is present in this 
cell line (Atwood et al. 2011). Although, to the best of my knowledge, no expression data of the 
CysLT1R in CHO cells is reported, several publications demonstrate that CHO cells do not respond to 
a challenge with cysteinyl leukotrienes (LTD4, LTC4), indicating the lack of their corresponding 
receptors in this cell line (Maekawa et al. 2009, Mellor et al. 2001, Sarau et al. 1999). Furthermore, as 
already mentioned above, cotransfection of both receptor proteins in HEK293 cells does not result in 
a reciprocal influence of CysLT1R on GPR17-mediated functional responses, as monitored by the 
Epic® system (data not shown, AK Kostenis), consequently it would be unlikely that inhibition of 
CysLT1R modifies GPR17-mediated signaling. Nevertheless, further investigations are necessary to 
elucidate the precise reciprocal interactions of both GPCRs. 
5.3.3.2 Mixed agonist-antagonist properties at the same receptor 
A mixed agonist-antagonist is a ligand that exhibits pharmacological characteristics alike to both 
agonists and antagonists at a particular receptor, thus representing an extension of the traditional 
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classification as full agonists, partial agonists, neutral antagonists or inverse agonists based on the 
extended ternary complex model (Samama et al. 1993). Already known examples provide evidence 
that the observed results demonstrating pranlukast acting as a biased partial agonist and pure 
antagonist at the same receptor depending on the end point under investigation (as summarized in 
Figure 91) is not an artifact.  
 
Figure 91 Multifaceted functions of pranlukast as a mixed agonist/antagonist at GPR17  
Activation of GPR17 with pranlukast causes endocytosis of the activated receptor and recruitment of 
β-arrestin2, whereby the latter was shown to be completely blocked by pertussis toxin (PTX) preincubation, 
indicating Gαi/o protein-dependence. Challenge of GPR17 with pranlukast triggers a partial coupling to PTX-
sensitive Gαi/o protein, which was demonstrated by the inhibition of adenylate cyclase leading to decrease of 
cyclic adenosine monophosphate (cAMP) synthesis. Furthermore, RA-II-150-induced activation of GPR17 is 
partially (β-arrestin-recruitment and Gαi/o-coupling) or completely (Gαs- and Gαq-coupling) inhibited by 
preincubation with pranlukast. (for detailed information see main text).  
The therapeutic and clinical relevance of functionally selective compounds has been exemplified in 
the medication of schizophrenia; especially the mode of action of the third generation antipsychotic 
prototype aripiprazole has been extensively described and controversially discussed (reviewed by 
Mailman 2007, Mailman & Murthy 2010). Aripiprazole (Abilify, Aripiprex) is an atypical antipsychotic 
and antidepressant drug developed by Otsuka in Japan, and applied for the treatment of 
schizophrenia, bipolar disorder and clinical depression. Originally, the clinical benefit is described to 
be based on a partial dopamine D2 receptor agonistic activity, demonstrated by D2 receptor-
mediated inhibition of cAMP accumulation (Lawler et al. 1999, Shapiro et al. 2003), “stabilizing” the 
dopamine system by normalization of both dopamine hypoactivity and hyperactivity in pathologically 
affected dopaminergic events (Stahl 2001, Tamminga 2002). But furthermore, aripiprazole has been 
demonstrated to act as a pure antagonist at both D2 agonist-mediated GTPγS binding and GIRK 
channel activity (Shapiro et al. 2003). Taken together, the available data support the hypothesis that 
aripiprazol acts as a functionally selective D2 agonist and antagonist depending on the evaluated 
outcome, thus the observed beneficial “dopamine stabilization” results from mixed direct effects on 
the receptor and not just from a simple partial agonism. Consequently, this example provides 
GTP
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evidence that the extreme ligand-induced differential signaling exhibiting agonistic and antagonistic 
properties at the same receptor constitutes a promising mode of action. Whether this is likewise the 
case for pranlukast modifying GPR17-mediated physiological effects still remains elusive, but 
represents an interesting task for the future.  
Postulating that the observed functionally selective signaling is linked to the structure of pranlukast, 
a structure-activity relationship analysis, using distinct pranlukast analogs, could be useful to identify 
the responsible moieties, thus helping to design more specific and as well more potent ligands, which 
would further help elucidating the physiological and pathophysiological role of GPR17 as well as 
represent a valuable tool for drug development, since GPR17 has been proposed to be a potential 
drug target for developing new therapeutic approaches to demyelinating diseases such as multiple 
sclerosis (Chen et al. 2009, Fumagalli et al. 2011, Ceruti et al. 2011) or ischemic and traumatic injury 
of CNS such as stroke and spinal cord injury (Ciana et al. 2006, Lecca et al. 2008, Ceruti et al. 2009). 
5.3.3.3 Importance of functional selectivity of pranlukast 
When GPR17 receptor density is upregulated, which has been demonstrated for specific 
pathophysiological conditions, such as early stages of ischemic and traumatic damage (Ceruti et al. 
2009, Lecca et al. 2008), demyelinating diseases (Chen et al. 2009) or chronic lymphocytic leukemia 
(Aalto et al. 2001), it could be hypothesized, based on the in vitro results of the present thesis, that 
the Gαs-linked signaling pathway gains in importance, and thus might play a central role during the 
acute phase of pathophysiological incidents. Furthermore, it is known that inflammatory mediators 
(such as nucleotides and leukotrienes) are upregulated during cell damage and CNS trauma, and 
although the endogenous ligand for GPR17 has not yet been identified, it is conceivable that the 
extracellular concentration of the so far unknown ligand is as well increased, which would be 
consistent with the gain of importance for Gαs-mediated events, since in vitro results of the present 
work clearly demonstrate the prevalence of the stimulating pathway by a challenge with high ligand 
concentrations, at least with our small molecule agonist RA-II-150. Now bearing these considerations 
in mind, pranlukast, exhibiting partial agonist properties for Gαi/o-mediated signaling and neutral 
“pure” antagonist qualities for Gαq- and Gαs-triggered functional responses, would represent a 
valuable tool to modify the postulated dual role of GPR17 during CNS dysfunctions. In the presence 
of high ligand concentrations, during an early and acute time-window, pranlukast would completely 
block Gαs- and Gαq-elicited functional responses, suggesting that it may afford neuroprotection and 
prevent cell death initiated by GPR17. Conversely, in situations where extracellular concentrations of 
the endogenous ligand are low and Gαi/o-linked signaling prevails, pranlukast can occupy GPR17 and 
induce partial Gαi/o-mediated functional responses, preserving and stabilizing ‘normal’ conditions. 
Since these postulations are based on our own in vitro studies, assuming differential physiological 
relevance of GPR17-mediated promiscuous coupling with distinct Gα protein subunits, further in vivo 
analyses are absolutely essential to prove the beneficial influence of the biased mixed 
agonist/antagonist pranlukast, and implication of these findings for the clinical relevance of 
pranlukast is yet to be explored.  
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Furthermore, it should be noted that several in vivo studies demonstrated that pranlukast exhibits 
neuroprotective effects on cerebral ischemia induced by middle cerebral artery occlusion (MCAO) in 
rats and mice (Zhang et al. 2002, Yu et al. 2005). However, since pranlukast originally has been 
identified as a selective CysLT1 receptor antagonist, exhibiting higher antagonistic potencies at this 
leukotriene receptor in comparison to GPR17, and further has been shown to inhibit the effects of 
nucleotides acting at P2Y receptors (Mamedova et al. 2005), it is difficult to distinguish between 
GPR17-, CysLT1- or even P2Y-mediated events, especially when receptor expression levels are not 
considered in the examinations. Furthermore, the demonstrated neuroprotective effects were also 
shown for montelukast that is, similar to pranlukast, known to inhibit CysLT1 as well as P2Y 
receptors, but in contrast lacking significant inhibition at ligand-activated GPR17, as demonstrated in 
the present thesis. Hence, physiologically relevant events monitored with both compounds in a 
comparable extent, obviously cannot be mediated by modification of GPR17-triggered responses. 
Interestingly, the dose-effect of pranlukast-induced neuroprotection was a bell-shaped relationship, 
and application of higher pranlukast doses was demonstrated to be ineffective, which has not been 
sufficiently explained by the authors (Zhang et al. 2002). Now, having the knowledge that pranlukast 
exhibits a higher potency to counteract CysLT1- than GPR17-mediated events, one could conclude 
that the controversial effects observed with high doses could be caused by modulation of GPR17, 
especially as this bell-shaped phenomenon was not observed with montelukast (Yu et al. 2005), and 
regarding the fact that GPR17 has been postulated to be related to ischemic brain damage (Ciana et 
al. 2006, Lecca et al. 2008). However, if these considerations are true, the previously mentioned 
treatment with pranlukast to modify GPR17 in the acute phase of ischemic damage would not 
represent a suitable approach. Accordingly, it is necessary to further investigate whether pranlukast 
exhibits beneficial in vivo effects on the implicated CNS dysfunctions or not, so far only speculations 
are possible.  
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Uncertain deorphanization attempts uncovered the seven-transmembrane receptor GPR17 as a dual 
nucleotide/lipid receptor activated by two distinct classes of signaling molecules: uracil nucleotides 
and cysteinyl-leukotrienes (Ciana et al. 2006). However, there are a number of inconsistencies, since 
the activity of postulated endogenous ligands and likewise the associated previously uncovered 
signaling properties could not be verified yet by independent laboratories, and thus remain a 
controversial matter. The identification of our synthetic small molecule GPR17 agonist (here referred 
to as RA-II-150), by means of a high throughput pharmacogenomic approach raised the possibility to 
carry out in vitro investigations on the molecular signaling events elicited by agonist-activated human 
GPR17.  
The present work increases our understanding of GPR17 pharmacology, since the observed 
experimental findings using RA-II-150 clearly demonstrate that GPR17 is a functionally active 
receptor that does not lack the common features of GPCR signaling, as shown by data in a set of 
diverse functional assays using two distinct recombinant cellular systems (CHO and HEK293 cells), 
engineered to stably express the short splice variant of human GPR17. These investigations reveal 
that the signaling pathway of ligand-activated GPR17 involves reduction of intracellular cyclic 
adenosine monophosphate (cAMP) as well as the generation of inositol monophosphate (IP1) and 
cAMP as determined by means of traditional second messenger assays based on the HTRF® 
technology, establishing GPR17 as a GPCR that promiscuously couples with three classes of G 
proteins, namely Gαi/o, Gαq/11 and Gαs. This signaling multiplicity is further confirmed by 
combination of pharmacological tools (PTX and YM) to counteract respective G protein subunits 
signaling in a recently developed label-free assay that involves optical measurement of dynamic mass 
redistribution (DMR) following receptor activation. Additionally, for the first time evidence is 
provided, that the putative G protein pan-inhibitor BIM-46178, postulated to abrogate signaling 
mediated by all G protein subunits (Ayoub et al. 2009), acts in a cell-type-dependent manner likely 
regulated by the particular expression levels of G protein subunits. 
The results of the present thesis indicate that despite some observed differences in potencies and 
efficacies, the coupling preferences are comparable between both analyzed cell systems. GPR17 is 
mainly coupled to Gαi/o proteins and, to a minor extent, to the Gαq/11 protein subtype and, to an 
even smaller degree, to the Gαs proteins. G protein subtype activation by our GPR17-agonist 
RA-II-150 is shown to depend on ligand-concentration and the presented data further provide new 
hints that receptor-density plays another important role for coupling specifity. This demonstrates 
how signaling can be channeled into specific routes in particular cells, depending on receptor 
expression levels and availability of activating ligand. Accordingly, such aspects must be taken into 
consideration to have a complete understanding of a given receptor’s signaling properties and 
cellular function.  
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Moreover, ELISA analyses and immunofluorescence investigations for the first time revealed that 
GPR17 internalizes upon ligand-stimulation, which represents a regulatory phenomenon common to 
most GPCRs to limit receptor activation.  
The experiments described in the present thesis further provide the first detailed information about 
β-arrestin recruitment to the agonist-activated GPR17, which is another hallmark of receptor 
activation, as the majority of GPCRs recruit β-arrestin independent of their signaling capacity. 
Bioluminescence resonance energy transfer (BRET2)-based approaches shed light on both kinetics 
and mechanistic procedure of β-arrestin2 translocation upon stimulation with RA-II-150. The findings 
indicate a ligand concentration- and time-dependent manner of β-arrestin2 recruitment to the 
activated receptor, establishing GPR17 as a class B receptor that interacts very rapidly with the 
scaffolding protein and forms stable and long lasting associations. Furthermore, β-arrestin2 
recruitment is shown to be promoted by G protein-dependent and -independent mechanisms. 
Whether this observed G protein-independent translocation to the activated GPR17 gives rise to β-
arrestin2-mediated signaling, such as activation of mitogen-activated protein kinases (MAPK), 
remains to be elucidated. Nevertheless, another interesting so far unknown technical phenomenon 
has emerged during these investigations, in particular that the Epic® optical biosensor technique fails 
to monitor the G protein-independent β-arrestin2 translocation, at least in the case of GPR17.   
Furthermore, the scaffolding protein β-arrestin is shown to exhibit a so far uncharacterized function 
for GPCR-mediated signaling, besides the already known and frequently described roles for 
desensitization and trafficking of GPCRs as well as the recently emerged function as signal transducer 
in its own right. The findings indicate that coexpression of β-arrestin2 can regulate specific signaling 
outcomes triggered by GPR17 through shifting the promiscuous G protein-coupling to the most 
preferred one (here Gαi/o) and preventing signaling via less favored G protein subunits (here 
Gαq/11). Consequently, it is possible that this mechanism is employed by a cell to tailor GPCR 
signaling to suit a specific physiological role, especially as it is known that expression levels of β-
arrestins vary amongst distinct cell types and may change during development or pathological 
conditions.  
Taken together, these findings help to resolve some of the issues surrounding the pharmacology of 
GPR17, and highlight differences in the effector coupling associated with distinct ligand-
concentration, receptor-density and the intracellular levels of β-arrestin2, which seem to have 
sufficient diversity and dynamic range to accommodate the physiological demands placed on GPR17. 
Whereas the cysteinyl leukotriene receptor (CysLTR) antagonists montelukast, zafirlukast and MK571 
are shown to lack significant antagonistic properties to counteract GPR17-elicited functional 
responses, pranlukast for the first time has been identified and characterized as a biased mixed 
agonist/antagonist at GPR17. Detailed analyses uncovered a functionally selective partial agonism 
mediated via Gαi/o protein upon stimulation of GPR17. The promiscuous G protein-coupling as well 
as β-arrestin2 recruitment elicited by RA-II-150 is shown to be diminished with IC50 values in 
micromolar range and very likely in a non-competitive manner. Thus, this already marketed drug 
could represent a valuable tool for further understanding the physiological and pathophysiological 
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roles of GPR17, and provide a chemical starting point that may lead to the development of more 
specific and more potent modifiers of GPR17 functionality.  
In the end it should be noted, that the presented data are all based on studies of recombinant 
human GPR17 in two distinct heterologous expression models. Therefore, further analyses of the 
signaling mechanisms by the natively occurring receptor are inevitable to unveil the accurate 
physiological relevance of the observed findings. Regarding recently published data (Chen et al. 2009, 
Fumagalli et al. 2011) oligodendrocyte precursor cells would represent a suitable primary cell line to 
examine the natively occurring functional responses elicited by GPR17 upon stimulation with 
RA-II-150. Furthermore, application of our specific GPR17 agonist would enable to unequivocally 
establish a link between GPR17 modulation and progression of preoligodendrocytes towards mature 
myelinating cells.  
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AC adenylate cyclase 
ad Latin word for up to 
ADP adenosine 5’-diphosphate 
ATP adenosine 5’-triphosphate 
AUC area under the curve 
bp base pairs 
BRET bioluminescence resonance energy transfer 
cAMP cyclic adenosine monophosphate 
cDNA complementary DNA 
CNS central nervous system 
CRC concentration-response curve 
CysLT cysteinyl-leukotriene 
CysLT1R type 1 cysteinyl-leukotriene receptor 
CysLT2R type 2 cysteinyl-leukotriene receptor 
DAG diacylglycerol 
DC Dendritic cell 
dH2O demineralized water 
DMR dynamic mass redistribution 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide phosphate 
DR dose ratio 
DRC dose-response curve 
EAE experimental autoimmune encephalomyelitis 
(animal model of multiple sclerosis) 
E.coli Escherichia coli 
EC50 concentration of half maximum effect 
e.g. exempli gratia (for example) 
ELISA enzyme linked immunosorbent assay 
endo 1-3 intracellular loops of 7TMR 
ERK extracellular-signal regulated kinase 
ES cell embryonic stem cell 
et al. et alia, Latin word for and others 
exo 1-3 extracellular loops of 7TMR 
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f.c. final concentration 
FITR Flp-InTM T-RexTM 
FRET fluorescence resonance energy transfer 
FSK forskolin 
g acceleration by gravity 
g gram 
GDP guanosine 5′-diphosphate 
GEF guanine nucleotide exchange factor 
GFP green fluorescent protein 
GIRK channel G protein-coupled inwardly-rectifying potassium channel 
GPCR G protein-coupled receptor 
G protein guanine nucleotide-binding protein 
GRK G protein-coupled receptor kinases 
GTP guanosine 5′-triphosphate 
h human 
h hour(s) 
HA haemagglutinin 
HSV-TK herpes simplex virus thymidine kinase 
HTRF® homogeneous time resolved fluorescence 
IC50 concentration of half maximum inhibition 
IP1 inositol 4-phosphate 
IP3 inositol 1,3,4-triphosphate 
JNK c-Jun N-terminal kinase 
kb kilo base(s) 
LTC4 / D4 leukotriene C4 / D4 
LTRA leukotriene receptor antagonist 
log M logarithm of molar concentration to base 10 
M molar concentration (mol/liter) 
m murine / mouse 
Mab monoclonal antibody 
MAPK mitogen-activated protein kinase 
mBRET milliBRET  
MCAO middle cerebral artery occlusion (focal ischemia model) 
min minute(s) 
ml milliliter 
mRNA messenger RNA 
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MS multiple sclerosis 
ms millisecond 
µl microliter 
µM micromolar 
n number 
n.d. no data 
neo neomycin 
nH Hill slope 
nm nanometer 
nM nanomolar 
n.r. no response 
ns non-significant 
N-terminus amino-terminus 
OD optical density 
ORF open reading frame 
OPC oligodendrocyte precursor cell 
P phosphate group 
pA2 negative logarithm of the antagonist concentration that produces a 2-fold 
shift in the CRC for an agonist 
PAR protease-activated receptor 
PCR polymerase chain reaction 
pEC50 negative logarithm of EC50 
PI phosphatidylinositol 
PI3 phosphatidylinositol 3-kinase 
pIC50 negative logarithm of IC50 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
pm picometer 
PP polypropylene 
PScr screening primer 
PTX Pertussis toxin 
q.s. quantum satis (as much as needed) 
RhoA Ras homolog gene family, member A 
RLuc Renilla luciferase 
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rpm rounds per minute 
RT room temperature 
RT-PCR reverse transcription polymerase chain reaction 
RWG resonant waveguide grating 
s second(s) 
SCI spinal cord injury 
s.e.m. standard error of mean 
7 TMR seven transmembrane receptor 
TC tissue culture 
TM transmembrane 
U unit 
UDP uridine diphosphate 
UTR untranslated region 
UV ultraviolet 
V volt 
w/o without 
zeo zeomycin 
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9 Annex 
9.1 Targeting vector maps 
The maps of the targeting vector used for homologous recombination of murine GPR17 were 
designed with the bioinformatic software Vector NTI. As already mentioned in the present thesis, the 
vector construct exhibits a neomycin resistance cassette (neo) as well as a herpes simplex virus 
thymidine kinase (HSV-TK) for positive-negative selection of targeted ES cell clones (see 3.4.4). A 
NotI/XhoI flanked 5’ homologous DNA fragment of 4.7kb (long arm) and a 3’ homologous DNA 
fragment of 1.5kb (short arm) flanked with BamHI/EcoRI were subcloned into pPNT vector by 
standard cloning techniques (see 3.4.1.1).  
In order to ensure the correct sequence and especially the absence of point mutations of the 
generated construct, oligonucleotides were designed to serve as sequencing primers. The sequences 
of these primers are listed in chapter 2.14.2, and their respective binding sites are depicted in Annex 
Figure 1Annex Figure 1 (A). The actual sequencing procedure was performed by GATC Biotech AG, 
Konstanz (see 3.1.6). The correctness of the constructed vector was further proven by restriction 
enzyme cleavages, as presented in Figure 29 and Figure 30. The endonuclease restriction recognition 
sites of the applied enzymes are illustrated in Annex Figure 1 (B).  
 
Annex Figure 1 Vector maps of targeting vector including sequencing primer binding and 
endonuclease restriction recognition sites 
These vector maps, designed by use of Vector NTI software, represent the self-constructed targeting vector for 
homologous recombination of murine GPR17, demonstrating the bindings sites of sequencing primers (PS1-12, 
A), as well as the endonuclease restriction enzyme recognition sites of the utilized enzymes (B). The applied 
pPNT vector exhibits a neomycin resistance sequence (neo) as well as a herpes simplex virus thymidine kinase 
(HSV-TK) that enables positive-negative selection of targeted ES cell clones. The homologous regions of murine 
GPR17 are denoted as long (5’) and short (3’) arm. Genes are represented by solid arrows, which indicate the 
direction of transcription.  
pPNT
13570 bp
long arm (4713bp)
short arm (1523bp)
neo (804bp)
HSV-TK (1127bp)
NotI (56)
XhoI (4776)
EcoRI (1272)
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BamHI (1424)
BamHI (3317)
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9.2 HEK293 cells stably expressing β-arrestin2 fused to GFP2  
HEK293 cells stably expressing distinct β-arrestin2 amounts were generously provided by J. M. 
Mathiesen, Department of Medicinal Chemistry, University of Copenhagen. These cells stably 
expressing β-arrestin2 N-terminally fused to autofluorescent tag green fluorescent protein 2 (GFP2) 
were sorted regarding their fluorescence intensity by means of fluorescence activated cell sorting 
(FACS) analyses, which were conducted by J. M. Mathiesen, Department of Medicinal Chemistry, 
University of Copenhagen. 
9.2.1 Fluorescence microscopy  
The investigations by use of immunofluorescence microscopy revealed that β-arrestin2 is mainly 
localized in the cytoplasm, which is in agreement with previously reported information (Wang et al. 
2003).  
 
Annex Figure 2 Subcellular localization of β-arrestin2 fused to GFP2 stably expressed HEK293 cells.  
A-C, The subcellular localization of GFP2 labeled β-arrestin2 stably transfected in HEK293 cells (A: very high, B: 
high, C: low) was analyzed by fluorescent microscopy, by application of the following settings for GFP2 
recordings (right panels): 200 fold magnification, 500 ms exposure time, 0.99 γ and 1-13 histogram. For 
transmitted light photos (left panels) exposure time was diminished to 10 ms and histogram was set 8-50. 
The three different cell lines stably expressing distinct amounts (referred to as very high, high and 
low) of β-arrestin2 amino-terminally fused with the autofluorescent epitope tag GFP2, are hardly 
distinguishable from each other, only slight descending intensities are visible using the employed 
transmitted light GFP2
A
B
C
9 Annex  
 
202
fluorescence microscope from the top panel (very high) down to the bottom panel (low). The 
observation of β-arrestin translocation upon GPR17-activation by use of fluorescence microscopy 
failed, but as a direct, agonist-dependent interaction of the GPR17-RLuc receptor and β-arrestin2-
GFP2 by means of BRET2 assays was possible (see 4.1.6.3), one could conclude that the applied 
BRET2 technology is a more sensitive method to discover such receptor/β-arrestin interactions. 
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